8-2015

Cardiac, vascular and metabolic characteristics in young women with abdominal obesity: Comparison and intervention

Bianca Louise Share

Follow this and additional works at: http://researchbank.acu.edu.au/theses

Part of the Sports Sciences Commons

Recommended Citation
Share, B. L. (2015). Cardiac, vascular and metabolic characteristics in young women with abdominal obesity: Comparison and intervention (Doctoral thesis, Australian Catholic University). Retrieved from https://doi.org/10.4226/66/5a9cb43eb0b6b

This Thesis is brought to you for free and open access by the Document Types at ACU Research Bank. It has been accepted for inclusion in Theses by an authorized administrator of ACU Research Bank. For more information, please contact LibResearch@acu.edu.au.
Cardiac, Vascular and Metabolic Characteristics in Young Women with Abdominal Obesity: Comparison and Intervention

By

Bianca Louise Share

Bachelor of Exercise Science (Honours)
Graduate Diploma in Education (Secondary)

School of Exercise Science, Faculty of Health Sciences
Australian Catholic University

August 2015

A thesis submitted in total fulfillment of the requirement of the degree of Doctor of Philosophy

ACU
AUSTRALIAN CATHOLIC UNIVERSITY
Thesis Declaration ............................................................................................................. 6
Acknowledgements .......................................................................................................... 7
Publications Contributing to this Thesis .......................................................................... 9
Conference Presentations During Candidature ............................................................... 11
List of Figures .................................................................................................................... 13
List of Tables ..................................................................................................................... 15
Thesis Abstract .................................................................................................................. 17
Abbreviations .................................................................................................................... 20
Chapter 1. Introduction and Overview .......................................................................... 23
  1.1. Cardiovascular Disease ............................................................................................ 23
  1.2. Obesity and CVD ..................................................................................................... 24
  1.3. Modifiable Risk Factors for CVD ............................................................................ 26
  1.4. Women’s Heart Health ............................................................................................ 27
  1.5. Lifestyle Modification .............................................................................................. 30
  1.6. Statement of the Problem ......................................................................................... 31
  1.6.1. Significance of the Study .................................................................................... 32
  1.6.2. Statement of Purpose ......................................................................................... 32
  1.7. Research Question ................................................................................................... 33
  1.8. Specific Aims ............................................................................................................ 34
  1.9. Research Hypotheses .............................................................................................. 35
Chapter 2. Literature Review ......................................................................................... 36
  2.1. Obesity and CVD ..................................................................................................... 36
  2.1.1. Adipose tissue ..................................................................................................... 36
  2.1.2. Obesity assessment ............................................................................................. 37
2.1.3. Abdominal obesity ................................................................. 38

2.2. Modifiable Risk Factors of CVD ................................................. 39
2.2.1. Inflammatory markers ......................................................... 41
2.2.2. The metabolic syndrome ..................................................... 42
2.2.3. Insulin resistance ............................................................... 45
2.2.4. Vascular dysfunction .......................................................... 46
2.2.5. Physical inactivity ............................................................... 48

2.3. Cardiac Dysfunction ............................................................... 49
2.3.1. Cardiac morphology and function ....................................... 50
2.3.2. Myocardial characteristics and mechanics .............................. 50
2.3.3. Cardiac assessment ............................................................ 52

2.4. CVD Risk in Premenopausal Women ....................................... 54

2.5. Prevention of CVD Risk .......................................................... 55
2.5.1. Lifestyle intervention research trends ................................... 56

Chapter 3. The effectiveness of randomised controlled trial lifestyle interventions on cardiovascular disease risk factors in premenopausal women with overweight and obesity: A systematic review .............................................................. 57

3.1. Abstract ................................................................................. 58
3.2. Introduction ........................................................................... 60
3.3. Methods ................................................................................. 61
3.3.1. Data sources and searches .................................................. 61
3.3.2. Study selection ................................................................. 65
3.3.3. Data extraction and quality assessment ................................. 66
3.3.4. Data analysis ................................................................. 67
3.4. Results .................................................................................. 69
3.4.1. Study selection and study inclusion .................................... 69
### 3.4.2. Study characteristics ......................................................... 72
### 3.4.3. Quality assessment and potential bias ........................................ 74
### 3.4.4. Outcome measures of included studies .................................... 75

### 3.5. Discussion ............................................................................... 78
   - 3.5.1. Lifestyle intervention effect on outcome measures ..................... 79
   - 3.5.2. Lifestyle intervention program evaluation .................................. 79
   - 3.5.3. Limitations and future directions ............................................. 81
   - 3.5.4. Conclusions ........................................................................ 82

### 3.5. Discussion ............................................................................... 78
   - 3.5.1. Lifestyle intervention effect on outcome measures ..................... 79
   - 3.5.2. Lifestyle intervention program evaluation .................................. 79
   - 3.5.3. Limitations and future directions ............................................. 81
   - 3.5.4. Conclusions ........................................................................ 82

### 3.5. Discussion ............................................................................... 78
   - 3.5.1. Lifestyle intervention effect on outcome measures ..................... 79
   - 3.5.2. Lifestyle intervention program evaluation .................................. 79
   - 3.5.3. Limitations and future directions ............................................. 81
   - 3.5.4. Conclusions ........................................................................ 82

### Chapter 4. Extended Methods ....................................................... 83
    - 4.1. Ethical Approval ........................................................................ 83
    - 4.2. Research Design ....................................................................... 83
    - 4.3. Participants ............................................................................... 85
    - 4.4. Lifestyle Intervention ................................................................. 86
      - 4.4.1. Participants ........................................................................ 86
      - 4.4.2. Sample size power ............................................................... 86
      - 4.4.3. Study design ....................................................................... 87
      - 4.4.4. Data collection .................................................................... 89
    - 4.5. Outcome Measures .................................................................... 90
      - 4.5.1. Vascular ultrasonography .................................................... 92
      - 4.5.2. Echocardiography ............................................................... 94
      - 4.5.3. Reliability analyses for echocardiography .............................. 100
      - 4.5.4. Survey documents ............................................................... 104
    - 4.6. Statistical Analysis ................................................................... 108
      - 4.6.1. Normal distribution ............................................................. 108
      - 4.6.2. Statistical tests .................................................................... 108
      - 4.6.3. Effect size .......................................................................... 110
4.6.4. Power analysis ................................................................. 111

4.7. Evaluation of the lifestyle intervention ...................................... 112

Chapter 5. Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures. ................................................................. 113

Chapter 6. Young women with abdominal obesity have sub-clinical myocardial dysfunction. ......................................................................................................................... 128

Chapter 7. Effects of a multi-disciplinary lifestyle intervention on cardiometabolic risk factors in young women with abdominal obesity: A randomised controlled trial. .......... 146

7.1. ADDENDUM: Perceived barriers to lifestyle change. ..................... 171

7.2. ADDENDUM: Evaluation of the program ........................................... 177

Chapter 8. Effects of a lifestyle intervention on cardiac measures in young women with abdominal obesity: A randomised controlled trial. ................................................................. 185

8.1. ADDENDUM: Cardiac and vascular measures in young women with abdominal obesity: Short-term sustainability of outcomes following completion of a lifestyle intervention ..................................................................................... 201

Chapter 9. Cardiovascular disease risk factor profile and lifestyle modification in young women with abdominal obesity: A one-year follow-up. ................................................................. 204

Chapter 10. Discussion and Conclusion ................................................ 211

10.1. Overview ................................................................................. 211

10.2. Linking of the studies ................................................................. 211

10.3. Practical applications ................................................................. 219

10.4. Limitations ............................................................................. 220

10.5. Future directions .................................................................. 223

10.6. Conclusion ............................................................................ 224

References ...................................................................................... 225

Appendices ..................................................................................... 251
Thesis Declaration

This thesis contains no material published elsewhere or extracted in whole or part from a thesis by which I have qualified for or been awarded another degree or diploma. This thesis has not been submitted for the award of any other degree or diploma in any other tertiary institution. No other person’s work has been used without date acknowledgement in the main text of the thesis. All research procedures reported in the thesis received approval from the Australian Catholic University Human Research Ethics Committees.

I give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the library catalogue, the Australian Digital Theses Program and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holders of those works.

Bianca Louise Share

Signed: ………………………………………………………… Date: August 2015
Acknowledgements

I would like to thank all of the people who have aided me on my PhD journey:

To my supervisory team: my Principal Supervisor, Justin Kemp, my Co-supervisor, Geraldine Naughton, and my Associate Supervisor, Philippe Obert, for their guidance and support at every stage of my five year doctoral journey. I am deeply grateful for everything I have learned from you.

To those who directly assisted with the Young Women’s Heart Health Study: Jenifer Peat, Elizabeth Aumand, Bianca Gazzola, Melissa Nicholls, Tania Wilson, Kathryn Duncan, Joseph Perry, Zoe Nicolaidis, Sandrine Gayrard, Claire Maunfrais, Krystle Saunders-Stent, and Chandra Lennie. This project would not have been possible without each and every one of you!

To those who offered professional expertise: Andre La Gerche, Janet Hiller, Guillaume Walthers, Andrew Wilson, Don Mooney, Melanie Cameron, and Helen Aucote.

To all my colleagues in the School of Exercise Science, and especially the assistance from: Christian Lorenzen, Brett O’Connell, Doug Whyte, and Taryn Miller. Similarly, to all the friends and colleagues I made during my two month adventure to the Laboratory of Cardiovascular Pharmacology at Avignon University, France.

To the camaraderie of my fellow PhD colleagues, especially, Trentham Furness, Corey Joseph, Eddy Crendal, Tania Gallo, and Blake McLean. A special part of my PhD journey has been the opportunity to be with fellow travelers along the way.
I am most indebted to the wonderful girls who were participants in the Young Women’s Heart Health Study and made the vision a reality. Many of you have made me very proud as you continue to shine beyond the completion of the study.

This thesis would not have been possible without the financial assistance of the Australian Catholic Superannuation Retirement Fund Postgraduate Scholarship, ACU and the Australian Postgraduate Award. Your contribution enabled me to be a full-time PhD student, and travel to several conferences. I am appreciative for the experience, which gave me the opportunity to fulfill my dreams of pursuing research.

To my closest friends who have kept me sane during this marathon event, including Trish, Mia, and “the girls” (Jess, Elise, Lisa), and to my mentor Peter Burke.

Finally, to my ever supportive and patient family; my parents John and Wilma, my sister Leanne, and my partner Mitchel. Your constant love and understanding has enabled me to get through the tough and challenging times! Now onto the next chapter…

“Go confidently in the directions of your dreams... and live the life you’ve imagined”

Henry David Thoreau
Publications Contributing to this Thesis

Published papers

Share, B.L., Naughton, G.A., Obert, P., Peat, J.K., & Kemp, J.G. (2014). Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures. *Journal of Science and Medicine in Sport, 17*(6), 656-661.

Copyright © 2013 Elsevier


Copyright © 2014 Elsevier

Manuscripts currently under construction

**Share, B.L.**, Naughton, G.A., Obert, P., La Gerche, A., & Kemp, J.G. (2014). Effects of a lifestyle intervention on cardiac, and myocardial measures in young women with abdominal obesity: A randomised controlled trial. (prepared for submission to *Canadian Journal of Cardiology*)

Conference Presentations During Candidature

2010

Australian Catholic University 3 Minute Thesis Competition.
Melbourne, Australia. 25\textsuperscript{th} November, 2010.

Oral presentation: The Metabolic Syndrome in Young Women.

Student award: Runners-up ($500)

Author/presenter: B L. Share

2011

Heart Foundation Conference.
Melbourne, Australia. 17-19 March, 2011.

Poster presentation: Cardiovascular Disease Risk in Young Women.

Authors: B L. Share (presenter), G. Naughton, P. Obert, A. Wilson, & J. Kemp

Australian Catholic University 3 Minute Thesis Competition.
Melbourne, Australia. 23\textsuperscript{rd} August, 2011.

Oral presentation: Cardiovascular Health in Young Women.

Student award: Best presentation ($1,000)

Author/presenter: B L. Share

Trans-Tasman 3 minute thesis FINAL
Perth, Australia. 29\textsuperscript{th} September, 2011.

Oral Presentation: Cardiovascular Health in Young Women.

Student award: Recognition of outstanding performance

Author/presenter: B L. Share
2012  
**International Congress on Physical Activity and Public Health**  
Sydney, Australia. 1-3 November, 2012.  
**Oral Presentation:** Lifestyle Intervention Improves Cardiovascular Disease Risk Factors in Young Overweight Women.  
**Authors:** B L. Share (presenter), G. Naughton, P. Obert, E. Aumand, J. Peat, & J. Kemp

**ACHPER conference**  
Melbourne, Australia. May 2012  
**Oral presentation:** Cardiovascular Disease in Young Women: The Young Women’s Heart Health Study  
**Author/presenter:** B L. Share

2014  
**World Congress of Cardiology**  
Melbourne, Australia. 4-7 May, 2014.  
**Poster presentation:** Assessment of Left Ventricular Mechanics Using Speckle Tracking Imaging Echocardiography in Young Women with Abdominal Obesity.  
**Authors:** B L. Share (presenter), G. Naughton, A. La Gerche, P. Obert, E. Crendal, & J. Kemp
List of Figures

Figure 1.1. Causes of death in Australian men and women .................................................. 24
Figure 1.2. Global prevalence of overweight and obesity .................................................. 25
Figure 1.3. Overweight and obesity in Australians ................................................................. 26
Figure 1.4. Relationship between increased adiposity, intermediate ‘modifiable risk factors’ and increased cardiovascular events in the general population ....................................... 27
Figure 1.5. Global prevalence of overweight and obesity .................................................. 29
Figure 1.6. Levels of exercise in premenopausal Australian women ..................................... 30
Figure 2.1. Increased risk of CVD among overweight/obese individuals .................................. 40
Figure 2.2. Schematic representation of the conditions implicated in the pathophysiology of the metabolic syndrome and their potential interactions .................................................. 44
Figure 2.3. Associations between obesity, insulin resistance, and endothelial dysfunction ... 47
Figure 2.4. Population attributable risk factors for heart disease in women ....................... 49
Figure 2.5. Schematic representation of the fibre orientation and mechanics of the LV ...... 51
Figure 2.6. Mechanics of LV untwisting/twisting ................................................................. 52
Figure 2.7. Radial, circumferential and longitudinal planes of deformation ....................... 53
Figure 3.1. Flow diagram of the process of study selection .................................................. 70
Figure 4.1. Study design for the Young Women’s Heart Health Study .................................. 84
Figure 4.2. Participation of individuals in the cross-sectional studies .................................. 85
Figure 4.3. Data collection design for intervention and wait-list control groups .................. 89
Figure 4.4. Outline of the experimental procedure for laboratory session one and two ........ 91
Figure 4.5. Image of the common carotid artery ................................................................. 93
Figure 4.6. Parasternal long-axis view of the heart ......................................................... 94
Figure 4.7. Apical four-chamber view of the heart ......................................................... 95
Figure 4.8. Apical five-chamber view of the heart .............................................................. 96
Figure 4.9. Apical two-chamber view of the heart .............................................................. 97
Figure 4.10. Grading scheme for LV diastolic dysfunction ................................................ 98
Figure 4.11. Parasternal short-axis view of the heart ....................................................... 99
Figure 4.12. Example of the processing and presentation of LV longitudinal strain .......... 100
Figure 4.13. The Transtheoretical Model of Behaviour Change ........................................ 106
Figure 7.1. CONSORT participant flow-chart of intervention and control participants ...... 152
Figure 7.2. Timeline of testing for intervention and wait-list control participants .......... 154
Figure 7.3. Results for intervention and control participants from the multi-disciplinary lifestyle intervention ....................................................................................................................... 166
Figure 8.1. Flow diagram of participants .................................................................. 189
Figure 9.1. “Stage of change for exercise” for participants at longitudinal follow-up .... 208
List of Tables

Table 2.1. Classification of body weight according to body mass index .......................... 37
Table 2.2. Historical overview of the metabolic syndrome criteria for adults. .................... 43
Table 3.1. Title, abstract and key words used across all database searches. ....................... 62
Table 3.2. MeSH terms specific to Medline used in the electronic search strategy .......... 63
Table 3.3. Subject headings specific to CINAHL used in the electronic search strategy ..... 64
Table 3.4. The Physiotherapy Evidence Database Scale items.............................................. 66
Table 3.5. The Physiotherapy Evidence Database Scale .......................................................... 67
Table 3.6. Cardiovascular disease risk factors and psychological inventories .................... 68
Table 3.7. Characteristics of included studies........................................................................ 71
Table 4.1. Outline of the training program for the physical activity ........................................ 88
Table 4.2. Outcome measures collected at each data collection time point ......................... 90
Table 4.3. Intra- and inter-rater reliability analyses for echocardiographic parameters .... 103
Table 5.1. Cardiometabolic risk factors in participants with and without abdominal obesity, as defined by waist circumference ................................................................. 120
Table 5.2. Cardiometabolic risk factors in participants with and without overweight/obesity, as defined by body mass index ................................................................. 121
Table 5.3. Associations between cardiometabolic risk factors and overweight/obesity .... 123
Table 5.4. Most prevalent perceived barriers to engaging in physical activity .............. 124
Table 5.6. Cardiometabolic risk factors in participants with and without abdominal obesity. ................................................................................................................................. 136
Table 6.2. Cardiac morphology and function in participants with and without abdominal obesity. ................................................................................................................................. 138
Table 6.3. Myocardial deformation and mechanics in participants with and without abdominal obesity. ................................................................................................................................. 139
Table 7.1. Outline of the 12-week multi-disciplinary lifestyle intervention ..................... 159
Table 7.2. Between group comparisons of cardiometabolic risk factors for the intervention and control groups ................................................................. 162
Table 7.3. Within-group comparisons of cardiometabolic risk factors for interventions ... 164
Table 7.4. Within-group comparisons of cardiometabolic risk factors for controls ...... 165
Table 7.5. Personal behavioural patterns: between-group comparisons for the control and intervention groups at pre-intervention/pre-control and post-intervention/post-control. ..... 173

Table 7.6. Personal behavioural patterns: within-group comparisons for the intervention group................................................................. 174

Table 7.7. Questions initiated by the facilitator in the focus group. ..................... 178

Table 8.1. Reliability analyses for waist circumference and echocardiography........ 192

Table 8.2. Metabolic and vascular characteristics for the intervention and control groups. 193

Table 8.3. Cardiac morphology and function, and myocardial deformation and mechanics for intervention and control groups. ................................................................. 195

Table 8.4. Within-group comparisons of cardiac and vascular for the intervention group. 202

Table 9.1. Metabolic, lifestyle and vascular data for a subsample of participants. ........ 206

Table 9.2. Echocardiographic data collected for a subsample of participants in the Young Women’s Heart Health Study. ................................................................. 207
Cardiovascular disease (CVD) is the leading cause of death in women worldwide. Despite this, CVD in women is under-researched. Overweight/obesity, particularly abdominal obesity, together other established risk factors, increases the chance of developing CVD. Previous research has also shown that young women with overweight/obesity have cardiac dysfunction that may predispose them to future CVD events, suggesting that early detection and prevention of underlying CVD risk factors may be the best public health approach. Lifestyle interventions incorporating exercise, diet and behavioural therapy are currently recommended as the cornerstone to reduce CVD risk factors in individuals with overweight/obesity.

**Part 1. Cross-sectional studies**

CVD risk factors were investigated in a cross-section of young women aged 18-30 years with abdominal obesity [waist circumference (WC) ≥ 80 cm, n=39] and compared with a non-obese [WC < 80 cm, n=33] aged-matched control group. Metabolic risk factors, including anthropometric, blood-borne (biochemical), fitness and dietary measures (Chapter 5), together with cardiac and vascular characteristics (Chapter 6), were assessed. Cardiac morphology and function, myocardial deformation and mechanics, and carotid intima-media thickness (c-IMT), were measured via ultrasonography. Results showed that women with abdominal obesity had elevated markers of insulin resistance, low-grade systemic inflammation (high-sensitivity C-reactive protein) and systolic blood pressure, and poorer fitness, compared to women without abdominal obesity. Furthermore, the unadjusted odds ratio of being classified with overweight/obesity [defined by WC or body mass index] was high for elevated homeostatic model assessment of insulin resistance (HOMA-IR) and low physical activity. Cardiac morphology was similar between groups, with the exception of dilated left atrium in women with abdominal obesity. Cardiac function measures demonstrated impaired left ventricular diastolic parameters and reduced systolic tissue velocity in women with abdominal obesity. Longitudinal strain and diastolic strain rate were also reduced in women with abdominal obesity but circumferential deformation indices,
myocardial mechanics and c-IMT did not differ between groups. Therefore, a young, otherwise-healthy group of adult women with abdominal obesity displayed elevated markers of insulin resistance and low-grade systemic inflammation and subclinical cardiac dysfunction compared with non-obese women.

**Part 2. Intervention study**

A systematic review (Chapter 3) found that multi-disciplinary lifestyle interventions incorporating exercise, diet and/or behavioural therapy improved CVD risk factors in premenopausal women with overweight/obesity. However, the systematic review highlighted a need for more rigorous studies involving younger (< 30 years of age) women, a deeper understanding of mechanisms that accompany intervention-induced changes in CVD risk, and long-term follow-up evaluating program sustainability.

Women identified with abdominal obesity (from Part 1) participated in a randomised wait-list control trial (RCT) involving a 12-week multi-disciplinary lifestyle intervention. The intervention design incorporated physical activity, nutrition education and cognitive behavioural therapy. Participants underwent screening for anthropometric, blood-borne, fitness and dietary risk factors for CVD (Chapter 7), as well as cardiac and vascular characteristics measured via ultrasonography (Chapter 8), at baseline, post-intervention, and at 12 weeks after post-intervention. A subsample of participants (n=7) was assessed again at 52 weeks post-intervention (Chapter 9). Results from a linear mixed model analysis comparing changes in CVD risk factors and lifestyle behaviours of women completing the intervention (n=19) and the overweight/obese control group (n=11) showed no notable between-group differences for any metabolic risk factors or markers derived from cardiac and vascular ultrasonography. However, within-group improvements were observed in the intervention group for anthropometric markers, blood pressure, aerobic fitness, physical activity engagement, dietary energy intake and left ventricular mass indexed, with some of these changes maintained 12 weeks after intervention completion. Similarly, women in the control group displayed significant within-group improvements in anthropometric markers and changes in left ventricular mass indexed, suggesting that a traditional RCT design may not be appropriate for this population. At one-year post-intervention, further improvements in
anthropometric measures were evident, along with improved lifestyle behaviours for physical activity and dietary intake. Therefore, despite complex compliance issues with the control group, a multi-disciplinary lifestyle intervention improved some metabolic and cardiac risk factors in women with abdominal obesity compared with controls, with evidence of long-term sustainability of behaviour modification.

In summary, this thesis provides new knowledge on the cardiac, vascular and metabolic profiles of young (premenopausal) adult women with abdominal obesity, and a better understanding of the effects on CVD risk factors, and their sustainability, of a multi-disciplinary lifestyle intervention in this under-research population.
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABS</td>
<td>Australian Bureau of Statistics</td>
</tr>
<tr>
<td>AIHW</td>
<td>Australian Institute of Health and Welfare</td>
</tr>
<tr>
<td>A&lt;sub&gt;m&lt;/sub&gt;</td>
<td>Late-diastolic mitral annulus tissue velocity</td>
</tr>
<tr>
<td>ANZCTR</td>
<td>Australian New Zealand Clinical Trials Registry</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>AusDiab</td>
<td>Australian Diabetes, Obesity and Lifestyle Study</td>
</tr>
<tr>
<td>A WAVE</td>
<td>Late-diastolic transmitral blood velocity</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>CBT</td>
<td>Cognitive behavioural therapy</td>
</tr>
<tr>
<td>CHO</td>
<td>Carbohydrates</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>c-IMT</td>
<td>Carotid intima-media thickness</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular disease</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DEXA</td>
<td>Dual-energy x-ray absorptiometry</td>
</tr>
<tr>
<td>DT</td>
<td>Deceleration time</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>E&lt;sub&gt;m&lt;/sub&gt;</td>
<td>Early-diastolic mitral annulus tissue velocity</td>
</tr>
<tr>
<td>E WAVE</td>
<td>Early-diastolic transmitral blood velocity</td>
</tr>
<tr>
<td>FM</td>
<td>Fat mass</td>
</tr>
<tr>
<td>GE</td>
<td>General Electric</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>HOMAR-IR</td>
<td>Homeostasis model of assessment – insulin resistance</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>hs-CRP</td>
<td>High sensitivity C-reactive protein</td>
</tr>
<tr>
<td>Hz</td>
<td>Hertz</td>
</tr>
<tr>
<td>ICC</td>
<td>Intraclass correlation coefficient</td>
</tr>
<tr>
<td>IDF</td>
<td>International Diabetes Federation</td>
</tr>
<tr>
<td>IR</td>
<td>Insulin resistance</td>
</tr>
<tr>
<td>IVRT</td>
<td>Isovolumetric relaxation time</td>
</tr>
<tr>
<td>IVS</td>
<td>Inter-ventricular septum</td>
</tr>
<tr>
<td>LA</td>
<td>Left atrium</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LM</td>
<td>Lean mass</td>
</tr>
<tr>
<td>LMM</td>
<td>Linear mixed model</td>
</tr>
<tr>
<td>LOA</td>
<td>Limits of agreement</td>
</tr>
<tr>
<td>LV</td>
<td>Left ventricle/ left ventricular</td>
</tr>
<tr>
<td>LVED</td>
<td>Left ventricular end-diastolic</td>
</tr>
<tr>
<td>LVES</td>
<td>Left ventricular end-systolic</td>
</tr>
<tr>
<td>ME</td>
<td>Measurement error</td>
</tr>
<tr>
<td>NHMRC</td>
<td>National Health and Medical Research Council</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>ROC</td>
<td>Receiver operating characteristic</td>
</tr>
<tr>
<td>RPE</td>
<td>Rating of perceived exertion</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>SDT</td>
<td>Self-determination theory</td>
</tr>
<tr>
<td>$S_m$</td>
<td>Systolic mitral annulus tissue velocity</td>
</tr>
<tr>
<td>SPSS</td>
<td>Statistical package for the social sciences</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>SR</td>
<td>Strain rate</td>
</tr>
<tr>
<td>STE</td>
<td>Speckle tracking echocardiography</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 diabetes mellitus</td>
</tr>
<tr>
<td>TDI</td>
<td>Tissue Doppler imaging</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
<tr>
<td>WHF</td>
<td>World Heart Foundation</td>
</tr>
<tr>
<td>WHR</td>
<td>Waist-to-hip-ratio</td>
</tr>
<tr>
<td>WHtR</td>
<td>Waist-to-height ratio</td>
</tr>
<tr>
<td>WC</td>
<td>Waist circumference</td>
</tr>
<tr>
<td>1RM</td>
<td>One repetition maximum</td>
</tr>
<tr>
<td>2D</td>
<td>Two-dimensional</td>
</tr>
</tbody>
</table>
Chapter 1. Introduction and Overview

1.1. Cardiovascular Disease

Cardiovascular disease (CVD) is a non-communicable disease involving the heart and blood vessels (arteries, capillaries, and veins), comprising coronary or ischaemic heart disease, cardiomyopathy, cerebrovascular disease, heart failure, rheumatic heart disease, peripheral arterial disease and hypertension (World Heart Federation, 2013). CVD is the leading cause of death, particularly in industrialised countries, despite improvements in life expectancy. An estimated 17 million people worldwide die from CVD each year, equating to approximately 30% of all deaths, with incidences projected to increase linearly (World Health Organisation, 2011).

In Australia, CVD is the primary cause of mortality in both men and women (Figure 1.1). In 2009, CVD accounted for 33 per cent of all deaths nationally (Australian Bureau of Statistics, 2013). Additionally, CVD contributes to the social, personal and financial burden of disease, costing the Australian economy six billion dollars in health care expenses annually. This cost represents 11 per cent of the total health expenditure (Australian Institute of Health and Welfare, 2012). Cardiovascular health is one of eight Australian National health priority areas, in recognition of its high prevalence, its impact on morbidity and mortality, and its potential for health improvements through prevention and treatment programs (The Department of Health, 2012).
1.2. Obesity and CVD

Excess body fat, particularly obesity, is established as a risk factor for CVD and increased mortality rates (Hubert, Feinleib, McNamara, & Castelli, 1983). The most serious form of obesity is central (i.e. abdominally located) rather than peripheral obesity, as it is associated with higher risks for CVD (Alberti, Zimmet, & Shaw, 2005). Incidences of overweight and obesity continue to rise, already reaching epidemic proportion (Figure 1.2). Worldwide, prevalence of overweight and obesity combined rose by 27% for adults and 47% for children between 1980 and 2013 (Ng et al., 2014). Globally, the proportion of adults who are either overweight or obese is currently 37% in men, and 38% in women (Ng et al., 2014). Furthermore, a large number of studies have demonstrated higher rates of death from obesity and CVD in people who are from a lower socioeconomic status (Houweling, Kunst, & Mackenbach, 2001; Woodward et al., 2015).

Figure 1.1. Causes of death in Australian men and women, 2009 (Data sourced from: Australian Bureau of Statistics, 2013).
The prevalence of overweight and obesity among Australians has been steadily increasing for the past 30 years (Australian Bureau of Statistics, 2013). According to the National Health Survey, in 2007-08, based on body mass index, an estimated 62% of Australian adults aged 18 years or older were overweight or obese (Australian Bureau of Statistics, 2013), equating to over 12 million Australian adults (Figure 1.3). It has been projected that by 2025, more than 75% (approximately 17 million) of Australian adults will be overweight or obese (Vic Health, 2014).
Figure 1.3. Overweight and obesity in Australians aged 15 years and older (data sourced from: (Australian Institute of Health and Welfare, 2012). Unshaded red, women overweight; solid red, women obese; unshaded blue, men overweight; solid blue, men obese.

1.3. Modifiable Risk Factors for CVD

Chronic accumulation of excess body fat can lead to the development of intermediate ‘modifiable’ CVD risk factors (Bastien, Poirier, Lemieux, & Després, 2014). Risk factors describe any attribute, characteristic or exposure of an individual that increases the likelihood of developing a disease or injury (World Health Organisation, 2011). Modifiable risk factors such as physical inactivity, dyslipidemia, hypertension, insulin resistance, glucose intolerance, systemic inflammation, type 2 diabetes mellitus (T2DM), a prothrombotic state, cardiac remodelling and impaired vascular function (Alberti et al., 2009; Tadic, Ivanovic, Petrovic, Celic, & Neskovic, 2013) are associated with obesity and are linked to the development of CVD (Figure 1.4) (Bastien et al., 2014). Furthermore, as many as six in every ten deaths from CVD are related to modifiable risk factors, and women have a higher prevalence of risk factors for CVD than men (Villablanca, Jayachandran, & Banka, 2010;
World Health Organisation, 2011). This suggests that much of the CVD burden is avoidable, and efforts to decrease modifiable risk factors are urgently needed.

![Diagram showing relationship between increased adiposity, intermediate 'modifiable risk factors', and increased cardiovascular events](image)

**Figure 1.4.** Relationship between increased adiposity (overweight/obesity), intermediate ‘modifiable risk factors’ (e.g. hypertension, insulin resistance, the metabolic syndrome) and increased cardiovascular events in the general population (adapted from Bastien et al., 2014).

### 1.4. Women’s Heart Health

Cardiovascular disease in women is described in the international literature as under-recognised, under treated and under researched (National Heart Foundation of Australia, 2011).

The Framingham Heart Study, initiated in 1948 (Dawber, Moore, & Mann, 1957), identified that overt CVD develops 10 years later in women than men, resulting in CVD being labelled a ‘male condition’. As a consequence, women experience poorer prognosis and receive suboptimal preventive care and treatment which, in turn, contributes to inferior outcomes in comparison to men (Worrall-Carter, Edward, & Page, 2012). Similarly, a systematic review investigating the major risk factors for CVD in women (aged > 18 years) in the published literature between 1999 and 2011 highlighted important differences between men and women relating to modifiable risk factors. Specifically, women are more likely to suffer from T2DM,
hypertension, physical inactivity, depression, and stress, which place them at high risk of CVD (Worrall-Carter, Ski, Scruth, Campbell, & Page, 2011). Similarly, others have reported the prevalence of several risk factors, such as hypertension, T2DM, high alcohol intake and low physical activity as being greater in women than men (Norhammar & Schenck-Gustafsson, 2013). Furthermore, hypertension, elevated fasting glucose, abdominal obesity and dyslipidemia may have a greater impact on deleterious left ventricular remodelling in women than men (Tadic et al., 2013). Given that women’s health research has traditionally focused primarily on matters of sexual and reproductive health, enormous improvements in women’s CVD outcomes through targeted research are possible (Norhammar & Schenck-Gustafsson, 2013).

In Australia alone, more than 26,000 women die each year from CVD, accounting for 41% of all female deaths (Australian Institute of Health and Welfare, 2012). The longitudinal, population-based Australian Diabetes, Obesity and Lifestyle (AusDiab) Study found that young (premenopausal) women gained more weight and waist circumference over a 12-year period than men and older (post-menopausal) women (Stewart, Tikellis, Carrington, Walker, & O’Dea, 2008). Specifically, an average weight gain of 6 to 12 kg was observed in women between the ages of 20 to 30 years (Adamson et al., 2007; Lucke et al., 2007). Currently, in Australia, the prevalence of overweight and obesity is 35% for women aged 18-24 years, and 42% for women aged 25-34 years (Australian Bureau of Statistics, 2013). Similarly, 51% of non-hispanic white American women aged 20-39 years are either overweight or obese (Flegal, Carroll, Kit, & Ogden, 2012), while the prevalence among women of a similar age (25-34 years) in the United Kingdom is 47% (Health and Social Care Information Centre, 2011). Figure 1.5 shows the global age pattern of overweight and obesity in 2013. For women, it is evident that rapid weight gains occurred between the ages of 20 and 40 years, with prevalence of overweight and obese doubling during this timeframe.
In addition to the increases in the prevalence of overweight and obesity, young women are also exhibiting low levels of physical activity (Figure 1.6). The greatest prevalence of ‘sedentary’ behavior exists for women aged 25 to 34 years, with almost 35% of these women performing no structured physical activity (Australian Bureau of Statistics, 2013). Even for women aged 18 to 24 years, ‘sedentary’ behaviour exceeds 30% for that age group, with another 40% exhibiting low physical activity behaviour.
Ultimately, carrying excessive weight and exhibiting sedentary exercise behaviours predisposes young adult women to CVD risk and premature death. This suggests that lifestyle modification is critical for halting CVD risk progression in premenopausal women.

1.5. Lifestyle Modification

Lifestyle management and behaviour modification has shown to be effective in the reduction of CVD risk by reducing overweight/obesity and improving the risk factor profile associated with CVD development (Irving et al., 2008). In a review assessing a range of management strategies to address overweight and obesity, multi-disciplinary lifestyle interventions that incorporate diet, exercise and behavioural therapy were most effective for weight loss and reduction of CVD risk factors (A. Lang & Froelicher, 2006) (Wing, 2002). Thus, CVD risk modification through lifestyle intervention is highly recommended (Deaton et al., 2011) (Mosca et al., 2004), with suggestions that a heart healthy lifestyle encouraged from youth and continuing into adulthood is the best approach for the prevention of CVD (Mitrakou, 2006). It is often suggested that women are underrepresented in cardiac research, in particular premenopausal women, because they are ‘protected’ against CVD due to the presence of
oestrogen, but this protective effect may not be the case (Maas et al., 2011). Therefore, the detection, prevention, and treatment of modifiable risk factors are strategically recommended for the reduction of CVD (Galassi, Reynolds, & He, 2006), and female-specific research and clinical programs should aim at a more multi-disciplinary approach to cardiovascular health in women (Worrall-Carter et al., 2011).

1.6. Statement of the Problem

Greater research is required to improve the understanding of CVD in women (Norhammar & Schenck-Gustafsson, 2013). However, most research of overweight/obesity and CVD risk to date has focused on women aged over 40 years, even though earlier detection and prevention of risk factors may be the best public health approach. In the Australian context, CVD accounts for 41% of all female deaths (Australian Institute of Health and Welfare, 2012). In parallel, the prevalence of overweight and obesity is 35% for women aged 18-24 years and 42% for women aged 25-34 years (Australian Bureau of Statistics, 2013). In these age groups, approximately 70% of women are also classified as exhibiting ‘sedentary’ or ‘low activity’ exercise behaviors (Australian Bureau of Statistics, 2012). Despite these and similar international figures, enrolment of young adult women in clinical and epidemiological research remains relatively low in studies of populations with chronic disease. Thus, the ability to detect the establishment and progression of CVD in younger populations, and then put in place preventative strategies, is limited. Moreover, while lifestyle modification has been recommended as the cornerstone treatment of obesity and CVD risk factors (Bantle et al., 2008), little is known about its effectiveness for reducing modifiable CVD risk factors in young adult women with overweight/obesity.
1.6.1. Significance of the Study

This study addressed the prominent gap in CVD research concerning young adult women with overweight/obesity. In this project, a range of traditional and contemporary initiatives were utilised to examine the CVD risk profile of young women. This research then explored the impact of a lifestyle modification program on these risk factors. Results from this study are expected to provide new insights into the detection and prevention of CVD in young adult women, and encourage health care providers to conduct appropriate and sustainable interventions. Ultimately, the outcome of this thesis aimed to inform new directions for the management of lifestyle factors to prevent CVD and, thus, enhance the long-term health of young women with overweight/obesity. The results of this research are important for policy makers, as the knowledge gained about the health status of young women with abdominal obesity can be utilised to reduce personal and societal burden. This thesis also provides insights to inform the direction of future studies, particularly when targeting a participant cohort of young adult women.

1.6.2. Statement of Purpose

The collective purpose of the studies in this thesis was to investigate cardiovascular health in young adult women and advance the knowledge of early detection and prevention of CVD risk. This was achieved by (i) profiling markers of CVD risk in a cross-section of young women with and without abdominal obesity, and (ii) providing proof of concept in the early detection and prevention of CVD risk in overweight/obese young women through a multi-disciplinary lifestyle intervention, using a randomised controlled trial (RCT) design and a sustainability component.
1.7. Research Question

The research questions for this study were:

1. What (cardio)metabolic, cardiac and vascular risk factors for CVD are associated with overweight/obesity, defined by abdominal obesity measured from waist circumference, in premenopausal adult women aged 18-30 years?

2. Does a multi-disciplinary lifestyle intervention comprising exercise, nutrition education and cognitive behavioural therapy (CBT) improve the CVD risk factor profile of young women with abdominal obesity? And if so, are these improvements sustainable beyond the completion of the program?
1.8. Specific Aims

The specific aims of this research were to:

1. Investigate blood-borne metabolic and lifestyle markers of CVD risk in a cross-sectional profile of young adult women with (and without) overweight/obesity, defined by both elevated waist circumference and BMI (Chapter 5).

2. Investigate cardiac and vascular remodelling and myocardial function in a cross-sectional profile of young women with and without overweight/obesity using traditional and advanced techniques of ultrasonography (Chapter 6).

3. Assess the efficacy and sustainability of a 12-week multi-disciplinary (exercise + nutrition education + CBT) lifestyle intervention, using a randomised wait-list control design, for improving the metabolic and lifestyle CVD risk factor profile in young adult women with abdominal obesity (Chapter 7 and 9).

4. Assess the efficacy and sustainability of a multi-disciplinary lifestyle intervention, using a randomised wait-list control design, for improving cardiac and vascular morphology, cardiac function, and myocardial deformation and mechanical indices, in young adult women with abdominal obesity, using traditional and advanced techniques of ultrasonography (Chapter 8 and 9).
1.9. Research Hypotheses

The hypotheses formulated for the research were:

*Hypothesis 1*

Young adult women with abdominal obesity exhibit metabolic markers of CVD risk and poorer lifestyle behaviours, when compared with age-matched women without abdominal obesity.

*Hypothesis 2*

Young adult women with abdominal obesity exhibit markers of cardiac and vascular remodelling, and cardiac and myocardial dysfunction, measured from ultrasonography, when compared with age-matched women without abdominal obesity.

*Hypothesis 3*

Involvement in a 12-week multi-disciplinary lifestyle intervention produces improvements in anthropometric measures, reductions in metabolic risk factors for CVD, and lifestyle modifications supporting weight management, with these changes sustained or improved at follow-up testing, in young adult women with abdominal obesity.

*Hypothesis 4*

Involvement in a 12-week multi-disciplinary lifestyle intervention produces improvements in cardiac, vascular and myocardial measures, using ultrasonography, with these changes sustained or improved at follow-up testing, in young adult women with abdominal obesity.
2.1. Obesity and CVD

The dramatic increase in obesity worldwide over the past 20-30 years has resulted in the World Health Organisation labelling it a “global epidemic” (World Health Organisation, 2000). Excess body fat is an established risk factor for CVD (Hubert et al., 1983), but it also increases the development of other intermediate risk factors for CVD (Australian Institute of Health and Welfare, 2012). The understanding of the role that adipose tissue plays in metabolic and homeostatic regulation has advanced in recent years (Berggren, Hulver, & Houmard, 2005; Kershaw & Flier, 2004; Matsuzawa, 2006b). Moreover, it is now established that, when in excess, adipose tissue is a significant contributor to biological dysregulation and disease progression (Kahn, Hull, & Utzschneider, 2006). Therefore, early identification and control of this dysregulation is critical for individual and societal health, especially given that obesity is a modifiable risk factor for many diseases. With respect to this work, adipose tissue and obesity is addressed in the context of CVD risk, development and progression.

2.1.1. Adipose tissue

Once thought to be simply a passive storage reservoir for excess energy in the form of triglycerides, adipose tissue is now considered an active autocrine, paracrine and endocrine organ (Brugger et al., 2014; Kershaw & Flier, 2004; Matsuzawa, 2006b). Adipose tissue plays a prominent role not only in energy metabolism and lipolysis but also contributes to other important metabolic processes such as regulation of inflammation, blood pressure, fibrinolysis and appetite (Mitrakou, 2006; Stears & Byrne, 2001). When adipose tissue has reached its maximum expansion capacity, a “spill over” of lipids from adipocytes occurs, resulting in an increase in circulating free fatty acids (Bastien et al., 2014). Lipids then start to accumulate at various sites in the form of subcutaneous adipose tissue, visceral adipose tissue, intra-hepatic fat, intra-muscular fat, renal sinus fat, epi/pericardial fat, myocardial fat and perivascular fat (Bastien et al., 2014; Montani et al., 2004). It is therefore unsurprising...
that the most critical factor in the emergence of metabolic diseases is excess adipose tissue (Kahn et al., 2006).

2.1.2. Obesity assessment

The most commonly used anthropometric tool to classify overweight and obesity is body mass index (BMI). BMI is an index of weight-for-height calculated as kg/m\(^2\) (World Health Organisation, 2000). According to this calculation, individuals with a BMI ranging from 25 to 29.9 kg/m\(^2\) are classified as overweight, whilst obesity is classified as a BMI ≥ 30 kg/m\(^2\) (Table 2.1).

Table 2.1. Classification of body weight according to body mass index (BMI) (adapted from: World Health Organisation, 2000).

<table>
<thead>
<tr>
<th>Classification</th>
<th>BMI (kg/m(^2))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>&lt; 18.5</td>
</tr>
<tr>
<td>Normal range</td>
<td>18.5 – 24.9</td>
</tr>
<tr>
<td>Overweight</td>
<td>25.0 – 29.9</td>
</tr>
<tr>
<td>Obese:</td>
<td>≥ 30.0</td>
</tr>
<tr>
<td>Obese class I</td>
<td>30.0 – 34.9</td>
</tr>
<tr>
<td>Obese class II</td>
<td>35.0 – 39.9</td>
</tr>
<tr>
<td>Obese class III</td>
<td>≥ 40.0</td>
</tr>
</tbody>
</table>

Although a useful and simple tool to estimate and classify obesity, BMI does not discriminate lean mass from fat mass, nor does it account for variations in body fat distribution (Dalton et al., 2003). Adiposity indices that incorporate a measure of waist circumference, including waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and waist circumference itself, should therefore be considered by clinicians in risk stratification and to discriminate individuals at higher risk of chronic disease (Bastien et al., 2014; National Health and Medical Research Council, 2003). A cross-sectional survey of anthropometric characteristics...
of Australian women (n = 4,487, aged 20-69 y) showed central adiposity measured by waist circumference, WHR, and WHtR to be better predictors of CVD risk than BMI (Goh, Dhaliwal, Welborn, Lee, & Della, 2014). Similarly, results from a meta-analysis of 24 cross-sectional studies in adults showed that WHtR had a stronger ratio of relative risk for cardiometabolic risk than BMI (Savva, Lamnisos, & Kafatos, 2013).

2.1.3. Abdominal obesity

The distribution of adipose tissue, in addition to the amount of body fat, is an important determinant of morbidity and mortality (Landin et al., 1990). Evidence indicates that excess intra-abdominal fat (abdominal adiposity) is associated with greater risk of obesity-related morbidity than overall adiposity (Dalton et al., 2003; Zhang, Rexrode, van Dam, Li, & Hu, 2008). Furthermore, abdominal adipose tissue plays a major role in the pathogenesis of atherosclerosis through various metabolic and hormonal pathways (Mitrakou, 2006). Abdominal obesity increases the risk of various health problems that predispose an individual to increased risk of CVD (Australian Institute of Health and Welfare, 2012). As a measure, elevated waist circumference is a reliable anthropometric index of abdominal obesity (Lucke et al., 2007) for the prediction of CVD risk (Goh et al., 2014); (Alberti et al., 2009). Based on expert consensus, the WHO has proposed sex-specific cut-off values for waist circumference that are associated with increased CVD risk (World Health Organisation, 2011). A waist circumference of ≥ 80 cm in women and ≥ 94 cm in men is indicative of increased risk, while a waist circumference of ≥ 88cm in women ≥ 102 cm in men and represents substantially increased risk. Therefore, measuring waist circumference, given its low cost and convenience, represents a valuable tool for health care professionals, in addition to BMI (Balkau et al., 2007).

International Day for Evaluation of Abdominal Obesity, conducted across 63 countries, evaluated waist circumference in 168,000 participants aged 18-80 years who consulted with a primary care provider between May and July 2005 (Balkau et al., 2007). According to the National Cholesterol Education Program – Third Adult Education Panel (NCEP:ATP III)
criteria, 48% of women had abdominal adiposity (i.e. WC > 88 cm), whilst 71% of women had a WC ≥ 80 cm (International Diabetes Federation, 2006) Furthermore, women with an elevated waist circumference had an odds ratio of 1.97 for CVD (Balkau et al., 2007). Additionally, the Australian Diabetes, Obesity and Lifestyle Study (AusDiab), a population-based cross-sectional survey of CVD risk factor prevalence in Australia, investigated waist circumference in adults aged ≥ 25 years (Dunstan et al., 2002). Abdominal obesity for women aged 25-34 years was 20% for WC ≥ 80 cm, and 17% for WC ≥ 88 cm (Cameron et al., 2003).

2.2. Modifiable Risk Factors of CVD

An excess in adipose tissue, or obesity, is associated with increased incidence of cardiovascular and cerebrovascular events in men and women (Landin et al., 1990) Large prospective studies such as the Framingham Heart Study have shown obesity is an independent predictor of CVD. Furthermore, the relationship between obesity, intermediate risk factors, and the development of CVD is evident (Bastien et al., 2014). Results suggest that increased adiposity leads to the development of CVD risk factors, and the burden of these risk factors, not adiposity itself, is critical to the development of CVD (Wilson, 2004) (Figure 1.4). Adipose tissue excess, particularly visceral (intra-abdominal) fat, is associated with insulin resistance, type 2 diabetes mellitus (T2DM), hyperglycemia, dyslipidemia, hypertension, atherosclerotic vascular disease, and prothrombotic and inflammatory states (Kershaw & Flier, 2004; Stears & Byrne, 2001). Furthermore, the International Diabetes Federation (International Diabetes Federation, 2006) has identified the direct role of visceral fat accumulation in the development of multiple risks and CVD. Figure 2.1 describes the abnormalities associated with increased risk of CVD among individuals with excessive adipose tissue.
The traditional approach to CVD risk assessment involves identifying and quantifying the presence of CVD risk factors. Estimating 10-year risk for CVD may also be performed using the Framingham risk score model (Dawber et al., 1957) for adults (aged ≥ 25 y). However, individuals at intermediate risk may benefit from identification of subclinical risk factors to further refine their CVD risk estimates (Stein et al., 2008).
2.2.1. Inflammatory markers

Systemic inflammation is believed to play a role in the pathogenesis of cardiovascular events, and CVD (Ridker, Hennekens, Buring, & Rifai, 2000). Many inflammatory mediators produced by adipose tissue are altered in the obese state, particularly in individuals with abdominal obesity or increased visceral adipose tissue (Berggren et al., 2005; Matsuzawa, 2006b). Adipose-secreted cytokines (or adipokines) play a role in the regulation of satiety (Kershaw & Flier, 2004), carbohydrate and lipid metabolism (Kondo, Kobayashi, & Murakami, 2006), and insulin sensitivity (Matsuzawa, 2006a). Adipokines can be classified into two main categories: 1) “healthy” adipokines, such as adiponectin, and 2) “unhealthy” adipokines, including markers of low-grade systemic inflammation (e.g. high-sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-6), indicators of a thrombotic state (e.g. plasminogen activator inhibitor-1, fibrinogen), and the satiety regulator, leptin (Ridker et al., 2000; You & Nicklas, 2008).

Chronic low-grade systemic inflammation, observed in obese populations, promotes atherogenic profiles, endothelial dysfunction, and insulin resistance and, ultimately, coronary artery disease, T2DM, and heart failure (Steinbaum, 2004). While there is an array of commercially available assays employed in clinical settings for the analysis of inflammatory markers, the Centre for Disease Control and Prevention favours high-sensitivity C-reactive protein (hsCRP) from a clinical chemistry perspective, given its predictive abilities for CVD events (Pearson et al., 2003). Synthesised and secreted by the liver, hsCRP is an acute reactant that reflects low-grade systemic inflammation and plays a pathogenic role by acting on endothelial cells (McWilliam & Riordan, 2010; Mitrakou, 2006). Studies have consistently shown hsCRP as a strong predictor of future coronary events in apparently healthy men and women. Therefore, hsCRP assays are used for risk assessment of CVD, and used in the stratification of patients into high- and low-cardiovascular risk groups (Ridker, 2001). Results from the Women’s Health Study showed that hsCRP was a strong predictor of future cardiovascular events even among subgroups of women with no history of hyperlipidemia, hypertension, smoking, diabetes, or family history of coronary heart disease (Ridker, Buring, Shih, Matias, & Hennekens, 1998; Ridker et al., 2000). Thus, hsCRP may play an important role as an adjunct in the comprehensive assessment of risk in the primary prevention of CVD (Ridker, 2001).
2.2.2. The metabolic syndrome

The metabolic syndrome, first described by Reaven as ‘syndrome X’ in 1988 (G. M. Reaven, 1988), is a combination of atherogenic risk factors that increase the chance of developing CVD and T2DM (Alberti, Zimmet, & Shaw, 2006; Byrne & Wild, 2005). The metabolic syndrome is characterised by a clustering of several risk factors, including abdominal obesity, raised serum triglyceride, reduced high-density lipoprotein (HDL) cholesterol, elevated blood pressure, and elevated fasting plasma glucose concentrations (Kassi, Pervanidou, Kaltasas, & Chrousos, 2011). In many individuals, the metabolic syndrome is associated with obesity and a sedentary lifestyle, and is being diagnosed with increasing frequency worldwide. It is estimated that 20 to 25% of the world’s adult population has the metabolic syndrome (International Diabetes Federation, 2006), with results from the AusDiab Study showing prevalence of the metabolic syndrome to be as high as 29% in Australian adults aged 25 years and over (Cameron, Magliano, Zimmet, Welborn, & Shaw, 2007). Individuals diagnosed with the metabolic syndrome are twice as likely to die from CVD and have a 1.5-fold increase in all-cause mortality (Mottillo et al., 2010). Moreover, the relative risk of CVD associated with the metabolic syndrome is higher in women than men (Galassi et al., 2006). Women with the metabolic syndrome are also at increased risk of complications during pregnancy, and offspring of obese mothers are at an elevated risk of developing the metabolic syndrome later in life (Ramos & Olden, 2008). Thus, the importance of early detection of the metabolic syndrome and its component risk factors is therefore critical in the attenuation of disease progression.

Over the years, a number of international expert groups have developed clinical criteria for the metabolic syndrome, and in particular, the WHO, European Group for the Study of Insulin Resistance (EGIR), National Cholesterol Education Program – Third Adult Education Panel (NCEP:ATP III), the American Heart Association/National Heart, Blood and Lung Institute (AHA/NHBLI), and the International Diabetes Federation (IDF). All groups agreed on the essential components of the metabolic syndrome being abdominal obesity, glucose intolerance, hypertension and dyslipidaemia (Table 2.2); however, each group’s definition differed in its numeric criterion for each component. The application of different criteria gave rise to a proliferation of varying data and, thus, highlighted the need for a globally standardised definition (Zimmet, Alberti, & Shaw, 2005). In 2005, the IDF released a definition for the metabolic syndrome that introduced abdominal obesity as the pre-requisite...
criterion in its diagnosis (Alberti et al., 2006; International Diabetes Federation, 2006). This definition addressed both clinical and research needs, focusing on abdominal obesity, and allowed for gender- and ethnic-specific values for waist circumference. Those involved in establishing this definition agreed that insulin resistance had largely been over-emphasized in earlier definitions, and that the essential component should be abdominal obesity, with its surrogate measure being waist circumference (Alberti et al., 2005). The IDF with the AHA/NHBLI updated the definition of the metabolic syndrome (Alberti et al., 2009) in an attempt to resolve the remaining differences that still existed between definitions. It was agreed that abdominal obesity should not be a prerequisite for its diagnosis but rather all individual components should be considered as important risk factors. Metabolic syndrome diagnosis now required the presence of any three of the five risk factors.

Table 2.2. Historical overview of the metabolic syndrome criteria for adults (Kassi et al., 2011).

<table>
<thead>
<tr>
<th>Year</th>
<th>Expert Group</th>
<th>Inclusion Criteria</th>
<th>Risk Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>World health Organisation (WHO)</td>
<td>Insulin resistance PLUS two other risk factors</td>
<td>abdominal obesity (WHR), ↑triglycerides, ↑BP, microalbuminuria</td>
</tr>
<tr>
<td>1999</td>
<td>European Group for the Study of Insulin Resistance (EGIR)</td>
<td>Insulin resistance PLUS two other risk factors</td>
<td>Abdominal obesity (WC), ↑triglycerides, ↑BP, ↑fasting glucose</td>
</tr>
<tr>
<td>2001</td>
<td>National Cholesterol Education Program – Third Adult Education Panel (NCEP – ATP III)</td>
<td>Any three or more risk factors</td>
<td>Abdominal obesity (WC), ↑triglycerides, ↓HDL, ↑BP, ↑fasting glucose</td>
</tr>
<tr>
<td>2004</td>
<td>American Heart Association/National Heart, Blood and Lung Institute (AHA/NHBLI)</td>
<td>Any three or more risk factors</td>
<td>Abdominal obesity (WC), ↑triglycerides, ↓HDL, ↑BP, ↑fasting glucose</td>
</tr>
<tr>
<td>2005</td>
<td>International Diabetes Federation (IDF)</td>
<td>Ethnic-specific abdominal obesity (WC) PLUS two other risk factors</td>
<td>↑triglycerides, ↓HDL, ↑BP, ↑fasting glucose</td>
</tr>
<tr>
<td>2009</td>
<td>AHA/NHBLI and IDF joint statement</td>
<td>Any three or more risk factors</td>
<td>Ethnic-specific abdominal obesity (WC), ↑triglycerides, ↓HDL, ↑BP, ↑fasting glucose</td>
</tr>
</tbody>
</table>
Although obesity and insulin resistance remain at the centre of the pathophysiology of the metabolic syndrome, a number of potential mechanistic factors are involved in its pathogenesis. Figure 2.2 presents a flowchart of the interaction of a complex multi-pathway relationship involving behavioural, genetic, and environmental interactions, which may ultimately lead to CVD. Specifically, chronic stress and dysregulation of the hypothalamic-pituitary-adrenal axis and autonomic nervous system, increases in cellular oxidative stress, renin-angiotensin-aldosterone system activity, and intrinsic tissue gluco-corticoid actions each play a part in the pathophysiology of the metabolic syndrome (Kassi et al., 2011). Other conditions such as dysfunction in uric acid metabolism, haemodynamic irregularity, an increased pro-inflammatory state, and hyperinsulinaemia are also associated with the development of the metabolic syndrome (G. Reaven, 2001).

![Figure 2.2](image.png)

*Figure 2.2. Schematic representation of the conditions implicated in the pathophysiology of the metabolic syndrome and their potential interactions. Abbreviations: HPA axis, hypothalamic-pituitary-adrenal axis; T2DM, type 2 diabetes mellitus; CRH, corticotrophin releasing hormone; AVP, arginine vasopressin (Image modified from: Kassi et al. (2011), p.5)*
2.2.3. Insulin resistance

In obese individuals, adipose tissue releases increased concentrations of many biomolecules, including non-esterified fatty acids, glycerol, hormones, and pro-inflammatory cytokines, that are involved in the development of insulin resistance (Kahn et al., 2006). Insulin resistance is recognised as an early metabolic abnormality that precedes the development of T2DM and contributes to increased incidences of CVD (Carroll & Dudfield, 2004); (Mitrakou, 2006). Impaired insulin action occurs when target tissues are unable to respond to normal circulating concentrations of insulin. As a compensatory response, pancreatic β-cells secrete increased amounts of insulin. Initially, this increased insulin secretion and hyperinsulinemia are adequate to preserve glucose homeostasis. However, when homeostasis is chronically disrupted, insulin resistance progressively occurs. Insulin resistance is defined as a defect in the ability of insulin to drive glucose into tissue (Hawley & Zierath, 2008). As a consequence, T2DM evolves due to the gradual development of insulin resistance and deterioration of the body’s ability to transport glucose from the blood across muscle, liver or other tissue cells. This dysfunction is typically followed by a decline in pancreatic β-cell function, resulting in the inability to secrete insulin in response to changes in blood glucose concentrations, and ultimately, a failure to produce insulin (Hawley & Zierath, 2008). In addition, inflammatory mediators, other adipokines, and proteins related to coagulation affecting glucose and fat metabolism (e.g. PAI-1) also contribute to the development of hepatic insulin resistance, and the progression of CVD (Mitrakou, 2006; Steinbaum, 2004).

Even mild impairments in insulin release may have important effects on metabolic homeostasis (Kahn et al., 2006). Thus, the assessment of insulin sensitivity is a valuable clinical tool (Bonora et al., 2000). Homeostatic model assessment of insulin resistance (HOMA-IR) is a method of assessing β-cell function and insulin resistance from fasting (basal) glucose and insulin concentrations. This technique, first described in 1985 (Matthews et al., 1985), uses a mathematical assessment of the interaction between β-cell function and insulin resistance. The relationship between glucose and insulin in the basal state reflects the balance between hepatic glucose output and insulin secretion. Consequently, a high HOMA-IR score denotes insulin resistance (Wallace, Levy, & Matthews, 2004).
2.2.4. Vascular dysfunction

Atherosclerosis is considered a chronic, inflammatory disease of the vascular system, and a degenerative process that starts in childhood and progresses throughout the lifetime (Epstein & Ross, 1999). Atherosclerosis arises when an artery wall thickens or hardens as a result of fatty substance and cholesterol deposit accumulation, commonly referred to as plaque. Obesity and the associated elevated blood lipids, such as triglycerides and high plasma concentrations of low-density lipoprotein (LDL) cholesterol, are considered principle risk factors for atherosclerosis (American Heart Association [AHA], 2014). Imaging of arteries to identify and quantify the presence of vascular disease has been suggested to refine CVD risk assessment (Stein et al., 2008). Non-invasive assessment of carotid intima-media thickness (c-IMT) is an established and validated surrogate assessment used to gauge the progression and regression of atherosclerosis (Hodis et al., 1998). Measured by ultrasound, c-IMT provides a quantitative evaluation of the morphological changes in the carotid artery. Findings from the Genetic Epidemiology of Metabolic Syndrome (GEMS) Study showed an increased cross-sectional c-IMT was associated with unfavourable levels of established CVD risk factors and atherosclerosis in middle-aged overweight/obese adults (Genoud et al., 2008). Furthermore, increases in the IMT of the common carotid artery and the number of atherosclerotic plaques were significantly greater in participants with an elevated lipid profile than in normolipidemic individuals (Genoud et al., 2008).

Arterial endothelial dysfunction precedes the development of atherosclerosis and is believed to play a central role in its pathophysiology (Juonala et al., 2004; Raitakari & Celermajer, 2000). The endothelium is the monolayer of endothelial cells covering the inner surface of blood vessels and plays a vital role in the regulation of vascular tone and structure, as well as vascular inflammation and thrombosis (Giannotti & Landmesser, 2007). Furthermore, the higher incidences of CVD events in obese populations are proposed to be related to endothelial dysfunction, along with low-grade systemic inflammation and insulin resistance (Bastien et al., 2014). Figure 2.3 describes potential mechanisms for the association of obesity, insulin resistance and endothelial dysfunction. Obesity, particularly abdominal obesity, leads to an imbalance in the production of several metabolic products including hormones (e.g. leptin, resistin) and cytokines (adipokines), which precede the development of insulin resistance and endothelial dysfunction (A. E. Caballero, 2003).
Figure 2.3. Mechanisms through which obesity, insulin resistance, and endothelial dysfunction are closely associated (Sourced from: Caballero (2003), p. 1284). Abbreviations: FFA, free fatty acids; TNF-α, tumor necrosis factor alpha; IL, interleukin; PAI, plasminogen activator inhibitor; CRP, c-reactive protein; coag/fib, coagulation/fibrinogen.

It has been suggested that systemic endothelial dysfunction may modify the association between atherosclerosis and its risk factors. Therefore, the non-invasive ultrasonographic assessment of endothelial function in the peripheral vascular system has been used as a risk marker for CVD (Sibal, Agarwal, & Home, 2011). Briefly, this technique involves assessing the response of the endothelium, usually of the brachial artery, to post-occlusive (transient occlusion of the forearm) reactive hyperaemia, known as flow-mediated dilation (FMD) (Raitakari & Celermajer, 2000). In the Cardiovascular Risk in Young Finns Study, c-IMT together with brachial artery FMD were measured in healthy young adults (n = 2,109; age 24-39 years), with participants grouped into ‘impaired’ or ‘normal’ FMD response. The number of CVD risk factors associated with increased cross-sectional c-IMT was highest in participants with evidence of endothelial dysfunction, but not in participants with preserved endothelial function (Juonala et al., 2004). This suggests a crucial link between c-IMT and endothelial dysfunction (Sibal et al., 2011).
2.2.5. Physical inactivity

Physical inactivity is the fourth highest risk factor for reducing Australian productivity, with the cost of physical inactivity to the Australian economy estimated at $13.8 billion per year (Keegan, Keegan, Daley, Ordway, & Edwards, 2013). Furthermore, physical inactivity is associated with an increase in ill-health and death, particularly relating to CVD. When assessed against the National Physical Activity Guidelines, the majority of adult Australians are insufficiently active, with 54% performing less than the national recommendations (< 150 minutes of activity per week) for health-related benefits (Australian Bureau of Statistics, 2013).

The current national guidelines for Australian adults recommend 300 minutes of accumulated moderate exercise, plus muscle strengthening activities on at least two days, each week (Australian Bureau of Statistics, 2013). However, only 20% of females aged 18-44 years participated in levels of physical activity recommended by these national guidelines (Australian Bureau of Statistics, 2013) (Figure 1.6). Moreover, results from the Australian Longitudinal Study on Women’s Health showed that the population predicted risk of heart disease was possibly highest from physical inactivity (Figure 2.4), outweighing that of other risk factors including obesity (BMI ≥ 25 kg/m²), from age 30 (Brown, Pavey, & Bauman, 2014). Smoking is also noted as an immense risk factor for heart disease in young women, especially between the ages of 22 to 30 years.
Despite the clear benefits of exercise, fewer women engage in recommended levels of physical activity than men (Moreno & Johnston, 2014). Researchers have identified gender differences in initiation and maintenance of regular physical activity (Speck & Harrell, 2003), with women experiencing multiple barriers to physical activity that significantly reduce the likelihood of engaging in physical activity long-term. These barriers are different from the experiences of men (Yeats, 2010), with women citing perceived lack of time, caring-giving demands, and self-consciousness about body size as reasons for not being physically active (Moreno & Johnston, 2014).

### 2.3. Cardiac Dysfunction

Overweight and obesity are an independent risk factor for cardiac dysfunction (Bastien et al., 2014; Wong et al., 2004). In a recent cross-sectional study of older adults, abdominal obesity and other cumulative metabolic risk factors (e.g. inflammation and glucose intolerance) were associated with impaired systolic and diastolic function (Crendal et al., 2013).
2.3.1. Cardiac morphology and function

Excess adipose tissue causes an increase in blood flow and, consequently, blood volume expands to compensate for the increased oxygen demand (Pascual et al., 2003). The subsequent expansion of blood volume results in dilation of the left ventricle (LV) and is accompanied by an eccentric hypertrophy of the myocardium, even in normotensive individuals (Di Bello et al., 2013). Furthermore, both eccentric and concentric patterns of LV hypertrophy have been described in overweight/obese adults (Wong et al., 2005). Additionally, changes in cardiac morphology and function associated with obesity are not isolated to adult populations, with the impact of overweight/obesity on myocardial dysfunction also noted in young adults (Peterson, Waggoner, et al., 2004) and youth (Obert et al., 2012).

Over time, excessive accumulation of body fat causes adaptations of the heart. Specifically, cardiac changes associated with overweight/obesity included atrial remodelling, increased cardiac output (due to augmentation in circulating blood flow), reduced peripheral resistance, LV hypertrophy, ventricular remodelling (e.g. increased LV wall thickness, increased LV mass), increased LV filling pressure, diastolic dysfunction and, eventually, impairment in systolic function (Pascual et al., 2003).

2.3.2. Myocardial characteristics and mechanics

The architectural layout of the heart muscle plays a critical role in the mechanical and electrical function of the ventricles (Sengupta et al., 2006). The myocardium is described as a transmural continuum of two helical fibre organisations, made up of a right-handed helical formation in the inferior aspect of the myocardium (sub-endocardium) which gradually rotates into a left-handed helical formation in the superior aspect of the myocardium (sub-epicardium) (Figure 2.5). Due largely to the architectural characteristics of fibres arranged in two helical orientations, contraction of these fibres causes a twisting or “wringing” motion of the LV around its longitudinal axis (Sengupta et al., 2006).
Figure 2.5. Schematic representation of the fibre orientation and mechanics of the LV. (A) LV fibre orientation changes from a right-handed helix in the sub-endocardium to a left-handed helix in the sub-epicardium at base and apex of the heart. (B) Isovolumetric contraction: endocardial fibres (blue dashed line) wrapped in a right-handed helix. (C) Ejection: epicardial fibres (red solid line) wrapped in an opposite, left-handed helix (Image modified from: Ashikaga, van der Spoel, Coppola, and Omens, 2009, p. 209).

During a cardiac cycle, the LV wall shortens, thickens, and then twists along its long axis. Viewed from the apex, a clockwise rotation of the base, and a counter-clockwise rotation of the apex is evident (Figure 2.6). An understanding of the heart’s function and mechanical intricacies are important for assessing risk and pathophysiology of CVD (Sengupta et al., 2007).
Figure 2.6. Mechanics of LV untwisting/twisting during isovolumetric contraction and ejection, respectively. Circumferential components of force (arrows) are generated by myocardial fibres shortening in opposite directions, causing a resultant “wringing” action. Endocardial fibres rotate clockwise (untwisting, blue arrow) while epicardial fibres rotate counter-clockwise (twisting, red arrow), as viewed from the apex (Image modified from: Ashikaga, van der Spoel, Coppola, and Omens, 2009, p. 209).

2.3.3. Cardiac assessment

The non-invasive imaging technique known as transthoracic echocardiography is used to quantify structural and functional changes of the heart. Echocardiography permits the evaluation of heart morphology, blood dynamics (global function) and, more recently, myocardial mechanics (regional function), with relatively new techniques shown to support conventional ones (Di Bello et al., 2013). Conventional two-dimensional (2D) echocardiography is used in the assessment of adverse arterial and ventricular remodelling via morphological and functional indices (measured with grey-scale M-Mode imaging), and of blood flow impairments (measured with pulsed Doppler). Furthermore, tissue Doppler imaging (TDI) echocardiography is used in the evaluation of global longitudinal tissue motion, specifically enabling measurement of systolic ($S_m$), early-diastolic ($E_m$), and late-diastolic ($A_m$) myocardial velocities. However, the assessment of myocardial tissue from TDI is limited by several factors including: (i) its inability to differentiate actively contracting myocardium from passive myocardial motion; (ii) measurements being susceptible to ‘tethering’ of neighbouring segments; and (iii) its insonation angle dependence (Anderson, 2007; Leitman et al., 2004). The introduction of 2D speckle tracking echocardiography (STE) in 2004 has overcome these limitations. STE is insonation angle-independent and considered
to be a more sensitive analysis of myocardial function (Leitman et al., 2004). Furthermore, the advantage of STE, compared with conventional echocardiographic and TDI techniques, is in the relative independence from load conditions and, in particular, from heart rotation and translational motion (Di Bello et al., 2013). Additionally, STE may permit earlier diagnosis of systolic and diastolic dysfunction, even when conventional indices of LV function remain within normal range (Obert et al., 2012). STE has shown excellent agreement with gold standard heart-imaging techniques such as Sonomicrometry (Amundsen et al., 2006) and tagged Magnetic-resonance imaging (Helle-Valle et al., 2005). However, STE is not without its limitations and may be influences by loading parameters within the human heart (Burns, La Gerche, D’hooge, MacIsaac, & Prior, 2010).

STE permits the measurement of myocardial velocities and assessment of myocardial contraction and relaxation, known as deformation. STE works by tracking the movement of natural acoustic markers, known as “speckles”, throughout the cardiac cycle in ultrasound on 2D grey scale images (Leitman et al., 2004). Deformation is typically referred to as strain, and its rate of deformation as strain rate (SR). Deformation occurs in three planes; circumferential, longitudinal, and radial (Figure 2.7). In addition to indices of deformation, STE permits the quantification of myocardial mechanics, including the magnitude, timing, and dynamics of regional LV rotation and twist/untwist.

**Figure 2.7.** During a cardiac cycle, the LV wall shortens, lengthens, and twists along its long axis. This myocardial deformation can be measured using STE in the radial, circumferential and longitudinal planes (Image sourced from: [http://123sonography.com/node/855](http://123sonography.com/node/855)).
The development of STE provides the potential for earlier detection of diastolic and systolic dysfunction and, consequently, earlier identification of subclinical diseases (Geyer et al., 2010). This makes it a popular tool for assessing myocardial dysfunction in populations with subclinical risk factors for CVD, particularly in those who are overweight or obese but who are not yet diagnosed with CVD (Edvardsen, Helle-Valle, & Smiseth, 2006).

2.4. CVD Risk in Premenopausal Women

The risk of CVD increases after menopause, with several CVD risk factors such as abdominal obesity, the metabolic syndrome, insulin resistance, hypertension, and dyslipidemia prevalent in post-menopausal women (Ardern & Janssen, 2007; Paul & Smith, 2005). This has been linked in part to the lower circulating concentrations of estrogen and progesterone after menopause. For example, estrogen exerts positive regulatory effects on the vascular endothelium (Cid, Schnaper, & Kleinman, 2002). Nevertheless, premenopausal women also incur increases in CVD risk. For example, in a sample of US women of “child bearing age” (n = 2,027, 18-44 years), 24% of non-Hispanic white women were obese (BMI ≥ 30 kg/m²), 42% had abdominal obesity (WC ≥ 88 cm), 25% had the metabolic syndrome, and 37% demonstrated clinical evidence of a pro-inflammatory state as defined by elevated serum hsCRP (i.e. > 3.0 mg/L) (Ramos & Olden, 2008). The pattern of prevalence was the same for Blacks and Hispanics, although the prevalence of each risk factor was higher in these racial/ethnic groups compared with non-Hispanic white women (Ramos & Olden, 2008). Similarly, the Madrid Riesgo Cardiovascular Study assessed the prevalence of CVD risk factors in a cross-section of premenopausal women aged 31-40 years (n=141). The frequency of abdominal obesity was 54% and 24% for an elevated waist circumference ≥ 80 cm and ≥ 88 cm, respectively, with the metabolic syndrome prevalent in 6% of Spanish women using both the IDF and NCEP:ATP III definitions (Martinez et al., 2008). Similarly, the prevalence of the metabolic syndrome (according to the IDF definition) was reported to be 6% in Australian women aged 25-34 years and 15% in women aged 35-44 years (Cameron et al., 2007). There is also evidence that obesity in young women is associated with concentric LV remodelling and decreased systolic and diastolic function (Peterson, Waggoner, et al., 2004).
These early abnormalities in cardiac morphology and function have implications for future myocardial dysfunction associated with increased cardiovascular morbidity and mortality.

2.5. Prevention of CVD Risk

Despite research-based gains in the treatment of CVD, it remains the leading cause of death in women in most developed areas of the world (World Heart Federation, 2013). Overweight and obesity are major preventable and modifiable risk factors for the disease. To achieve long-term weight loss and maintenance requires a lifelong commitment to behavioural change (Wing, 2002). Therefore, early detection and prevention of CVD risk factors through innovative lifestyle interventions may be the best public health approach in chronic disease management. For example, the Chicago Heart Association Detection Study assessed young women (n = 7302, baseline age = 18 to 39 y) for CVD risk, including overweight/obesity, T2DM, hypertension, elevated serum cholesterol and smoking. Those who possessed greater numbers of risk factors at baseline also experienced a 6-fold increase in CVD mortality risk at 31-year follow-up, compared to women with no risk factors at baseline (Daviglus et al., 2004). Similarly, the Health Hunters study implemented an obesity prevention program targeting young women considered ‘high-risk’ (n = 30, aged 18-28 y), in that they had at least one severely obese parent (BMI ≥ 37 kg/m^2). In the 12-month program, participants received customised dietary and physical activity advice, while the control group received standard care (Eiben & Lissner, 2006). At program completion, intervention participants had reduced their weight (group mean: -1.9 kg), while control participants experienced weight gain (+1.4 kg).

Non-pharmacological lifestyle management and behaviour modification have a ‘first line of treatment’ role in the prevention of CVD risk (Steinbaum, 2004). It has been suggested that the primary treatment of overweight/obesity, through lifestyle interventions, should focus on weight management/reduction, increased physical activity, and a heart-healthy diet, to reduce intermediate risk factors and prevent their progression to CVD (Paul & Smith, 2005). Furthermore, prevention of the development of risk factors through a positive lifestyle approach (lifestyle intervention) may minimise the future need for intensive or alternative treatment, such as drug therapy or surgery (Mosca et al., 2004). Yet for people with whom lifestyle change has had limited success and are considered ‘high risk’ for CVD, appropriate
pharmacological agents or surgical intervention (Sjöström et al., 2007) may be required (International Diabetes Federation, 2006). Nevertheless, lifestyle modification will continue to be the cornerstone of CVD treatment, irrespective of the availability of new pharmacological therapies (Bantle et al., 2008).

2.5.1. Lifestyle intervention research trends

The majority of research investigating the effects of lifestyle intervention on CVD risk has been conducted in middle-aged and older adults (Dutheil et al., 2013; Kosmala, O’Moore-Sullivan, Plaksej, Przewlocka-Kosmala, & Marwick, 2009; Watkins et al., 2003) or adolescent populations (Obert et al., 2013; Tjonna et al., 2009). Meanwhile, the majority of studies focusing solely on female participants have assessed post-menopausal women (Kuller et al., 2006). This highlights the paucity of CVD-related research addressing the effects of lifestyle interventions on, premenopausal women, with only limited studies available (Cotie, Josse, Phillips, & MacDonald, 2014; Esposito et al., 2003; Thomson et al., 2008). Weight loss programs that use a multi-disciplinary or multi-component (e.g. exercise + diet + behavioural therapy) lifestyle intervention approach have been mostly proven effective for reducing risk factors for CVD. Markers of body composition, insulin resistance, lipid profile and/or systemic inflammation have been reduced with multi-disciplinary lifestyle interventions ranging in duration from 12 weeks to 4.5 years (Esposito et al., 2003; Kuller et al., 2006; Kuller, Simkin-Silverman, Wing, Meilahn, & Ives, 2001; Tjonna et al., 2009; Watkins et al., 2003). Furthermore, multi-disciplinary lifestyle interventions have a positive effect on endothelial function, LV function, myocardial mechanics, and atherosclerosis in programs lasting from 16 weeks to 9 months, albeit in older or youth populations (Cotie et al., 2014; Dutheil et al., 2013; Kosmala et al., 2009; Obert et al., 2013). Moreover, in light of some recent large, longitudinal intervention trials in middle-aged and older adults (Ross et al., 2012; The Look AHEAD Research Group, 2013), it is apparent that multi-disciplinary lifestyle interventions have a strong evidence base for success in reducing CVD risk in a variety of populations. However, lifestyle interventions specifically targeting treatment or management in young women are limited in number and quality and, thus, the needs of this age group are currently unmet (Hutchesson, Hulst, & Collins, 2013).
Chapter 3. The effectiveness of randomised controlled trial lifestyle interventions on cardiovascular disease risk factors in premenopausal women with overweight and obesity: A systematic review

Bianca L. Share; Geraldine A. Naughton; Justin G. Kemp

Publication Statement:
This work has been prepared for submission to the International Journal of Behavioral Nutrition and Physical Activity, please see Appendix 1.

Acknowledgements:
The authors are grateful to Ms Kathryn Duncan for her assistance with the literature search.
3.1. Abstract

**Background and objectives:** Cardiovascular disease (CVD) is the leading cause of death in women worldwide, with overweight and/or obesity a principle risk factor. To address overweight and obesity and reduce CVD, lifestyle modification is recommended. Therefore, the aim of this paper was to systematically review the effectiveness of multi-disciplinary lifestyle interventions on CVD risk factors in overweight/obese premenopausal women.

**Data sources and study selection:** A systematic search was conducted to capture all randomised controlled trials assessing the effect of a lifestyle intervention on CVD risk factors in overweight/obese premenopausal women published from 2004 to 2014. Included studies required the lifestyle intervention to have at least two of the following three components (1) exercise, (2) diet, and/or (3) behavioural therapy. Studies were excluded if the lifestyle intervention was less than eight weeks in duration. Three electronic databases were searched (MEDLINE, CINAHL, and EMBASE) during March 2014, and additional studies were included following manual search of eligible studies and recent reviews.

**Results:** Five studies met the inclusion criteria. Length of the lifestyle interventions ranged from 10 to 104 weeks, with three studies performing follow-up. All five studies had an exercise component. Specifically, the lifestyle interventions consisted of: (1) exercise + diet + behavioural therapy (n=3), (2) exercise + diet (n=1), and (3) exercise + behavioural therapy (n=1). Independent of the components of the lifestyle intervention, all studies observed changes in some CVD risk factors, with improvements in body composition the most reported, while albeit few in number, blood-borne markers of CVD risk remained unchanged.
Conclusion: Multi-disciplinary lifestyle interventions are modestly effective in reducing CVD risk factors in overweight/obese premenopausal women, with no specific type of lifestyle intervention prevailing as demonstrating greater success than others. There remains a need for more rigorous studies, with long-term follow-up evaluating program sustainability.

Keywords: Overweight, exercise, physical activity, female, nutrition, diet, behavioural therapy, metabolic syndrome, weight loss
3.2. Introduction

In the USA, United Kingdom and Australia, 45-50% of women aged 20-39 years are overweight or obese (Australian Bureau of Statistics, 2013; Flegal et al., 2012; Health and Social Care Information Centre, 2011). Clinical and community studies have demonstrated a relationship between overweight and/or obesity and increased cardiovascular disease (CVD) risk factors in young women (Peterson, Waggoner, et al., 2004; Sokmen et al., 2013). Most modifiable CVD risk factors, including being overweight or obese can be improved through lifestyle interventions (Irving et al., 2008; Kemmler, Von Stengel, Engelke, & Kalender, 2009). With CVD being the leading cause of death in women worldwide (World Health Organisation, 2011), early intervention of CVD risk may lead to more effective attenuation of disease progression.

The therapeutic role of lifestyle interventions in the prevention, treatment and/or, control of CVD risk has been effective in adolescents (Obert et al., 2013), middle-aged women (Meckling & Sherfey, 2007) and older adults (Ross et al., 2012; The Look AHEAD Research Group, 2013). Furthermore, the management of overweight and/or obesity using lifestyle interventions in adults (aged 19 – 74 y) have been reviewed for their effects on long-term weight-loss and maintenance. It was concluded that the most effective lifestyle interventions were those combining diet, exercise and behavioural modification (A. Lang & Froelicher, 2006). More recently, (Aguiar, Morgan, Collins, Plotnikoff, & Callister, 2014) reviewed the effects of multi-component lifestyle interventions involving diet, aerobic exercise and resistance training on body composition and fasting glucose in pre-diabetic middle-aged/older adults (54 ± 7 y). The results showed lifestyle interventions were effective for inducing modest weight loss and eliciting small improvements in glycemic control, together with improvements in aerobic fitness and dietary intake. Despite global strategies for preventive health, research assessing the effectiveness of lifestyle interventions specifically targeting overweight and/or obese premenopausal women is currently limited (Hutchesson; Hulst & Collins, 2013), with longer-term sustainability of multi-component lifestyle interventions unclear.

Therefore, the aim of this work was to systematically review the effects of randomised controlled trial, multi-disciplinary lifestyle interventions that included at least two of
exercise, diet and/or behavioural therapy components in overweight/obese premenopausal women. Specifically, this review assessed the effects of these interventions on CVD (metabolic, cardiac and vascular) risk factors, including anthropometric measures, markers of the metabolic syndrome, blood biochemistry, fitness, nutrition and psychological outcomes.

3.3. Methods

The Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (Moher, Liberati, Tetzlaff, & Altman, 2009) guided the conduct and reporting of this review.

3.3.1. Data sources and searches

A systematic review was performed on the literature published between 2004 and February 2014. The search strategy consisted of three online databases: Medline, EMBASE, and CINAHL. The general search strategy is shown in tables 3.1, 3.2 and 3.3.
Table 3.1. Title, abstract and key words used across all database searches (Medline, CINAHL, EMBASE) in the electronic search strategy.

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention components</th>
<th>Study type</th>
<th>Risk factors</th>
<th>“NOT”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>PART A.</td>
<td>Randomized control*</td>
<td>METABOLIC</td>
<td>Pregnan*</td>
</tr>
<tr>
<td>Female</td>
<td>Exercise</td>
<td>trial</td>
<td>Cardiovascular disease</td>
<td>Breast feed*</td>
</tr>
<tr>
<td></td>
<td>Exercise therapy</td>
<td>Randomised control*</td>
<td>Metabolic syndrome</td>
<td>Postpartum</td>
</tr>
<tr>
<td></td>
<td>Resistance train*</td>
<td>trial</td>
<td>Cardiometabolic</td>
<td>Polycystic ovar*</td>
</tr>
<tr>
<td></td>
<td>Weight train*</td>
<td>Controlled clinical trial</td>
<td>Abdominal obesity</td>
<td>syndrome</td>
</tr>
<tr>
<td></td>
<td>Fitness</td>
<td>Clinical trial</td>
<td>Waist circumference</td>
<td>Post menopaus*</td>
</tr>
<tr>
<td></td>
<td>Aerobic</td>
<td></td>
<td>Obes*</td>
<td>Elderly</td>
</tr>
<tr>
<td></td>
<td>Physical activity</td>
<td></td>
<td>Sedentary</td>
<td>Older</td>
</tr>
<tr>
<td>PART B.</td>
<td>Diet</td>
<td></td>
<td>CARIOVASCULAR</td>
<td>Middle age*</td>
</tr>
<tr>
<td></td>
<td>Diet therapy</td>
<td></td>
<td>Myocardial dysfunction</td>
<td>Child*</td>
</tr>
<tr>
<td></td>
<td>Nutrition</td>
<td></td>
<td>Myocardial function</td>
<td>Adolescen*</td>
</tr>
<tr>
<td></td>
<td>Nutrition therapy</td>
<td></td>
<td>Global strain</td>
<td>Youth</td>
</tr>
<tr>
<td>PART C.</td>
<td>Lifestyle</td>
<td></td>
<td>Carotid intima-media</td>
<td>Juvenile</td>
</tr>
<tr>
<td></td>
<td>Life style</td>
<td></td>
<td>thickness</td>
<td>HIV</td>
</tr>
<tr>
<td></td>
<td>Counsel*</td>
<td></td>
<td>Echocardiogra*</td>
<td>Bariatric surgery</td>
</tr>
<tr>
<td></td>
<td>Cognitive therapy</td>
<td></td>
<td>Speckle tracking imaging</td>
<td>Supplement*</td>
</tr>
<tr>
<td></td>
<td>Cognitive behaviour*</td>
<td></td>
<td>echocardiography</td>
<td>Drug*</td>
</tr>
<tr>
<td></td>
<td>therapy</td>
<td></td>
<td>Tissue Doppler imaging</td>
<td>Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Motivational interviewing</td>
<td></td>
<td>Left ventric*</td>
<td>Cancer</td>
</tr>
</tbody>
</table>

Table 3.2. MeSH (2014) terms specific to Medline used in the electronic search strategy.

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention components</th>
<th>Publication type</th>
<th>Risk factors</th>
<th>“NOT”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women Female</td>
<td>Exercise</td>
<td>Randomized controlled trial</td>
<td>METABOLIC</td>
<td>Pregnant women</td>
</tr>
<tr>
<td></td>
<td>Exercise therapy</td>
<td>Clinical trial</td>
<td>Cardiovascular diseases</td>
<td>Breast feeding</td>
</tr>
<tr>
<td></td>
<td>Resistance training</td>
<td></td>
<td>Metabolic syndrome X</td>
<td>Postpartum period</td>
</tr>
<tr>
<td></td>
<td>Physical fitness</td>
<td></td>
<td>Obesity</td>
<td>Polycystic ovary syndrome</td>
</tr>
<tr>
<td>PART A.</td>
<td></td>
<td></td>
<td>Waist circumference</td>
<td>Postmenopause</td>
</tr>
<tr>
<td>PART B.</td>
<td>Diet</td>
<td></td>
<td>Abdominal fat</td>
<td>Middle aged</td>
</tr>
<tr>
<td></td>
<td>Diet, Reducing</td>
<td></td>
<td>Abdominal obesity</td>
<td>Aged</td>
</tr>
<tr>
<td></td>
<td>Diet therapy</td>
<td></td>
<td>Sedentary lifestyle</td>
<td>Child</td>
</tr>
<tr>
<td></td>
<td>Nutrition therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PART C.</td>
<td>Cognitive therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Life style</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Counselling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Motivational interviewing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3.3. Subject headings specific to CINAHL used in the electronic search strategy.

<table>
<thead>
<tr>
<th>Population</th>
<th>Intervention components</th>
<th>Publication type</th>
<th>Risk factors</th>
<th>“NOT”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>PART A.</td>
<td>Randomized controlled trial</td>
<td>METABOLIC</td>
<td>Expectant mothers</td>
</tr>
<tr>
<td>Female</td>
<td>Exercise</td>
<td>Clinical trials</td>
<td>Cardiovascular risk factors</td>
<td>Breast feeding</td>
</tr>
<tr>
<td></td>
<td>Resistance training</td>
<td></td>
<td>Metabolic syndrome X</td>
<td>Postnatal period</td>
</tr>
<tr>
<td></td>
<td>Group exercise</td>
<td></td>
<td>Obesity</td>
<td>Polycystic ovary syndrome</td>
</tr>
<tr>
<td></td>
<td>Physical fitness</td>
<td></td>
<td>Waist circumference</td>
<td>Middle aged</td>
</tr>
<tr>
<td></td>
<td>Physical activity</td>
<td></td>
<td>Abdominal fat</td>
<td>Aged</td>
</tr>
<tr>
<td></td>
<td>PART B.</td>
<td></td>
<td>Life style, sedentary</td>
<td>Child</td>
</tr>
<tr>
<td></td>
<td>Diet</td>
<td></td>
<td></td>
<td>CARDIOVASCULAR</td>
</tr>
<tr>
<td></td>
<td>Diet, reducing</td>
<td></td>
<td>Left ventricular hypertrophy</td>
<td>Adolescence</td>
</tr>
<tr>
<td></td>
<td>Diet therapy</td>
<td></td>
<td>Ventricular remodelling</td>
<td>HIV</td>
</tr>
<tr>
<td></td>
<td>Nutrition</td>
<td></td>
<td>Left ventricular function</td>
<td>Bariatric surgery</td>
</tr>
<tr>
<td></td>
<td>PART C.</td>
<td></td>
<td>Carotid intima-media thickness</td>
<td>Drug therapy</td>
</tr>
<tr>
<td></td>
<td>Cognitive therapy</td>
<td></td>
<td>Echocardiography</td>
<td>Pharmacological and biological treatments</td>
</tr>
<tr>
<td></td>
<td>Life style changes</td>
<td></td>
<td>Echocardiography, Doppler</td>
<td>Dietary supplementation</td>
</tr>
<tr>
<td></td>
<td>Counselling</td>
<td></td>
<td>Echocardiography, Doppler, Pulsed</td>
<td>Rehabilitation</td>
</tr>
<tr>
<td></td>
<td>Motivational interviewing</td>
<td></td>
<td>Heart left ventricle</td>
<td>Cancer</td>
</tr>
</tbody>
</table>

Individual databases were searched with specific MeSH terms (Medline), subject headings (CINAHL) and/or title, abstract, and keywords (Medline, CINAHL, EMBASE). Select terms were excluded by using the Boolean operator “NOT”. Results were limited to ‘English language’ and publication type ‘journal article’. Age was also limited to 19-44 years for Medline and CINAHL, and 18-64 years for EMBASE.

Although medication and the surgical treatment of obesity are important and critical for certain circumstances, this review regarding overweight and/or obesity emphasised non-pharmacological behavioural lifestyle interventions. Thus, all studies incorporating a medical or surgical intervention were excluded.
3.3.2. Study selection

Intervention studies investigating CVD risk factors in overweight/obese pre-menopausal women were included. The search strategy included the use of terms in four broad categories. Each category was individually searched with ‘OR’, then combined with ‘AND’ to form the overarching search strategy, including:

(i) Population: only female data were included in the review. If studies incorporated both female and male participants, data were only included if the female data were presented separately. Women had to be overweight and/or obese, pre-menopausal, free from polycystic ovarian syndrome, and not pregnant or lactating. Studies were excluded if the mean age of the sample was > 40 years. Studies including women with a history of bariatric surgery were also excluded.

(ii) Intervention components: the lifestyle intervention was required to have at least two of the following three components (or derivations of these terms): (A) exercise, (B) diet, (C) behavioural therapy (Tables 3.1-3.3). For the purpose of this review, exercise was referred to as aerobic and/or resistance training. Diet was referred to as a restriction of calories or nutrition education but excluded drug trials or supplementation. The behavioural therapy component was referred to as counselling or motivational interviewing, either as a group or provided on an individual basis. A minimum duration of 8 weeks was required for the lifestyle intervention.

(iii) Study type: The search was limited to randomised controlled trials (RCT).

(iv) Risk factors: The search was limited to key risk factors with the known potential to increase the development of CVD, such as overweight and/or obesity, the metabolic syndrome, and sedentary behaviour (referred to as metabolic in Tables 3.1-3.3). Ultrasound techniques used in the detection of cardiac and vascular dysfunction, including echocardiography, intima-media thickness and Doppler, were also searched (referred to as cardiovascular in Tables 3.1-3.3).

One author (BS) conducted all electronic searches and collated the abstracts. After duplicate deletion, two authors (BS and GN) screened all articles based on title and abstract for preliminary inclusion, using the eligibility criteria below. If the abstract did not provide a clear indication of eligibility, the full text was obtained and reviewed. After screening titles
and abstracts, full text was retrieved for all potentially relevant articles and assessed according to the selection criteria outlined below. Manual searches were also conducted from the reference lists of the retrieved included articles and recent reviews.

3.3.3. Data extraction and quality assessment

After duplicate deletion, characteristics and results of studies were extracted by one author (BS). A single study with multiple published articles was reported as one study. Quality assessment of all studies included in the review were categorised via the Physiotherapy Evidence Database (PEDro) scale (Table 3.4). The PEDro scale is an 11-item measure of the methodological quality of RCTs (Maher, Sherrington, Herbert, Moseley, & Elkins, 2003). Each item was scored with a ‘1’ for ‘yes’ or ‘0’ for ‘no’ (Table 3.5).

Table 3.4. The Physiotherapy Evidence Database (PEDro) scale items (Maher et al., 2003).

<table>
<thead>
<tr>
<th>Number</th>
<th>Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Eligibility criteria</td>
</tr>
<tr>
<td>2.</td>
<td>Random allocation</td>
</tr>
<tr>
<td>3.</td>
<td>Concealed allocation</td>
</tr>
<tr>
<td>4.</td>
<td>Baseline comparability</td>
</tr>
<tr>
<td>5.</td>
<td>Blind subjects</td>
</tr>
<tr>
<td>6.</td>
<td>Blind therapists</td>
</tr>
<tr>
<td>7.</td>
<td>Blind assessors</td>
</tr>
<tr>
<td>8.</td>
<td>Adequate follow-up</td>
</tr>
<tr>
<td>9.</td>
<td>Intention-to-treat analysis</td>
</tr>
<tr>
<td>10.</td>
<td>Between-group comparisons</td>
</tr>
<tr>
<td>11.</td>
<td>Point estimates and variability</td>
</tr>
</tbody>
</table>
Table 3.5. The Physiotherapy Evidence Database (PEDro) Scale (Maher et al., 2003).

<table>
<thead>
<tr>
<th>Reference</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>Score (%)</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carroll et al</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>7/9 (78)</td>
<td>High</td>
</tr>
<tr>
<td>Chang et al</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>6/9 (67)</td>
<td>High</td>
</tr>
<tr>
<td>Kerksick et al</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>5/9 (55)</td>
<td>High</td>
</tr>
<tr>
<td>Schmitz et al</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>7/9 (78)</td>
<td>High</td>
</tr>
<tr>
<td>Silva et al</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>NA</td>
<td>NA</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>7/9 (78)</td>
<td>High</td>
</tr>
<tr>
<td>Total</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>NA</td>
<td>NA</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>6.4 (71)</td>
<td>High</td>
</tr>
</tbody>
</table>

NA, not applicable.

3.3.4. Data analysis

The primary outcomes of the review were between-group differences in metabolic, cardiac and/or vascular risk factors for CVD following the multi-disciplinary lifestyle intervention. Vast differences were observed in the lifestyle interventions implemented in each study in this review. For example, differences were apparent in exercise mode, length and intensity, and use of nutrition education versus calorie restriction. Therefore a meta-analysis was not conducted. Furthermore, it has been noted previously that meta-analysis is deemed inappropriate for variables where results from fewer than three studies are (Aguiar et al., 2014); which was common in this review (Table 3.6).
Table 3.6. Cardiovascular disease (CVD) risk factors and psychological inventories reported across the studies used in the review.

<table>
<thead>
<tr>
<th>Variable</th>
<th># of studies</th>
<th>Reference/s</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>5</td>
<td>Silva, Schmitz, Kerksick, Carroll, Chang</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>4</td>
<td>Silva, Schmitz, Kerksick′, Carroll</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>4</td>
<td>Carroll′, Silva, Schmitz, Kerksick</td>
</tr>
<tr>
<td>Fat mass &amp; lean mass (kg)</td>
<td>3</td>
<td>Schmitz, Silva, Kerksick</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>2</td>
<td>Carroll*, Kerksick</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers/ blood biochemistry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>2</td>
<td>Carroll, Kerksick</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>2</td>
<td>Carroll, Kerksick</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>3</td>
<td>Carroll, Chang, Kerksick</td>
</tr>
<tr>
<td>Systolic &amp; diastolic blood pressure (mmHg)</td>
<td>2</td>
<td>Carroll, Kerksick</td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>2</td>
<td>Carroll′, Kerksick</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol·L⁻¹)</td>
<td>1</td>
<td>Kerkisk</td>
</tr>
<tr>
<td>Insulin (pmol·L⁻¹)/ HOMA-IR</td>
<td>1</td>
<td>Kerkisk</td>
</tr>
<tr>
<td><strong>Fitness markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VO₂ (ml·kg⁻¹·min⁻¹)</td>
<td>2</td>
<td>Carroll, Kerkisk</td>
</tr>
<tr>
<td>Physical activity§</td>
<td>3</td>
<td>Silva, Chang, Schmitz</td>
</tr>
<tr>
<td>Bench-press/ leg-press 1RM (kg)</td>
<td>2</td>
<td>Schmitz, Kerkisk</td>
</tr>
<tr>
<td><strong>Dietary outcomes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caloric intake§</td>
<td>2</td>
<td>Schmitz, Kerkisk</td>
</tr>
<tr>
<td>Fat intake§</td>
<td>2</td>
<td>Chang, Kerkisk</td>
</tr>
<tr>
<td>Carbohydrate &amp; protein intake (g·kg⁻¹·d⁻¹)</td>
<td>1</td>
<td>Kerkisk</td>
</tr>
<tr>
<td>Fruit &amp; vegetable intake (cups·d⁻¹)</td>
<td>1</td>
<td>Chang</td>
</tr>
<tr>
<td><strong>Psychological characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perceived Stress Scale (PSS)</td>
<td>2</td>
<td>Carroll, Chang</td>
</tr>
<tr>
<td>General Wellbeing (GWB)</td>
<td>1</td>
<td>Carroll</td>
</tr>
<tr>
<td>Positive Affect and Negative Affect Scale (PANAS)</td>
<td>1</td>
<td>Chang</td>
</tr>
<tr>
<td>Health Care Climate Questionnaire (HCCQ)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Treatment Self-regulation Questionnaire (TSRQ)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Self-determination Scale (SDS)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Locus of Causality for Exercise Scale (LCE)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Self-regulation Questionnaire (SRQ-E)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Intrinsic Motivation Inventory (IMI)</td>
<td>1</td>
<td>Silva</td>
</tr>
<tr>
<td>Exercise Motives Inventory-2 (EMI-2)</td>
<td>1</td>
<td>Silva</td>
</tr>
</tbody>
</table>

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; 1RM, one repetition max.

′baseline only; § presented as mins/d or MET; § presented as kcal/kg/day or kcal. † presented as % of total calories or g/kg/day.
3.4. Results

3.4.1. Study selection and study inclusion

Electronic searches returned 100, 200 and 87 results for Medline, CINAHL and EMBASE, respectively (Figure 3.1). From these electronic searches, duplicates were removed and 52 articles were identified as potentially relevant after an initial examination of titles and abstracts. After retrieval of full text, 44 articles were excluded due to the following: data were calculated as the average from male and female results (n = 23); the study design did not include a control group (n = 6); the intervention did not have at least two of the three intervention components (n = 4), the study design was not randomised (n = 4); participants were not classified as overweight/obese (n = 3); participants ingested a supplement as part of the diet component (n = 2); the lifestyle intervention was less than 8 weeks in duration (n=1); or the intervention was investigating an acute response (n = 1). In total, eight papers from the search met the inclusion criteria. Additional manual searches, including a search of reference lists of included articles and recent reviews, returned four additional results, with one meeting the inclusion criteria (Carroll, Borkoles, & Polman, 2007). From these nine papers, five intervention trials were identified (i.e. three cases of multiple papers stemming from a single research study) and these are described in Table 3.7.
Figure 3.1. Flow diagram of the process of study selection.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Population characteristics</th>
<th>Lifestyle intervention</th>
<th>Data collection</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authors (Year)</td>
<td>Mean age (y)</td>
<td>Age range (y)</td>
<td>Baseline sample size (int, control)</td>
<td>Post sample size (int, control) [total retention]</td>
</tr>
<tr>
<td>Carroll et al (2007)</td>
<td>40 ± 8</td>
<td>24-55</td>
<td>31 (17, 14)</td>
<td>20 (10, 10) [72%]</td>
</tr>
<tr>
<td>Carroll et al (2012)</td>
<td>38 ± 7</td>
<td>25-50</td>
<td>239 (123, 116)</td>
<td>208 (115, 93) [87%]</td>
</tr>
<tr>
<td>Chang et al (2010)</td>
<td>25 ± 4</td>
<td>18-34</td>
<td>129 (64, 65)</td>
<td>At 6 wk: 70 (28, 42) [49%]</td>
</tr>
<tr>
<td>Chang et al (2009)</td>
<td>39 ± 8</td>
<td>NR</td>
<td>216 (203, 13)</td>
<td>141 (132, 9) [65%]</td>
</tr>
<tr>
<td>Exercice + Behavioural therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exercice + Diet</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes: BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; Trig, triglycerides; FG, fasting glucose; CI, cardiac intake; IN, insulin; HOMA-IR, homeostasis model assessment of insulin resistance; VO2, maximal oxygen uptake; PSS, perceived stress scale; GWB, general well-being; HCCQ, health care climate questionnaire; TSBQ, treatment self-regulation questionnaire; SIDS, self-determination scales; LCE, locus of causality for exercise scale; SRQ-E, self-regulation questionnaire; IR, intrinsic motivation inventory; EMI-2, exercise motives inventory-2; PANAS, Positive Affect and Negative Affect Scale; CHO, carbohydrate; Veg, vegetable; HC, high-carbohydrate diet; VLCHP, very low-carbohydrate, low protein; LCMP, low carbohydrate, moderate protein; HCLP, high carbohydrate, low protein; NS, not reported.
3.4.2. Study characteristics

Of the five included studies, three were conducted in the United States (Chang, Nitzke, & Brown, 2010; Kerksick et al., 2010; Schmitz et al., 2007), one in the United Kingdom (Carroll et al., 2007) and one in Portugal (Silva et al., 2010). Inclusion criteria were similar across all five studies, requiring participants to be overweight and/or obese (based on BMI), premenopausal, sedentary, free from major illness, and not taking medication known to interfere with weight loss (e.g. anti-depressive). All studies stated exclusion criteria for participants not in good health, pregnant, or with a history of cardiovascular disorders or chronic disease.

The collective sample size of the studies at baseline was 779 participants, with a range of 31 to 239. Of these 779 participants, 577 completed post-intervention testing (range: 20 to 208). Participant samples were predominantly Caucasian, with Chang et al. (2010) also including African American participants, and Schmitz et al. (2007) using an ethnically diverse sample (Caucasian, Black, Asian, Native American, and Pacific Islanders). Age ranged from 18-55 years across all studies. However, only Chang et al. (2010) had a mean participant age below 30 years, while the other studies presented a mean age of 36 to 40 years.

The research design components of each study are outlined in detail in Table 6. Of the five studies, three comprised Exercise + Diet + Behavioural therapy (Carroll; Chang; Silva), one comprised Exercise + Diet (Kerksick), and one comprised Exercise + Behavioural therapy (Schmitz). The lifestyle intervention duration ranged from 10 to 104 weeks. Data were collected at baseline and post-intervention time points, with three studies performing data collection at mid-intervention (Kerksick; Schmitz; Silva). Additionally, three studies performed follow-up testing at 6 months (Chang), 9 months (Carroll), and 24 months (Silva) after completion of the intervention, but only Chang et al. (2010) reported these data. Compliance rates were reported in four studies (Carroll; Chang; Schmitz; Silva), with adherence to the lifestyle intervention ranging from 61-89%. One study (Chang) provided monetary incentives to reimburse participants for their time, whilst another study provided free child care (Schmitz) when participants performed their supervised exercise sessions.

The nature of the control group varied across studies. Three studies (Carroll; Chang; Schmitz) provided usual care (maintenance of usual lifestyle behaviour). Of these, one provided control participants with brochures (Schmitz) detailing the current recommendations for
weekly physical activity, and one used a wait-list (delayed start) design, during which participants were scheduled to start the intervention at the completion of the control period. One study (Kerksick) used a two control group design, with a (i) no diet and no exercise control group or (ii) exercise only (no diet) control group. One study (Silva) provided bi-monthly, face-to-face sessions for their control group, lasting 120 minutes, on ‘lifestyle themes’.

**Exercise component**
All studies incorporated exercise as part of their lifestyle intervention. Three studies (Carroll; Kerksick; Schmitz) provided a combination of structured, supervised sessions conducted by a trainer and unsupervised sessions, 2-3 times per week, ranging from 30-120 minutes in duration. The exercise training comprised aerobic activities and/or strength/resistance training, using gym facilities to deliver the exercise component. In comparison, two studies (Chang; Silva) encouraged participation in physical activity and promoted the importance of exercise via a theory-based module designed by exercise physiologists. In both cases, physical activity was unstructured, unsupervised and self-driven. Silva et al. (2010) also offered additional, supervised dance classes and an ‘activity challenge’.

**Diet component**
Four studies provided a dietary component (Carroll; Chang; Kerksick; Silva). One study provided nutrition education delivered by a dietitian (Carroll). Two studies had nutrition ‘themes’ designed by dieticians that were embedded in the behavioural therapy sessions (Chang; Silva). And one study (Kerksick) provided modest caloric restriction, with women randomised into one of four groups of a specific macronutrient profile, being either (i) high-carbohydrate, (ii) low-carbohydrate with high-protein, (iii) low-carbohydrate with moderate-protein, or (iv) high-carbohydrate with low-protein. In contrast, the other study (Schmitz) requested all participants to maintain their current diet throughout their trial.
**Behavioural therapy component**

Four studies provided a behavioural therapy component (Carroll; Chang; Schmitz; Silva). Two studies conducted weekly (Carroll) or 120 minute bi-monthly (Silva) small group sessions, using a face-to-face mode as the means of intervention delivery. In both studies, self-determination theory (Deci & Ryan, 1985) guided the ‘lifestyle change’ program. Two studies (Chang, Schmitz) used social cognitive theory (Bandura, 1991) as a framework for developing support networks amongst intervention participants. One study (Schmitz) conducted semi-annual gatherings and provided a study website and monthly newsletters. One study (Chang) encouraged participants to view health behavioural change themes presented bi-weekly in their homes via DVD, and these participants were asked to complete a weekly worksheet to self-monitor progress and partake in a fortnightly peer-support teleconference lasting 30 minutes with a moderator and 10-15 other participants.

3.4.3. Quality assessment and potential bias

To estimate the quality of methods in each study, the previously validated 11-item PEDro scale with a cut-off at 6 was used (Maher et al., 2003). In this review, the PEDro scale was modified to exclude criteria 5 and 6 (blinding of all subjects to the intervention and blinding of therapists, respectively) which were considered difficult to implement in exercise intervention trials (Sherrington, Moseley, Herbert, Elkins, & Maher, 2009).

All studies specified their eligibility criteria for participation (criterion 1) and randomised participants into either an intervention or control group (criterion 2). No studies reported group-allocation concealment (criterion 3). The analysis of baseline differences was reported in all studies, with no differences found between intervention and control groups (criterion 4), suggesting homogeneity between groups at baseline. Blinding of assessors (criterion 7) was reported in two studies (Chang; Schmitz), in which the measurement staff were blinded to group assignment during data collection and analyses. Three studies (Carroll; Schmitz; Silva) satisfied the criterion of obtaining key outcome measurements in 85% of participants (criterion 8), with a retention rate across the five studies ranging from 49-87% from baseline to post-intervention (see Table 6). Two studies (Carroll; Silva) specified intention-to-treat statistics were used (criterion 9). The determination of sample size with sufficient power was reported in three studies (Kerksick; Schmitz; Silva). All studies performed between-group
statistical comparisons (criterion 10). Both point measures and measures of variability were satisfactorily reported in all studies (criterion 11). Based on the remaining 9-item scale, the average quality of the trials was 71% (range from 55-78%), with a mean point score of 6.4 out of 9. A score of ≥ 5 for the modified scale was indicative of ‘high’ quality (Sherrington et al., 2009), and was met by all studies (Table 3.5).

3.4.4. Outcome measures of included studies

A summary of the outcome measures is presented in Table 3.7. A description of the effects of the lifestyle interventions on key CVD risk factors for the five studies is presented below. Body composition was the most commonly reported outcome measure across the five studies (Table 3.6). Conversely, none of the studies measured cardiac or vascular outcomes using echocardiographic or ultrasonographic techniques.

**Anthropometric measures**

All participants in the five studies were classified as overweight or obese defined by BMI (≥ 25 kg/m²) at baseline. A variety of anthropometric measures were also reported across the studies, with body mass reported in all studies, and BMI and body composition (body fat percentage, fat mass, lean mass) calculated in four studies (Carroll; Kerksick; Schmitz; Silva).

Two of the five studies (Kerksick; Silva) reported greater *between group* reductions in body mass (kg) for their respective interventions. Silva et al. (2010) reported a *time x group* interaction for the intervention group compared with controls in percentage weight change at 4 and 12 months (3% and 6% mean difference, respectively) compared with baseline. Silva et al. (2010) also demonstrated a reduction in BMI (INT -2.3 ± 1.9 vs CON 0.7 ± 1.9 kg/m²) at the end of the intervention. Similarly, the diet + exercise groups in the study of Kerksick et al. (2010) displayed greater *group x time* anthropometric (body mass) and body composition (fat mass, lean mass) changes, measured using dual-energy x-ray absorptiometry, compared with the control groups. Moreover, the intervention groups, irrespective of macronutrient distribution (with the exception of the high-carbohydrate diet), showed *within-group* differences from baseline for waist circumference, body mass, lean mass, fat mass and
percentage body fat. Overall, the largest weight loss at the conclusion of their 14-week intervention was reported by participants in the very-low carbohydrate, high-protein diet + exercise group (-5.0 ± 4.2 vs CON 0.5 ± 2.9 kg). Conversely, three studies (Carroll; Chang; Schmitz) reported no *between-group* differences in body mass at post-intervention. In addition, participants at post-intervention in the Schmitz et al. (2007) and Carroll et al. (2007) studies reported no differences in BMI compared with controls. Two studies (Silva; Schmitz) reported greater reductions in percentage body fat for the intervention group (Silva: -6.9 ± 7.9% vs CON -2.5 ± 7.5%; Schmitz: -3.7 ± 1.0% vs CON -0.1 ± 1.0%) after one and two years, respectively. Silva et al. (2010) also reported greater reductions in fat mass (-5.6 ± 4.1 vs CON -1.5 ± 4.3 kg) and lean mass (-1.1 ± 1.8 vs CON -0.2 ± 1.6 kg) in their intervention group. Conversely, fat mass, lean mass, and subcutaneous abdominal fat were not different *between groups* at post-intervention in Schmitz et al. (2010), while there were gains in intra-abdominal fat in both groups but these gains were less for the intervention group (7.0 ± 5.1% vs CON 21.4 ± 5.3%).

**Markers of the metabolic syndrome and other blood biochemistry**

Three studies (Carroll; Chang; Kerksick) examined markers of the metabolic syndrome (Alberti et al., 2009) and, collectively, none of the markers were different *between groups* at post-intervention in all three studies. Specifically, HDL-cholesterol, triglycerides, glucose and blood pressure were unchanged in the intervention group compared with controls at three months, although both intervention and control participants showed favourable *within-group* changes for HDL-cholesterol and diastolic blood pressure at post-intervention (Carroll). Similarly, Kerksick et al. (2010) found no *group x time* differences for metabolic syndrome markers (HDL-cholesterol, triglycerides, and glucose). However, *within-group* analysis showed a reduction in fasting glucose for the high-carbohydrate, low-protein group at post-intervention. Chang et al. (2010) examined fasting glucose exclusively and found ‘trends’ but no significant differences between intervention and control groups at 2 and 8 months post-intervention.

In addition, two studies (Carroll; Kerksick) investigated other biochemical markers associated with increased CVD risk; specifically cholesterol and indicators of insulin resistance (IDF, 2006). Both studies reported baseline total cholesterol, but only one (Kerksick) reported post-intervention results. Kerksick et al. (2010) reported no differences
between the intervention and control groups for total cholesterol and LDL-cholesterol, or for fasting insulin and the homeostasis model assessment of insulin resistance (HOMA-IR). However, a \textit{within-group} improvement in both insulin and HOMA-IR was observed in the very-low carbohydrate, high protein intervention group.

\textit{Fitness markers}

A variety of physical activity, aerobic and strength outcome measures were investigated via questionnaires or exercise testing across the five studies. Two studies (Carroll; Kerksick) measured cardiorespiratory capacity ($VO_{2\text{max}}$) using a maximal treadmill walking test to volitional exhaustion, with both studies showing improvements in $VO_{2\text{max}}$ (ml·kg$^{-1}$·min$^{-1}$) following lifestyle intervention compared with controls. One study (Schmitz) used accelerometers to objectively assess physical activity, with no differences over at least a four-day measurement period from the control group at one or two years of intervention. In contrast, self-reported physical activity was used in two studies (Chang; Silva), with participants detailing frequency, intensity and duration of physical activity over a 7 day period. Chang et al. (2010) found no \textit{between} or \textit{within group} differences for physical activity at 2 or 8 months post-intervention, while the intervention group of Silva et al. (2010) showed greater physical activity after the 12-months intervention.

Two studies (Kerksick; Schmitz) measured improvements in muscular strength via a one-repetition maximum (1RM) bench-press and leg-press. For both measures, Schmitz et al. (2007) reported improvements at 1 and 2 years of intervention compared to controls, while Kerksick et al. (2010) did not observe such improvements. However, Kerksick et al. (2010) did report \textit{within group} improvements in 1RM (kg/kg) leg-press for three Exercise + Diet intervention groups, and \textit{within group} improvements for 1RM bench-press for four Exercise + Diet groups.

\textit{Dietary outcomes}

Diet composition (e.g. calories, macronutrient distribution) was assessed in three (Chang; Kerksick; Schmitz) of the five studies. Kerksick et al. (2010) was the only study to manipulate the dietary intake of participants, reporting \textit{within group} reductions in caloric intake (kcal/kg/day) compared with baseline at 10 and 14 weeks. However, inadequate
dietary recording by control group participants prevented between group analyses. In contrast, Schmitz et al. (2007) found no between or within group differences at any time point for total energy intake (kcal/day) measured via a food-frequency questionnaire. Chang et al. (2010) reported increases in fruit and vegetable intake behaviour at post-intervention compared with their control group, but this difference was no longer significant at 8-month follow-up.

Psychological characteristics

A variety of psychological approaches were used across three studies (Carroll; Chang; Silva). Carroll et al. (2007) reported improvements from pre- to post-intervention on all variables of the General Well-Being (GWB) schedule compared with controls. However, no between group differences were observed for the 9-item Perceived Stress Scale (PSS) score or its two subscales. In contrast, at post-intervention, Chang et al. (2007) reported improvements in the PSS for the intervention group compared with controls. However, no between-group differences were reported for the Positive Affect and Negative Affect Scale (PANAS). In the study of Silva et al. (2007), using seven self-determination theory-based instruments to investigate psychological variables, the intervention group reported higher levels of self-determination and autonomous self-regulation after 12 months of intervention. Participants scored higher for exercise-related intrinsic motivation, autonomous self-regulation, and exercise motives.

3.5. Discussion

We aimed to systematically review the evidence in the existing literature (2004-2014) on the effectiveness of multi-disciplinary lifestyle interventions in reducing CVD risk in overweight and/or obese premenopausal women. With respect to the inclusion criteria of this review, there were only five RCT-designed studies, and there was pronounced heterogeneity in their research designs, intervention characteristics, and outcome measures. It was found that lifestyle interventions incorporating exercise, diet and/or behavioural therapy were effective in eliciting improvements in CVD risk in this population, appearing to induce modest weight loss and improve fitness and selected measures of psychological behaviour. However, four
studies had mean age of 36 to 40 years, highlighting the paucity of data for younger women below 30 years of age. Moreover, only one study reported longer term follow-up data, at 8 months after intervention completion. Thus, the effectiveness of multi-disciplinary interventions for sustaining improvements in CVD risk or behavioural change is still unclear in this population.

3.5.1. Lifestyle intervention effect on outcome measures

All interventions in this review produced improvements in at least some markers of CVD risk. The most prominent change was noted in markers of weight loss, with three (Kerksick; Schmitz; Silva) of the five studies reporting improvements in body composition (percentage body mass, fat mass, lean mass) and/or anthropometric measures (body mass, BMI) compared to controls. Similarly, lifestyle interventions had a positive effect on estimates of cardiovascular fitness, represented by increased physical activity, improved aerobic capacity and/or improved muscular strength, reported in four (Carroll; Kerksick; Schmitz; Silva) of the five studies. Moreover, two (Carroll; Chang) studies incorporating a behavioural therapy component within their lifestyle intervention group compared with controls demonstrated improved scores on psychological behaviour inventories. A moderate intervention effect was observed in dietary composition changes, with two (Chang; Kerksick) of three studies showing selective improvements in dietary outcomes. In contrast, lifestyle interventions had no influence on markers of the metabolic syndrome (Alberti et al., 2009; Alberti et al., 2005), including blood lipids, fasting glucose and blood pressure, and on other measures of blood biochemistry (insulin, HOMA-IR, total cholesterol).

3.5.2. Lifestyle intervention program evaluation

No specific type of multi-disciplinary lifestyle intervention included in this review appeared to be more successful program than others, with each displaying improvements in some CVD risk factors. Three studies (Carroll; Silva; Schmitz) had retention rates above 72%, and these studies included regular contact with participants through exercise, nutrition and/or behavioural sessions. In contrast, the lifestyle intervention delivered via the theory-based education program (Chang), reported the poorest retention rates, of 49% at post-intervention and 34% at 8-month follow-up. Chang et al. (2009) speculated that this could be due to
population characteristics and economic hardship. This lifestyle intervention also delivered the fewest improvements for CVD risk factors. For the study of Kerksick et al. (2010), the retention rate was only 65%, and we speculate that this could be due to difficulties in adhering to a dietary intervention involving caloric restriction and macronutrient modification (Wycherley, Mohr, Noakes, Clifton, & Brinkworth, 2012).

The range of body composition measures used made cross study comparisons problematic. Three studies (Kerksick; Schmitz; Silva) measured markers of body composition, including percentage body fat, fat mass and lean mass using pencil-beam scanning (Silva), dual-energy X-ray absorptiometry (Kerksick; Schmitz) and computed tomography scans (Schmitz), respectively. These techniques of body composition measurement are generally more accurate than standard anthropometric (e.g., body mass, WC, BMI) assessment. In the two studies (Carroll; Chang) not using these more sophisticated measures of body composition no changes were observed in anthropometric markers at post-intervention. With standard anthropometric measures weight loss as an outcome by itself can be confounded by the inability to discriminate between loss of fat mass and gains in lean mass, so the results from these two studies must be interpreted with caution.

All studies included the implementation of exercise/physical activity. Exercise programs were well described in two studies (Kerksick; Schmitz) for duration, exercise mode, sets and repetitions prescribed. Conversely, the description of exercise intensity in the other studies (Carroll; Schmitz; Silva) was poor. Moreover, measures of exercise-related outcomes across the studies ranged from self-reported questionnaires (Chang; Silva) to physical tests for aerobic capacity and muscular strength testing (Carroll; Kerksick; Schmitz). Exercise delivery also appeared to influence the chances of demonstrating improved fitness and physical activity outcomes. Three (Carroll; Kerksick; Schmitz) of the five studies provided regular supervised exercise training, one study (Silva) provided a combination of group exercise classes and promotion of physical activity through theory, and one (Chang) provided education about the importance of exercise only. The latter (Chang) was the only study not to produce improvements in fitness or physical activity at post-intervention, which may imply, that contact with fitness professionals and others during the intervention phase is important for realising improvements in fitness and/or physical activity outcomes.
Four studies implemented a dietary component in their lifestyle intervention. However, Carroll et al. (2007) and Silva et al. (2010) failed to report any dietary outcomes, and Chang et al. (2010) only reported changes in fat, fruit and vegetable intake. And while Kerksick et al. (2010) controlled nutritional intake by prescribing four different dietary regimens, inadequate dietary recording by the control group prevented any between group analyses. Therefore, collectively, the heterogeneity in the dietary components among studies and the inadequate reporting of post-intervention data do not provide additional understanding of dietary behaviour for weight management in premenopausal women.

Four of the five studies incorporated a behavioural therapy component in their lifestyle intervention: two (Carroll; Silva) were guided by self-determination theory, and two (Chang; Schmitz) used the social cognitive theory framework. Only two (Carroll; Chang) of these studies measured the success of their behavioural therapy component through various psychological inventories. Without evaluation of behavioural change, it is difficult to determine if the addition of a behavioural therapy component in multi-disciplinary programs contributes to improvements in CVD risk.

### 3.5.3. Limitations and future directions

This review has limitations. Meta-analyses were not performed due to the lack of consistency in the reporting of data across studies, as well as the differences in intervention design characteristics. We did not include unpublished data, nor studies that were published in languages other than English, with the review limited to papers dating from 2004 onwards. Therefore, we acknowledge that there might be work that meets our inclusion criteria in the greater literature pool. Nonetheless, findings from this systematic review confirm that multi-disciplinary lifestyle interventions are associated with health benefits for overweight/obese premenopausal women.

It is recommended that future studies involving multi-disciplinary lifestyle interventions provide comprehensive descriptions of their exercise programs, and evaluate fitness and physical activity outcomes with objective testing measures. Furthermore, there is a need to include more comprehensive assessments of cardiac and vascular effects as a result of intervention. The non-invasive use of echocardiography and ultrasonography techniques have shown promise as sensitive early detection markers of CVD, particularly in young adult
women (Peterson, Waggoner, et al., 2004). Moreover, these techniques may provide insight into mechanistic changes that accompany weight loss and increased fitness. Studies that conduct a lifestyle intervention on a mixed-sex population should discriminate their results to enable sex-specific comparisons.

3.5.4. Conclusions

While the evidence is limited to only five studies, the data suggest promising trends for multi-disciplinary lifestyle interventions which incorporate exercise, diet and/or behavioural therapy to improve the CVD risk profile of overweight/obese premenopausal women. However, these data are distinctly lacking with respect to young adult women (< 30 years of age). The internal validity of these and future data would be improved with more explicit and detailed reporting of research designs and outcome measures. Similarly, external validity could be improved with greater homogeneity among study designs and the reporting of data from longer-term follow-up. The inclusion of more advanced techniques of metabolic, cardiac and vascular assessment is also suggested for earlier identification of, or greater sensitivity to change in, CVD risk.
Chapter 4. Extended Methods

The methods used in this thesis are described in full or in part in subsequent experimental chapters. Therefore, this chapter is included to detail methodological procedures not comprehensively described within the experimental chapters. Some methods were germane to all studies. The same researcher (i.e. the author of this thesis) performed all aspects of the methods, here and in the experimental chapters, unless otherwise stated.

4.1. Ethical Approval

The study and its protocols were approved by the Australian Catholic University Human Research Ethics Committee (V2009 91; Appendix 2). Additionally, the study was registered with the Australian New Zealand Clinical Trials Registry [ANZCTR] (Identifier: ACTRN12612001017819; Appendix 3). Written informed consent was obtained from all participants prior to testing (Appendix 4 & 5).

4.2. Research Design

The Young Women’s Heart Health Study was an efficacy trial, with all experimental procedures and data collection conducted on campus at the Australian Catholic University, Melbourne, Australia. Two separate components: (i) the cross-sectional studies and (ii) the lifestyle intervention (Figure 4.1), were completed between August 2010 and February 2012.

In the cross-sectional studies, women with abdominal obesity (WC ≥ 80cm) were compared with an aged-matched, non-obese (WC < 80cm) control group (Figure 4.2; Chapters 5 and 6). Women participating in the cross-sectional studies who presented with abdominal obesity (WC ≥ 80cm) were invited to participate in a 12-week randomised controlled lifestyle intervention trial, which incorporated an experimental intervention group and a wait-list control group. The study design ensured all women had access to the intervention.
Figure 4.1. Study design for the Young Women’s Heart Health Study conducted between August 2010 and February 2012, incorporating a cross-sectional and lifestyle intervention component. *four participants from the wait-list control group continued into the intervention phase.
4.3. Participants

Women were recruited to participate in the University-based Young Women’s Heart Health Study by local advertisement (Appendix 7) and internal email service. The following inclusion and exclusion criteria applied: All participants were Caucasian females, aged between 18 to 30 years, and fluent in spoken and written English. Ethnicity-related differences in cardiovascular risk limited recruitment to Caucasian (Ajjan, Carter, Somani, Kain, & Grant, 2007). Participants were excluded from the study if they were current smokers, pregnant or lactating, taking medication treatment for lipid abnormalities, diagnosed with cardiovascular or respiratory conditions that might limit participation in exercise, had a pre-existing physical or medical condition (liver or kidney disease, heart arrhythmia, insulin dependent diabetes mellitus, gestational diabetes, polycystic ovarian syndrome, or thyroid...
abnormalities), or previous bariatric surgery. Women also completed a cardiovascular risk assessment (Appendix 6). Women who responded to the advertisement had their eligibility confirmed by attending a short consultation with the researcher before inclusion was permitted.

4.4. Lifestyle Intervention

4.4.1. Participants

In addition to the previously listed set of inclusion criteria, eligibility for the lifestyle intervention was based on abdominal obesity, defined using the IDF definition [(Alberti et al., 2005); the current definition at the time of initial recruitment] as a raised waist circumference \( \geq 80\text{cm} \), and leading a sedentary lifestyle according to the then guidelines for physical activity (Department of Health and Ageing, 1999). All participants were willing and able to increase daily physical activity. A detailed CONSORT flow diagram of participants in the lifestyle intervention is presented in Chapters 7 and 8.

4.4.2. Sample size power

A power analysis was performed to determine the appropriate sample size. Estimates were based on a moderate within-subject effect size for the primary outcome criterion of waist circumference. With approximately 18 women per group and by offering the control group access to the intervention, this number per group was predicted to provide the appropriate statistical power to detect a large within-subject difference of 1.0 standard deviation in the major variable between baseline and post-intervention (\( \beta = 80\% \), statistically significant at an alpha level of \( P < 0.05 \)), assuming equal variances within groups. Allowing for 20% attrition (drop-out), it was calculated that 44 women (22 in each group) were required to retain statistical power (Peat, 2001).
4.4.3. Study design

A 12-week multi-disciplinary lifestyle intervention was comprised of three components: (1) moderate-intensity physical activity (Table 4.1); (2) non-dieting nutrition education (i.e. strategies of everyday choices for nutritional balance rather than restrictive eating regimes); and (3) weekly (60 min) small-group cognitive behavioural therapy (CBT) sessions entitled “Mission Possible”. In contrast, participants in the wait-list control group were requested to continue existing lifestyle choices, and after 12 (control) weeks were invited to complete the lifestyle intervention. The multi-disciplinary lifestyle intervention is described in detail in Chapters 7 and 8.

Sustainability component

The lifestyle intervention incorporated a sustainability component, in which all participants had outcome measures tested at 12 weeks after the conclusion of the lifestyle intervention; that is, 24 weeks from pre-intervention measures. During this phase, participants did not attend structured sessions, and despite minimal contact with the research team, were encouraged to maintain their new lifestyle habits. Each participant received a fortnightly follow-up newsletter from the researcher, via email, until the time of re-testing at 24 weeks. The newsletter contained lifestyle and healthy living tips. Participants were also provided with a booklet containing the activities they had completed during the exercise component of the lifestyle intervention.
Table 4.1. Outline of the training program for the physical activity component of the 12-week multi-disciplinary lifestyle intervention.

<table>
<thead>
<tr>
<th>Week</th>
<th>Circuit Training</th>
<th>Interval training</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aerobic activity</td>
<td>Strength/resistance activity</td>
</tr>
<tr>
<td>1</td>
<td>Cycling, rowing, step-ups</td>
<td>Bicep curls, squats, chest press, triceps extensions, push-ups, calf-raises, lunges</td>
</tr>
<tr>
<td>2</td>
<td>Cycling, rowing, step-ups</td>
<td>Squats, triceps dips, lunges, calf-raises, push-ups</td>
</tr>
<tr>
<td>3</td>
<td>Boxing, skipping, step-ups</td>
<td>Squats, push-ups, lunges, triceps dips, box jumps</td>
</tr>
<tr>
<td>4′</td>
<td>Boxing, skipping, step-ups</td>
<td>Squats, push-ups, calf-raises, lunges, triceps dips, single-leg (SL) dead lift</td>
</tr>
<tr>
<td>5</td>
<td>Cycling, running, step-ups</td>
<td>Triceps pull down, lunges, upright row, squats, bicep curls, push-ups, sprints</td>
</tr>
<tr>
<td>6</td>
<td>Cycling, running, step-ups</td>
<td>Squats, push-ups, calf-raises, lunges, triceps dips, SL dead lift</td>
</tr>
<tr>
<td>7′</td>
<td>Interval cycling</td>
<td>Squats, push-ups, lunges, triceps dips</td>
</tr>
<tr>
<td>8</td>
<td>Interval cycling</td>
<td>Squats, lunges, triceps dips, SL dead lift, box jumps, push-ups, SL hopping</td>
</tr>
<tr>
<td>9</td>
<td>Stair climbing</td>
<td>Squats, push-ups, lunges, triceps dips, calf raises, SL dead lift</td>
</tr>
<tr>
<td>10′</td>
<td>Stair climbing</td>
<td>Calf-raises, push-ups, squats, triceps dips, lunges, bridging, SL dead lift</td>
</tr>
<tr>
<td>11</td>
<td>Cycling, boxing, step-ups</td>
<td>Push-ups, bridging, lunges, bicep curls, upright row, triceps pull down, squats</td>
</tr>
<tr>
<td>12</td>
<td>Cycling, boxing, step-ups</td>
<td>Box jumps, lunges, triceps dips, squats, push-ups, bridging, calf raises, SL dead lift</td>
</tr>
</tbody>
</table>

**Footnotes:** Format for circuit training included alternating between aerobic (2-8 minutes in duration per activity) and strength activities (1-4 minutes in duration per activity); plus alternating between upper and lower body strength activities. Interval session pace was personal choice of brisk walking, jogging or running. OMNI picture scale was used for RPE (Robertson, 2004; Appendix 18). Sessions were conducted every 3 weeks (i) as an anchoring procedure for RPE and (ii) to direct progressive exercise prescription. **Warm-up:** Each session began with gentle physical activity (OMNI-scale RPE 4) that elevated body temperature (e.g. walking or jogging): weeks 1-3 (5 min) and weeks 4-12 (10 min). **Core strength:** Each session included three core/abdominal activities (e.g. crunches, plank, oblique) after the completion of the circuit training. **Cool-down:** Each session concluded with 5 min of static stretching of each major muscle group, including hamstrings, quads, hip flexors, adductors, calves, back, shoulders and trunk.

*RPE, ratings of perceived exertion (Robertson, 2004).*

**Table 4.1. Outline of the training program for the physical activity component of the 12-week multi-disciplinary lifestyle intervention.**
4.4.4. Data collection

For participants allocated to the intervention group, testing was performed at pre-intervention (0 weeks), post-intervention (12 weeks), and again at sustainability (24 weeks post-intervention) (Figures 4.3). For participants allocated to the wait-list control group, testing was performed at pre-control (0 weeks) and at post-control (12 weeks). Participants in this group were then provided the opportunity to continue into the intervention phase of the study. All measurements were taken at the same time of day (±2 hr) and by the same researcher.

Figure 4.3. Data collection design for intervention and wait-list control groups showing each time point and the 12-week multi-disciplinary lifestyle intervention.
*Also used as pre-intervention data for participants who continued into the intervention phase (n=4).
4.5. Outcome Measures

Each data collection time point for the cross-sectional and intervention studies comprised two laboratory testing sessions, separated by 7 days. On each occasion, participants were requested to refrain from strenuous physical activity in the 24 hours prior to testing. For the first of the two laboratory sessions at each time point, participants were also required to fast from all food and beverages including vitamins, minerals and medications for a minimum period of 12 hours (overnight). This laboratory session lasted 75 min and involved anthropometric, blood, and vascular ultrasound measures. The second laboratory session only required participants to abstain from caffeine and alcohol in the preceding 12 hours and lasted 60 min for fitness, echocardiography and survey measures (Figure 4.4). Menstrual cycle phase was recorded on the initial day of testing to ensure that re-testing occurred during the same phase at subsequent sessions. The same request applied to both the cross-sectional and intervention studies. Environmental conditions within the laboratory were maintained at 20-23°C and 40-60% humidity. Outcome measures collected during each of the two laboratory visits are presented in Table 4.2.

Table 4.2. Outcome measures collected at each data collection time point.

<table>
<thead>
<tr>
<th>Laboratory session ONE</th>
<th>Category</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anthropometry measures</td>
<td>Body mass; stature; WC; hip circumference</td>
</tr>
<tr>
<td></td>
<td>Metabolic syndrome markers</td>
<td>Fasting glucose; HDL-cholesterol; triglycerides; BP</td>
</tr>
<tr>
<td></td>
<td>Additional blood biochemistry</td>
<td>Total cholesterol; insulin; hs-CRP</td>
</tr>
<tr>
<td></td>
<td>Vascular ultrasonography</td>
<td>Carotid IMT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory session TWO</th>
<th>Category</th>
<th>Outcome measure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fitness assessment</td>
<td>Estimated aerobic capacity</td>
</tr>
<tr>
<td></td>
<td>Echocardiography</td>
<td>Morphology, function, deformation, mechanics</td>
</tr>
<tr>
<td></td>
<td>Survey documents</td>
<td>Custom survey; psychological inventories; food recall</td>
</tr>
</tbody>
</table>

WC, waist circumference; HDL, high-density lipoprotein; BP, blood pressure; hs-CRP, high sensitivity C-reactive protein; IMT, intima-media thickness
## LABORATORY SESSION ONE

<table>
<thead>
<tr>
<th>PREPARATION</th>
<th>ASSESSMENT</th>
<th>EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasted</td>
<td>Blood collection (10 ml)</td>
<td>Take-home survey</td>
</tr>
<tr>
<td>Consent form</td>
<td>Anthropometric measures (body mass, height, girths)</td>
<td>Vascular ultrasound</td>
</tr>
<tr>
<td></td>
<td>Seated</td>
<td>Food recall</td>
</tr>
<tr>
<td></td>
<td>Blood pressure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Resting HR</td>
<td></td>
</tr>
</tbody>
</table>

## LABORATORY SESSION TWO

<table>
<thead>
<tr>
<th>PREPARATION</th>
<th>ASSESSMENT</th>
<th>EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>No caffeine</td>
<td>Anthropometric measures (body mass, waist circumference)</td>
<td>Fitness evaluation</td>
</tr>
<tr>
<td>CV risk form</td>
<td>Seated</td>
<td>Training diary</td>
</tr>
<tr>
<td></td>
<td>Blood pressure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Resting HR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Echocardiography ultrasound</td>
<td></td>
</tr>
</tbody>
</table>

**Figure 4.4.** Outline of the experimental procedure for laboratory session one and two.
In this study, WC was used to define abdominal obesity (i.e. WC ≥ 80cm) and acted as the primary measure to calculate sample power. WC was measured to the nearest 0.1 cm in the horizontal plane at the level of the midpoint between the iliac crest and lower costal margin (Alberti et al., 2009) using a non-elastic measuring tape, with the average of two measures reported. Consequently, to ensure that the measurement technique for WC assessment was reliable, intra-rater reliability analysis was conducted on a sample of 20 participants (see section 4.5.3 for calculations used for reliability measures). WC was evaluated twice by the same observer (i.e. author of this thesis) and reliability was determined to be: coefficient of variation (CV), 1.3%; intra-class coefficient [ICC (3, 1)], 0.98; limits of agreement (LOA), -4.4 to 3.0; and measurement error (ME), ± 2.6 cm.

Detailed explanations of the data collection procedures for anthropometric measures, metabolic syndrome markers, additional biochemical, and fitness assessments are presented in Chapter 5 and 7. Details of the procedures for vascular ultrasonography and echocardiography are briefly discussed in Chapters 6 and 8, with a comprehensive explanation of these techniques, and of the survey documents, presented below.

4.5.1. Vascular ultrasonography

As an assessment of CVD risk, the carotid artery wall can be examined to identify areas of increased thickness and plaque, and is used as an early marker of atherosclerosis (Bots, 2006; Stein et al., 2008). Specifically, the assessment of carotid arterial intima-media thickness (c-IMT) is used as a non-invasive measure to gauge progression and regression of vascular pathology (Hodis et al., 1998). Examination of the right common carotid artery was performed with B-mode ultrasonography using standard ultrasound equipment (Vivid-i, GE Healthcare, Horten, Norway) in a dark, temperature-controlled room, after participants had rested quietly for 10 minutes in the supine position. All scans were performed according to a pre-determined standardised scanning protocol (Jarvisalo et al., 2002). The right common carotid artery was scanned longitudinally, 2cm proximal to the bulb (carotid bifurcation), using a high-resolution 12 MHz linear-array probe (Figure 4.5). All scans were digitally stored for subsequent off-line analyses (EchoPAC v108.1.5, GE Medical Systems, Horton, Norway). Images were analysed at the end-diastolic frame (captured adjacent to the R-wave on continually recorded echocardiogram), performed on the far (posterior) wall of the right
common carotid artery. Semi-automated, edge-detection, wall-tracking software was used to determine mean c-IMT, which is measured from the leading edge of the lumen-intima interface and the leading edge of the media-adventia interface (Chodakauskas, 2006). All reported measurements were averaged from three frames.

All ultrasound data collection and analyses were performed by the same experienced operator, with intra-rater reliability analysis conducted for mean c-IMT on a sample of 20 participants (see section 4.5.3 for calculations used for reliability measures). A scan of the right common carotid artery was evaluated twice, using off-line software analyses, by the same operator (author of this thesis). Reliability for mean c-IMT was determined to be: CV, 2.3%; ICC (3, 1), 0.81; LOA, -0.03 to 0.03; and ME ± 0.02 mm. This reliability is consistent with previous research, with a CV of 3.9% (n=22) established for mean c-IMT (Järvisalo et al., 2004).

Figure 4.5. Image of the common carotid artery, illustrating the carotid bifurcation and intima-media thickness (c-IMT) of the far wall (Image sourced from: Wald et al., 2009, p.156).
4.5.2. Echocardiography

Echocardiography is a popular, non-invasive technique for obtaining markers of cardiac structure and function, including quantitative measures of cardiac chamber size, wall thickness, blood flow, and wall motion velocities (Sahn, DeMaria, Kisslo, & Weyman, 1978). Standard two-dimensional (2D) transthoracic echocardiographic examinations were conducted in accordance with American Society of Echocardiography standards (R. M. Lang et al., 2005). All image acquisition and subsequent off-line analyses (EchoPAC, GE Medical Systems; Appendix 22) were performed by the same experienced operator using standard ultrasound equipment (Vivid-i, GE Healthcare, Horten, Norway)

*Conventional echocardiography*

Motion-mode (M-Mode) measurements were obtained in the parasternal long-axis view (Figure 4.6). Left atrial (LA) and LV dimensions and wall thickness were assessed at both end-diastole and end-systole. LV mass was calculated by the Penn-Cube method (Devereux et al., 1984) and indexed for height (Cornell adjustment). LV ejection fraction was quantified by the Simpson’s bi-plane method, with systolic dysfunction diagnosed if the ejection fraction was less than 50% (Nagueh et al., 2009).

*Figure 4.6.* Parasternal long-axis view of the heart, showing (i) the probe and scanning view, (ii) 2D ultrasound image, and (iii) schematic representation of the view. (Image sourced from: http://www.123sonography.com).
Pulsed-Doppler LV transmitral flow velocity for early-diastolic (E) and late-diastolic (A) waves was performed in the apical four-chamber view (Figure 4.7). Isovolumetric relaxation time (IVRT), and aortic ejection velocity were measured by pulsed-Doppler in the apical five-chamber view (Figure 4.8).

**Figure 4.7.** Apical four-chamber view of the heart, showing (i) the probe and scanning view, (ii) 2D ultrasound image, and (iii) schematic representation of the view. LA, left atrium; MV, mitral valve; LV, left ventricle; RA, right atrium; TV, tricuspid valve; RV, right ventricle. (Image sourced from: http://www.123sonography.com).
Figure 4.8. Apical five-chamber view of the heart, showing (i) the probe and scanning view, (ii) 2D ultrasound image, and (iii) schematic representation of the view. LA, left atrium; LVOT, left ventricular outflow tract; LV, left ventricle; AO, aorta; RA, right atrium; RV, right ventricle.

Pulsed tissue Doppler imaging (TDI)
Pulsed-TDI was used to assess myocardial wall motion velocities at the mitral annulus of the LV, in the apical four-chamber (septal and lateral walls) and apical two-chamber (inferior and anterior walls) views (Figure 4.9). Systolic ($S_m$), early diastolic ($E_m$) and late-diastolic ($A_m$) velocity was calculated at each site.
Figure 4.9. Apical two-chamber view of the heart, showing (i) the probe and scanning view, (ii) 2D ultrasound image, and (iii) schematic representation of the view. LA, left atrium; LV, left ventricle. (Image sourced from: http://www.123sonography.com).

Several estimates of diastolic function were subsequently calculated using diastolic velocities from transmitral flow and TDI, and measurements from IVRT. These measurements included: (i) the $E/E_m$ ratio, recorded at the lateral wall of the mitral annulus, used as an index of LV filling pressure; (ii) the $E/A$ ratio, indicative of LV diastolic filling efficiency; and (iii) E-wave deceleration time (DT), representative of myocardial relaxation capacity. LV diastolic dysfunction was graded according to well-documented criteria (Nagueh et al., 2009) using indices of diastolic function (Figure 4.10).
Figure 4.10. Grading scheme for LV diastolic dysfunction. Av, average; LA, left atrium; Val, Valsalva; DT, deceleration time; $e'$, early diastolic (referred to as Em in this thesis); E, early diastolic; A, late diastolic; Ar, pulmonary venous flow reversal (Figure sourced from: Nagueh et al., 2009, p. 188).

Speckle tracking echocardiography (STE)

STE was used to quantify myocardial wall motion for the assessment of LV systolic and diastolic function (Leitman et al., 2004). Peak myocardial tissue deformation (or strain) and its rate of deformation (strain rate or SR) were assessed in the longitudinal and circumferential axes of the LV. In addition, myocardial mechanics, including rotation, twist and twist/untwist rate, were analysed. Longitudinal LV strain and SR were obtained from 2D harmonic grey scale images in the apical four-chamber view. Radial and circumferential strain and SR analysis was obtained from the parasternal short-axis view, at apical, mid, and basal levels of the LV (Marwick et al., 2009) (Figure 4.11). Data were recorded for subsequent offline analyses.
Figure 4.11. Parasternal short-axis view of the heart at the: A. apex, B. mid (papillary muscle), and C. base (mitral valve) level of the LV. RV, right ventricle; LV, left ventricle; PMPM, posteromedial papillary muscle; ALPM, anterolateral papillary muscle; AML, anterior mitral leaflet; PML, posterior mitral leaflet (Image sourced from: echocardiographer.org/TTE).

For STE measures, following manual endocardial border tracing (Marwick et al., 2009), proprietary software (EchoPAC v108.1.5, GE Medical Systems, Horton, Norway) automatically tracked myocardial motion (Figure 4.12). Subsequently, LV Lagrangian strain and SR, and their time to peak values, were obtained from six anatomical segments (i.e. anterior, antero-septal, inferior, lateral, posterior, septal). LV rotation was assessed from basal and apical short axis views, with care taken to ensure that the basal short-axis plane contained the mitral valve, and the apical short-axis plane was acquired distally to the papillary muscle. LV twist was calculated as the maximal apical LV rotation, minus the maximal basal LV rotation (Helle-Valle et al., 2005). Only cine-loops with adequate frame rate (≥ 70 Hz), as well as endocardial border definition and good image tracking as determined by the proprietary software, were used (Leitman et al., 2004; Marwick et al., 2009).
4.5.3. Reliability analyses for echocardiography

For this study, the same experienced operator performed all ultrasonography scans and relevant off-line analyses, using the same equipment and settings for each participant. The relative disadvantage of ultrasonography is that it is difficult to perform, requiring a skilled sonographer and an appropriate training period (Raitakari & Celermajer, 2000). A measure is considered reliable if it produces the same result under a number of possible situations (Peat & Barton, 2005). Intra-rater reliability describes the agreement between measures performed by the same rater on the same data on different occasions (test-retest), while inter-rater reliability is the agreement between measurements performed on the same data by different raters. In order to demonstrate that the off-line echocardiographic analyses were reproducible, intra- and inter-rater reliability testing was conducted for this study. For major conventional and TDI echocardiography variables, 10 participant scans were randomly selected for analysis, and for selected STE variables, 20 participant scans were randomly selected for analysis. Each variable was analysed twice by the same observer separated by at least two
days (O1 and O2), and once by another experienced observer (O3) blinded to previous results. The following data set comparisons were performed: O1 vs. O2, and O1 vs. O3. In this study, O1 and O2 represented the author of this thesis, while O3 represented an operator experienced in all measures listed in Table 4.3. Four measures of reliability were calculated for the echocardiography variables (Table 4.3), and these were:

**Coefficient of variation (CV)**

The mean ($\bar{x}$) and standard deviation (SD) of two data points were calculated and CVs established (below). A CV less than 10% is generally accepted to represent ‘good’ reliability (Atkinson & Nevill, 1998). Intra- and inter-observer CVs are shown in Table 3.

\[
CV\% = \left( \frac{SD}{\bar{x}} \right) \times 100
\]

**Intra-class correlation coefficient (ICC)**

To calculate ICCs, a two-way, mixed effect (repeated) model ICC (3, 1) was computed in SPSS. The ICC reflects the degree of correspondence and agreement among ratings, with an ICC of 1.00 indicating perfect agreement and minimal variation within measures of interest. Generally, an ICC $\geq 0.75$ is indicative of good reliability, whilst an ICC $< 0.75$ describes moderate to poor reliability (Portney & Watkins, 2008).
Limits of agreement (LOA)

Upper and lower LOA were calculated from the Bland and Altman method (below), to provide a range in which 95% of the differences lie (Bland & Altman, 1999).

\[
LOA = \text{mean difference} \pm (1.96 \times \text{SD})
\]

Measurement error (ME)

ME represents the deviation of the outcome of a measurement from the true value. ME was calculated (below) and subsequently converted to an error range (±) by multiplying by the critical value, 1.96 (Peat & Barton, 2005).

\[
ME = \left(\frac{\text{SD of difference}}{\sqrt{2}}\right) \times 1.96
\]
Table 4.3. Intra- and inter-rater reliability analyses for echocardiographic parameters.

<table>
<thead>
<tr>
<th></th>
<th>Intra-rater</th>
<th></th>
<th>Inter-rater</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CV (%)</td>
<td>ICC</td>
<td>LOA</td>
<td>ME</td>
</tr>
<tr>
<td><strong>Morphology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV mass</td>
<td>2.66</td>
<td>0.96</td>
<td>-6.75 to 5.98 ± 8.04 g</td>
<td>2.12</td>
</tr>
<tr>
<td>LVED diameter</td>
<td>1.11</td>
<td>0.98</td>
<td>-0.13 to 0.21 ± 1.19 mm</td>
<td>1.98</td>
</tr>
<tr>
<td>IVS thickness</td>
<td>3.20</td>
<td>0.91</td>
<td>-0.07 to 0.14 ± 0.76 mm</td>
<td>4.85</td>
</tr>
<tr>
<td>LV PW thickness</td>
<td>2.35</td>
<td>0.85</td>
<td>-0.12 to 0.12 ± 0.86 mm</td>
<td>3.55</td>
</tr>
<tr>
<td><strong>Function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E velocity</td>
<td>1.95</td>
<td>0.96</td>
<td>-0.09 to 0.22 ± 4.8 cm·s⁻¹</td>
<td>1.60</td>
</tr>
<tr>
<td>A velocity</td>
<td>2.53</td>
<td>0.99</td>
<td>-0.04 to 0.05 ± 3.0 cm·s⁻¹</td>
<td>1.85</td>
</tr>
<tr>
<td>E/A Ratio</td>
<td>2.51</td>
<td>0.97</td>
<td>-0.16 to 0.20 ± 0.13</td>
<td>1.97</td>
</tr>
<tr>
<td>Septal Sa velocity</td>
<td>1.41</td>
<td>0.68</td>
<td>-0.01 to 0.01 ± 0.70 cm·s⁻¹</td>
<td>2.35</td>
</tr>
<tr>
<td>Septal Ea velocity</td>
<td>2.21</td>
<td>0.83</td>
<td>-0.01 to 0.02 ± 0.10 cm·s⁻¹</td>
<td>4.03</td>
</tr>
<tr>
<td>Septal Aa velocity</td>
<td>1.47</td>
<td>0.74</td>
<td>-0.01 to 0.01 ± 0.80 cm·s⁻¹</td>
<td>4.18</td>
</tr>
<tr>
<td><strong>Speckle tracking echocardiography</strong> (n=20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV L strain</td>
<td>5.87</td>
<td>0.86</td>
<td>-2.78 to 3.65 ± 2.27 %</td>
<td>7.83</td>
</tr>
<tr>
<td>LV L diastolic SR</td>
<td>4.33</td>
<td>0.96</td>
<td>-0.21 to 0.16 ± 0.13 S·s⁻²</td>
<td>5.48</td>
</tr>
<tr>
<td>LV L systolic SR</td>
<td>4.10</td>
<td>0.89</td>
<td>-0.09 to 0.14 ± 0.08 S·s⁻²</td>
<td>5.51</td>
</tr>
<tr>
<td>LV C strain</td>
<td>4.67</td>
<td>0.91</td>
<td>-3.42 to 2.97 ± 2.26 %</td>
<td>8.30</td>
</tr>
<tr>
<td>LV C diastolic SR</td>
<td>5.73</td>
<td>0.95</td>
<td>-0.30 to 0.35 ± 2.23 S·s⁻³</td>
<td>5.38</td>
</tr>
<tr>
<td>LV C systolic SR</td>
<td>5.78</td>
<td>0.79</td>
<td>-1.10 to 1.01 ± 0.74 S·s⁻³</td>
<td>11.52</td>
</tr>
<tr>
<td><strong>Myocardial mechanics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apical rotation</td>
<td>7.08</td>
<td>0.92</td>
<td>-1.12 to 0.92 ± 0.72 °</td>
<td>10.04</td>
</tr>
<tr>
<td>Basal rotation</td>
<td>6.56</td>
<td>0.97</td>
<td>-1.25 to 0.64 ± 0.67 °</td>
<td>9.73</td>
</tr>
<tr>
<td>LV twist</td>
<td>7.95</td>
<td>0.97</td>
<td>-1.35 to 1.97 ± 1.18 °</td>
<td>11.75</td>
</tr>
<tr>
<td>LV twist/untwist rate</td>
<td>9.20</td>
<td>0.82</td>
<td>-21.72 to 27.19 ± 8.82 °s⁻¹</td>
<td>11.75</td>
</tr>
</tbody>
</table>

CV, coefficient of variation; ICC, intra-class correlation coefficient; LOA, limits of agreement; ME, measurement error; TDI, tissue Doppler imaging; LV, left ventricle; LVED, left ventricular end diastolic; IVS, intra-ventricular septum; LV PW, left ventricular posterior wall; L, longitudinal; SR, strain rate; C, circumferential; S, strain; NA, not available. Circumferential and radial are the average of base and apex. Twist/untwist rate is the average of diastolic and systolic.

In summary, all variables measured using conventional and TDI echocardiography showed good reliability, with CVs < 5% for both intra-rater (range: 1.1 to 3.2%) and inter-rater (range: 1.6 to 4.8%) reliability (Table 4.3). In comparison, CVs of variables measured using STE were moderate to good for intra-rater (range: 4.0 to 9.2%) and moderate to weak for inter-rater (range: 5.1 to 11.7%) reliability.
Additionally, the variables with the strongest CV for both intra- and inter-rater reliability were LV end-diastolic diameter and transmitral $E$ velocity, while the weakest CV for both intra- and inter-rater reliability was observed in LV twist measures. For ICC, values ranged between 0.46 to 0.99, with the strongest variable being transmitral $A$ velocity, and the weakest ICCs were found in the variables of septal $S_m$ velocity (intra-rater) and inter-ventricular septum (inter-rater). Limits of agreement were similar for intra- and inter-rater reliability, with the exception of LV mass, which was greater for inter-rater reliability. In agreement with previous statistical reliability calculations, measurement error was similar for intra- and inter-rater reliability. However, measurement errors for LV end-diastolic diameter and LV twist were greater for the inter-rater measure. The same rater performed all image acquisition and subsequent data analyses, and all values for intra-rater CV (< 10%) and ICC (< 0.75) were within an acceptable range (Atkinson & Nevill, 1998; Portney & Watkins, 2008).

4.5.4. Survey documents

Self-administered, take-home survey documents were completed by participants; once for the cross-sectional studies, and at the pre-intervention/pre-control, post-intervention/post-control, and sustainability time points for the intervention study. These documents comprised:

*Customised survey*

All participants completed a written custom survey (Appendix 9). It was difficult to use currently available surveys because they lacked detailed questions, and showed some deficits in age appropriateness, for the population targeted in this study. For this reason, the survey that participants completed was customised and based on a collection of other questionnaires. i.e. (i) Dietary Questionnaire for Epidemiological Studies (The Cancer Council Victoria, 2005); (ii) Barriers to Healthy Eating Scale (Fowles & Feucht, 2004); (iii) 7-day Physical Activity Recall (Sallis, Buono, Roby, Micale, & Nelson, 1993); (iv) The Short Form (36) Health Survey (Ware, 1996); and (v) Women’s Health Australia Survey (Women's Health Australia, 2009). The custom survey was subsequently validated using the method of face validation. Face validation describes the extent to which a method (i.e. the custom survey) measures what it is intended to measure. A measure was therefore deemed valid if it
measured the construct that it aimed to measure (Peat & Barton, 2005). Based on subjective judgement, face validation is acknowledged to be the simplest form of validity (Gravetter & Forzano, 2012). To validate the customised survey used in this study, a pilot study with face validation was conducted. A group of young women, representative of the population (n=5) and several experts in the field of qualitative research (n=5), each completed the survey and provided feedback on its design (Appendix 8). Participants were asked if the language and layout of the survey were clear and easy to understand; how long it took to complete; and to provide comments on areas of ambiguity and/or difficult questions (Fink & Koseoff, 1985). Based on this peer-review process, the survey was revised before implementation.

The survey document was divided into three sections: (i) health and lifestyle; (ii) nutrition; and (iii) physical activity. Data were collected on demographic parameters and living conditions, family medical history, health status, medication use, food-frequency, reproductive and body weight history, and frequency, duration, intensity and importance of physical activity. The importance (or value) placed on physical activity was assessed using a single-item question. Participants responding to the question using a Likert-scale (1 = not at all important, 5 = very important). Furthermore, physical activity records were edited for completeness and clarity by the researcher in the presence of the participant. These details provided information about each participant’s background and current lifestyle trends, which assisted the researcher with program design during the lifestyle intervention study.

**Psychological inventories**

Participants completed three self-reported psychological inventories, including:

1) Motives for Physical Activity Measure – Revised (MPAM-R) (Ryan, Frederick, Lepes, Reubio, & Sheldon, 1997). The MPAM-R is a 30-item inventory intended to assess the strength of five general motives for participation in physical activities including: enjoyment (7 items), competence (7 items), appearance (6 items), fitness (5 items), and social (5 items); with each rated on a 5-point Likert scale (1 = not at all true, 5 = very true).
2) Perceived Barriers to Activity (Booth, Bauman, Owen, & Gore, 1997; King et al., 2000). This inventory consists of 18 often-reported personal barriers to physical activity participation. Participants were required to identify the frequency with which barriers occurred, rated on a 5-point Likert scale (1 = never, 5 = very often).

3) Stage of Change for Exercise (B. Marcus, Selby, Niaura, & Rossi, 1992). Participants provided details of their stage of exercise behaviour change by selecting the most appropriate response. The model, which provides an indication of readiness to exercise, is modelled on the Transtheoretical Stage of Change Model (Figure 4.13) (Prochaska & Diclemente, 1986), 1983). Participants were classified as: (i) pre-contemplation [do not perform exercise and have no intentions of doing so within the next six months], (ii) contemplation [do not perform exercise, but have the intention of doing so within the next six months], (iii) preparation [I currently exercise, but not regularly], (iv) action [have performed exercise for less than six months], (v) maintenance [have performed exercise for more than six months], and (vi) relapse [performed exercise regularly, but abandoned it recently].

![Figure 4.13. The Transtheoretical Model of Behaviour Change, also known as the Stage of Change Model (image adapted from (Prochaska & Diclemente), 1983).](image)
Food recall
Participants completed a 3-day food recall (Appendix 10). This document required each participant to record a detailed account of all food and beverage intake for a 3-day period (two consecutive weekdays and either a Saturday or Sunday), without altering their normal consumption pattern during the recall period. Documenting began upon waking in the morning until going bed that evening. Information was entered into the FoodWorks® 7 Professional (Edition 2006; Xyris Software, Highgate Hill, Queensland, Australia) database software system by a dietitian accredited by the Dietitians Association of Australia to calculate daily energy balance, macronutrient (i.e. carbohydrate, fat, protein), and micronutrient (i.e. iron, calcium, magnesium) intake. Information obtained at pre-intervention from the food recall, together with data attained from the Barriers to Healthy Eating Scale (Fowles & Feucht, 2004), and food frequency questions, contained within the custom survey, was used by the dietitian to develop the theoretical material for the nutrition component of the lifestyle intervention.

Training diary
Participants completed a training diary to record structured physical activities performed during the lifestyle intervention. Participants were required to detail the frequency, type, intensity and duration of any extra sessions they performed (in addition to those prescribed by the researcher) during the intervention period (Appendix 11). A training diary of weekly physical activity was also kept during the sustainability phase (Appendix 12).
4.6. Statistical Analysis

This section describes the statistical tests conducted for the cross-sectional and intervention studies. All statistical procedures were performed using SPSS (Statistical Package for Social Sciences) version 21.0, with an alpha level of $P < 0.05$ representing statistical significance.

4.6.1. Normal distribution

All continuous variables were checked for normal distribution according to established standards, with the following critical appraisal criteria applied (Peat & Barton, 2005):

1. Data are continuous, interval or ratio
2. Difference between mean and median is $< 10\%$
3. The mean is greater than twice the SD
4. Skewness and kurtosis scores do not exceed $\pm 1.00$
5. The Shapiro-Wilk test ($n<100$) has $P > 0.05$

Variables that did not satisfy the above Gaussian distribution criteria were log-transformed before being evaluated with parametric statistical analyses (Peat & Barton, 2005) (Appendix 21).

4.6.2. Statistical tests

After checks for normal distribution and subsequent log transformation, data were treated with a variety of statistical approaches. Both parametric and non-parametric analyses were performed, where appropriate.
Cross-sectional studies

Differences in descriptive characteristics between women with abdominal obesity (WC ≥ 80cm) and control participants (WC < 80cm) were assessed using an independent-samples t-test. Descriptive data were generally presented as mean ± SD, with select non-normally distributed data presented as median ± interquartile range. Effect sizes and power were calculated with Hedge’s g (uneven groups) described below. Chi-square analyses were used in the comparison of categorical data and for the evaluation of incidences of specific parameters [for example, the percentage of women with abdominal obesity who have elevated insulin resistance (i.e HOMA-IR score ≥ 2.0) compared with control participants who display elevated HOMA-IR]. Unadjusted odds ratios estimated the disease risk between overweight/obesity (classified by WC, BMI and WHtR) and cardiometabolic risk factors, with continuity correction used to establish significance (Peat & Barton, 2005). Furthermore, receiver operating characteristic (ROC) curves were used to establish the cut-off point and positive likelihood ratio in continuously distributed variables (i.e. WC, BMI, WHtR). Pearson’s r correlation coefficient analyses were used to measure the strength of association between cardiometabolic risk factors and cardiac morphology, function and myocardial measures (Chapter 6).

Lifestyle intervention study

Data were analysed with a linear mixed model (LMM) analysis. LMM is a longitudinal, multi-level model that allows for assessment of both within-subject and between-group differences (Chapters 7, 8 and 9). LMM is similar to a multiple regression, in which a separate regression is created for each individual, then the regression coordinates are combined into a single model (Peat & Barton, 2005). LMM has several advantages compared with a repeated measures analysis of variance (ANOVA), including: (i) all participants are included regardless of missing cells and incomplete data sets; (ii) there is no requirement for cell balance, sphericity or homogeneity of variance across the model; (iii) it is based on regression modelling, therefore allowing for unequal distances between time points; and (iv) interactions are not automatically included (Cnaan, Laird, & Slasor, 1997; Peat & Barton, 2005). Conversely, one disadvantage of LMM is that no estimates of effect size are included in the statistical model. In this study, LMM was used to compare differences in outcome
measures between groups and across time (i.e. pre-intervention, post-intervention and sustainability) for the intervention and control groups.

The statistical analysis included a linear mixed model using “starters” compared with “completers”. In addition, a per-protocol comparison was made by which only data of those who completed the entire trial according to protocol were counted towards the final results and removed participants who withdrew from the study. The same strategy applied to the intervention and control groups. No differences were found using both analyses. Furthermore, a sensitivity analysis was performed to compare differences between participants who represented both the wait-list control and intervention participants, with participants from the intervention and control groups who did not change groups. No differences were found using both analyses and the findings were not altered.

4.6.3. Effect size

Effect size was used to calculate the magnitude of the difference for both cross-sectional and intervention study variables. Equal variances were assumed An effect size of >0.2 was considered small, >0.5 moderate, and >0.8 large (Cohen, 1988). The following formula for Cohen’s $d$ was used, where $\bar{x}_1$ and $\bar{x}_2$ represent the mean of two populations:

$$
d = \frac{\bar{x}_1 - \bar{x}_2}{SD_{pooled}}
$$

The SD $pooled$ was derived from the following formula (Cohen, 1988), where $n_1$ and $n_2$ represents the sample sizes for the two populations, and $SD_1$ and $SD_2$ represents the standard deviation of the mean in the variable compared between each population:

$$
SD_{pooled} = \sqrt{\frac{(n_1 - 1)SD_1^2 + (n_2 - 1)SD_2^2}{n_1 + n_2}}
$$
Due to uneven group sizes, Hedge’s $g$ effect size was subsequently calculated. Therefore, following the calculation of Cohen’s $d$, Hedge’s $g$ was obtained:

$$g = \frac{d}{\sqrt{\frac{n_1 - n_2}{n_1 - n_2 - 2}}}$$

4.6.4. Power analysis

A power analysis was conducted to determine the power achieved for effect size for variables were there was a significant between-group difference. Table C.1.2 in Portney and Watkins (2008), p. 845 was used, together with effect size achieved from Hedge’s $g$, to calculate $1-\beta$ for a two-tailed t-test ($\alpha = 0.05$). The following equation was used to determine the harmonic mean of the two unequal samples, where $n_1$ and $n_2$ represents the sample sizes for the two populations:

$$n' = \frac{2n_1n_2}{n_1 + n_2}$$
4.7. Evaluation of the lifestyle intervention

At the completion of the intervention phase, a focus group (n = 7) was conducted to gather rich data from participants about their experience during the lifestyle intervention. In addition, a process evaluation survey was completed anonymously by all participants at the completion of the intervention. Similarly, wait-list control participants who withdrew from the study were invited to provide feedback regarding reasons for withdrawal. These procedures are described in more detail in Addendum 7.2.

In summary, this chapter has presented details of methods and procedures not elsewhere included in the thesis. The descriptions here are provided to strengthen the rigour and rationale for all selected physical and statistical tests as well as protocols and procedures used throughout the thesis.
Chapter 5. Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures.

**Bianca L. Share;** Geraldine A. Naughton; Philippe Obert; Jennifer K. Peat; Justin G. Kemp

Publication Statement:
This work was accepted for publication in the *Journal of Science and Medicine in Sport* (September, 2013), please see Appendix 1 and 15.

Acknowledgements:
The authors would like to express their gratitude to all participants involved in the Young Women’s Heart Health Study. Thanks are also extended to Bianca Gazzola, Tanya Wilson and Melissa Nicholls.
Abstract

Objectives: This study aimed to (1) investigate cardiometabolic risk markers in young women (18-30 years) with overweight/obesity, and (2) establish whether the measures of waist circumference (WC) and body mass index (BMI) possess similar associations of cardiometabolic risk.

Methods: Cross-sectional study design. Cardiometabolic risk factors including, anthropometric, metabolic syndrome markers, biochemical, and other health/fitness indicators were assessed in women when classified as overweight/obese by WC [WC 91.9 ± 10.1 cm, age 22.3 ± 3.5 y, n=38] versus control [n=30, WC 71.4 ± 3.5 cm, age 20.1 ± 0.9 y], and when classified by BMI [n=35, BMI 32.2 ± 5.2 kg·m$^{-2}$, age 22.5 ± 3.6 y] versus control [BMI 21.7 ± 1.9 kg·m$^{-2}$, age 20.1 ± 0.9 y, n=33].

Results: Compared with controls, women with overweight/obesity (classified by WC or BMI) displayed elevated body mass, systolic blood pressure and HOMA-IR, and reduced estimated VO$_2$max and weekly physical activity, with no differences in self-reported energy intake. The unadjusted odds ratio of being classified with overweight/obesity and an elevated HOMA-IR and/or less than recommended physical activity ranged between 5.1 to 10.0. Receiver operator characteristic curves indicated WC, BMI and waist-to-height ratio cut-off points of ≥ 84.2 cm, ≥ 30.6 kg·m$^{-2}$ and ≥ 0.5, respectively, for HOMA-IR, and ≥ 80.6 cm, ≥ 25.2 kg·m$^{-2}$ and ≥ 0.46, respectively, for less than recommended physical activity.

Conclusion: WC and BMI have similar associations with cardiometabolic risk, with greater HOMA-IR and lower physical activity, rather than differences in traditional metabolic syndrome markers, observed in young women with overweight/obesity.

Keywords: Obese, waist circumference, body mass index, waist-to-height ratio, cardiovascular disease, physical activity.
Introduction

In Australia, the prevalence of overweight/obesity is 35% for women aged 18-24 years, and 42% for women aged 25-34 years (Australian Bureau of Statistics, 2012). However, cardiometabolic risk data are more frequently described in adolescents (Wedin, Diaz-Gimenez, & Convit, 2012) and even more so in older people (Fogelholm, 2010), with women in young adulthood under-represented. The gains in weight in young adult women are paralleled by substantial declines in physical activity (Adamson et al., 2007), with the greatest declines occurring between 25 to 34 years of age (Australian Bureau of Statistics, 2012). When assessed against current National Physical Activity Guidelines (Department of Health and Ageing, 2005), 59% of Australian women aged 18-34 years failed to achieve recommended weekly amounts (210 min) of moderate exercise (Cleland, Schmidt, Salmon, Dwyer, & Venn, 2011), while the Australian Longitudinal Study on Women’s Health found that 45% of overweight/obese women aged 18-23 years performed none or very low levels of daily physical activity (Lucke et al., 2007). A better understanding of cardiometabolic risk factors in this age group is important for early detection of chronic disease risk, especially given the rise in overweight/obesity and low prevalence of physical activity of young women.

With overweight/obesity being a modifiable risk factor for cardiovascular disease (CVD), Type 2 diabetes mellitus, and the metabolic syndrome (Alberti et al., 2009), simple anthropometric measures of body mass index (BMI) and waist circumference (WC) are in frequent clinical use. BMI is an estimate of total fat mass and has been used as a predictor of health risk (National Health and Medical Research Council, 2003). For adults, a BMI of 25.0 to 29.9 kg·m$^{-2}$ is classified as overweight, and a BMI $\geq$ 30 kg·m$^{-2}$ is classified as obese (World Health Organisation, 2000). Correspondingly, centrally distributed (abdominal) obesity using WC has gender and ethnic-specific criteria available (Alberti et al., 2009). For Caucasian women, abdominal obesity is defined as a WC $\geq$ 80 cm (Alberti et al., 2009). Given the differing criteria for BMI and WC in classifying overweight/obesity in young women, it is important to establish whether these anthropometric measures identify the presence and/or similar relative risk of other markers of cardiometabolic risk.
Therefore, the aims of this study were to: (1) investigate blood-borne and lifestyle markers of cardiometabolic risk in young women (18-30 years) with overweight/obesity classified by clinically useful methods, and (2) establish whether WC and BMI possess similar associations of cardiometabolic disease risk in these women. For comparative purposes, waist-to-height ratio (WHtR) was included in some statistical analyses.

Methods

Ninety-three university-enrolled participants responded to recruitment advertisements and emails. Of these, 11 did not meet the inclusion criteria (below) and a further 14 eligible participants did not continue through testing. Therefore, 68 Caucasian women aged 18 to 30 years completed all testing, between 2010-2012. Participants were divided into two groups: (1) an “elevated” waist circumference ≥ 80 cm [n = 38, abdominal obesity, mean ± standard deviation, WC 91.9 ± 10.1 cm, age 22.3 ± 3.5 y], or (2) a waist circumference < 80 cm control group [n=30, WC 71.4 ± 3.5 cm, age 20.1 ± 0.9 y]. There was no difference between groups in socio-economic status [$\chi^2(4, n = 66) = 0.42, p = 0.382$], with 51.4% of participants in the elevated WC group and 62.1% of participants in the control group living in metropolitan suburbs of the most advantaged quintile of socio-economic status (Australian Bureau of Statistics, 2011). Exclusion criteria included being pregnant or breastfeeding, liver or kidney disease, heart arrhythmia, insulin dependent diabetes mellitus, gestational diabetes, polycystic ovarian syndrome, thyroid abnormalities and a history of bariatric surgery or liposuction. All participants were non-smokers. For additional analysis, the same 68 participants were divided into two groups according to the classifications of BMI, resulting in participants being classified as either overweight/obesity [n=35, defined as a BMI ≥ 25 kg·m$^{-2}$, BMI 32.2 ± 5.2 kg·m$^{-2}$, age 22.5 ± 3.6 y] or normal BMI [n=33, BMI 18.5 - 24.9 kg·m$^{-2}$, BMI 21.7 ± 1.9 kg·m$^{-2}$, age 20.1 ± 0.9 y].

Following approval by the University Human Research Ethics Committee (V2009-91), written informed consent was obtained and all participants completed a Cardiovascular Risk Assessment Form prior to testing. Participants arrived at the laboratory following a 12 hour fast. They were also requested to refrain from strenuous physical activity in the 24 h prior to testing.
Waist circumference (WC) was measured (Alberti et al., 2009) to the nearest 0.1 cm using a non-elastic measuring tape, with the average of two measurements reported. The coefficient of variation for WC, assessed from duplicate measures, was 1.26%, with an intra-class correlation (ICC, 2, 1) of 0.986 and measurement error of 1.34%, which equates to an error range of ± 2.6 cm. Body mass was measured to the nearest 0.1 kg using digital scales (Tanita, Tokyo, Japan). Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer (Seca, Germany). Body mass index (BMI) (weight [kg]/height [m²]), was defined as overweight BMI 25.0 – 29.9 kg·m⁻² and obese BMI ≥ 30.0 kg·m⁻² (World Health Organisation, 2000). Participants were dichotomised by waist-to-height ratio (WHtR) using WC divided by height. A ratio of 0.5 was defined as the boundary value (Browning, Hsieh, & Ashwell, 2010).

Metabolic syndrome was defined according to the most recent and unified criteria (Alberti et al., 2009), where three of the following five are met: 1) waist circumference ≥ 80 cm, 2) raised serum triglycerides ≥ 1.7 mmol·l⁻¹, 3) reduced HDL-cholesterol < 1.30 mmol·l⁻¹, 4) raised systolic blood pressure ≥ 130 mmHg or raised diastolic blood pressure ≥ 85 mmHg, and 5) elevated fasting plasma glucose ≥ 5.6 mmol·l⁻¹ or previously diagnosed type 2 diabetes. No participants in this study were taking medication to treat elevated triglycerides or reduced HDL-cholesterol, which is considered an alternative indicator of abnormal levels (Alberti et al., 2009). Additional measurements of insulin resistance, including fasting insulin and HOMA-IR, and the pro-inflammatory marker high sensitivity C-reactive protein (hs-CRP) were also measured in participants.

Intravenous blood sampling provided blood lipid profiles: serum concentrations of triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol (Reflotron Plus, Roche, Switzerland). A CV of 3.8% was found between Reflotron measurements for total cholesterol and a standardised wet-chemistry method (Statland, 1990). Fasting plasma glucose, insulin and hs-CRP concentrations were analysed by a pathology unit at a leading hospital (reagents Beckman Coulter, assays on Olympus AU2700, Abbott Architect i1000, and Olympus AU640 analyser). Insulin resistance was estimated by the homeostasis model assessment (HOMA-IR), using the equation: HOMA-IR = fasting insulin concentration (µU/mL) x fasting glucose concentration (µU/mL) / 22.5 (Matthews et al., 1985). HOMA-IR was used as a surrogate measure of whole body insulin sensitivity and β-cell functioning and has been shown to correlate well with estimates using the euglycemic clamp method (r =
0.88) (Bonora et al., 2000; Matthews et al., 1985). A HOMA-IR value ≥ 2.0 was considered indicative of insulin resistance (Jensterle et al., 2008). For hs-CRP, a value of > 3.0 mg·l⁻¹ was deemed high risk (Pearson et al., 2003). Blood pressure was obtained with an automated digital sphygmomanometer (Dinamap, GE technology, USA).

The YMCA submaximal cycle ergometer test (Golding, Meyers, & Sinning, 1989) (Appendix 19) was used to estimate maximal oxygen uptake (predicted VO₂max). After completing a short submaximal warm-up, participants cycled (Monark, Ergomedic 838E, Sweden) for three consecutive 3-min work rates at a constant cadence of 50 rpm, and an initial power output of 25 W, resulting in a total test time of 9 min. Heart rate during the last 15 s of stage one was used to determine subsequent workloads. At the completion of the test, heart rate was extrapolated against work rate (W) using regression analysis to estimate maximal aerobic capacity.

Within the acknowledged limitations of dietary recall (Magarey et al., 2011), participants completed a three-day food diary of food and beverage intake on two weekdays and one weekend day. Macro and micro nutrients, and average daily energy intake were estimated (FoodWorks® 7 Professional) by a research dietician, blinded to grouping.

Participants completed a self-administered lifestyle survey addressing (i) health status and medical conditions, (ii) self-reported physical activity and exercise, (iii) nutrition habits, and (iv) perceived barriers to physical activity (King et al., 2000). Additionally, type, frequency and duration of typical leisure and/or sporting activities were confirmed during an interview with the researcher.

Data were analysed using IBM SPSS Statistics, Version 19 for Windows (SPSS Inc, Chicago IL) and first tested for normal distribution using the Shapiro-Wilk statistic and skewness and kurtosis values (Peat & Barton, 2005). Log transformation was used when data were not normally distributed. All data are presented as mean ± standard deviation, with the exception of medians [interquartile range] for non-normally distributed data, reported prior to log transformed treatment. An alpha level of p < 0.05 was used to determine significance. Group comparisons were performed using independent t-tests. Due to uneven group size, Hedge’s g calculated effect size. An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995). The mean difference between
overweight/obesity and control participants for each cardiometabolic risk factor included 95% confidence intervals.

Unadjusted odds ratios were used to estimate disease risk given exposure and describe the strength of association between overweight/obesity (classified by WC, BMI and WHtR) and cardiometabolic risk factors. Continuity correction was used to establish significance (Peat & Barton, 2005)

Receiver operating characteristic (ROC) curves were plotted to determine the point that maximises the likelihood ratio and cut-off points for WC, BMI and WHtR. Furthermore, the positive likelihood ratio was computed for each cut-off point. Pearson’s Chi-square analysis was used to compare the frequency of scores for barriers to being physically active between the two groups.

Results

Anthropometric and cardiometabolic data are shown in Table 5.1 and Table 5.2 (see also graphs in Appendix 14). Compared with controls, women with abdominal obesity (WC ≥ 80 cm) had greater body mass, body mass index, waist circumference and waist-to-height ratio (p < 0.001). Similar differences were observed for BMI.
Table 5.1. Cardiometabolic risk factors in participants with and without abdominal obesity, as defined by waist circumference

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control WC &lt; 80cm (n=30)</th>
<th>Abdominal obesity WC ≥ 80cm (n=38)</th>
<th>P-value</th>
<th>Effect size Hedge's g</th>
<th>Power (1-ß)</th>
<th>Mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>60.3 ± 6.7</td>
<td>86.7 ± 18.3</td>
<td>&lt;0.0001*</td>
<td>1.61</td>
<td>1.00</td>
<td>26.4 (19.9, 32.8)</td>
</tr>
<tr>
<td>Stature (m)</td>
<td>1.7 ± 0.06</td>
<td>1.7 ± 0.06</td>
<td>0.311</td>
<td>0.15</td>
<td>-</td>
<td>-0.01 (-0.44, 0.01)</td>
</tr>
<tr>
<td>Body mass index (kg·m⁻²)</td>
<td>21.6 ± 1.9</td>
<td>31.5 ± 5.5</td>
<td>&lt;0.0001*</td>
<td>2.00</td>
<td>1.00</td>
<td>9.9 (7.9, 11.8)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>71.4 ± 3.5</td>
<td>91.9 ± 10.1</td>
<td>&lt;0.0001*</td>
<td>2.28</td>
<td>1.00</td>
<td>20.5 (16.9, 24.0)</td>
</tr>
<tr>
<td>Waist-to-height ratio (WHtR)</td>
<td>0.43 ± 0.02</td>
<td>0.55 ± 0.06</td>
<td>&lt;0.0001*</td>
<td>2.41</td>
<td>1.00</td>
<td>0.13 (0.11, 0.15)</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>114 ± 8</td>
<td>121 ± 8</td>
<td>0.007</td>
<td>0.60</td>
<td>0.75</td>
<td>5.7 (1.6, 9.7)</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>67 ± 8</td>
<td>67 ± 7</td>
<td>0.834</td>
<td>0.04</td>
<td>-</td>
<td>-0.4 (-4.0, 3.3)</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>1.5 ± 0.3</td>
<td>1.6 ± 0.5</td>
<td>0.241</td>
<td>0.26</td>
<td>-</td>
<td>0.13 (-0.08, 0.33)</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>1.1 ± 0.3</td>
<td>1.2 ± 0.4</td>
<td>0.400</td>
<td>0.17</td>
<td>-</td>
<td>0.07 (-0.10, 0.25)</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>4.8 ± 0.4</td>
<td>4.7 ± 0.5</td>
<td>0.152</td>
<td>0.29</td>
<td>-</td>
<td>-0.2 (-0.4, 0.1)</td>
</tr>
<tr>
<td><strong>Additional biochemical parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.6 ± 1.0</td>
<td>4.4 ± 0.6</td>
<td>0.313</td>
<td>0.26</td>
<td>-</td>
<td>-0.2 (-0.6, 0.2)</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)⁹</td>
<td>5.0 [2.2]</td>
<td>8.0 [5.0]</td>
<td>&lt;0.0001*</td>
<td>0.84</td>
<td>0.94</td>
<td>3.7 (2.0, 5.4)</td>
</tr>
<tr>
<td>HOMA-IR⁹</td>
<td>1.1 [0.5]</td>
<td>1.7 [1.1]</td>
<td>&lt;0.0001*</td>
<td>0.75</td>
<td>0.87</td>
<td>0.7 (0.3, 1.1)</td>
</tr>
<tr>
<td>hs-CRP (mg·L⁻¹)⁹</td>
<td>1.4 [1.4]</td>
<td>1.9 [3.5]</td>
<td>0.024</td>
<td>0.46</td>
<td>0.42</td>
<td>1.2 (0.2, 2.3)</td>
</tr>
<tr>
<td><strong>Health and fitness evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PredictedVO₂max (mL·kg⁻¹·min⁻¹)</td>
<td>41.3 ± 8.14</td>
<td>30.4 ± 8.2</td>
<td>&lt;0.0001*</td>
<td>1.61</td>
<td>1.00</td>
<td>11.0 (7.0, 15.0)</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)⁶</td>
<td>285 [194]</td>
<td>100 [124]</td>
<td>&lt;0.0001*</td>
<td>1.11</td>
<td>1.00</td>
<td>-193 (-275, -111)</td>
</tr>
<tr>
<td>Daily energy intake (KJ)</td>
<td>5797 ± 1421</td>
<td>6263 ± 2478</td>
<td>0.343</td>
<td>0.187</td>
<td>-</td>
<td>-466 (-1443, 511)</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD or median [IQ range]; ⁹ log₁₀ transformation; * p ≤ 0.05; blood pressure (BP); high-density lipoprotein (HDL); high sensitive C-reactive protein (hs-CRP); homeostasis model assessment of insulin resistance (HOMA-IR). An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995).
### Table 5.2. Cardiometabolic risk factors in participants with and without overweight/obesity, as defined by body mass index.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control BMI &lt;24.9 kg·m⁻² (n=33)</th>
<th>Overweight/obesity BMI ≥25.0 kg·m⁻² (n=35)</th>
<th>P-value</th>
<th>Effect size Hedge’s g</th>
<th>Power (1-ß)</th>
<th>Mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>60.8 ± 6.6</td>
<td>88.6 ± 18.0</td>
<td>&lt;0.0001</td>
<td>2.00</td>
<td>1.00</td>
<td>27.7 (21.1, 34.4)</td>
</tr>
<tr>
<td>Stature (m)</td>
<td>1.7 ± 0.05</td>
<td>1.6 ± 0.06</td>
<td>0.254</td>
<td>0.36</td>
<td>-</td>
<td>-0.02 (-0.05, 0.01)</td>
</tr>
<tr>
<td>Body mass index (kg·m⁻¹)</td>
<td>21.7 ± 1.9</td>
<td>32.2 ± 5.2</td>
<td>&lt;0.0001</td>
<td>2.60</td>
<td>1.00</td>
<td>10.4 (8.5, 12.3)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>72.5 ± 4.8</td>
<td>92.6 ± 10.3</td>
<td>&lt;0.0001</td>
<td>2.44</td>
<td>1.00</td>
<td>20.0 (16.1, 24.0)</td>
</tr>
<tr>
<td>Waist-height-ratio (WHtR)</td>
<td>0.43 ± 0.03</td>
<td>0.56 ± 0.05</td>
<td>&lt;0.0001</td>
<td>3.09</td>
<td>1.00</td>
<td>0.12 (0.10, 0.15)</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>115 ± 8</td>
<td>120 ± 9</td>
<td>0.014</td>
<td>0.60</td>
<td>0.75</td>
<td>5.1 (1.0, 9.2)</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>66.8 ± 7.9</td>
<td>67.3 ± 6.9</td>
<td>0.770</td>
<td>0.07</td>
<td>-</td>
<td>0.5 (-3.0, 4.1)</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>1.5 ± 0.3</td>
<td>1.7 ± 0.5</td>
<td>0.114</td>
<td>0.38</td>
<td>-</td>
<td>0.17 (-0.04, 0.38)</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>1.2 ± 0.4</td>
<td>1.2 ± 0.3</td>
<td>0.959</td>
<td>0.01</td>
<td>-</td>
<td>-0.00 (-0.18, 0.17)</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>4.7 ± 0.4</td>
<td>4.7 ± 0.5</td>
<td>0.811</td>
<td>0.06</td>
<td>-</td>
<td>-0.03 (-0.25, 0.20)</td>
</tr>
<tr>
<td><strong>Additional biochemical parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.7 ± 0.9</td>
<td>4.3 ± 0.6</td>
<td>0.128</td>
<td>0.40</td>
<td>-</td>
<td>-0.3 (-0.7, 0.1)</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)</td>
<td>5.0 [3.0]</td>
<td>8.00 [5.00]</td>
<td>&lt;0.0001</td>
<td>1.00</td>
<td>0.99</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.1 [0.7]</td>
<td>1.81 [1.08]</td>
<td>&lt;0.0001</td>
<td>1.00</td>
<td>0.99</td>
<td>0.7 (0.3, 1.1)</td>
</tr>
<tr>
<td>hs-CRP (mg·L⁻¹)</td>
<td>1.4 [2.0]</td>
<td>1.98 [2.95]</td>
<td>0.079</td>
<td>0.43</td>
<td>-</td>
<td>1.0 (-0.1, 2.0)</td>
</tr>
<tr>
<td><strong>Health and fitness evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted VO₂max (mL·kg⁻¹·min⁻¹)</td>
<td>40.9 ± 8.8</td>
<td>30.0 ± 7.7</td>
<td>&lt;0.0001</td>
<td>1.31</td>
<td>1.00</td>
<td>10.87 (6.89, 14.85)</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)</td>
<td>260 [220]</td>
<td>100 [112.50]</td>
<td>&lt;0.0001</td>
<td>1.13</td>
<td>1.00</td>
<td>-179.00 (103, 257)</td>
</tr>
<tr>
<td>Daily energy intake (KJ)</td>
<td>6164 ± 1615</td>
<td>5946 ± 2434</td>
<td>0.671</td>
<td>0.10</td>
<td>-</td>
<td>218.14 (-804, 1241)</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD or median [IQ range]; ° log₁₀ transformation; °° p ≤ 0.05; blood pressure (BP); high-density lipoprotein (HDL); high sensitive C-reactive protein (hs-CRP); homeostasis model assessment of insulin resistance (HOMA-IR). An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995).
None of the women with overweight/obesity were diagnosed with the metabolic syndrome (Alberti et al., 2009). Of the metabolic syndrome markers, only systolic blood pressure was higher than controls in participants with overweight/obesity, regardless of classification. The proportion of women in the intervention and control groups, respectively exhibiting each of the metabolic syndrome markers were: WC (100%, 0%); triglycerides (8%, 6%); HDL-cholesterol (32%, 27%); systolic blood pressure (10%, 3%); diastolic blood pressure (0%, 0%); glucose (3%, 0%).

Again, independent of the classification used, the two predictors of glycaemic risk, fasting insulin and HOMA-IR were more elevated in participants with a raised WC and/or BMI > 25 kg.m\(^{-2}\) than controls (Tables 5.1 and 5.2).

The pro-inflammatory marker hs-CRP was significantly (40%) higher in women with elevated WC than controls but did not differ when using BMI thresholds. Additionally, the prevalence of elevated hs-CRP > 3 mg.l\(^{-1}\) (Pearson et al., 2003) was 35% for women with overweight/obesity compared with 20% in the control group, for WC \(\chi^2 (1, n = 67) = 1.20, p = 0.274\) and BMI \(\chi^2 (1, n = 67) = 0.22, p = 0.642\).

Aerobic fitness estimated from a submaximal cycling protocol was 26% lower in participants with elevated WC than controls. Similarly, subjective approximations of weekly physical activity were 63% less in women with elevated WC than controls. Estimated daily energy intake did not differ between groups. Similar results were observed using BMI (Tables 5.1 and 5.2).

HOMA-IR, fasting insulin, hs-CRP and physical activity were used as dependent variables and anthropometric measures of WC, BMI and WHtR were the independent variables in calculating unadjusted odds ratios. From this analysis only HOMA-IR and physical activity produced significant unadjusted odds ratios (Table 5.3). Approximately 41% of participants in the exposed group (overweight/obesity – classified by WC, BMI and WHtR) and 6.7 to 11.0% in the non-exposed group (controls) were diagnosed with elevated HOMA-IR. Furthermore, the unadjusted odds ratio for the association between overweight/obesity and elevated HOMA-IR ranged between 5.1 to 10.0. The percentage of less than recommended physical activity levels in the exposed group (approximately 80%) was double that of the non-exposed group (approximately 40%) (Table 5.3).
Table 5.3. Associations between cardiometabolic risk factors and overweight/obesity.

<table>
<thead>
<tr>
<th>Variable</th>
<th>% diagnosed in exposed group</th>
<th>% diagnosed in non-exposed group</th>
<th>Unadjusted odds ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist circumference</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WC ≥ 80 cm</td>
<td>41.7%</td>
<td>6.7%</td>
<td>10.0 (2.1, 48.6)</td>
<td>0.003</td>
</tr>
<tr>
<td>WC &lt; 80 cm</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 2.0</td>
<td>42.4%</td>
<td>9.1%</td>
<td>7.4 (1.9, 29.1)</td>
<td>0.005</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)</td>
<td>80.0%</td>
<td>39.4%</td>
<td>6.1 (2.1, 18.2)</td>
<td>0.002</td>
</tr>
<tr>
<td>Body mass index</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI ≥ 25 kg·m⁻²</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 25 kg·m⁻²</td>
<td>42.4%</td>
<td>9.1%</td>
<td>7.4 (1.9, 29.1)</td>
<td>0.005</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)</td>
<td>80.0%</td>
<td>39.4%</td>
<td>6.1 (2.1, 18.2)</td>
<td>0.002</td>
</tr>
<tr>
<td>Waist-to-height-ratio</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHtR ≥ 0.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 0.5</td>
<td>40.6%</td>
<td>11.0%</td>
<td>5.1 (1.4, 18.0)</td>
<td>0.016</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)</td>
<td>82.0%</td>
<td>38.2%</td>
<td>7.6 (2.4, 23.1)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

A participant with a HOMA-IR score of ≥ 2.0 or physical activity levels of ≤ 210 minutes per week was allocated to the exposed group. Please note, two data sets for HOMA-IR were unavailable due to compromised samples.

ROC curves determined the cut-off point for three anthropometric (WC, BMI, WHtR) measures. The area under the curve (AUC) for elevated HOMA-IR was 0.79 (p < 0.001) and a cut-off value of 84.25 cm when calculated for WC. Additionally, the positive likelihood ratio was 2.9. Less than recommended physical activity produced a value of 0.72 for the AUC (p = 0.002), with a cut-off value of 80.65 cm and a positive likelihood ratio of 3.3 for WC. For BMI, HOMA-IR produced a value of 0.82 for the AUC (p < 0.001), with a BMI cut-off value of 30.61 kg·m⁻², and a positive likelihood ratio of 4.9. Moreover, the AUC for less than recommended physical activity levels was 0.73 (p = 0.002), with a BMI cut-off of 25.25 kg·m⁻², and a positive likelihood ratio of 3.7. For WHtR, HOMA-IR value for AUC was 0.76 (p < 0.001), with a WHtR cut-off value of 0.50, and a positive likelihood ratio of 1.2. Additionally, the AUC for less than recommended physical activity levels was 0.71 (p = 0.003), with a WHtR cut-off of 0.46, and a positive likelihood ratio of 2.8.

Participants completed a questionnaire, rating their perceived barriers to physical activity. Chi-square frequencies revealed 84% of participants agreed that exercise was important to them. Despite this, 65% of women with elevated WC or BMI >25 kg·m⁻² shared difficulties in motivation for physical activity (17% in controls), however both groups ranked feeling too
tired as their number one barrier (Table 5.4). Additionally, 56% of participants with elevated WC or BMI >25 kg·m^{-2} reported that being self-conscious about their looks was a major barrier to regular physically active (3% in controls).

Table 5.4. Most prevalent perceived barriers to engaging in physical activity.

<table>
<thead>
<tr>
<th>Perceived Barrier</th>
<th>% overweight/obesity (rank)</th>
<th>% control (rank)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feeling too tired</td>
<td>79 (1)</td>
<td>63 (2)</td>
</tr>
<tr>
<td>High cost of classes or venues</td>
<td>68 (2)</td>
<td>47 (4)</td>
</tr>
<tr>
<td>Lack of motivation</td>
<td>65 (3)</td>
<td>17 (7)</td>
</tr>
<tr>
<td>Poor weather</td>
<td>58 (4)</td>
<td>53 (3)</td>
</tr>
<tr>
<td>Lack of time</td>
<td>55 (5)</td>
<td>73 (1)</td>
</tr>
<tr>
<td>Self-conscious about physical appearance</td>
<td>55 (5)</td>
<td>3 (9)</td>
</tr>
</tbody>
</table>

Discussion

Data on the prevalence, characteristics and consequences of overweight/obesity in young women are important for providing an indication of the need for early detection, timely treatment, and the adaptation of lifelong interventions (van Emmerik et al., 2012). In this study, classification of overweight/obesity using WC and BMI were associated with similar cardiometabolic risk. Risk markers commonly used in standard health checks did not differentiate between women with overweight/obesity and those in healthy anthropometric ranges, while women with overweight/obesity did display higher markers of insulin resistance (fasting insulin and HOMA-IR) and lower estimates of physical activity (weekly exercise duration and aerobic fitness). This finding suggests that anthropometric measures are useful first-line diagnostic measures of cardiometabolic risk, with insulin resistance and lifestyle factors providing deeper insight into this risk for young adult women than traditional metabolic syndrome markers.

No individual was diagnosed with the metabolic syndrome (Alberti et al., 2009) and, as a group mean, none of the markers (i.e., other than WC) was elevated to that of the current
metabolic syndrome definition. In contrast, data from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) reported the prevalence of the metabolic syndrome in women aged between 25-34 years to be 6% (Cameron et al., 2007). Given the younger age of our participants (22.3 ± 3.5 years) compared with those in the AusDiab Study (Cameron et al., 2007), these data suggest that traditional metabolic syndrome markers may not be sufficiently sensitive to indicate cardiometabolic risk in young adulthood (< 30 years). Therefore, markers of insulin resistance may be more useful indicators of future cardiometabolic risk in younger women with overweight/obesity than markers currently used in the metabolic syndrome definitions and during standard health checks.

As a marker of insulin dysfunction, elevated HOMA-IR ≥ 2.0 (Jensterle et al., 2008), was present in more than 41% of women with overweight/obesity in the present study, compared with 6.7 - 11.0% of the control group. Moreover, the odds ratio for the association between overweight/obesity and an elevated HOMA-IR score was large, suggesting a strong relationship between these two variables. Raised concentrations of circulating hs-CRP were also present in women with an elevated WC, in agreement with previous reports (Da Costa et al., 2012; Ramos & Olden, 2008). These raised hs-CRP concentrations could have contributed to higher HOMA-IR scores in the overweight/obesity group, given that hs-CRP disrupts insulin signalling and action (Da Costa et al., 2012).

Similar predictors of cardiometabolic risk were found when using WC and BMI as proxy measures of overweight/obesity, suggesting that both are useful markers for potential insulin resistance in young women. This agrees with previous results showing WC and BMI have a similar strength of association with CVD risk in adults, when assessed using individual records from 58 cohorts (Emerging Risk Factors Collaboration [ERFC], 2011). Results from ROC curves showed that the WC cut-off point for determining increased risk of insulin resistance, as measured by both fasting insulin and HOMA-IR, was ≥ 84 cm. This value is higher than current guidelines of ≥ 80 cm for Caucasian females (Alberti et al., 2009). Similar trends were observed for the cut-off point for classifications of BMI, in which a measure of ≥ 30.0 kg·m⁻², rather than ≥ 25 kg·m⁻², was identified an increased risk of elevated HOMA-IR. In contrast, the dichotomization cut-off points for cardiometabolic risk associated with low physical activity (≤ 210 min of weekly exercise) in our study were determined to be ≥ 80 cm for WC and ≥ 25.25 kg·m⁻² for BMI, strongly supporting the probability of risk within the
existing overweight/obesity classification scores (Alberti et al., 2009; World Health Organisation, 2000).

The use of WHtR may also be a suitable and easy to administer anthropometric screening tool for the prediction of cardiometabolic outcomes applicable to a variety of populations (Browning et al., 2010). ROC curves showed that the WHtR margin for determining increased risk of insulin resistance, as measured by HOMA-IR, was ≥ 0.5, strongly supporting the current global boundary value (Browning et al., 2010). Additionally, a cut-off value of ≥ 0.46 was determined for cardiometabolic risk associated with low physical activity (≤ 210 min of weekly exercise), which is lower than the current threshold. Furthermore, the unadjusted odds ratios of WHtR in predicting risk factors are comparable to WC and BMI.

In the present study, 80% of women with overweight/obesity failed to achieve minimum weekly exercise recommendations compared with 35% of the control group, while 3-day dietary recall data showed no differences in daily energy intake between the groups. Although dietary recall has limitations, these data show insufficient energy expenditure from physical activity relative to energy intake appears to be a significant factor in weight gain in the young women in our study. From data reported in a qualitative questionnaire, a prominent barrier to being active for the overweight/obesity women was self-conscious feelings about their own appearance. Therefore, lifestyle interventions for the prevention/reduction of overweight/obesity need to address psychological barriers to physical activity.

The study has several limitations. The cross-sectional design could conceivably be a weakness, but it provided proof of concept prior to larger trials. Future studies using a prospective design could provide predictive data that addresses WC/BMI and the development of cardiometabolic disease. Ideally, central fat distribution would be measured using MRI, but waist circumference still provided a level of sensitivity relevant to most clinical settings (National Health and Medical Research Council, 2003). Additionally, the results are specific to Caucasian women at a tertiary institution and largely from suburbs in the most advantaged quintile of socio-economic status. Given this however, our data raise concerns that key health promotion messages are either poorly sourced or understood, and/or are very difficult to apply. When more educated, advantaged young women have difficulties, it may be assumed that individuals from less advantaged backgrounds may at least share these health issues.
Conclusion

This study supports the use of WC and BMI as first-line diagnostic measures of cardiometabolic risk. However, risk markers beyond the traditional metabolic syndrome blood-borne criteria, such as fasting insulin and HOMA-IR, may be required when screening further for cardiometabolic risk in young women. A higher order of investigation (e.g. blood sampling) may help convince young women of the need to take action. Furthermore, sedentary behaviour in young women with overweight/obesity is a lifestyle risk factor of concern, with a need for addressing identified age- and gender-specific barriers to engagement. The value of additional research into managing cardiometabolic risk in young women cannot be understated.

Practical Implications

- In young adult women, WC and BMI as measures of overweight/obesity have similar associations with other cardiometabolic risk factors.

- Markers of insulin and HOMA-IR may be useful indicators of future cardiometabolic risk in younger women with overweight/obesity.

- The first line of treatment for cardiometabolic risk should be centred on modifiable lifestyle changes, such as those associated with sedentary behaviour through increased physical activity.

- Given the poor engagement in physical activity in our study population, the approach to engagement should be age and gender appropriate, and take into account perceived barriers to physical activity.
Chapter 6. Young women with abdominal obesity have sub-clinical myocardial dysfunction.

Bianca L Share, André La Gerche, Geraldine A Naughton, Philippe Obert, Justin G Kemp

Publication Statement:
This work was accepted for publication in the Canadian Journal of Cardiology (February, 2015), please see Appendix 1 and 15.

Acknowledgements
The authors would like to express their gratitude to all participants involved in the Young Women’s Heart Health Study. Thanks are also extended to Professor Jennifer Peat for her statistical assistance and to Associate Professor Guillaume Walther for his contribution to the manuscript.
Abstract

**Background:** Abdominal obesity is an independent risk factor for cardiovascular disease. The impact of abdominal obesity on myocardial function in young obese women remains unknown. Therefore, we aimed to investigate cardiac morphology and function, myocardial deformation and mechanical indices, in young women with and without abdominal obesity.

**Methods:** Cross-sectional analyses of 39 women with abdominal obesity (waist circumference ≥ 80 cm) and 33 non-obese controls (waist circumference < 80 cm) aged 18-30 years underwent conventional echocardiographic measures of cardiac morphology and function together with tissue Doppler, and 2D speckle tracking measures of myocardial deformation and mechanics. Cardiometabolic risk factors including anthropometric, hypertension, biochemistry and fitness were also assessed.

**Results:** Standard echocardiography results for cardiac morphology and function were similar between women with abdominal obesity and their age and-gender-matched controls, with the exception of larger left atrial dimensions in women with abdominal obesity (P ≤ 0.05). Compared with controls, women with abdominal obesity also demonstrated reduced systolic (S_m) and diastolic (E_m) mitral annular plane velocities, increased LA pressure surrogates (E/E_m), and prolonged timing measures of diastolic function including isovolumic relaxation time and transmitral deceleration time (P ≤ 0.05). In addition, longitudinal strain and diastolic strain rate were reduced in women with abdominal obesity (P ≤ 0.05) but circumferential deformation and myocardial mechanics (twist indices and rotation) were preserved.

**Conclusion:** A young, otherwise-healthy group of women with abdominal obesity displayed sub-clinical cardiac dysfunction indicated by selected TDI and STE measures.

**Keywords:** Waist circumference, cardiometabolic, speckle tracking imaging, echocardiography, female, tissue Doppler imaging.
Introduction

Obesity is an established independent risk factor for cardiovascular disease (CVD), with a global, increasing prevalence reaching epidemic proportions (Grundy, 2008; World Health Organisation, 2000). In countries such as Australia, the prevalence of obesity in young women appears to be increasing at an exponential rate (Lucke et al., 2007). Elevated waist circumference, is a reliable anthropometric index of abdominal obesity (Klein et al., 2007), allowing early identification of CVD risk (Share, Naughton, Obert, Peat, & Kemp, 2013). However, the cardiac consequences of risk factors are poorly understood in young women; a population emerging as highly vulnerable to cardiometabolic disorders.

Young women specifically continue to be underrepresented in cardiac research (Rosenfeld, 2006), perhaps due to the misperception that females are ‘protected’ against CVD via the role of oestrogen in pre-menopausal females (Maas et al., 2011). Additionally, enrolment of women in clinical and epidemiological research remains relatively low in studies of populations with chronic disease (Melloni et al., 2010).

Obesity can unfavourably alter left ventricular (LV) morphology and function with greater LV hypertrophy and cardiac remodelling observed in both adolescent (Obert et al., 2012; Shah et al., 2011) and older females populations (Orhan et al., 2010). Early detection of myocardial abnormalities in obese individuals may represent a critical and cost-effective strategy to attenuate the time-related consequences of CVD (Orhan et al., 2010). Despite this, the understanding of the effects of obesity on CVD risk in women is largely limited to middle-aged and older individuals with scarce attention to young obese females (Di Bello et al., 2013; Peterson, Waggoner, et al., 2004). Therefore, it remains unclear whether or not obesity in young women is associated with cardiac dysfunction. As such, identification of sub-clinical disease such as myocardial dysfunction in young women with obesity would highlight a group in which targeted interventions may be of greatest impact. Furthermore, the recently described “obesity paradox” (Lavie et al., 2013) creates some ambiguity surrounding the effects of obesity on cardiac function and it may be argued this issue is particularly pertinent to young women with obesity in whom targeted interventions may be of greatest value.
Sub-clinical cardiac dysfunction can be detected using non-invasive conventional and tissue Doppler imaging (TDI) echocardiography (Ho & Solomon, 2006; Wong, Leano, & Marwick, 2006). However, speckle tracking echocardiography (STE), a deformation imaging technique, was developed to address potential limitations in the sensitivity of existing measures for detecting subtle myocardial dysfunction. Speckle tracking echocardiography may help overcome the limitations of conventional and TDI echocardiography by permitting angle-independent evaluation of strain and strain rate (SR) in the longitudinal and circumferential planes, as well as rotation and twist mechanics (Esch & Warburton, 2009; K. A. Marcus et al., 2011).

The aim of this study was to investigate cardiac morphology and function, myocardial deformation and mechanical indices, in a cross-sectional profile of young women with and without abdominal obesity using traditional and advanced techniques of echocardiography.

Methods

Participants
Ninety-three university-enrolled women aged 18 to 30 years responded to recruitment advertisements. Participants were a low-risk population, free of CVD risk factors (hypertension, diabetes, and smoking), or endocrine disorders who had not undergone bariatric surgery and were not pregnant. Eleven women did not meet the inclusion criteria and a further ten eligible participants did not complete testing. Therefore, 72 women (all Caucasian) completed testing between August 2010 and February 2012. Participants were divided into two groups; (1) 39 women with abdominal obesity defined by a waist circumference (WC) ≥ 80 cm, and (2) 33 women without abdominal obesity (WC < 80 cm). Participants arrived at the laboratory following a 12 hour fast and were requested to refrain from strenuous physical activity in the 24 hours prior to testing.

The study was approved by the Australian Catholic University Human Research Ethics Committee (V2009-91), and participants provided written informed consent.
Cardiometabolic risk factors

A range of clinical characteristics were assessed to profile the population. Body mass was measured to the nearest 0.1 kg (Tanita, Tokyo, Japan). Height was measured to the nearest 0.1 cm (Seca, Germany). Body mass index (BMI) was subsequently calculated as weight [kg]/height [m²] (World Health Organisation, 2000). Waist circumference and hip circumference were measured (Alberti et al., 2009) to the nearest 0.1 cm, with the average of two measurements reported. Measurements relating to waist circumference including, waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) were also calculated. Values of ≥ 0.8 for WHR (Dalton et al., 2003; World Health Organisation, 2000) and 0.5 for WHtR (Browning et al., 2010) have been considered indicative of increased CVD risk.

Blood pressure and resting heart rate were obtained with an automated digital sphygmomanometer (Dinamap, GE technology, USA). Fasting venous blood samples were analysed for the following biochemical parameters: triglycerides, total cholesterol, high-density lipoprotein (HDL), plasma glucose, insulin and high sensitivity C-reactive protein (hs-CRP). Insulin resistance (IR) was estimated by the homeostasis model assessment (HOMA-IR) (Matthews et al., 1985), with values > 2.5 considered indicative of IR (Jensterle et al., 2008). For hs-CRP, a value of > 3.0 mg·l⁻¹ was considered high CVD risk (Pearson et al., 2003).

A submaximal cycle ergometer test (Golding et al., 1989) was used to predict maximal oxygen uptake (estimated VO₂max) by extrapolating heart rate against work rate (W) on a regression analysis to estimate maximal aerobic capacity. Estimated VO₂max was indexed for body mass to provide a relative measurement. Participants self-reported habitual weekly physical activity levels.

Echocardiography examination

Participants underwent a standard two-dimensional (2D) transthoracic echocardiography examination for the assessment of both global and regional ventricular function in accordance with the recommendations of the American Society of Echocardiography (R. M. Lang et al., 2005). Image acquisition was performed by the same experienced operator using a commercially available ultrasound (Vivid i, GE Healthcare, Horten, Norway) with a 3.5 MHz phased-array transducer. Participants were examined in the left-lateral decubitus position in a
dark room and connected to a 3-lead ECG. A minimum frame rate of 70 Hz was used when acquiring gray-scale cine-loops. Digital data were stored for subsequent off-line analyses with specific software (EchoPAC v108, GE Medical Systems, Horton Norway) by an observer blinded to group assignment. All reported measurements were averaged from three consecutive cardiac cycles.

M-mode measurements were obtained in the parasternal long-axis view for the quantification of cardiac chamber size and ventricular mass, using the Penn-Cube method (Devereux et al., 1984) and indexed for height (Cornell adjustment). LV volumes and ejection fraction were quantified using a Simpson’s bi-plane method.

Pulsed-wave Doppler-derived transmitral inflow velocities were obtained from the apical four-chamber view with the sample volume at the tips of the mitral leaflets. Early-diastolic (E), E-wave deceleration time, late-diastolic (A) waves and the E/A ratio were calculated. Isovolumetric relaxation time (IVRT) was obtained from pulse-wave Doppler in the apical five-chamber view. Pulsed tissue Doppler Imaging (TDI) was used to measure mitral annular velocities during systole (S_m), early-diastole (E_m) and late-diastole (A_m). The S_m, E_m, and A_m are means of four sites at the mitral annulus from apical 4-chamber (septal, lateral) and 2-chamber views (inferior, anterior). The E/E_m ratio, recorded from the mitral annulus lateral wall, was used as an index of LV diastolic filling pressure.

STE analysis of myocardial wall motion was performed using frame-by-frame tracking of natural acoustic markers known as “speckles” in a region of interest from greyscale images. Using proprietary software (EchoPAC v108, GE Medical Systems, Horton Norway), endocardial borders were manually traced and the region of interest was adjusted to include all of the myocardium. Results were expressed as the average from all segments but strain and SR data was excluded if there were more than two segments in which tracking was inadequate (assessed visually). Both systolic and diastolic strain rate (SRs and SRe, respectively) were calculated in the longitudinal and circumferential axis of the LV. The values from circumferential apical and basal views were averaged. Twist (calculated as the difference between basal and apical rotations), twist rate, untwist rate, and apical and basal rotational mechanics of the LV, were calculated. To allow for inter-participant differences in heart rate, customised software (Scilab 4.1, Avignon University, Avignon, France) was used to normalise time sequence as a percentage of systolic duration.
Statistics

Data were analysed using IBM SPSS Statistics, Version 20 for Windows (SPSS Inc, Chicago IL). Normal distribution of qualitative variables was checked using skewness, kurtosis and the Shapiro-Wilk test (Peat & Barton, 2005). Log transformation was used where appropriate. Variables were analysed as continuous variables, and are presented as mean (standard deviation). Group comparisons were performed using independent t-tests. Additionally, Hedge’s $g$ was used to calculate magnitudes of differences, with an effect size of $\geq 0.2$ considered small, $\geq 0.5$ considered medium, and $\geq 0.8$ considered large (Cohen, 1988). Pearson’s $r$ correlation analysis was used to identify associations between cardiometabolic risk factors and morphological, global function and myocardial measures. An alpha level of $p < 0.05$ was considered statistically significance.

Intra and inter-observer reproducibility were estimated for major cardiac variables in randomly selected participants (conventional echocardiography and TDI, n=10; STE, n=20) in order to demonstrate the reproducibility of off-line analyses. Variables were evaluated twice by the same observer, and once more by another experienced observer, both blinded to participant details.

Results

Cardiometabolic risk factors

Table 6.1 summarises the clinical characteristics of the two groups. No differences were found for height, blood pressure, triglycerides, HDL-cholesterol, or resting heart rate when comparing women with abdominal obesity (WC 92.5 ± 10.6 cm, range 80.5 -123.0 cm, age 22.4 ± 3.5 y) and the control group (WC 72.5 ± 4.8 cm, range 63.6 – 77.8 cm, age 20.0 ± 0.7 y). Independent of obesity status, all participants were eumenorrhoeic. Additionally, the young women with abdominal obesity in this study can be described as non-diabetic, non-insulin resistant and normotensive. When anthropometric measures were compared with controls, women with abdominal obesity had greater body mass, BMI, waist circumference, hip circumference, WHR and WHtR ($P < 0.001$). The average BMI for women with abdominal obesity placed them in the obese category and average WHR and WHtR placed them in an increased CVD risk range. Women with abdominal obesity also had greater elevated fasting
insulin, HOMA-IR, and hs-CRP (P < 0.05) than the control group. However, the mean HOMA-IR value remained within normal range. In contrast, the elevated hs-CRP in the women with abdominal obesity was deemed ‘high’ risk (> 3.0 mg·l⁻¹). Pearson’s r correlation showed a strong relationship between abdominal obesity and both fasting insulin (r = 0.521, P < 0.01) and HOMA-IR (r = 0.455, P < 0.01), without a significant relationship with hs-CRP. Relative to controls, women with abdominal obesity performed 63% less weekly physical activity (P < 0.001) and had reduced aerobic capacity (predicted VO₂max). Perhaps surprisingly, control participants had slightly higher fasting glucose and total cholesterol (P < 0.05) than women with abdominal obesity but notably values remained within normal ranges.
Table 6.1. Cardiometabolic risk factors in participants with and without abdominal obesity.

<table>
<thead>
<tr>
<th></th>
<th>Controls WC &lt; 80 cm (n = 33)</th>
<th>Abdominal obesity WC ≥ 80 cm (n = 39)</th>
<th>P-value</th>
<th>Hedge’s g Effect size</th>
<th>Power (1-ß)</th>
<th>Mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>61.6 ± 7.4</td>
<td>88.2 ± 19.6</td>
<td>&lt;0.001*</td>
<td>1.72</td>
<td>1.0</td>
<td>26.6 (19.7, 33.4)</td>
</tr>
<tr>
<td>Stature (cm)</td>
<td>1.7 ± 0.1</td>
<td>1.7 ± 0.1</td>
<td>0.44</td>
<td>0.00</td>
<td>-</td>
<td>0.0 (-0.04, 0.02)</td>
</tr>
<tr>
<td>BMI (kg·m⁻²)</td>
<td>22.1 ± 2.5</td>
<td>31.9 ± 6.0</td>
<td>&lt;0.001*</td>
<td>2.05</td>
<td>1.0</td>
<td>9.8 (7.6, 11.9)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>72.5 ± 4.8</td>
<td>92.5 ± 10.6</td>
<td>&lt;0.001*</td>
<td>2.34</td>
<td>1.0</td>
<td>20.0 (16.3, 23.8)</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>96.9 ± 5.9</td>
<td>115.2 ± 12.5</td>
<td>&lt;0.001*</td>
<td>1.80</td>
<td>1.0</td>
<td>18.3 (13.8, 22.8)</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.75 ± 0.03</td>
<td>0.80 ± 0.04</td>
<td>&lt;0.001*</td>
<td>1.38</td>
<td>1.0</td>
<td>0.05 (0.03, 0.07)</td>
</tr>
<tr>
<td>Waist-to-height ratio</td>
<td>0.43 ± 0.03</td>
<td>0.56 ± 0.06</td>
<td>&lt;0.001*</td>
<td>2.64</td>
<td>1.0</td>
<td>0.13 (0.10, 0.14)</td>
</tr>
<tr>
<td><strong>Blood Pressure evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>115.6 ± 8.3</td>
<td>119.5 ± 9.9</td>
<td>0.08</td>
<td>0.42</td>
<td>-</td>
<td>3.9 (-0.5, 8.1)</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>67.8 ± 7.5</td>
<td>65.9 ± 7.2</td>
<td>0.26</td>
<td>0.26</td>
<td>-</td>
<td>-1.9 (-5.4, 1.5)</td>
</tr>
<tr>
<td><strong>Blood biochemistry</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>4.9 ± 0.4</td>
<td>4.6 ± 0.5</td>
<td>0.01*</td>
<td>0.65</td>
<td>0.75</td>
<td>0.3 (-0.5, -0.1)</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>1.1 ± 0.3</td>
<td>1.2 ± 0.4</td>
<td>0.31</td>
<td>0.28</td>
<td>-</td>
<td>0.1 (-0.1, 0.3)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol·L⁻¹)</td>
<td>1.4 ± 0.3</td>
<td>1.7 ± 0.5</td>
<td>0.13</td>
<td>0.70</td>
<td>-</td>
<td>0.3 (0.1, 0.5)</td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.7 ± 1.0</td>
<td>4.3 ± 0.5</td>
<td>0.01*</td>
<td>0.51</td>
<td>0.60</td>
<td>-0.4 (-0.8, 0.1)</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)⁺</td>
<td>5.9 ± 2.6</td>
<td>8.9 ± 4.6</td>
<td>0.01*</td>
<td>0.78</td>
<td>0.94</td>
<td>3.0 (1.2, 4.7)</td>
</tr>
<tr>
<td>HOMA-IR⁹</td>
<td>1.3 ± 0.6</td>
<td>1.8 ± 1.0</td>
<td>0.03*</td>
<td>0.59</td>
<td>0.75</td>
<td>0.5 (0.1, 0.9)</td>
</tr>
<tr>
<td>hs-CRP (mg·L⁻¹)⁹</td>
<td>1.7 ± 1.6</td>
<td>3.3 ± 2.9</td>
<td>0.01*</td>
<td>0.66</td>
<td>0.75</td>
<td>1.6 (0.5, 2.7)</td>
</tr>
<tr>
<td><strong>Fitness variables</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>73.9 ± 12.6</td>
<td>71.9 ± 12.1</td>
<td>0.49</td>
<td>0.16</td>
<td>-</td>
<td>2.0 (-7.9, 3.8)</td>
</tr>
<tr>
<td>Estimated VO₂max (mL·kg⁻¹·min⁻¹)</td>
<td>40.7 ± 7.8</td>
<td>30.1 ± 9.1</td>
<td>&lt;0.001*</td>
<td>1.23</td>
<td>1.0</td>
<td>10.6 (-14.6, -6.5)</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)⁹</td>
<td>302 ± 201</td>
<td>110 ± 82</td>
<td>&lt;0.001*</td>
<td>1.28</td>
<td>1.0</td>
<td>192 (-267, -116)</td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD. WC: waist circumference, BMI: body mass index, BP: blood pressure; HDL: high-density lipoprotein, HOMA-IR: homeostatic model assessment of insulin resistance, hs-CRP: high sensitivity C-reactive protein, CI: confidence interval. "Data are log transformed. * P ≤ 0.05. An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995)."
**Cardiac morphology and function**

Despite similar LV ejection fractions, women with abdominal obesity displayed greater LA dimensions than controls (P < 0.05). A modest correlation was also observed between abdominal obesity and the internal diameter of the LA (r = 0.437, P < 0.01). In contrast, no differences were found between groups for LV structural parameters such as mass, internal dimensions, or wall thickness (Table 6.2).

Women with abdominal obesity displayed impaired LV diastolic parameters, including greater decreases in transmitial $E$, $E_m$, and greater increases in $E/E_m$, IVRT and DT (P < 0.05) than controls. Additionally, systolic tissue velocity ($S_m$) was reduced in women with abdominal obesity (P < 0.05) relative to controls. Although these values remained within ranges that would be considered “normal” in clinical settings, statistically significant differences were supported by moderate effect sizes. No differences were found between groups for $E/A$ ratio, and parameters of late-diastolic function including transmitial $A$, and $A_m$. 
Table 6.2. Cardiac morphology and function parameters measured from conventional and tissue Doppler imaging echocardiography in participants with and without abdominal obesity.

<table>
<thead>
<tr>
<th></th>
<th>Control WC &lt; 80 cm (n = 33)</th>
<th>Abdominal obesity WC ≥ 80 cm (n = 39)</th>
<th>P-value</th>
<th>Hedge’s g Effect size</th>
<th>Power (1-B)</th>
<th>Mean difference (95% CI)</th>
<th>Reference values/ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac Morphology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA diameter (mm)</td>
<td>30.2 ± 4.3</td>
<td>32.7 ± 4.6</td>
<td>0.02*</td>
<td>0.55</td>
<td>0.60</td>
<td>2.5 (0.04, 0.5)</td>
<td>27.0 to 38.0^d</td>
</tr>
<tr>
<td>LV mass (g)</td>
<td>148 ± 31</td>
<td>149 ± 40</td>
<td>0.98</td>
<td>0.03</td>
<td>-</td>
<td>1.0 (-17.8, 18.1)</td>
<td>103.9 ± 28.3^c</td>
</tr>
<tr>
<td>LV mass indexed (g·m⁻³)</td>
<td>37.5 ± 7.4</td>
<td>40.5 ± 7.0</td>
<td>0.11</td>
<td>0.41</td>
<td>-</td>
<td>3.0 (-0.7, 6.6)</td>
<td>-</td>
</tr>
<tr>
<td>LVED diameter (mm)</td>
<td>44.4 ± 4.5</td>
<td>44.0 ± 3.8</td>
<td>0.71</td>
<td>0.09</td>
<td>-</td>
<td>0.4 (-0.2, 0.2)</td>
<td>43.0 ± 4.1^e</td>
</tr>
<tr>
<td>LVES diameter (mm)</td>
<td>28.8 ± 3.5</td>
<td>29.4 ± 4.4</td>
<td>0.55</td>
<td>0.15</td>
<td>-</td>
<td>0.6 (-0.1, 0.2)</td>
<td>28.8 ± 4.3^c</td>
</tr>
<tr>
<td>LV PW thickness (mm)</td>
<td>9.7 ± 1.4</td>
<td>10.3 ± 1.7</td>
<td>0.12</td>
<td>0.38</td>
<td>-</td>
<td>0.6 (-0.02, 0.1)</td>
<td>8.5 ± 1.5^i</td>
</tr>
<tr>
<td>IVS thickness (mm)</td>
<td>10.0 ± 1.4</td>
<td>10.5 ± 1.7</td>
<td>0.21</td>
<td>0.31</td>
<td>-</td>
<td>0.5 (-0.03, 0.1)</td>
<td>8.2 ± 1.5^i</td>
</tr>
<tr>
<td>LV shortening fraction (%)</td>
<td>34.9 ± 5.7</td>
<td>32.7 ± 6.9</td>
<td>0.17</td>
<td>0.34</td>
<td>-</td>
<td>-2.2 (-5.3, 1.0)</td>
<td>-</td>
</tr>
<tr>
<td><strong>Cardiac Function</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV ejection fraction (%)</td>
<td>64.0 ± 8.1</td>
<td>61.0 ± 10.2</td>
<td>0.09</td>
<td>0.32</td>
<td>-</td>
<td>-3.0 (-6.6, 6.7)</td>
<td>59.2 ± 4.6^a</td>
</tr>
<tr>
<td>Stroke volume (ml)</td>
<td>58.8 ± 16.0</td>
<td>53.7 ± 12.7</td>
<td>0.16</td>
<td>0.35</td>
<td>-</td>
<td>-5.1 (-12.3, 2.0)</td>
<td>-</td>
</tr>
<tr>
<td>E velocity (cm·s⁻¹)</td>
<td>96.7 ± 13.0</td>
<td>87.0 ± 14.7</td>
<td>0.01*</td>
<td>0.70</td>
<td>0.87</td>
<td>-9.7 (-0.2, -0.03)</td>
<td>72.0 ± 12.0^e</td>
</tr>
<tr>
<td>A velocity (cm·s⁻¹)</td>
<td>44.7 ± 12.0</td>
<td>42.4 ± 11.0</td>
<td>0.40</td>
<td>0.20</td>
<td>-</td>
<td>-2.5 (-0.08, 0.03)</td>
<td>40.0 ± 8.0^a</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.3 ± 0.7</td>
<td>2.2 ± 0.6</td>
<td>0.44</td>
<td>0.15</td>
<td>-</td>
<td>-0.1 (-0.4, 0.2)</td>
<td>1.85 ± 0.38^a</td>
</tr>
<tr>
<td>Deceleration time (ms)</td>
<td>174.4 ± 34.9</td>
<td>209.0 ± 29.8</td>
<td>&lt;0.001*</td>
<td>1.06</td>
<td>1.00</td>
<td>34.6 (19.2, 50.1)</td>
<td>166.0 ± 14.0^b</td>
</tr>
<tr>
<td>IVRT (ms)</td>
<td>78.4 ± 9.9</td>
<td>85.8 ± 10.7</td>
<td>0.01*</td>
<td>0.71</td>
<td>0.87</td>
<td>7.4 (2.5, 12.4)</td>
<td>77.9 ± 8.8^a</td>
</tr>
<tr>
<td>Sₐ velocity (cm·s⁻¹)</td>
<td>10.4 ± 1.3</td>
<td>9.0 ± 1.4</td>
<td>&lt;0.001*</td>
<td>0.94</td>
<td>0.99</td>
<td>-1.4 (-0.02, -0.01)</td>
<td>-</td>
</tr>
<tr>
<td>Eₐ velocity (cm·s⁻¹)</td>
<td>17.2 ± 2.3</td>
<td>14.6 ± 2.7</td>
<td>&lt;0.001*</td>
<td>1.10</td>
<td>1.00</td>
<td>-2.6 (-0.04, -0.01)</td>
<td>14.9 ± 2.0^f</td>
</tr>
<tr>
<td>Aₐ velocity (cm·s⁻¹)</td>
<td>6.9 ± 1.2</td>
<td>6.9 ± 1.1</td>
<td>0.99</td>
<td>0.00</td>
<td>-</td>
<td>0.0 (-0.01, 0.01)</td>
<td>-</td>
</tr>
<tr>
<td>E/Eₐ lateral wall</td>
<td>4.9 ± 0.7</td>
<td>5.4 ± 1.4</td>
<td>0.04*</td>
<td>0.47</td>
<td>0.60</td>
<td>0.5 (0.02, 1.1)</td>
<td>5.5 ± 1.0^i</td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD. LA: left atrium, LV: left ventricle, LVED: left ventricular end-diastolic; LVES: left ventricle end-systolic, PW: posterior wall, IVS: inter-ventricular septum, IVRT: isovolumic relaxation time, CI: confidence interval. Sₐ, Eₐ, & Aₐ are means of four sites at the mitral annulus from apical 4-chamber (septal, lateral) and 2-chamber views (inferior, anterior). #Data are log transformed. * P ≤ 0.05. An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995). Reference values/ranges: ^adults 25-32 y (Takahashi et al., 2010); ^b adults 21-40 y(Nagueh et al., 2009); ^c women 20-40 y (Kou et al., 2014); ^d adults 20-60 y (Roberto M Lang et al., 2015); ^e adults 20-40 y (L. Caballero et al., 2015).
Myocardial deformation and mechanics

Women with abdominal obesity had lower longitudinal strain and diastolic SR (P < 0.05) than controls (Table 6.3). Circumferential strain and SR parameters were not different between the groups with and without abdominal obesity. No differences were found between groups in apical and basal rotation, as well as resultant twist. Similarly, twist and untwist rate did not differ between women with abdominal obesity and controls.

Table 6.3. Myocardial deformation and mechanics measured using speckle tracking imaging echocardiography in participants with and without abdominal obesity.

<table>
<thead>
<tr>
<th></th>
<th>Control WC &lt; 80 cm (n = 33)</th>
<th>Abdominal obesity WC ≥ 80 cm (n = 39)</th>
<th>P-value</th>
<th>Hedge’s g</th>
<th>Effect size</th>
<th>Power (1-ß)</th>
<th>Mean difference (95% CI)</th>
<th>Reference values/ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Myocardial Deformation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L Strain (%)</td>
<td>-17.6 ± 3.0</td>
<td>-16.1 ± 2.1</td>
<td>0.05</td>
<td>0.55</td>
<td>0.60</td>
<td>-1.5 (-0.01, 3.0)</td>
<td>-18.6 ± 0.3</td>
<td></td>
</tr>
<tr>
<td>L Systolic SR (strain.s⁻¹)</td>
<td>-0.9 ± 0.2</td>
<td>-0.9 ± 0.1</td>
<td>0.18</td>
<td>0.00</td>
<td>-</td>
<td>0.0 (-0.03, 0.1)</td>
<td>-1.10 ± 0.01</td>
<td></td>
</tr>
<tr>
<td>L Diastolic SR (strain.s⁻¹)</td>
<td>1.4 ± 0.3</td>
<td>1.1 ± 0.3</td>
<td>0.01</td>
<td>0.87</td>
<td>0.94</td>
<td>-0.3 (-0.5, -0.1)</td>
<td>1.02 ± 0.01</td>
<td></td>
</tr>
<tr>
<td>C Strain (%)</td>
<td>-20.8 ± 2.4</td>
<td>-19.8 ± 2.9</td>
<td>0.15</td>
<td>0.37</td>
<td>-</td>
<td>-1.0 (-0.4, 2.3)</td>
<td>-20.9 to -27.8</td>
<td></td>
</tr>
<tr>
<td>C Systolic SR (strain.s⁻¹)</td>
<td>-1.3 ± 0.2</td>
<td>-1.3 ± 0.2</td>
<td>0.19</td>
<td>0.00</td>
<td>-</td>
<td>0.0 (-0.03, 0.1)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>C Diastolic SR (strain.s⁻¹)</td>
<td>2.0 ± 0.3</td>
<td>1.8 ± 0.3</td>
<td>0.08</td>
<td>0.66</td>
<td>-</td>
<td>0.2 (-0.3, 0.02)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Myocardial Mechanics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apical rotation (°)</td>
<td>4.6 ± 1.8</td>
<td>4.7 ± 1.9</td>
<td>0.78</td>
<td>0.05</td>
<td>-</td>
<td>0.1 (-0.8, 1.1)</td>
<td>8.9 ± 3.5</td>
<td></td>
</tr>
<tr>
<td>Basal rotation (°)</td>
<td>-5.6 ± 2.3</td>
<td>-5.8 ± 2.3</td>
<td>0.85</td>
<td>0.09</td>
<td>-</td>
<td>0.2 (-1.5, 1.3)</td>
<td>-4.8 ± 2.5</td>
<td></td>
</tr>
<tr>
<td>Twist (°)</td>
<td>6.2 ± 2.7</td>
<td>7.2 ± 3.1</td>
<td>0.26</td>
<td>0.34</td>
<td>-</td>
<td>1.0 (-0.8, 2.8)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Twist rate (°.s⁻¹)</td>
<td>68.8 ± 22.1</td>
<td>70.3 ± 18.8</td>
<td>0.80</td>
<td>0.07</td>
<td>-</td>
<td>1.5 (-10.4, 13.4)</td>
<td>62.5 ± 17.4</td>
<td></td>
</tr>
<tr>
<td>Untwist rate (°.s⁻¹)</td>
<td>-76.8 ± 39.1</td>
<td>-62.2 ± 18.8</td>
<td>0.11</td>
<td>0.48</td>
<td>-</td>
<td>-14.6 (-2.8, 32.0)</td>
<td>-82.3 ± 32.8</td>
<td></td>
</tr>
</tbody>
</table>

Data expressed as mean ± SD. LV: left ventricle, L: longitudinal, C: circumferential, SR: Strain rate. CI: confidence interval. Circumferential (average of apical and basal views). *Data are log transformed. °P ≤ 0.05. Nb. four data sets were excluded from STE analysis in the abdominal obesity group (n=35) due to poor image quality. An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large (Vincent, 1995). Reference values/ranges: "young adults 25-32 y (Takahashi et al., 2010); "adults 18-80 y, data expressed as mean ± standard error (Marwick et al., 2009); "adults 47± 11 y (Yingchoncharoen, Agarwal, Popović, & Marwick, 2013).
Reliability

Intra and inter-observer CVs for selected conventional echocardiographic and TDI indices were: 1.9% and 1.6%, respectively for $E$ velocity; 2.5% and 1.8%, respectively for $A$ velocity; 2.2% and 4.0%, respectively for Septal $E_m$; 1.5% and 4.2%, respectively for Septal $A_m$, and 1.4% and 2.4%, respectively for Septal $S_m$. Additionally, intra and inter-observer CVs for select STE indices were: 5.9% and 5.1%, respectively for longitudinal strain; 4.3% and 7.8%, respectively for longitudinal diastolic SR; 4.7% and 5.5%, respectively for circumferential strain; 7.0% and 11.5%, respectively for apical rotation; 6.5% and 10.0%, respectively for basal rotation, and 9.2% and 10.0% respectively for LV twist. Previous research reports an intra and inter-observer CV of 7.1% and 8.1%, respectively for global longitudinal strain and, 7.5% and 10.2%, respectively for circumferential strain (K. A. Marcus et al., 2011). A CV of 1.26% in WC measures was also reported in 20 participants.

Discussion

This cross-sectional study used a combination of cardiometabolic risk factors and comprehensive measures of cardiac morphology and function, myocardial deformation and mechanical indices in young women with and without abdominal obesity. We showed that young women with relatively moderate abdominal obesity displayed subtle early myocardial impairment identified by traditional and advanced echocardiography measures compared with controls. The value of using both traditional echocardiography methods (conventional and TDI markers) and more advanced techniques (STE) lies in a comprehensive description of some measures of cardiac morphology and function that may be associated with obesity in young females. This data advances the understanding of CVD risk factors in a population which is currently under-represented in the literature. Specifically, our findings extend existing knowledge by demonstrating that young women with moderate abdominal obesity displayed some markers of (1) sub-clinical cardiac abnormalities that may have been associated with remodelling, and (2) myocardial dysfunction. We can confirm, for the first time in this population, the presence of subtle early myocardial dysfunction in the
longitudinal axis but preserved circumferential deformation and twist mechanics - identified using STE - of young women with abdominal obesity.

**Effects of obesity on sub-clinical cardiac abnormalities in cardiac morphology**

Women with abdominal obesity had larger LA dimensions than controls but otherwise cardiac morphology were similar. The LA enlarges in response to increases in LV pressure due to impaired LV filling, making it a useful adjunct in the assessment of chronic diastolic dysfunction (Gottdiener et al., 2004). Prior studies have found an association between LA dimensions and obesity in females. Specifically, abnormalities in LA diameter have been linked to obesity in a group of young women (29 ± 10 years, n=48) with isolated obesity (Pascual et al., 2003), in a population of slightly older (32 ± 4 years) obese young adults (Peterson, Waggoner, et al., 2004), and in obese middle-aged adults (Orhan et al., 2010; Wong et al., 2004), with normal EF. In light of this, the findings from our study is potentially of even greater concern in a population of women who were notably younger and had milder obesity than previously reported studies. Mechanisms behind this link may occur as a consequence of the hemodynamic changes associated with obesity (Wong & Marwick, 2007a). LV structure was similar between groups, as were the load -dependent echocardiographic indices of systolic function. Similarly, no between-group differences were observed for LV end-systolic and LV end-diastolic diameters.

**Effects of obesity on sub-clinical cardiac abnormalities in cardiac function**

Obesity impairs cardiac loading (Wong et al., 2004). In our study, conventional load-dependent parameters of LV diastolic function, including reduced mitral inflow velocity (E-wave), and indicators of filling and relaxation, including elevated $E/E_m$, and elongated IVRT, and elongated DT (a measure of LV stiffness), were observed more frequently in women with abdominal obesity than controls. These observations are supported by previous literature on diastolic dysfunction, suggesting underlying abnormalities in relaxation and/or myocardial compliance, in obese individuals without hypertension or cardiac hypertrophy (Crendal et al., 2013). However, this is the first study to identify diastolic impairment in such a young group of females in the absence of cardiac ventricular hypertrophy and hypertension.
In the present study, women with abdominal obesity also demonstrated attenuated TDI-derived velocities including significantly lower systolic ($S_m$) and early-diastolic ($E_m$) function than the control group. The TDI echocardiography parameters of $S_m$, $E_m$ and $E/E_m$ have established independent prognostic value in a wide variety of cardiac disorders and are powerful predictors of cardiac mortality (Wang et al., 2003). In the present study, we reported decreased $S_m$ indicating systolic dysfunction in women with abdominal obesity. Additionally, low $E_m$ values may be indicative of abnormal LV relaxation, has previously been reported to correlate with IVRT. In our study, IVRT was elongated and $E_m$ reduced, albeit only minimal, which may link to early onset of cardiac dysfunction in this young population. Despite significant differences between groups, women with abdominal obesity displayed normal “within range” LV filling pressure, indicated by the $E/E_m$ ratio being $\leq 8$ (Nagueh et al., 2009). Thus, early but not late diastolic dysfunction was associated with obesity among the young women in the present study.

The negative impact of obesity on early diastolic function has been reported but, again, these results were found in older, less healthy adults. Also, in a group of 29 middle-aged adults (49 ± 8 years) with isolated obesity (average BMI of 37.2 ± 2.7 kg/m$^2$), participants had reduced $E_m$ velocity, and significantly increased IVRT, DT, and $E/E_m$ ratio than 20 aged-matched non-obese controls (Orhan et al., 2010). It is again striking that we identified similar diastolic changes to those observed in this older mixed gender population of more profoundly obese participants who also had greater LV mass. It may be possible that the observed dysfunction is part of a disease progression from subtle myocardial dysfunction and atrial remodelling to also eventually involve structural remodelling of the ventricles. Longitudinal studies are required to investigate this question further. In addition, a focus on weight reduction, including the prevention and early detection of cardiometabolic risk factors in young obese adults, might be advantageous for inducing positive reversible changes in cardiac morphology and function.

**Effects of obesity on myocardial dysfunction via deformation**

Non-invasive ultrasound techniques such as conventional and TDI echocardiography have a major role in the diagnosis and management of CVD. An inability to accurately differentiate actively contracting myocardium from passive myocardial motion is one of the principle limitations of conventional and TDI echocardiography in the assessment of LV structure and function.
function (Anderson, 2007). The innovation of STE enables unique acoustic speckles within the myocardium to be tracked thereby permitting analysis of the relative regionalst of the myocardium, thus separating deformation from passive motion (Brugger et al., 2014). In some settings, STE has enabled early diagnosis of systolic and diastolic dysfunction, even when conventional and TDI echocardiography parameters of LV function remain within normal range (Di Bello et al., 2013; Nagueh et al., 2009). In our study, we confirmed and extended previous data by demonstrating that young women with abdominal obesity displayed impaired longitudinal myocardial dysfunction, but preserved circumferential function, compared with the control group. While the exact mechanisms behind this remain unclear, the finding is consistent with previous studies in older, disease-free populations (Crendal et al., 2013). The reduced longitudinal strain and SR in our women with abdominal obesity highlight early diastolic and systolic dysfunction that could be explained by depressed relaxation and compromised contractile properties of myocardial fibres. Although measures of deformation are less load dependent than some traditional parameters, it is clear that strain and SR are still influenced by loading conditions and it is difficult to completely isolate change in contractility from the aforementioned change in load (Burns et al., 2010). It is possible that increases in ventricular and atrial filling pressure are both a cause and consequence of reduced myocardial deformation.

The reduced LV strain observed in our young women with abdominal obesity has been reported previously. A study of obese middle-aged women (n=663, 47.8 ± 13.6 years, waist circumference 88.5 ± 11.7 cm) showed a strong relationship between elevated waist circumference and an undesirable reduction in LV strain (Dalen et al., 2011). Similarly, other research has shown reduced strain indices and reduced E velocity in 26 middle-aged women (49 ± 8 years) with isolated obesity (WC 105 ± 7.0 cm), compared with 18 age-matched non-obese controls (Orhan et al., 2010). The identification of these pre-clinical myocardial abnormalities in obese young women provides a marker which could be followed through treatment interventions with the logical hypothesis that weight reduction and increased physical activity may attenuate further decline in myocardial function.

Effects of obesity on myocardial dysfunction via mechanics

Speckle tracking echocardiography can also be used to assess myocardial mechanics such as twist and twist rate which describe the torsional rotation of the heart produced by the helical
structure in which the myocardial fibres are arranged (Sengupta et al., 2007; Wong, Leano, et al., 2006). Twist and the resulting rate of untwist have been promoted as sensitive determinants of cardiac performance, particularly during diastolic relaxation and filling (Beladan, Calin, Rosca, Gingham, & Popescu, 2014). However, their acceptance in clinical practice has been limited by reproducibility issues (Beladan et al., 2014). Therefore, the improvements in sensitivity provided by deformation and the twist-based mechanical actions of the LV remain unclear.

Nevertheless, the role of LV twist as a major contributor to LV filling has generated much interest (Sengupta, Tajik, Chandrasekaran, & Khandheria, 2008). For example, reductions in diastolic and systolic LV twist as well as basal rotation showed a stronger correlation with waist circumference (r=-0.24, P<0.05) in obese middle-aged (44 ± 10 years) participants compared with non-obese controls (Wong, Leano, et al., 2006). Similarly, obese adolescents had more pronounced LV twist and greater apical rotation than lean controls, confirming the feasibility of detection in younger populations (Obert et al., 2012). It was postulated that, even in adolescent populations, the greater LV twist in the obese individuals could be viewed as a compensatory phenomenon for their depressed longitudinal function, critical for LV filling and ejection (Obert et al., 2012). However, previous LV myocardial mechanics in rotational indices of twist/untwist rates were not supported by the results from the present study. Variability may have limited accurate conclusions from these results, with the coefficient of variability for intra-and inter-observer differences averaging around 9.6%. Discrepancies in twist mechanics between obese and control could also be related to difficulties in imaging capacities, particularly for apical rotation (Beladan et al., 2014).

Obesity is strongly associated with insulin resistance, impaired glucose tolerance and diabetes. The metabolic changes, as well as activation of the sympathetic nervous system and renin-angiotensin-aldosterone system, provide possible links between obesity and myocardial dysfunction (Wong & Marwick, 2007a). In our study, changes in cardiac and myocardial parameters were accompanied by some but not all biological markers in women with abdominal obesity compared with non-obese controls. However, the correlations between significant markers of TDI and STE with biomarkers of CVD risk were only moderate. We propose that obesity is directly related to a sequence of yet to be clarified early markers of cardiac risk.
Study limitations

The cross-sectional design of this study means that we cannot address the intriguing hypotheses regarding changes in myocardial function over time and the resulting clinical consequences. However, this novel demonstration of significant myocardial dysfunction in a young population provides necessary motivation for longitudinal interventional studies. Moreover, results are specific to Caucasian women at a tertiary institution; however, the selected population could also be interpreted as truly representative of a relatively educated group of young women in Australia. Also, ultrasound acquisition and analyses are dependent on operator skill. Whilst this is a potential explanation of the failure to demonstrate differences in some myocardial mechanical indices, the reliability reported for the current study was similar to previously published work. Additionally, we did not assess right ventricular function or myocardial reserve during exercise studies and it is possible these specialised measures may have corroborated our findings of diminished cardiac performance (La Gerche, Claessen, & Burns, 2013). Finally, central fat distribution in these young women could have been more ideally measured using more precise estimations from devices such as MRI and dual energy x-ray absorptiometry.

Conclusion

Young women with moderate abdominal obesity, measured by waist circumference, displayed larger left atrial dimensions and reduced measures of diastolic and systolic myocardial function, compared with non-obese controls. Low grade systemic inflammation was also present in young women with abdominal obesity. These findings may provide important insights into the links between obesity and the increased incidences of cardiometabolic disease. Furthermore, our data provides additional motivation for prospective studies which assess whether lifestyle interventions may attenuate the increased risk of cardiovascular morbidity.
Chapter 7. Effects of a multi-disciplinary lifestyle intervention on cardiometabolic risk factors in young women with abdominal obesity: A randomised controlled trial.

Bianca L. Share; Geraldine A. Naughton; Philippe Obert; Jennifer K. Peat; Justin G. Kemp

Publication Statement:
This work was accepted for publication in the PLoS One (May, 2015), please see Appendix 1 and 15.

Acknowledgements:
The authors are grateful to Bianca Gazzola for her work as the dietitian. Thanks are also extended to all of those women who participated in the Young Women’s Heart Health Study.
Abstract

Background: Young women are under-represented in chronic disease research, with interventions for obesity and other CVD risk factor generally targeting older adults. Therefore, this study aimed to assess the impact of a 12 week multi-disciplinary lifestyle intervention on reducing cardiometabolic risk in sedentary Caucasian women with abdominal obesity.

Methods: Women aged 18-30 y with abdominal obesity [waist circumference (WC) ≥ 80 cm] participated in a 12 week lifestyle intervention. Using a randomised controlled design, an intervention group undertook physical activity, nutrition education and cognitive behavioural therapy (n = 26) alongside a wait-list (delayed-start) control group (n = 17). Both groups completed anthropometric, biochemical, nutrition and fitness testing, at pre-intervention/pre-control (0 week) and post-intervention/post-control (12 week), and with intervention participants only, completing follow-up testing at 24 weeks. Physical activity and dietary behaviour were also documented at each time-point

Results: Results from a linear mixed model showed no between-group differences other than increased physical activity (minutes/week) in the intervention group following the intervention. In the intervention group alone, positive within-group changes were observed in WC, waist-hip-ratio (WHR), waist-height-ratio (WHR), resting heart rate, blood pressure, predicted VO2max, and total energy intake, with most of these changes maintained at 12 weeks after intervention cessation. Similar within-group improvements in WC, WHR, WHtR, and systolic blood pressure were observed in control participants, but no changes were detected in their self-reported markers of nutrition and physical activity.

Conclusions: CVD risk factors were decreased as a result of a lifestyle intervention in young women with abdominal obesity. It is difficult to describe observations in the control group without a greater understanding of the behaviour of wait-list participants. New thinking for control group designs in studies with Generation Y women is recommended.
Trial registration: Australian New Zealand Clinical Trials Registry (anzctr.org.au) Identifier: ACTRN12612001017819

Key words: Female, waist circumference, abdominal obesity, physical activity, sustainability, cardiovascular disease, control group, multi-disciplinary.
Background

Cardiovascular disease (CVD) represents a major health threat to women worldwide (World Health Organisation, 2006), consequently placing substantial burden on public health systems. Most risk factors for CVD, including overweight/obesity and physical inactivity, can be modified through lifestyle interventions (Irving et al., 2008; Kemmler et al., 2009). The rising prevalence of overweight and obesity is a worldwide concern among young women from developed and developing nations (Stewart et al., 2008). Currently, 51% of non-hispanic white American women aged 20-39 years are either overweight or obese (Flegal et al., 2012), while prevalences among women in the United Kingdom (Health and Social Care Information Centre, 2011), and Australia (Australian Bureau of Statistics, 2013) aged 25-34 years are 47% and 42%, respectively. An average weight gain of 6 to 12 kg between the ages of 20 to 30 years was noted in a large longitudinal study of women’s health (Lucke et al., 2007), and this weight gain was more than for any other age group (Adamson et al., 2007; Lucke et al., 2007). Concurrently, sedentary behaviour is increasing in young women (Cleland et al., 2011), with 85% of women aged 18-35 years reporting inactive lifestyles and decreased physical activity (Adamson et al., 2007). Among women, weight gain is not only a risk factor for CVD but increases the risk of the metabolic syndrome (Alberti et al., 2009), type 2 diabetes mellitus, depression, polycystic ovarian syndrome, infertility and adverse pregnancy outcomes (Emaus et al., 2008).

Despite global strategies for preventive health, there is poor understanding of early risk factors (cardiometabolic risk factors) in young women, and lifestyle interventions can improve health outcomes. Moreover, research assessing the effectiveness of weight management interventions specifically targeting young women is relatively recent (Hutchesson et al., 2013). Effective age-appropriate interventions for improving cardiometabolic risk are required for young adults born between 1977 to 1994 (“Generation Y”) who share an urgency for feedback and success (Gokee-LaRose et al., 2009; Martin, 2005). The limited research that has been conducted in young overweight/obese women suggests they are difficult to recruit for weight management trials, with high attrition and limited success in losing weight compared with older populations (Griffin, O'Connor, Rooney, & Steinbeck, 2013).
Therefore, the primary aim of this study was to assess the feasibility of a lifestyle intervention for reducing CVD risk in young women with abdominal obesity, using a randomised controlled trial (RCT) design. Specifically, the RCT involved a 12-week multidisciplinary program (physical activity, nutrition education, cognitive behavioural therapy) with Caucasian women aged 18 to 30 years, who shared the cardiometabolic risk factor of abdominal obesity [elevated waist circumference (WC) ≥ 80 cm]. A secondary aim was to examine the effectiveness of the intervention through an improved understanding of the sustainability of any changes. It was hypothesised that the lifestyle intervention would be effective (and sustainable) in reducing cardiometabolic risk in young women with abdominal obesity.

**Methods**

**Ethics statement**

The study protocol was approved by the Australian Catholic University Human Research Ethics Committee (V2009-91). Written informed consent was obtained, together with a cardiovascular risk assessment, from all participants prior to testing.

**Participants**

Sixty-two female Caucasian tertiary students at risk of CVD volunteered for this study. Data were collected between August 2010 and February 2012. Advertisements for recruitment specifically sought young women with abdominal obesity (WC ≥ 80 cm), who were also leading a sedentary lifestyle. Prospective participants were contacted and underwent an initial screening to confirm eligibility. Included were women aged 18 to 30 years; with a waist circumference ≥ 80 cm, and who were physically inactive (< 210 minutes per week of organised physical activity in the past six months). Exclusion criteria were being pregnant or breastfeeding; with a history of bariatric surgery; and/or having a diagnosis of liver or kidney disease; heart arrhythmia; insulin dependent diabetes mellitus; polycystic ovarian syndrome; thyroid abnormalities. All participants were non-smokers.
A power analyses estimated that 18 participants per group would provide the appropriate sample size to detect a large within-subject difference of 1.0 standard deviation ($\beta = 80\%$, alpha $P < 0.05$) in waist circumference from pre-intervention to post-intervention. To allow for 20% attrition, there was an attempt to recruit an initial sample size of 44 participants (22 per group). Figure 7.1 shows the participation of individuals in this study. From 62 women who responded to the recruitment strategy, 11 prospective participants were excluded, and a further 12 did not respond to preliminary contact. Therefore, 39 willing participants underwent pre-intervention/pre-control testing, after which group (block) randomisation occurred via a central administrator who allocated participants to either the intervention group or wait-list (delayed-start) control group. Block randomisation involved a block size of four participants thus allowing for six sequences for allocating participants to the two arms of the intervention (Peat & Barton, 2005). Group allocations occurred using identical opaque envelopes. Anecdotally, none of the participants assigned to the control group provided an immediately negative response. A wait-list control design was chosen because the investigators desired an ethically-sound model which provided all participants with access to the lifestyle intervention. Also, a wait-list control group was considered more appropriate than a passive control group given that health risks were comparable in both groups. After allocation to the wait-list control group for 12 weeks, only four participants continued into the lifestyle intervention phase. Participants were not blinded to their group, but where possible assessors were blinded to group allocation.
Figure 7.1. CONSORT participant flow-chart of intervention and control participants. (note: four participants from the wait-list control group continued into the intervention phase.)
Experimental design

For each testing period (0, 12, 24 weeks), participants attended the laboratory on two occasions. They were requested to refrain from strenuous physical activity in the 24 hours prior to all laboratory sessions. The first visit required the participant to arrive in a fasted state and clinical testing lasted 75 minutes. The second visit of 60 minutes required participants to abstain from caffeine and alcohol for 12 hours. A time course of the experimental procedures in these testing sessions is presented in Figure 4.4.

For the intervention group, testing of cardiometabolic risk factors was performed at pre-intervention (0 weeks), post-intervention (12 weeks) and following a sustainability phase (24 weeks). The control group underwent testing at pre-control and post-control (12 weeks) time periods only (Figure 7.2). For all testing, measurements were taken at the same time of day (±2 hours) and by the same researcher. For participants in the control group, monthly contact was made to remind them of the control criteria. For the sustainability phase between post-intervention (12 weeks) testing and the following 12 weeks, a sustainability strategy was delivered electronically to the intervention group. This involved a fortnightly newsletter on healthy living tips from evidence-based resources.

Neither the investigators nor the participants were blinded to group allocation as this was considered impractical for the long-term investigation and limited members of the research team. However, to minimise contamination, participants in the intervention group were asked to refrain from disclosing their intervention experience to researchers assigned to data collection and/or analysis and to wait-list control participants. To further minimise bias, assessor blinding occurred within dietary measures and biochemical analyses. For the primary outcome variable of WC, measures were completed in duplicate with reported measures of reliability: coefficient of variation (CV), intraclass correlation coefficient (ICC) and measurement error (ME).
Figure 7.2. Timeline of testing for intervention and wait-list control participants
Testing measures

Survey data
A self-administered lifestyle survey was completed to provide data on (i) health status and medical conditions, (ii) nutrition (including alcohol consumption), and (iii) current physical activity habits. The lifestyle survey was developed specifically for the study and validated using the process of face validation (Gravetter & Forzano, 2012).

Anthropometric assessment
Body composition was assessed via waist circumference (WC), hip circumference, body mass index (BMI), and body mass. WC was measured to the nearest 0.1 cm in the horizontal plane at the level of the midpoint between the iliac crest and lower costal margin (Alberti et al., 2009) using a non-elastic measuring tape, with the average of two measures reported. For WC, CV = 1.26%, ICC (3, 1) = 0.986 and ME = 1.34%, which equates to an error range of ±2.6 cm. Body mass was measured to the nearest 0.1 kg using digital scales (Tanita, Tokyo, Japan) with participants wearing light clothing and no footwear, and height was estimated to the nearest 0.1 cm using a wall-mounted stadiometer (Seca, Germany). BMI was calculated as weight (kg)/height (m²), with overweight/obesity defined as BMI ≥ 25 kg·m⁻² (World Health Organisation, 2006).

Metabolic syndrome markers and additional biochemical parameters
Metabolic syndrome was defined according to the most recent and unified criteria (Alberti et al., 2009), in which three of the following five markers were met: (1) waist circumference ≥ 80 cm, (2) serum triglycerides ≥ 1.7 mmol·l⁻¹, (3) HDL-cholesterol <1.29 mmol·l⁻¹, (4) systolic blood pressure (SBP) > 130 mmHg or diastolic blood pressure (DBP) > 85 mmHg, and (5) fasting plasma glucose ≥ 5.6 mmol·l⁻¹ or previously diagnosed type 2 diabetes. Markers of insulin resistance, including fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR), and the pro-inflammatory marker high sensitivity C-reactive protein (hs-CRP), were also measured in this study.
Following an overnight fast, intravenous blood was collected (8:00-11:00am) from the antecubital vein. Blood lipid profiling of serum concentrations of triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol were measured using the Reflotron Plus desktop analyser (Roche, Switzerland). A CV of 3.8% is reported between Refloton measurements for total cholesterol and a standardised wet-chemistry method (Statland, 1990). Fasting plasma glucose, insulin and hs-CRP concentrations were analysed by clinical pathology at a leading hospital. Insulin resistance was estimated by HOMA-IR using the equation: 

HOMA-IR = fasting insulin concentration (µU/mL) x fasting glucose concentration (mmol/L) / 22.5 (Matthews et al., 1985). HOMA-IR is a surrogate measure of whole body insulin sensitivity and β-cell functioning correlates (r = 0.88) well with estimates using the euglycemic clamp method (Bonora et al., 2000) with a value ≥ 2.0 considered indicative of insulin resistance (Jensterle et al., 2008). For hs-CRP, a value > 3.0 mg·l⁻¹ was deemed high risk (Pearson et al., 2003).

For SBP and DBP, duplicate assessments were obtained from the left arm with an automated digital sphygmomanometer (Carescape V100, Dinamap, GE technology, USA).

**Health and Fitness evaluations**

The YMCA graded submaximal cycle ergometer test (Golding et al., 1989) was used to estimate aerobic power (predicted VO₂max), where heart rate was extrapolated against work rate (W) using regression analysis. Physical activity behaviour was obtained via a 7-day recall (Sallis et al., 1993).

Within the acknowledged limitations of dietary recall (Magarey et al., 2011), participants completed a three-day food and beverage recall (including vitamins, minerals and/or supplements) on two consecutive weekdays and on either a Saturday or Sunday of their usual diet. Participants were encouraged not to alter their habitual diet during the recall period. Macro- and micro-nutrient intakes were analysed by a research dietician, blinded to grouping, using the FoodWorks® 7 Professional program (Xyris software, Highgate Hill, Queensland, Australia). An estimation of average daily energy intake was also calculated.
**Intervention**

The 12-wk lifestyle intervention was comprised of three main components: (1) physical activity (2) nutrition education, and (3) cognitive behavioural therapy (Table 7.1). Total time for participants in the intervention group was approximately 4.5 hours per week. Specifically, exercise participation time averaged 3 hours per week. The intervention also included 60 minutes of psychological support (CBT) plus a 30 minutes nutrition session weekly. Participants met in smaller groups for nutrition and exercise sessions while the CBT was one larger group per week. In contrast, participants in the wait-list control group (n=17) were instructed to continue existing lifestyle choices, and after 12 weeks were invited to complete the lifestyle intervention.

**Physical activity**

Participants undertaking the intervention completed two supervised exercise sessions (progressive circuit training) and one unsupervised, but were prescribed one home-based session (brisk walk or jog) per week. The supervised sessions were administered by a qualified Exercise Scientist and consisted of a general warm-up, a combination of aerobic activities, dynamic strength and/or resistance training, abdominal conditioning, and stretching. Session duration lasted approximately 60 min, with the intensity of the exercise increasing from 60% to 85% on the OMNI Picture System (range (Robertson, 2004), by the end of the 12-week period. The OMNI Picture System is a rating of perceived exertion (RPE) scale (ranging from 0 = extremely easy to 10 = extremely hard), with which participants were well-familiarised prior to intervention commencement. Evidence supports the use of the OMNI-RPE scale by young women (n=34, 18-36 y) to estimate RPE (Utter et al., 2004). A positive linear relationship was found between the OMNI-RPE scale and %VO₂max (r² = 0.72), and heart rate (r² = 0.63), respectively, during a graded treadmill exercise test (Utter et al., 2004). Intensity was verified by comparing heart rates with RPE during most exercise sessions with a Polar heart rate monitor (Polar Electro, Finland). This occurred at the completion of the aerobic component of the exercise session. The home-based, unsupervised training session involved a brisk walk or jog at an RPE of 5-7 on the OMNI Picture System (Robertson, 2004). Participants were encouraged to incorporate intermittent high-intensity intervals into their session. Duration of the session progressed from 30 minutes at
intervention commencement to 45 minutes at program completion. As a measure of compliance, participants maintained a detailed training diary including any extra activities they completed during the intervention. The Bruce protocol (Bruce et al., 1973) was completed every three weeks to ensure accuracy of progressive overload of aerobic fitness during the program. Upper (chest-press) and lower (leg-press) body strength was tested via a 5-repetition maximum test to guide the strength and resistance component of the exercise intervention (Abadie & Wentworth, 2000). Results from the Bruce protocol and strength test provided individualised heart rate and RPE zones and initial loads for the training program, respectively. To replicate community resources, sessions occurred in both the gym on campus and at a local park.

**Nutrition education**
Participants in the intervention group received weekly nutrition education sessions guided by a dietician about healthy eating choices from the existing Australian Dietary Guidelines (National Health and Medical Research Council, 2005). This information provided education regarding non-dieting weight management and healthy eating principles. Following baseline analysis of a three-day food and beverage recall, nutrition education topics targeted the perceived needs of the female participants, such as appropriate snacks, portion sizes, and responsible alcohol consumption.

**Cognitive behavioural therapy**
Within the framework of self-determination theory (Deci & Ryan, 1985), weekly 60-minute group sessions with a counsellor provided participants with psychosocial support and developed skills to overcome personal barriers to lifestyle change. Topics included changing behaviour, goal setting, self-efficacy and building self-confidence. The program aimed, ultimately, to empower individuals to develop healthier eating and physical activity patterns (Miller & Jacob, 2001).
Table 7.1. Outline of the 12-week multi-disciplinary lifestyle intervention of physical activity, nutrition education and cognitive behavioural therapy.

<table>
<thead>
<tr>
<th>Week</th>
<th>Supervised session intensity (%)</th>
<th>Unsupervised session duration (mins)</th>
<th>Fitness testing</th>
<th>Physical Activity</th>
<th>Nutrition Education</th>
<th>Cognitive Behavioural Therapy (CBT)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bruce, 5-RM</td>
<td>Australian dietary guidelines for adults</td>
<td>Group formation and introductions</td>
</tr>
<tr>
<td>1</td>
<td>60</td>
<td>30</td>
<td></td>
<td></td>
<td>Australian physical activity guidelines for adults</td>
<td>Changing Behaviour: Benefits of change</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>30</td>
<td></td>
<td></td>
<td>Label reading and interpretation</td>
<td>Identifying strengths: Building momentum</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>30</td>
<td></td>
<td>Bruce, 5-RM</td>
<td>Serving size</td>
<td>Motivation: Goal setting for success</td>
</tr>
<tr>
<td>4</td>
<td>65</td>
<td>35</td>
<td></td>
<td></td>
<td>Glycemic index</td>
<td>Overcoming the barriers to change</td>
</tr>
<tr>
<td>5</td>
<td>70</td>
<td>35</td>
<td></td>
<td></td>
<td>Separating fact from fiction</td>
<td>Food for health: Making nutrition work for you</td>
</tr>
<tr>
<td>6</td>
<td>70</td>
<td>35</td>
<td></td>
<td>Bruce, 5-RM</td>
<td>Food variety, dietary fibre and snack choices</td>
<td>Letting go of the ‘uncontrollable’</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>40</td>
<td></td>
<td></td>
<td>Dietary fats and take-away food</td>
<td>Examining self-talk and building self-confidence</td>
</tr>
<tr>
<td>8</td>
<td>75</td>
<td>40</td>
<td></td>
<td></td>
<td>Fluids, hydration and alcohol</td>
<td>Physical activity and mood</td>
</tr>
<tr>
<td>9</td>
<td>80</td>
<td>40</td>
<td></td>
<td>Bruce, 5-RM</td>
<td>Protein and iron</td>
<td>Social support</td>
</tr>
<tr>
<td>10</td>
<td>80</td>
<td>45</td>
<td></td>
<td></td>
<td>Fad diets and body image</td>
<td>Behavioural change for life</td>
</tr>
<tr>
<td>11</td>
<td>85</td>
<td>45</td>
<td></td>
<td>Bruce, 5-RM</td>
<td>Dairy products and calcium</td>
<td>Group endings</td>
</tr>
<tr>
<td>12</td>
<td>85</td>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5-RM repetition max
Statistical analyses

Data were analysed using IBM SPSS Statistics, Version 20 for Windows (SPSS Inc, Chicago IL). Data were tested for normal distribution using the Shapiro-Wilk statistic and skewness and kurtosis (Peat & Barton, 2005). Log transformation was performed with data not normally distributed. All data are presented as means ± standard deviation. Statistical significance was set at \( P \leq 0.05 \). A linear mixed-model analysis was used to calculate the differences between groups and across time for the intervention and control groups. Hedge’s \( g \) effect size was used to assess the magnitude of effect. An effect size \( \geq 0.2 \) was considered small, \( \geq 0.5 \) medium, and \( \geq 0.8 \) large (Cohen, 1988). Mean differences and 95% confidence intervals (CI) are reported.

Results

A total of 39 participants were included in the analysis. For reasons described in Figure 7.1, 27% of intervention participants and 35% of control participants failed to maintain study involvement beyond pre-intervention/pre-control measures. However, for those completing the intervention, compliance rates were high with 80% attendance at physical activity and nutrition sessions and 74% at CBT sessions.

A per-protocol analysis (n=30) was performed on participants who completed the entire study excluding those who withdrew (n=9). Additionally, a sensitivity analysis was conducted to compare the means of those participants (n=4) who were allocated to the wait-list control group and who then undertook the intervention. No differences were found using both analyses and the findings were not altered.
Between group differences

Table 7.2 shows the results of comparisons between the intervention and control groups before and following the intervention, using a linear mixed model analysis. With only one difference observed between groups at pre-intervention, this supports the homogeneity of the groups. The baseline difference was found in a higher resting heart rate, in the intervention group, with a moderate effect size ($g=0.79$). At post-intervention, only physical activity was higher in the intervention group than the control group, with a large effect size ($g=2.14$).
Table 7.2. Between group comparisons of cardiometabolic risk factors for the intervention and control group at pre (0 weeks) and post (12 weeks).

<table>
<thead>
<tr>
<th></th>
<th>Pre-control/pre-intervention (0 weeks)</th>
<th>Post-control/post-intervention (12 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=17)</td>
<td>Intervention (n=26)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td>Effect size (Hedge’s g)</td>
</tr>
<tr>
<td><strong>Anthrometric assessment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>86.1 ± 17.8</td>
<td>0.564</td>
</tr>
<tr>
<td>Body mass index (kg·m⁻²)</td>
<td>31.4 ± 6.6</td>
<td>0.674</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>92.8 ± 10.8</td>
<td>0.930</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>113.8 ± 11.5</td>
<td>0.537</td>
</tr>
<tr>
<td>Waist-hip-ratio</td>
<td>0.81 ± 0.03</td>
<td>0.242</td>
</tr>
<tr>
<td>Waist-height-ratio</td>
<td>0.56 ± 0.06</td>
<td>0.989</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>119 ± 8</td>
<td>0.669</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>64 ± 8</td>
<td>0.115</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>1.7 ± 0.6</td>
<td>0.887</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>1.2 ± 0.4</td>
<td>0.838</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>4.5 ± 0.6</td>
<td>0.353</td>
</tr>
<tr>
<td><strong>Additional biochemical parameters</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.3 ± 0.5</td>
<td>0.645</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)</td>
<td>8.1 ± 4.4</td>
<td>0.720</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.6 ± 1.0</td>
<td>0.331</td>
</tr>
<tr>
<td>hs-CRP (mg·L⁻¹)</td>
<td>2.9 ± 2.6</td>
<td>0.495</td>
</tr>
<tr>
<td><strong>Fitness appraisal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>67 ± 10</td>
<td>0.019</td>
</tr>
<tr>
<td>Predicted VO₂ max (L·min⁻¹)</td>
<td>2.7 ± 0.2</td>
<td>0.515</td>
</tr>
<tr>
<td>Predicted VO₂ max (ml·kg⁻¹·min⁻¹)</td>
<td>32.0 ± 10.3</td>
<td>0.133</td>
</tr>
<tr>
<td>Physical activity (min·week⁻¹)</td>
<td>118 ± 89</td>
<td>0.870</td>
</tr>
<tr>
<td><strong>Nutrition evaluation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>6657 ± 3310</td>
<td>6555 ± 2183</td>
</tr>
<tr>
<td>CHO (g)</td>
<td>194 ± 88</td>
<td>0.386</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>135 ± 93</td>
<td>0.397</td>
</tr>
<tr>
<td>Total fat (g)</td>
<td>66 ± 38</td>
<td>0.734</td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation, *log10 transformation, P ≤ 0.05. BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein, CHO carbohydrates. Effect size ≥ 0.2 small, ≥ 0.5 medium, ≥ 0.8 large (Vincent, 1995).
**Intervention group**

For the intervention group, there were positive significant (P ≤ 0.05) changes pre-to post-intervention for WC (-6.4%), WHR (-2.5%), WHtR (-5.5%), SBP (-3.4%), DBP (-5.8%), resting heart rate (-11%), predicted VO$_{2\text{max}}$ (+15%), physical activity (+97%) and total energy intake (-22%) (Table 7.3 and Figure 7.3). Absolute protein intake (g) decreased but this difference disappeared when the decreased total energy intake was accounted for. Many of these improvements were maintained at sustainability (24 weeks) testing, and while predicted VO$_{2\text{max}}$ and physical activity reduced during the 12-week sustainability phase, physical activity remained greater than at pre-intervention.

**Control group**

Despite being requested to maintain normal lifestyle habits, the control group displayed several improvements from pre- to post-testing, including WC (-6.2%), WHR (-3.8%), WHtR (-5.5%) and SBP (-7.0%), while circulating triglycerides rose (Table 7.4 and Figure 7.3). In contrast to the intervention group, there were no changes in reported DBP, reported physical activity, predicted VO$_{2\text{max}}$, resting heart rate and energy intake following the 12-week control period.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-int. (0 weeks) (n=26)</th>
<th>Post-int. (12 week) (n=19)</th>
<th>Sustainability (24 week) (n=19)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthropometric assessment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>89.8 ± 21.1</td>
<td>86.9 ± 20.5</td>
<td>86.1 ± 20.3</td>
<td>0.791</td>
</tr>
<tr>
<td>Body mass index (kg·m⁻²)</td>
<td>32.2 ± 5.9</td>
<td>31.3 ± 0.9</td>
<td>31.0 ± 6.1</td>
<td>0.447</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>93.1 ± 11.7</td>
<td>87.3 ± 9.8</td>
<td>87.8 ± 9.4</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>116.3 ± 13.3</td>
<td>114.2 ± 13.50</td>
<td>114.5 ± 13.9</td>
<td>0.309</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.79 ± 0.05</td>
<td>0.77 ± 0.04</td>
<td>0.77 ± 0.04</td>
<td>0.002*</td>
</tr>
<tr>
<td>Waist-height-ratio</td>
<td>0.56 ± 0.06</td>
<td>0.53 ± 0.05</td>
<td>0.53 ± 0.05</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>120 ± 11</td>
<td>116 ± 9</td>
<td>116 ± 11</td>
<td>0.047*</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>68 ± 6</td>
<td>64 ± 9</td>
<td>64 ± 6</td>
<td>0.040*</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>1.7 ± 0.5</td>
<td>1.9 ± 0.5</td>
<td>1.9 ± 0.4</td>
<td>0.193</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)¹</td>
<td>1.3 ± 0.5</td>
<td>1.4 ± 0.7</td>
<td>1.5 ± 1.0</td>
<td>0.855</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)²</td>
<td>4.6 ± 0.4</td>
<td>4.6 ± 0.4</td>
<td>4.6 ± 0.5</td>
<td>0.728</td>
</tr>
<tr>
<td><strong>Additional biochemical parameters</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.4 ± 0.6</td>
<td>4.3 ± 0.8</td>
<td>4.3 ± 0.6</td>
<td>0.542</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)⁰³</td>
<td>9.4 ± 4.7</td>
<td>8.1 ± 2.6</td>
<td>8.8 ± 4.7</td>
<td>0.957</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.9 ± 1.0</td>
<td>1.6 ± 0.5</td>
<td>1.80 ± 0.97</td>
<td>0.176</td>
</tr>
<tr>
<td>hsCRP (mg·L⁻¹)³</td>
<td>3.5 ± 3.0</td>
<td>4.6 ± 4.9</td>
<td>4.7 ± 3.8</td>
<td>0.743</td>
</tr>
<tr>
<td><strong>Fitness appraisal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>76 ± 12</td>
<td>68 ± 8</td>
<td>66 ± 9</td>
<td>0.020*</td>
</tr>
<tr>
<td>Predicted VO₂ max (L·min⁻¹)</td>
<td>2.4 ± 0.5</td>
<td>2.8 ± 0.6</td>
<td>2.5 ± 0.6</td>
<td>0.029*</td>
</tr>
<tr>
<td>Predicted VO₂ max (mL·kg⁻¹·min⁻¹)</td>
<td>27.9 ± 7.0</td>
<td>32.6 ± 6.8</td>
<td>30.9 ± 9.7</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Physical activity (min·week⁻¹)²</td>
<td>97 ± 62</td>
<td>280 ± 67</td>
<td>143.7 ± 48.4</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td><strong>Nutrition evaluation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>6535 ± 2183</td>
<td>5223 ± 1725</td>
<td>5538 ± 2588</td>
<td>0.007*</td>
</tr>
<tr>
<td>CHO (g)</td>
<td>166 ± 74</td>
<td>178 ± 96</td>
<td>154 ± 83</td>
<td>0.638</td>
</tr>
<tr>
<td>Protein (g)³</td>
<td>173 ± 86</td>
<td>138 ± 63</td>
<td>150 ± 86</td>
<td>0.012*</td>
</tr>
<tr>
<td>Total fat (g)³</td>
<td>66 ± 34</td>
<td>55 ± 14</td>
<td>56 ± 20</td>
<td>0.227</td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation, * log₁₀ transformation. * P ≤ 0.05. Int, intervention. BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein, CHO carbohydrates.
Table 7.4. Within-group comparisons of cardiometabolic risk factors for the control group at pre-control and post-control.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-control (0 weeks)</th>
<th>Post-control (12 weeks)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 17</td>
<td>n = 11</td>
<td></td>
</tr>
<tr>
<td><strong>Anthropometric assessment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>86.1 ± 17.8</td>
<td>82.5 ± 19.5</td>
<td>0.893</td>
</tr>
<tr>
<td>Body mass index (kg·m(^{-2}))</td>
<td>31.4 ± 6.6</td>
<td>30.0 ± 6.6</td>
<td>0.775</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>92.8 ± 10.8</td>
<td>87.2 ± 10.5</td>
<td>&lt; 0.001*</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>113.8 ± 11.5</td>
<td>111.1 ± 11.9</td>
<td>0.894</td>
</tr>
<tr>
<td>Waist-hip-ratio</td>
<td>0.81 ± 0.03</td>
<td>0.78 ± 0.03</td>
<td>0.001*</td>
</tr>
<tr>
<td>Waist-height-ratio</td>
<td>0.56 ± 0.06</td>
<td>0.53 ± 0.06</td>
<td>0.011*</td>
</tr>
<tr>
<td><strong>Metabolic syndrome markers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>119 ± 8</td>
<td>110 ± 12</td>
<td>0.012*</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>64 ± 8</td>
<td>59 ± 5</td>
<td>0.115</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L(^{-1}))</td>
<td>1.7 ± 0.6</td>
<td>2.0 ± 0.5</td>
<td>0.194</td>
</tr>
<tr>
<td>Triglycerides (mmol·L(^{-1}))(#)</td>
<td>1.2 ± 0.4</td>
<td>1.5 ± 0.6</td>
<td>0.034*</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L(^{-1}))(#)</td>
<td>4.5 ± 0.6</td>
<td>4.4 ± 0.6</td>
<td>0.662</td>
</tr>
<tr>
<td><strong>Additional biochemical parameters</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol·L(^{-1}))</td>
<td>4.3 ± 0.5</td>
<td>4.3 ± 0.4</td>
<td>0.730</td>
</tr>
<tr>
<td>Fasting insulin (mU·L(^{-1}))(#)</td>
<td>8.1 ± 4.4</td>
<td>7.4 ± 2.7</td>
<td>0.775</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.6 ± 1.0</td>
<td>1.4 ± 0.5</td>
<td>0.522</td>
</tr>
<tr>
<td>hsCRP (mg·L(^{-1}))(#)</td>
<td>2.9 ± 2.6</td>
<td>3.9 ± 3.7</td>
<td>0.727</td>
</tr>
<tr>
<td><strong>Fitness appraisal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>67 ± 10</td>
<td>67 ± 9</td>
<td>0.919</td>
</tr>
<tr>
<td>Predicted (\text{VO}_2)\text{max (L·min}^{-1})</td>
<td>2.7 ± 0.2</td>
<td>2.5 ± 0.6</td>
<td>0.962</td>
</tr>
<tr>
<td>Predicted (\text{VO}_2)\text{max (mL·kg}^{-1}·\text{min}^{-1})</td>
<td>32.0 ± 10.3</td>
<td>31.7 ± 10.9</td>
<td>0.945</td>
</tr>
<tr>
<td>Physical activity (min·week}^{-1})(#)</td>
<td>118 ± 89</td>
<td>121 ± 81</td>
<td>0.362</td>
</tr>
<tr>
<td><strong>Nutrition evaluation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>6657 ± 3310</td>
<td>5065 ± 1346</td>
<td>0.115</td>
</tr>
<tr>
<td>CHO (g)</td>
<td>194 ± 87</td>
<td>205 ± 101</td>
<td>0.745</td>
</tr>
<tr>
<td>Protein (g)(#)</td>
<td>135 ± 93</td>
<td>137 ± 59</td>
<td>0.947</td>
</tr>
<tr>
<td>Total fat (g)(#)</td>
<td>66 ± 38</td>
<td>50 ± 13</td>
<td>0.213</td>
</tr>
</tbody>
</table>

BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein, CHO carbohydrates. Data presented as mean ± standard deviation, \(\#\) log\(_{10}\) transformation, *P ≤ 0.05
Figure 7.3. Mean and 95% CI for intervention (n=26) and control (n=11) participants during the multi-disciplinary lifestyle intervention at pre-intervention, n=26/pre-control, n=17 (0 weeks), post-intervention, n=19/post-control, n=11 (12 weeks) and sustainability, n=19 (24 weeks) for (i) waist circumference, (ii) physical activity, and (iii) energy intake.

'a' denotes. $P \leq 0.05$ from pre-intervention to post-intervention.

'b' denotes. $P \leq 0.05$ from pre-intervention to sustainability.

'c' denotes. $P \leq 0.05$ from post-intervention to sustainability

'd' denotes. $P \leq 0.05$ between intervention and control groups (at post).

'e' denotes. $P \leq 0.05$ from pre-control to post-control.
Discussion

The effectiveness of the multi-disciplinary lifestyle intervention for reducing CVD risk in young women was highlighted by within-group improvements in a range of risk factors for the intervention group, with several of these improved markers retained 12 weeks after completion of the lifestyle intervention. Thus, these data suggest a relatively successful intervention for reducing CVD risk with promising sustainability. However, when between-group comparisons were made with the control group, the findings suggested a research design that was largely unsuccessful in identifying the effectiveness of the intervention phase. This raises several concerns associated with a wait-list control design when used with overweight/obese young women. Concerns from the current study support previous findings that describe more difficulties in retaining younger than older females to research trials (Hutchesson et al., 2013).

Positive changes within the intervention group were demonstrated with improvements in WC related measures, systolic and diastolic blood pressure, aerobic fitness and physical activity, and dietary energy intake. Collectively, these measures imply that the intervention produced cardiovascular, more so than metabolic, benefits for the intervention group. The use of investigative procedures such as non-invasive echocardiography or MRI may provide insight into the significance of these changes (Kosmala et al., 2008).

Improvements in fitness and physical activity and reduced energy intake also suggest that the exercise and nutrition education components of the intervention, respectively, were effective. Moreover, there was strong evidence for sustainability of intervention-induced improvements at 24 weeks, suggesting that the CBT component produced positive behavioural change in participants.

However, similar post-intervention changes in our wait-list control group, made it difficult to detect any anthropometric, biochemical, fitness or dietary differences between groups following the 12-week intervention phase. The control group in this RCT also displayed a decrease in WC that paralleled the intervention group, despite undetectable changes in self-reported physical activity and nutrition. The decreased WC of the control group is particularly difficult to explain without further investigative procedures such as accelerometry for physical activity and more rigorous dietary monitoring, but does suggest
that basic awareness of CVD risk might be enough to evoke change in targeted populations (Wake et al., 2013; Waters, George, Chey, & Bauman, 2012).

Randomised controlled trials provide the highest level of evidence for the effects of an intervention and are deemed to be scientifically rigorous (Peat, 2001), with control groups employed to provide a contrast for the experimental group (Elliott & Brown, 2002) and for establishing the efficacy of an intervention (Baucom, Hahlweg, & Kuschel, 2003). But changed outcomes that arise from a wait-list control condition can be detrimental rather than beneficial to a randomised controlled trial (Elliott & Brown, 2002), and this occurred in the current study. Therefore, wait-list control designs might not be appropriate for this population.

Retention and compliance of wait-list participants is also an issue for consideration when planning control conditions essential for maintaining the rigour of a randomised control design. In this study, more than one-third of the control group failed to return for post-testing at 12 weeks despite researcher attempts to maintain contact. In contrast, once engaged in the intervention group, retention to lifestyle change was high for at least 24 weeks. It is postulated that assigning participants to the control group decreased their motivation to participate. Thus, the duration (12 weeks) and/or conditions (no changes to existing lifestyle) of the control group do not appear suitable for women of this age group and demographic. Alternative strategies for immediate engagement, perhaps via topics of interest using multimedia such as health-related apps or support groups might improve commitment and maintain control group compliance. There were also some difficulties encountered with recruitment, with almost a quarter of interested and eligible participants failing to engage after initial commitment (prior to group allocation). Complexities associated with recruiting young women for weight management trials, especially from ‘Generation Y’, may result in smaller sample sizes and require shorter periods of engagement (Griffin et al., 2013).

Although not always the case (Crist et al., 2012), successful outcomes have been observed following lifestyle interventions with middle-aged (Irving et al., 2008) and older women (Kemmler et al., 2009). But there is a lack of effective lifestyle interventions for young adults, with no weight loss programs to date developed specifically to address the needs of this age group. Outcomes, enrolment and retention rates have been compared between younger (18-35 years, n=21) and more mature (> 35 years, n = 277) adults (66% female) engaged in similar behavioural weight loss and physical activity programs (Gokee-LaRose et
al., 2009). Results showed attendance was 30% lower in young adults and they were 30% less likely to be retained for the 6-month assessment. Weight loss and increases in total physical activity from baseline to 6 months were significantly less in the younger population. Although the number of younger adults was relatively small, these results indicated that traditional interventions were less successful in young adults (Gokee-LaRose et al., 2009). These findings are supported by results from other studies attempting to engage young adults (Chang et al., 2010; Donnelly et al., 2003; Thomson et al., 2008).

This study is not without limitations. Despite recruitment and retention strategies, the sample size, particularly in the control condition, was lower than anticipated at completion of the study, suggesting it was slightly under-powered. Additionally, the results are specific to Caucasian women at a tertiary institution. To capture any potential changes to control groups in a wait-list design, objective measures (e.g. accelerometers, fortnightly anthropometric measures) might be useful. In addition, the use of more objective measures of physical activity and dietary compliance would strengthen evidence of change in this age group of women.

Nonetheless, the study contributes to a very limited number of healthy lifestyle interventions in young adult women (< 30 years of age) with cardiometabolic risk factors (Chang et al., 2010). The multi-disciplinary lifestyle intervention confirms the potential value in health changes observed post-intervention, with favourable sustainability at a 12 weeks.
Conclusions

Within-group analysis showed that the multi-disciplinary lifestyle intervention comprising physical activity, nutrition education and CBT was positive for the reduction of CVD risk factors both immediately after and beyond the completion of the program. However, we also observed positive, but unexpected and difficult to explain, changes in the wait-list control group. Therefore, comparative lifestyle benefits for the intervention group may have been masked by undetectable weight management behaviour in the control group. When considered alongside the difficulties faced with recruitment and retention, especially in the nature of the control group, these results provide a challenge for prospective study designs with young women with cardiometabolic risk factors. Traditional RCT designs may be problematic for healthy lifestyle interventions in young women.
7.1. ADDENDUM: Perceived barriers to lifestyle change.

Introduction

While participation in regular physical activity is vital for health, women experience many and varied barriers to participating in physical activity (Yeats, 2010). In adult women, lack of time is often cited as the most prominent barrier to participation in physical activity, with work and study attributed to lack of time (Arango, Patiño, Quintero, & Arenas, 2011). Parenting/caring demands, body image and safety concerns are also highly ranked as perceived barriers for women (Yeats, 2010).

In the present study, selected psychological instruments were surveyed for a range of personal behavioural patterns. The objective was to determine the importance, motives, stage of change, and perceived barriers for participation in physical activity, together with information about perceived barriers to healthy eating.

Methods

At the pre-intervention/pre-control, post-intervention/post-control, and sustainability testing periods, participants completed three psychological instruments to address physical activity/exercise related behaviours. These inventories, described in Chapter 4, were:

1) Motives for Physical Activity Measure – Revised (MPAM-R) (Ryan et al., 1997).

2) Perceived Barriers to Activity (Booth et al., 1997; King et al., 2000).

3) Stage of Change for Exercise (B. Marcus et al., 1992).

In addition, participants specified their perception of ‘exercise importance’ and rated perceived barriers for healthy eating (Fowles & Feucht, 2004) on a 5-point Likert-scale.
Results

Table 7.5 presents the personal behavioural patterns for the intervention and control groups at the pre-intervention/pre-control (0 weeks) and post-intervention/post-control (12 weeks) time periods. The three major barriers to physical activity and healthy eating are shown. For the motives for physical activity, the responses are ranked from most (1) to least (5) important. For the stage of change for exercise, the percentage distribution for each participant group is provided, as is the distribution of responses for perceived exercise importance, calculated from cross-tabulations. Similarly, Table 7.6 presents the responses for participants who completed the lifestyle intervention, with data gathered at the pre-intervention (0 weeks), post-intervention (12 weeks) and the ‘sustainability’ (24 weeks) time periods.
### Table 7.5. Personal behavioural patterns: between-group comparisons for the control and intervention groups at pre-intervention/pre-control and post-intervention/post-control.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control group (n=17)</th>
<th>Intervention group (n=19)</th>
<th>Control group (n=11)</th>
<th>Intervention group (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barriers to physical activity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Feeling too tired (87.5%)</td>
<td>Feeling too tired (89%)</td>
<td>Feeling too tired (89%)</td>
<td>Feeling too tired (84%)</td>
</tr>
<tr>
<td>2</td>
<td>Cost of classes or venue (75%)</td>
<td>Unmotivated (79%)</td>
<td>Cost of classes or venue (78%)</td>
<td>Cost of classes or venue (78%)</td>
</tr>
<tr>
<td>3</td>
<td>Poor weather (89%)</td>
<td>Cost of classes or venue (74%)</td>
<td>Poor weather (78%)</td>
<td>Feeling self-conscious (63%)</td>
</tr>
<tr>
<td><strong>Barriers to healthy eating</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Engaging in comfort eating (87%)</td>
<td>Comfort eating (100%)</td>
<td>Don’t feel like eating healthy (100%)</td>
<td>Comfort eating (83%)</td>
</tr>
<tr>
<td>2</td>
<td>Don’t feel like eating healthy (75%)</td>
<td>Food cravings (84%)</td>
<td>Don’t feel like eating healthy (79%)</td>
<td>Don’t feel like eating healthy (83%)</td>
</tr>
<tr>
<td>3</td>
<td>Eat when I’m not hungry (75%)</td>
<td>Don’t feel like eating healthy (79%)</td>
<td>Eat when I’m not hungry (67%)</td>
<td>Eat when I’m not hungry (72%)</td>
</tr>
<tr>
<td><strong>Motives for physical activity</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Appearances</td>
<td>Appearance</td>
<td>Appearances</td>
<td>Appearance</td>
</tr>
<tr>
<td>2</td>
<td>Fitness</td>
<td>Fitness</td>
<td>Fitness</td>
<td>Fitness</td>
</tr>
<tr>
<td>3</td>
<td>Interest</td>
<td>Competence</td>
<td>Interest</td>
<td>Competence</td>
</tr>
<tr>
<td>4</td>
<td>Competence</td>
<td>Interest</td>
<td>Competence</td>
<td>Competence</td>
</tr>
<tr>
<td>5</td>
<td>Social</td>
<td>Social</td>
<td>Social</td>
<td>Social</td>
</tr>
<tr>
<td><strong>Stage of Change</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-contemplation</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Contemplation</td>
<td>18%</td>
<td>22%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Preparation</td>
<td>64%</td>
<td>56%</td>
<td>67%</td>
<td>10%</td>
</tr>
<tr>
<td>Relapse</td>
<td>18%</td>
<td>22%</td>
<td>11%</td>
<td>5%</td>
</tr>
<tr>
<td>Action</td>
<td>0%</td>
<td>0%</td>
<td>22%</td>
<td>68%</td>
</tr>
<tr>
<td>Maintenance</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td>16%</td>
</tr>
<tr>
<td><strong>Exercise Importance</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very important or important</td>
<td>64%</td>
<td>50%</td>
<td>56%</td>
<td>84%</td>
</tr>
<tr>
<td>Neutral</td>
<td>36%</td>
<td>33%</td>
<td>44%</td>
<td>16%</td>
</tr>
<tr>
<td>Very unimportant or unimportant</td>
<td>0%</td>
<td>16%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>
Table 7.6. Personal behavioural patterns: within-group comparisons for the intervention group at pre-intervention, post-intervention, and sustainability.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-intervention (n=19)</th>
<th>Post-intervention (n=19)</th>
<th>Sustainability (n=19)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barriers to Physical Activity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Feeling too tired (89%)</td>
<td>Feeling too tired (84%)</td>
<td>Feeling too tired (74%)</td>
</tr>
<tr>
<td>2</td>
<td>Unmotivated (79%)</td>
<td>Feeling self-conscious (63%)</td>
<td>Lack of time (63%)</td>
</tr>
<tr>
<td>3</td>
<td>Cost of classes or venue (74%)</td>
<td>Lack of time (58%)</td>
<td>Cost of classes or venues (58%)</td>
</tr>
<tr>
<td><strong>Barriers to Healthy Eating</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Comfort eating (100%)</td>
<td>Comfort eating (83%)</td>
<td>Comfort eating (89%)</td>
</tr>
<tr>
<td>2</td>
<td>Food cravings (84%)</td>
<td>Don’t feel like eating healthy (83%)</td>
<td>Don’t feel like eating healthy (72%)</td>
</tr>
<tr>
<td>3</td>
<td>Don’t feel like eating healthy (79%)</td>
<td>Food cravings (56%)</td>
<td>Food cravings (67%)</td>
</tr>
<tr>
<td><strong>Motives for Physical Activity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>Appearance</td>
<td>Fitness</td>
<td>Appearance</td>
</tr>
<tr>
<td>2</td>
<td>Fitness</td>
<td>Appearance</td>
<td>Fitness</td>
</tr>
<tr>
<td>3</td>
<td>Competence</td>
<td>Interest</td>
<td>Competence</td>
</tr>
<tr>
<td>4</td>
<td>Interest</td>
<td>Competence</td>
<td>Interest</td>
</tr>
<tr>
<td>5</td>
<td>Social</td>
<td>Social</td>
<td>Social</td>
</tr>
<tr>
<td><strong>Stage of Change</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-contemplation</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Contemplation</td>
<td>22%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Preparation</td>
<td>55%</td>
<td>10%</td>
<td>37%</td>
</tr>
<tr>
<td>Relapse</td>
<td>22%</td>
<td>5%</td>
<td>16%</td>
</tr>
<tr>
<td>Action</td>
<td>0%</td>
<td>68%</td>
<td>32%</td>
</tr>
<tr>
<td>Maintenance</td>
<td>0%</td>
<td>16%</td>
<td>16%</td>
</tr>
<tr>
<td><strong>Exercise Importance</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very important or important</td>
<td>50%</td>
<td>84%</td>
<td>79%</td>
</tr>
<tr>
<td>Neutral</td>
<td>33%</td>
<td>16%</td>
<td>21%</td>
</tr>
<tr>
<td>Very unimportant or unimportant</td>
<td>16%</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>
Discussion

An understanding of the barriers to behaviour change, and the motives and importance given to such change by individuals, is important when considering the implementation and assessment of intervention programs and their outcomes. For the young women involved in the intervention study of this thesis, the majority of participants viewed exercise as very important or important. The motives for exercise participation and the barriers to healthy lifestyle change were similar to previous reports of in adults < 40 years of age (Arango et al., 2011; Lovell, El Ansari, & Parker, 2010).

At baseline, the spread of behaviour patterns reported by participants was similar between the intervention and control groups (Table 7.5). In the present study, the primary barriers to exercise was “feeling too tired”. This agrees with previous work with adults (age 37 ± 8 y, 60% female) in which the highest ranked perceived barrier to physical activity was ‘lack of will power’ (Arango et al., 2011). In this same study, women reported higher barrier scores than men, and obese participants reported a greater proportion of barriers than their non-obese counterparts. Thus, analysis of barriers to physical activity faced by overweight/obese women is essential when planning any strategy to increase the motivation and adherence to an active lifestyle. For motives to engage in physical activity in the present study, “fitness” was ranked second behind “appearance” as the most prominent. This is in agreement with work with non-exercising female university students (age 19 ± 1 y) who reported their greatest perceived benefit from exercise to be ‘physical performance’ (Lovell, El Ansari & Parker, 2010).

At baseline for “stage of change for exercise”, the majority of participants in the intervention and control groups were in the contemplation/preparation. This is consistent with other work (Arango et al., 2011) with adults (age 37 ± 8 y, 60% female) where the most prevalent stage of change for exercise was ‘contemplation’, followed by ‘preparation’. It was concluded that barriers to increased physical activity were most prominent in women and obese individuals who identified themselves as being in the ‘contemplation’ and ’preparation’ stage of change (Arango et al., 2011). This further highlights the importance of collecting and understanding these types of semi-quantitative data when designing and implementing lifestyle programs.
Following the 12-week intervention, participants demonstrated shifts in “stage of change for exercise” ratings, from a pre-intervention value of 0% for the ‘action phase’ to 68% by intervention completion. The intervention group also demonstrated a change in their perspective of exercise importance, with 84% of the group expressing exercise as ‘very important or important’ compared with only 50% at pre-intervention. These shifts could indicate a greater knowledge in the participants of the value of exercise and of strategies for incorporating it into their lifestyle routines, as highlighted in post-intervention focus group testing and anonymous program evaluations (see Addendum 7.2 for more details). However, at the ‘sustainability’ testing phase at 12 weeks after completion of the intervention (Table 7.6), a move back towards relapse/preparation was observed. This might reflect the rebound previously reported once an intervention program has been withdrawn, even when behavioural change strategies have been implemented (Wycherley et al., 2012).

Similarly, the control group displayed a shift in “stage of change for exercise” ratings in the same direction, although to a lesser extent, as the intervention group. Specifically, 22% of the control group reported being in the ‘action phase’ at post-control assessment, compared with 0% at the pre-control phase. This general change from pre-contemplation/contemplation to preparation/action in the control group provided evidence of a shift in motivation to commence lifestyle change, despite instructions to maintain current behaviours for the 12-week control period. The shift might be associated with improvements observed in some CVD risk factors (in particular, waist circumference) at the post-control testing, despite no detectable changes in self-reported physical activity and nutrition behaviours (see Chapter 7).

The results of the current study have implications for the design of physical activity programs and lifestyle interventions. The analysis of barriers that hinder physical activity engagement of participants, and their stage of change for exercise, is essential if successful behavioural change strategies are to be maintained. This is of particular importance if strategies are to target overweight/obese women and if exercise is to be a component of the intervention. Therefore, results of psychological changes in the current study support the need for age- and context-specific programs when attempting to engage sedentary young women in exercise programs.
7.2. ADDENDUM: Evaluation of the program

Introduction

A RCT design is widely accepted as the most reliable method for determining effectiveness (Oakley, Strange, Bonell, Allen, & Stephenson, 2006); (Campbell et al., 2000). Additionally, if possible, a RCT should always be considered because it is the most robust method of preventing bias (Campbell et al., 2000). The present study employed a “complex intervention” design that was multi-disciplinary, with three interacting components (i.e. physical activity, nutrition education, CBT). Due to their multifaceted nature and dependence on social context, complex interventions pose methodological challenges (Medical Research Council, 2000; Oakley et al., 2006). Therefore, it has been suggested that a lack of intervention impact may reflect implementation failure rather than genuine ineffectiveness and, thus, process evaluation is needed to identify implementation problems (Medical Research Council, 2000). Including a process evaluation of a RCT intervention is recommended to explain discrepancies between expected and observed outcome, to understand how context influences outcomes, and to provide insight to direct future implementation (Medical Research Council, 2000).

In the present work, several processes were implemented with the aim to better understand the experiences of the participants and, ultimately, to inform the evaluation of the lifestyle intervention and study overall. Three methods were used for the data collection process evaluation including:

- A focus group session at the completion of the intervention.
- Anonymous completion of an evaluation form at the completion of the intervention.
- Feedback from wait-list control group participants who withdrew from the study.
- An appraisal of recruitment, attendance, and retention rates of intervention participants.
Methods

At the completion of the lifestyle intervention, a focus group was conducted to gather rich data from participants about their experiences (Appendix 16). A facilitator qualified in the area of counselling conducted a 60-minute focus group with participants from the study, selected at random (n=7). The facilitator asked a series of semi-structured questions (Table 7.7) to encourage discussion within the group. The session audio was digitally recorded and transcribed verbatim to allow for theoretical analyses. Data were categorised and coded according to the researcher’s perspectives of emergent themes.

Table 7.7. Questions initiated by the facilitator used to develop discussion in the focus group.

<table>
<thead>
<tr>
<th></th>
<th>Question</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>What did being involved in the study mean to you?</td>
</tr>
<tr>
<td>2</td>
<td>Why did you respond to the initial email request for participants?</td>
</tr>
<tr>
<td>3</td>
<td>What is your current exercise regimen?</td>
</tr>
<tr>
<td>4</td>
<td>How have your nutritional choices been affected by your participation?</td>
</tr>
<tr>
<td>5</td>
<td>What or who are the biggest challenges to your healthy lifestyle?</td>
</tr>
<tr>
<td>6</td>
<td>What or who helps you lead a healthy lifestyle?</td>
</tr>
<tr>
<td>7</td>
<td>What are your short and long term healthy lifestyle goals?</td>
</tr>
<tr>
<td>8</td>
<td>What are two main things you learnt about changes you needed to make?</td>
</tr>
</tbody>
</table>

In addition to the focus group, an evaluation survey was completed anonymously by all participants, to gather feedback on the lifestyle intervention program (Appendix 17). The questionnaire evaluated several aspects of the program including: characteristics of the exercise instructor (who also delivered key nutrition messages prepared by a dietician) and group CBT counsellor; attainment of personal goals; each of the three intervention components (i.e. physical activity, nutrition education, and CBT); and, if the program met personal expectations.
Throughout the course of the control period, six wait-list control participants withdrew from the study. These participants were invited to provide feedback regarding reasons for withdrawal and three participants responded. These participants were asked two questions:

1) How did you feel when you were initially assigned to the control group?

2) Did your involvement in the study as a control participant trigger you to change anything about your current lifestyle?

A record of the flow of participants through the intervention was maintained using the CONSORT guidelines (Schulz, Altman, & Moher, 2010) to detail; (i) number of initial responses to study advertisements, (ii) number of eligible and ineligible participants, (ii) participant withdrawal/retention rates for the intervention and control groups, and (iv) those participants who were represented in both the intervention and control groups. Furthermore, attendance at training sessions and the group CBT classes, together with a detailed training diary kept by all intervention participants, were used to evaluate program adherence.

Results

Focus group (intervention participants)
A record of the post-intervention focus group session, transcribed from an audio recording, was analysed for emergent themes. From this analysis, the top five emergent themes were:

1. ‘OPPORTUNITY’.

Participants enrolled in the lifestyle intervention program because they considered it an opportunity for much needed lifestyle change, and were attracted by the program’s convenient location (i.e. based at on campus).
2. ‘LIFESTYLE’.

Prior to involvement in the lifestyle intervention, the greatest challenge to participating in regular physical activity included:

(i) themselves (i.e. ‘being lazy’);
(ii) feeling too tired from juggling university and work life;
(iii) leading a sedentary lifestyle that involved a lot of sitting. Moreover, participants agreed that portion size, excessive alcohol intake, and no money for ‘healthy’ food (such as vegetables) were their barriers to a healthy diet.

3. ‘ACCEPTABLE CHANGES’.

After program completion, participants now:

(i) engage in ‘active transport’ (e.g. walk rather than take the tram/bus; take the stairs rather than the elevator) as a means of incidental exercise;
(ii) structure physical activity into their daily routine;
(iii) use exercise as a means of socialising with friends (i.e. go for a walk together);
(iv) are generally more aware of portion sizes and ‘healthy’ food in general.

4. ‘WALKING’.

Walking (structured and/or incidental) as a means of physical activity was the most popular choice of exercise, performed alone or with family/friends.

5. ‘POSITIVE EXPERIENCE’.

Participants agreed that, overall, the lifestyle intervention had motivated them to be healthier, had empowered them with the skills for lifelong change, and had been a positive experience.
Anonymous evaluation (intervention participants)

Analysis of the anonymous completion by participants of the post-intervention evaluation form demonstrated that:

1. Attitudes toward exercise had changed as a result of participation in the lifestyle intervention, with the following themes emerging about feelings towards exercise participation: feeling more motivated; exercise had become an important aspect of their life; exercise is now a priority; they now enjoyed physical activity.

2. The nutrition education component appeared to have resulted in: more awareness/conscious of healthy options; eating better foods; consuming smaller portions.

3. The emotional state of participants had improved as a result of the CBT sessions, with participants feeling ‘much happier’ and less moody after the completion of the lifestyle intervention.

4. There was consensus that the most enjoyable part of the intervention was: training with others; social interactions; being part of a group.

5. Participants had a preference for ‘more variety’ in the exercise program because there was ‘too much repetition’.

Reasons for withdrawal (wait-list control participants)

Of the three wait-list control participants who provided feedback regarding their withdrawal from the study:

- In response to Question 1, “How did you feel when you were initially assigned to the control group?”:

Two participants stated that they were ‘disappointed’ once allocated to the wait-list control group, while the other said she was ‘not fussed’ by the allocation.
In response to Question 2, “Did your involvement in the study as a control participant trigger you to change anything about your current lifestyle?”:

One participant said she maintained her usual lifestyle habits as instructed to by the researcher. However, two participants indicated that their participation in pre-control testing triggered them to increase exercise and become more conscious about food choices, despite being allocated to the wait-list control and asked to maintain normal lifestyle habits.

**Attendance, recruitment and retention rates.**

Results showed that of the initial 62 women who inquired about participation in the Young Women’s Heart Health Study, 63% (n=39) underwent baseline testing, with 77% of these participants (n=30) going on to complete post-intervention/post-control and sustainability testing. Retention in the intervention group was higher (73%) compared with wait-list control participants (64%). At the completion of the wait-list control period, only four women went on to complete the lifestyle intervention and associated testing. Adherence to the physical activity (80%) and CBT (74%) components of the lifestyle intervention was high.

**Discussion**

The appraisal of the lifestyle program by participants in this study is in line with recommendations that process evaluation of an intervention should be conducted to better understand study outcomes and to direct future implementation (Medical Research Council, 2000; Oakley et al., 2006). Collectively, the major findings from the focus group and anonymous evaluations demonstrated five emergent themes including ‘opportunity’, ‘lifestyle’, ‘acceptable changes’, ‘walking’, and ‘positive experience’. This information suggested that the program had provided participants with strategies to implement both exercise and dietary planning into their behavioural routines. Moreover, the social interaction components of the intervention were expressed as critical to their enjoyment of the program.

The evaluation processes revealed that participants perceived all three components (exercise, nutrition education, CBT) of the lifestyle intervention to be of importance in fostering
positive lifestyle behaviour changes. This was most apparent in the responses regarding
planning and engagement in exercise. Participants offered evidence that the program had
imparted to them strategies to incorporate both incidental and structured physical activity into
their current lifestyle, with walking as the principle exercise modality. Similarly, participants
expressed a greater knowledge of the importance of dietary planning and of strategies to
achieve improvements in their nutritional choices. The importance of socialising reported by
the participants, particularly in the context of exercise, is consistent with findings in the
systematic review (Chapter 3), where only studies that included contact with fitness
professionals and others during the intervention phase resulted in increases in fitness or
physical activity engagement (Carroll et al., 2007; Kerksick et al., 2010; Silva et al., 2010).

In contrast, although the data are from three wait-list control participants only, the responses
support the notion that a RCT study design may not be appropriate when study volunteers are
ready for lifestyle change. The responses of these participants provided evidence of a
motivation to commence lifestyle change, despite the study requirement of maintaining
current behaviours during the control period. This is supported by the “state of change for
exercise” data presented in Addendum 7.1, where wait-list control participants were primarily
in ‘preparation’ for change, similar to the participants allocated directly to the intervention
phase. Similarly, the majority of wait-list control participants rated “exercise importance” as
‘very important or important’ (see Addendum 7.1), suggesting a desire to commence an
intervention for lifestyle change. These are critical insights given that the control group
demonstrated a reduction in WC and improvements in CVD risk profile (see Chapter 7) while
undertaking the ‘control’ phase of the intervention study. This might be, in part, a response to
knowledge of their pre-control test data, which was provided as a condition and incentive for
taking part in the study (Appendix 20). Upon reflection, this knowledge may have influenced
subsequent behaviour change, given that unanticipated weight loss is not normally observed
in participants under wait-list control conditions (Waters et al., 2012).

Appraisal of recruitment rates demonstrated that the conversion rate of participants from
initial recruitment to baseline testing was modest. However, the retention rate of participants
in the intervention and control groups was lower than expected, with an allowance of 20%
drop-out calculated to maintain sample power. In the current study, drop-out rates were 27%
and 36% for the intervention and control groups, respectively. Moreover, there was evidence
of poor transition from the wait-list control condition into the lifestyle intervention, with only
23% of women initially allocated to the control group completing the intervention phase. In contrast, program adherence for physical activity and CBT components was high among intervention participants. This data may provide insight into recruitment and retention of young women with abdominal obesity to a lifestyle intervention, and important information about the behaviour of participants initially allocated to a wait-list control group. Furthermore, because of the richness of data provided by process evaluation, future studies could be enhanced by the inclusion of perceptions from compliant control group members as well as intervention drop-outs.

In summary, the responses from participants who completed the lifestyle intervention indicated that its multi-disciplinary focus was a crucial feature in producing behaviour change and associated strategies for future weight control. This is in agreement with recommendations (A. Lang & Froelicher, 2006; Wing, 2002) that management strategies to address overweight and obesity should incorporate diet, exercise and behavioural therapy.
Chapter 8. Effects of a lifestyle intervention on cardiac measures in young women with abdominal obesity: A randomised controlled trial.

**Bianca L Share**, Geraldine A Naughton, Philippe Obert, André La Gerche, Justin G Kemp

**Publication Statement:**
This work has been prepared as a short report for submission to the *Canadian Journal of Cardiology*, please see Appendix 1.

**Acknowledgements**
The authors would like to express their gratitude to all participants involved in the Young Women’s Heart Health Study. Thanks are also extended to Professor Jennifer Peat for her statistical assistance and to Associate Professor Guillaume Walther and Dr Edward Crendal for their contribution to the manuscript.
Abstract

Young adult women with obesity have shown subclinical cardiac dysfunction. Lifestyle interventions are recommended for prevention of cardiovascular disease in obese populations. In a randomised controlled trial using conventional, tissue Doppler imaging, and 2D speckle tracking imaging echocardiography, we assessed changes in cardiac morphology and function, including myocardial deformation and mechanical indices, in women (18-30 y) with abdominal obesity (n = 26) following a 12-week, multi-disciplinary lifestyle intervention. Echocardiographic measures at baseline and post-intervention were compared to a wait-list control group (n = 17). The 12-week lifestyle intervention did not result in significant changes in cardiac function.

Keywords: Waist circumference, speckle-tracking-imaging, echocardiography, exercise, physical activity, female

Summary

Lifestyle interventions are recommended for preventing cardiovascular disease and obesity. Abdominal obesity, even in young adults, is linked to abnormal cardiac remodelling and dysfunction. Technical advances in echocardiography can permit early detection and prevention of cardiac abnormalities using 2D speckle tracking imaging. The potential effect of lifestyle interventions on cardiovascular health of obese young women requires attention.
Introduction

Cardiovascular disease (CVD) is the leading cause of death among women (World Health Organisation, 2000), with abdominal obesity (Alberti et al., 2009) increasing the chance of developing cardiac and vascular dysfunction (Wong, Byrne, et al., 2006). In the USA, United Kingdom and Australia, 45-50% of women aged 20-39 years are overweight or obese (Australian Bureau of Statistics, 2013; Flegal et al., 2012; Health and Social Care Information Centre, 2011). Although the cardiovascular complications of obesity have been documented, efficacious lifestyle intervention strategies in obese young women are yet to be established. Understanding the impact of lifestyle interventions on cardiovascular impairment is important for lifelong cardiovascular health.

Cardiac dysfunction may be identified as changes in cardiac morphology and function using conventional techniques and tissue Doppler imaging (TDI) echocardiography. Using these techniques, previous cross-sectional work found subclinical abnormalities in left ventricular (LV) structure and function in young women (mean 32 ± 4 y; range 21-37 y) with obesity (Peterson, Herrero, et al., 2004). More recently [Share et al. (2014) under review], cardiac and myocardial dysfunction was explored in young women (mean 22 ± 4 y; range 18-30 y) with abdominal obesity, using a combination of these traditional echocardiographic techniques and the newer technique of 2D speckle tracking imaging echocardiography (STE), which may possess greater sensitivity for detecting early changes (K. A. Marcus et al., 2011). The women with abdominal obesity were found to display subclinical cardiac remodelling of the left atrium (LA), reduced mitral annular plane velocities, increased LA pressure surrogates, and prolonged timing measurements of diastolic dysfunction, when compared to aged-matched, non-obese controls. These women also exhibited reductions in LV longitudinal strain and systolic strain rate when using STE. These findings show that early intervention strategies in this population have emerging importance (K. A. Marcus et al., 2011), to arrest further progression of subclinical cardiac dysfunction and other markers of CVD. However, there are few randomised controlled trial (RCT) investigations (Chang et al., 2010) of such strategies in young adult women (< 30 yr), despite the increasing prevalence of overweight/obesity in this population.
Therefore, the primary aim of this RCT was to examine the effects of a multi-disciplinary lifestyle intervention on measures of cardiac function, using conventional, TDI and STE echocardiography, in young adult women with abdominal obesity.

Methods

Ethics statement
Participants provided written informed consent following approval of the Australian Catholic University Human Research Ethics Committee (V2009-91). The intervention received clinical trial registration from the Australian New Zealand Clinical Trials Registry (ACTRN12612001017819). All testing was completed between August 2010 and February 2012.

Participants
Sixty-two university-enrolled women aged 18 to 30 years with abdominal obesity [waist circumference (WC) ≥ 80 cm] and leading a sedentary lifestyle (< 210 min per week of organised physical activity in the past six months (Department of Health and Ageing, 1999) were invited to participate in a randomised controlled trial. Participants were free from CVD risk factors (hypertension, diabetes, and smoking) and endocrine disorders, had not undergone bariatric surgery, and were not pregnant.

From 62 women who responded to recruitment, 11 women did not meet the inclusion criteria and a further 12 eligible participants did not complete testing (Figure 8.1). Therefore, 39 participants who underwent baseline testing were randomisation to either the intervention or wait-list control group. A wait-list (delayed-start) control design was chosen to allow all participants access to the lifestyle intervention.

All participants who attended two testing sessions at both pre-intervention (0 wk) and post 12-wk intervention, had refrained from strenuous physical activity in the preceding 24 hours. For the first testing session (anthropometric, blood biochemical, vascular measures), participants were in a fasted state, while for the second session (echocardiography, fitness measures), participants refrained from caffeine and alcohol in the preceding 24 hours. Wait-
list control participants were assessed at three times (0 wk; post-control period (12-wk); post 12 wk intervention).

Figure 8.1. Flow diagram of participants
Metabolic and vascular characteristics

Body mass was measured to the nearest 0.1 kg (Tanita, Tokyo, Japan), and stature was measured to the nearest 0.1 cm (Seca, Germany). Body mass index was calculated (World Health Organisation, 2000). WC was measured to the nearest 0.1 cm at the midpoint between sub-costal and supra-iliac landmarks, with the average of two measurements reported. Blood pressure and heart rate were measured in a supine position after 15 minutes rest using an automated digital sphygmomanometer (Dinamap, GE Technology, USA). Following an overnight fast, intravenous blood was collected from the antecubital vein. Blood lipids [triglycerides, total cholesterol, high-density lipoprotein (HDL)] were measured using the Reflotron Plus desktop analyser (Roche, Switzerland). Fasting plasma glucose, insulin and high sensitivity C-reactive protein (hs-CRP) concentrations were analysed in a clinical pathology laboratory. Insulin resistance (IR) was estimated by the homeostasis model assessment (HOMA-IR) (Matthews et al., 1985). A graded submaximal cycle ergometer test (Golding et al., 1989) was used to estimate cardiorespiratory fitness (Predicted VO2max). Participants self-reported habitual weekly physical activity.

Ultrasonography scans for carotid intima-media thickness (c-IMT) were performed on the far (posterior) wall of the right common carotid artery. Semi-automated edge-detection wall-tracking software was used to analyse images (Chodakauskas, 2006).

Echocardiography

Standard 2D transthoracic echocardiography examination was conducted in accordance with the recommendations of the American Society of Echocardiography (R. M. Lang et al., 2005). Image acquisition was performed by the same experienced operator using a commercially available ultrasound device (Vivid i, GE Healthcare, Horten, Norway). Digital data were stored for subsequent off-line analyses (Echopac, GE Medical Systems). All measurements were the averages derived from three consecutive cardiac cycles.

M-mode measurements were obtained in the parasternal long-axis. LV volumes and ejection fraction were quantified using a Simpson’s bi-plane method. Pulsed-wave Doppler-derived transmitsral inflow velocities were obtained from the apical four-chamber view with the sample volume at the tips of the mitral leaflets. TDI was used to measure mitral annular
velocities. Data are reported as the average of four sites from apical 4-chamber (septal and lateral wall) and 2-chamber (inferior and anterior walls) views.

STE analysis of myocardial wall motion was performed on greyscale images acquired at a minimum frame rate of 70 Hz. The values from circumferential apical and basal views were averaged. Twist, twist/untwist rate, and apical and basal rotational mechanics of the LV were also calculated. Customised software (Scilab 4.1, Avignon University, Avignon, France) was used to normalise time sequence as a percentage of systolic duration.

*Lifestyle intervention*

The 12-wk multi-disciplinary lifestyle intervention comprised three main components: (1) moderate-intensity physical activity, (2) nutrition education, and (3) small-group cognitive behavioural therapy (CBT). In contrast, participants in the wait-list control group were instructed to continue existing lifestyle choices, and after 12 weeks were invited to complete the same lifestyle intervention (Table 7.1).

*Statistics*

Descriptive statistics are presented as mean ± SD. Following tests for normal distribution, group comparisons over time were performed using a general liner mixed-model analysis. This statistical test was chosen based on its ability to analyse unbalanced repeated measures data (Cnaan et al., 1997). IBM SPSS statistical software, Version 20 for Windows (SPSS Inc, Chicago IL) was used for analyses and statistical significance was set at $P \leq 0.05$. Hedge’s $g$ was used for effect size calculations. Intra- and inter-observer reliability was performed for key variables and reported as coefficient of variation (CV) (Table 8.1)
Table 8.1. Reliability analyses for waist circumference and major echocardiographic parameters.

<table>
<thead>
<tr>
<th></th>
<th>Coefficient of variation (CV) (%)</th>
<th>n</th>
<th>Intra-observer</th>
<th>Inter-observer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist circumference</td>
<td></td>
<td>20</td>
<td>1.26</td>
<td>NA</td>
</tr>
<tr>
<td>Carotid IMT</td>
<td></td>
<td>20</td>
<td>2.26</td>
<td>NA</td>
</tr>
<tr>
<td>Conventional &amp; TDI echocardiography</td>
<td></td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV mass</td>
<td></td>
<td></td>
<td>2.7</td>
<td>2.1</td>
</tr>
<tr>
<td>LVED diameter</td>
<td></td>
<td></td>
<td>1.1</td>
<td>2.0</td>
</tr>
<tr>
<td>IVS thickness</td>
<td></td>
<td></td>
<td>3.2</td>
<td>4.8</td>
</tr>
<tr>
<td>PW thickness</td>
<td></td>
<td></td>
<td>2.3</td>
<td>3.5</td>
</tr>
<tr>
<td>E velocity</td>
<td></td>
<td></td>
<td>1.9</td>
<td>1.6</td>
</tr>
<tr>
<td>A velocity</td>
<td></td>
<td></td>
<td>2.5</td>
<td>1.8</td>
</tr>
<tr>
<td>E/A ratio</td>
<td></td>
<td></td>
<td>2.5</td>
<td>2.0</td>
</tr>
<tr>
<td>Septal S_m velocity</td>
<td></td>
<td></td>
<td>1.4</td>
<td>2.3</td>
</tr>
<tr>
<td>Septal E_m velocity</td>
<td></td>
<td></td>
<td>2.2</td>
<td>4.0</td>
</tr>
<tr>
<td>Septal A_m velocity</td>
<td></td>
<td></td>
<td>1.5</td>
<td>4.2</td>
</tr>
<tr>
<td>Speckle tracking echocardiography</td>
<td></td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV L strain</td>
<td></td>
<td></td>
<td>5.9</td>
<td>5.1</td>
</tr>
<tr>
<td>LV L diastolic SR</td>
<td></td>
<td></td>
<td>4.3</td>
<td>7.8</td>
</tr>
<tr>
<td>LV L systolic SR</td>
<td></td>
<td></td>
<td>4.1</td>
<td>5.5</td>
</tr>
<tr>
<td>LV C strain</td>
<td></td>
<td></td>
<td>4.7</td>
<td>5.5</td>
</tr>
<tr>
<td>LV C diastolic SR</td>
<td></td>
<td></td>
<td>5.7</td>
<td>8.3</td>
</tr>
<tr>
<td>LV C systolic SR</td>
<td></td>
<td></td>
<td>5.7</td>
<td>5.3</td>
</tr>
<tr>
<td>Apical rotation</td>
<td></td>
<td></td>
<td>7.0</td>
<td>11.5</td>
</tr>
<tr>
<td>Basal rotation</td>
<td></td>
<td></td>
<td>6.5</td>
<td>9.7</td>
</tr>
<tr>
<td>LV twist</td>
<td></td>
<td></td>
<td>9.2</td>
<td>10.0</td>
</tr>
</tbody>
</table>


Results

Thirty-nine participants were included in the analysis. After baseline testing and commencement of the intervention period, 27% of intervention participants (n = 7) and 35% of control participants (n = 6) withdrew from the study (Figure 8.1). In contrast, compliance rates within the intervention group showed 80% attendance for the physical activity sessions and 74% for the CBT sessions.

Table 8.2 lists the anthropometric, metabolic, fitness and vascular characteristics of the intervention and control groups at pre- and post-intervention. All markers were similar between groups at baseline, with physical activity being the only between-group difference post-intervention, with an effect size (g) of 2.14. Within-group changes for the intervention
group from baseline to post-testing were a reduction in WC and systolic blood pressure, and improvements in markers of fitness (predicted VO\textsubscript{2max} and physical activity – see table 8.2) and a Bruce treadmill protocol time increased from \(10.5 \pm 2.2\) min to \(11.8 \pm 2.2\) min \((P < 0.001)\). The vascular measure of c-IMT was unchanged by the intervention. In the control group, despite participants reporting maintained lifestyle habits during the control period, a reduction in both WC and systolic blood pressure was observed.

Table 8.2. Metabolic and vascular characteristics for the intervention and control groups at pre-intervention/pre-control, and post-intervention/post-control.

<table>
<thead>
<tr>
<th></th>
<th>Pre-control/Pre-intervention (0 wk)</th>
<th>Post-control/Post-intervention (12 wk)</th>
<th>Between group P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n=17)</td>
<td>Intervention (n=26)</td>
<td>Control (n=11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Intervention (n=19)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>22.8 ± 3.4</td>
<td>22.0 ± 3.7</td>
<td>82.5 ± 19.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>86.9 ± 20.5</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>86.1 ± 17.8</td>
<td>89.8 ± 21.1</td>
<td>30.0 ± 6.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>31.3 ± 0.9</td>
</tr>
<tr>
<td>BMI (kg·m\textsuperscript{-2})</td>
<td>31.4 ± 6.6</td>
<td>32.2 ± 5.9</td>
<td>92.8 ± 10.8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>93.1 ± 11.7</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>64 ± 8</td>
<td>68 ± 6</td>
<td>119 ± 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>120 ± 11</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>64 ± 8</td>
<td>68 ± 6</td>
<td>119 ± 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>120 ± 11</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>4.5 ± 0.6</td>
<td>4.6 ± 0.4</td>
<td>4.5 ± 0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.6 ± 0.4</td>
</tr>
<tr>
<td>Triglycerides (mmol·L\textsuperscript{-1})</td>
<td>1.2 ± 0.4</td>
<td>1.3 ± 0.5</td>
<td>1.2 ± 0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.3 ± 0.5</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L\textsuperscript{-1})</td>
<td>1.7 ± 0.6</td>
<td>1.7 ± 0.5</td>
<td>1.7 ± 0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.7 ± 0.5</td>
</tr>
<tr>
<td>Total cholesterol (mmol·L\textsuperscript{-1})</td>
<td>4.3 ± 0.5</td>
<td>4.4 ± 0.6</td>
<td>4.3 ± 0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>4.4 ± 0.6</td>
</tr>
<tr>
<td>Fasting insulin (mU·L\textsuperscript{-1})</td>
<td>8.1 ± 4.4</td>
<td>9.4 ± 4.7</td>
<td>8.1 ± 4.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>9.4 ± 4.7</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.6 ± 1.0</td>
<td>1.9 ± 1.0</td>
<td>1.6 ± 1.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1.9 ± 1.0</td>
</tr>
<tr>
<td>hs-CRP (mg·L\textsuperscript{-1})</td>
<td>2.9 ± 2.6</td>
<td>3.5 ± 3.0</td>
<td>2.9 ± 2.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3.5 ± 3.0</td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>63 ± 12</td>
<td>69 ± 10</td>
<td>63 ± 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>69 ± 10</td>
</tr>
<tr>
<td>Predicted VO\textsubscript{2max} (mL·kg\textsuperscript{-1}·min\textsuperscript{-1})</td>
<td>32.0 ± 10.3</td>
<td>27.9 ± 7.0</td>
<td>32.0 ± 10.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>27.9 ± 7.0</td>
</tr>
<tr>
<td>Physical activity (min·wk\textsuperscript{-1})</td>
<td>118 ± 89</td>
<td>97 ± 62</td>
<td>118 ± 89</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>97 ± 62</td>
</tr>
<tr>
<td>Carotid IMT (mm)</td>
<td>0.41 ± 0.04</td>
<td>0.41 ± 0.03</td>
<td>0.41 ± 0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.41 ± 0.03</td>
</tr>
</tbody>
</table>

Data are mean ± standard deviation. BMI: body mass index, HDL: high-density lipoproteins, HOMA-IR: homeostatic model assessment of insulin resistance, hs-CRP: high sensitivity C-reactive protein, IMT: intima media thickness. CI: confidence interval. \( ^* P \leq 0.05 \). \# data were log transformed before reported \( P \)-values were obtained. \( ^\dagger \) between-group differences (at post) \( P < 0.001 \). \( ^\ddagger \) within-group differences \( P \leq 0.05 \).
Table 8.3 shows the primary variables of interest in this study. Specifically, there were no differences between intervention and control groups for cardiac morphology, cardiac function, myocardial deformation or myocardial mechanics at baseline or post-intervention. However, a within-group change was observed for both groups, with an increase in LV mass indexed.
### Table 8.3. Cardiac morphology and function, and myocardial deformation and mechanics for intervention and control groups at pre-intervention/pre-control, and post-intervention/post-control.

<table>
<thead>
<tr>
<th></th>
<th>Pre-control/Pre-intervention (0 wk)</th>
<th>Pre-control/Post-intervention (12 wk)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control n = 17</td>
<td>Intervention n = 26</td>
</tr>
<tr>
<td><strong>Cardiac morphology</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA diameter (mm)</td>
<td>32.5 ± 3.8</td>
<td>32.9 ± 5.3</td>
</tr>
<tr>
<td>LV mass indexed (g·m^{-2})</td>
<td>34.1 ± 10.2</td>
<td>40.3 ± 10.8</td>
</tr>
<tr>
<td>LV ED diameter (mm)</td>
<td>44.6 ± 2.5</td>
<td>43.5 ± 4.5</td>
</tr>
<tr>
<td>LV ES diameter (mm)</td>
<td>29.5 ± 3.6</td>
<td>29.3 ± 5.0</td>
</tr>
<tr>
<td>LV PW thickness (mm)</td>
<td>9.7 ± 1.1</td>
<td>10.5 ± 1.6</td>
</tr>
<tr>
<td>IVS thickness (mm)</td>
<td>10.3 ± 2.0</td>
<td>10.6 ± 1.5</td>
</tr>
<tr>
<td><strong>Cardiac function</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV ejection fraction (%)</td>
<td>62.1 ± 5.8</td>
<td>64.1 ± 4.3</td>
</tr>
<tr>
<td>A velocity (cm·s^{-1})</td>
<td>86.1 ± 16.6</td>
<td>87.7 ± 13.5</td>
</tr>
<tr>
<td>A velocity (cm·s^{-1})</td>
<td>41.3 ± 9.5</td>
<td>43.3 ± 12.2</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.2 ± 0.5</td>
<td>2.2 ± 0.6</td>
</tr>
<tr>
<td>S_m, velocity (cm·s^{-1})</td>
<td>8.6 ± 1.2</td>
<td>9.4 ± 1.6</td>
</tr>
<tr>
<td>E_m, velocity (cm·s^{-1})</td>
<td>14.6 ± 2.9</td>
<td>14.6 ± 2.6</td>
</tr>
<tr>
<td>A_m, velocity (cm·s^{-1})</td>
<td>6.8 ± 1.1</td>
<td>7.2 ± 1.1</td>
</tr>
<tr>
<td><strong>Myocardial deformation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal strain (%)</td>
<td>-15.9 ± 2.2</td>
<td>-16.3 ± 2.0</td>
</tr>
<tr>
<td>Circumferential strain (%)</td>
<td>-19.5 ± 2.5</td>
<td>-20.1 ± 3.2</td>
</tr>
<tr>
<td><strong>Myocardial mechanics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apical rotation (°)</td>
<td>4.5 ± 1.7</td>
<td>4.4 ± 1.4</td>
</tr>
<tr>
<td>Basal rotation (°)</td>
<td>-5.3 ± 1.9</td>
<td>-5.5 ± 1.8</td>
</tr>
<tr>
<td>Twist (°)</td>
<td>6.7 ± 1.8</td>
<td>8.2 ± 3.3</td>
</tr>
<tr>
<td>Twist rate (°·s^{-1})</td>
<td>68.1 ± 18.0</td>
<td>72.0 ± 19.9</td>
</tr>
<tr>
<td>Untwist rate (°·s^{-1})</td>
<td>-58.2 ± 17.8</td>
<td>-65.1 ± 19.6</td>
</tr>
</tbody>
</table>

Data are mean ± standard deviation. LA: left atrium, LV: left ventricle, LVED: left ventricular end-diastolic. LVES: left ventricle end-systolic IVS: inter-ventricular septum, PW: posterior wall, Circumferential is the average of apical and basal views. \( S_m, E_m, & A_m \) are means of four sites at the mitral annulus from apical 4-chamber (septal, lateral) and 2-chamber views (inferior, anterior). CI: confidence interval. ^9 data were log transformed before reported \( P \)-values were obtained. ^9 between-group differences \( P \) \leq 0.05. ^8 within-group differences \( P \) \leq 0.05.
Discussion

The aim of this study of young women with abdominal obesity (a group under-represented in the literature) was to examine the effects of a multi-disciplinary lifestyle intervention on cardiac, vascular and myocardial measures. Specifically, we assessed the effects of an intervention which incorporated physical activity, nutrition education and CBT, using conventional, TDI and 2D speckle-tracking echocardiographic techniques. The 12-week lifestyle intervention produced no marked changes in cardiac morphology or function, c-IMT, or myocardial deformation or mechanical indices, despite significant changes in WC, systolic blood pressure and cardiorespiratory fitness.

Similar to our study, an 8-week lifestyle intervention of exercise and diet was not associated with improvements in LV diastolic function measured using conventional and TDI makers in a cohort of obese middle-aged adults (47 ± 11 y), despite reduced body composition markers (Wong, Byrne, et al., 2006). Likewise, Millen et al. (2014) delivered a 6-week exercise program (without a dietary component) to overweight and obese middle-aged adults (42 ± 18 y) of similar WC (94 ± 18 cm) to our study. Again, the intervention failed to produce improvements in indices of LV diastolic function, including tissue velocities measured with TDI, despite improved cardiorespiratory fitness.

There are several possible reasons to explain why we observed no changes in myocardial function following the multi-disciplinary lifestyle intervention. The 12-week duration may not have been sufficient to drive significant reductions in the cardiac, vascular and myocardial measures of interest. Similarly, the intensity and/or frequency of the exercise sessions may have been too low to produce changes in these measures. In comparison, using a 12-month lifestyle intervention of daily endurance exercise and resistance training, Dutheil et al. (2013) reported that adults (59 ± 5 y) with central adiposity (WC: 102 ± 9 cm) had improved c-IMT, although their greater age and WC might be factors in the observed improvements. Similarly, Eriksson et al. (2010) conducted a 6-month, low-intensity exercise intervention with women (47 ± 8 y) with abdominal obesity (WC: 103 ± 8 cm). Again, these women were older and more obese than the women in our study. Their intervention produced improvements in longitudinal right ventricular (RV) systolic function, and small but significant changes in LV systolic and RV diastolic dimensions (), when using conventional and Doppler echocardiography.
Another reason for no changes in myocardial function could be related to the nutritional component of our study. Specifically, we provided nutrition education as a means for behaviour change in dietary habits, rather than implementing caloric restriction which may not be sustainable in the longer term (Wycherley et al., 2012). However, successful outcomes have been observed with programs based on diet restriction. For example, severely obese adolescents \((15 \pm 2 \text{ y})\) who participated in a 9-month lifestyle intervention of caloric restriction and exercise had improved LV mitral annular plane velocities, and longitudinal strain (Obert et al., 2013). However, myocardial twist mechanics and LV morphology remained unchanged following the 9-month program.

This study has some possible limitations. Firstly, there is potential masking of comparative benefits for the intervention group due to unexpected decreases in WC in the control group, despite undetectable changes in their weight management behaviour. However, these undetected changes might be a consequence of problems associated with self-reporting of nutritional and/or physical activity habits over the 12-week control period. Some may argue shortcomings associated with ultrasonography acquisition and analyses being dependent on operator skill, but intra- and inter-reliability measures for the present study were similar to previous reports (K. A. Marcus et al., 2011). Finally, central fat distribution was not measured using more precise estimations (e.g., MRI and dual energy x-ray absorptiometry), but WC does provide a level of sensitivity relevant to most clinical settings (National Health and Medical Research Council, 2005).

**Conclusion**

This work contributes to the limited RCT literature addressing lifestyle interventions on cardiovascular risk in young adult women, providing novel data from conventional and TDI echocardiography and STE. Although decreases in WC and increases in cardiorespiratory fitness were noted following the lifestyle intervention, there were no changes in cardiac morphology or function, or in myocardial deformation or mechanical indices.
Supplementary Material

This section contains supplementary method which will accompany the short report during submission. This information is presented in Chapters 4 and 7.

Participants

All participants attended the laboratory on two occasions at both baseline and post-intervention, and were requested to refrain from strenuous physical activity in the 24 hours prior to testing on all occasions. During the first visit participant arrived in a fasted state and clinical testing lasted 75 min. The second visit only required participants to abstain from caffeine and alcohol for 12 hr and lasted 60 min. Testing was performed at pre-intervention/pre-control (0 wks) and again at post-intervention/post-control (12 wks). All measurements were taken at the same time of day (±2 hr) and by the same researcher.

Metabolic and vascular characteristics

Blood samples were drawn from an antecubital vein into a 10 ml evacuated, lithium heparin anticoagulant vacutainer tube by a qualified phlebotomist. Blood samples were then centrifuged at 3000 rpm for 10 min (Spinton, Australia, GT-175BR) to obtain plasma for subsequent analysis by spectrophotometrically using a Reflotron PLUS™ analyser, and further analyses performed by pathology. The Reflotron requires a 30 μL droplet of blood placed on specialised measuring strips to be fed into the desktop analyser. Insulin resistance (IR) was estimated by the homeostasis model assessment (HOMA-IR), using the equation: HOMA-IR = fasting insulin concentration (µU/mL) x fasting glucose concentration (mmol/l) / 22.5 (Matthews et al., 1985), with values more than 2.5 considered indicative of IR (Jensterle et al., 2008). For hs-CRP, a value of > 3.0 mg·l⁻¹ was considered high risk (Pearson et al., 2003)
Echocardiography

Image acquisition was performed by the same experienced operator using a commercially available ultrasound (Vivid i, GE Healthcare, Horten, Norway) with a 3.5 MHz phased-array transducer. Participants were examined in the left-lateral decubitus position in a dark room, and connected to a 3-lead ECG. A minimum frame-rate of 70 Hz was used when acquiring gray-scale cine-loops. Digital data were stored for subsequent off-line analysis with specific software (Echopac, GE Medical Systems) by an observer blinded to subject assignment.

Speckle tracking imaging echocardiography (STE) analysis of myocardial wall motion was performed using frame-by-frame tracking of natural acoustic markers known as “speckles” in a region of interest from greyscale images. Using proprietary software (EchoPAC v108.1.5, GE Medical Systems, Horton Norway), endocardial borders were manually traced and region of interest adjusted to include all of the myocardium.

Lifestyle intervention

The 12-wk lifestyle intervention was comprised of three main components: (1) moderate-intensity physical activity (2) nutrition education, and (3) small-group cognitive behavioural therapy. In contrast, participants in the wait-list control group were instructed to continue existing lifestyle choices, and after 12 weeks were invited to complete the same lifestyle intervention.

1. Physical activity: participants completed two supervised exercise sessions (progressive aerobic and resistance training circuit) with a qualified Exercise Scientist, and one unsupervised, but prescribed home-based session (brisk walk or jog with intermittent high-intensity intervals) per week. The supervised sessions lasted approximately 60 min, with the intensity of the exercise increasing from 60% to 85% on the OMNI Picture System (Robertson, 2004), by the end of the 12-wk period. To replicate community resources, sessions occurred in both the gym on campus and at a local park. Participants maintained a detailed training diary. The standard Bruce treadmill protocol (Bruce et al.,
1973) was completed every three weeks (0, 4, 8, 12 weeks) by intervention participants to assist with prescription of progressive overload of aerobic activities during the program.

2. Nutrition education: participants in the intervention group received weekly nutrition education sessions from a dietician about healthy eating choices from the existing Australian Dietary Guidelines (National Health and Medical Research Council, 2005). Information provided education regarding non-dieting weight management and healthy eating principles tailored to the perceived needs of the female participants.

3. Cognitive behavioural therapy (CBT): intervention participants undertook weekly 60-min group cognitive CBT sessions with a counsellor, which provided psychosocial support and developed skills to overcome personal barriers to lifestyle change. The program aimed to empower individuals to develop healthier eating and physical activity patterns.

**Statistics**

Data were tested for normal distribution using the Shapiro-Wilk statistic and skewness and kurtosis (Peat & Barton, 2005). Log transformation was performed on data not normally distributed. Hedge’s $g$ calculated effect size to assess magnitude, with an effect size of $\geq 0.2$ considered small, $\geq 0.5$ considered medium, and $\geq 0.8$ considered large (Cohen, 1988). Mean differences and 95% confidence intervals (CI) for each variable were also reported.

Where possible, measures were completed in duplicate and intra and inter-observer coefficient of variation (CV) was reported. CV was conducted on major cardiometabolic risk factors ($n=20$), and cardiac variables in randomly selected participants (conventional and TDI echocardiography, $n=10$; STE, $n=20$) in order to demonstrate the off-line analyses were reproducible. Variables were evaluated twice by the same observer, and once more by another experiences observer, both blinded to participant details.
8.1 ADDENDUM: Cardiac and vascular measures in young women with abdominal obesity: Short-term sustainability of outcomes following completion of a lifestyle intervention.

Introduction

The data presented in Chapter 8, entitled “Effects of a lifestyle intervention on cardiac measures in young women with abdominal obesity: A randomised controlled trial, have been prepared for submission to the Canadian Journal of Cardiology. In Chapter 8, pre- and post-intervention data are presented for cardiac morphology and function, myocardial deformation and mechanical indices, and carotid IMT following a 12-week, multi-disciplinary lifestyle intervention. These data were obtained from conventional, TDI, and STE-derived ultrasonography.

In this addendum, data for cardiac morphology and function, myocardial deformation and mechanical indices and carotid IMT, collected at follow-up testing performed at 24 weeks (i.e. 12 weeks after post-intervention testing), are presented. These within-group ‘sustainability’ data were collected from all participants who completed the lifestyle intervention (n=19), using conventional, TDI and STE-derived ultrasonography. These data were not included in the manuscript forming Chapter 8 given that the lifestyle intervention did not result in any significant changes in these measures at the post-intervention period compared with the control group.

Methods

The experimental methods are described in Chapters 4, 6 and 8. All data were checked for normality according to established standards (Peat & Barton, 2005) prior to statistical analyses. A linear mixed model was then computed to assess within-group comparison across time period.
Results

Table 8.4 describes and compares the cardiac and vascular data derived from ultrasonography analyses for all participants at pre-intervention (n=26) and for participants completing the intervention and returning for sustainability testing at 24 weeks (n = 19). The majority of cardiac measures did not change from pre-intervention to sustainability testing. Specifically, for cardiac morphology and function parameters measured via conventional and TDI echocardiography, there were no changes over the 24-week period. Differences in myocardial measures obtained from STE, were observed for circumferential strain and in twist and twist rate. For the vascular measure of carotid IMT, there was no change at the sustainability phase.

Table 8.4. Within-group comparisons of cardiac and vascular data collected from conventional, TDI and STE-derived ultrasonography at pre-intervention (0 week) and sustainability (24 week) for the intervention group.

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Pre-intervention (n = 26)</th>
<th>Sustainability (n = 19)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2D and m-mode</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA diameter (mm)</td>
<td>32.9 ± 5.3</td>
<td>31.8 ± 3.6</td>
</tr>
<tr>
<td>LV mass indexed (g/m²)</td>
<td>40.3 ± 10.8</td>
<td>43.8 ± 8.9</td>
</tr>
<tr>
<td>LV end-diastolic diameter (mm)</td>
<td>43.5 ± 4.5</td>
<td>44.8 ± 3.9</td>
</tr>
<tr>
<td>LV end-systolic diameter (mm)</td>
<td>29.3 ± 5.0</td>
<td>30.2 ± 4.6</td>
</tr>
<tr>
<td>LV PW thickness (mm)</td>
<td>10.5 ± 1.6</td>
<td>11.0 ± 1.6</td>
</tr>
<tr>
<td>IVS thickness (mm)</td>
<td>10.6 ± 1.5</td>
<td>10.6 ± 1.5</td>
</tr>
<tr>
<td>LV ejection fraction (%)³</td>
<td>64.1 ± 4.3</td>
<td>62.4 ± 7.0</td>
</tr>
<tr>
<td>Carotid IMT (mm)</td>
<td>0.41 ± 0.03</td>
<td>0.40 ± 0.03</td>
</tr>
<tr>
<td><strong>Pulsed-wave Doppler</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>E velocity (cm·s⁻¹)</td>
<td>87.7 ± 13.5</td>
<td>81.1 ± 14.8</td>
</tr>
<tr>
<td>A velocity (cm·s⁻¹)</td>
<td>43.3 ± 12.2</td>
<td>42.1 ± 9.8</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.2 ± 0.6</td>
<td>2.0 ± 0.4</td>
</tr>
<tr>
<td><strong>Tissue Doppler imaging</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>S_m (cm·s⁻¹)</td>
<td>9.4 ± 1.6</td>
<td>8.8 ± 1.3</td>
</tr>
<tr>
<td>E_m (cm·s⁻¹)</td>
<td>14.6 ± 2.6</td>
<td>14.7 ± 2.8</td>
</tr>
<tr>
<td>A_m (cm·s⁻¹)</td>
<td>7.2 ± 1.1</td>
<td>7.1 ± 1.2</td>
</tr>
<tr>
<td><strong>Speckle tracking echocardiography</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Longitudinal strain (%)</td>
<td>-16.3 ± 2.0</td>
<td>-16.6 ± 1.5</td>
</tr>
<tr>
<td>Circumferential strain (%)</td>
<td>-20.1 ± 3.2</td>
<td>-17.3 ± 4.3</td>
</tr>
<tr>
<td>Apical rotation (˚)</td>
<td>4.4 ± 1.4</td>
<td>3.9 ± 1.7</td>
</tr>
<tr>
<td>Basal rotation (˚)</td>
<td>-5.5 ± 1.8</td>
<td>-4.5 ± 2.4</td>
</tr>
<tr>
<td>Twist (˚)</td>
<td>8.2 ± 3.3</td>
<td>4.8 ± 1.5</td>
</tr>
<tr>
<td>Twist rate (˚·s⁻¹)</td>
<td>72.0 ± 19.9</td>
<td>51.1 ± 17.9</td>
</tr>
<tr>
<td>Untwist rate (˚·s⁻¹)</td>
<td>-65.1 ± 19.6</td>
<td>-53.7 ± 20.3</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD. IMT, intima-media thickness. * log10 transformation. ** significant difference (P < 0.05). LA, left atrium. LV, left ventricular. IVS, Inter-ventricular septum. PW, posterior wall.
Discussion

At 12 weeks after completion of the lifestyle intervention (i.e. 24 weeks from study commencement), there were no changes in cardiac morphology or function or c-IMT for participants who had completed the 12-week multidisciplinary program. These within-group outcomes are consistent with the data collected immediately upon completion of the lifestyle intervention (presented in Chapter 8), with the exception of left ventricle mass indexed to height. There was an increase in mass indexed at post-intervention in Chapter 8, but at the testing scheduled for the sustainability phase of the intervention (Table 1), the increase no longer reached statistical significance. It is hypothesised that this loss in mass indexed from post-intervention could be related to a rebound in lifestyle behaviours, such as losses in physical activity and dietary improvements (see Chapters 7 and 9), when the intensive support of the intervention has ceased (Wycherley et al., 2012)

With respect to myocardial deformation and mechanical indices, three STE-derived parameters changed from pre-intervention at 24 weeks. These parameters were circumferential strain, twist and twist rate (with twist rate dependent on the ‘twist’ measure). These ‘sustainability’ changes are difficult to explain, in magnitude and direction, given that they were not different from baseline when assessed immediately post-intervention (see Chapter 8). Therefore, future CVD intervention studies should incorporate these STE-derived measures to substantiate these findings.

In summary, when the ‘sustainability’ data were considered alongside post-intervention data (Chapter 8), it was apparent that the 12-week intervention delivered in this thesis was not associated with improvements in echocardiographic measures or c-IMT. Some possible reasons for this are addressed in more detail in Chapter 8, including an intervention duration, exercise intensity and/or dietary component insufficient to produce significant cardiac or vascular adaptations. However, the findings of Chapter 6 should also be considered, in which women with abdominal obesity, when compared to those with a WC < 80 cm, displayed cardiac abnormalities associated with remodelling and myocardial dysfunction. These ‘abnormalities’ were not considered of ‘clinical’ consequence, given that each parameter was still within its ‘normal’ range. Therefore, it is possible that the degree of CVD progression in these markers, at this stage of early detection, is not substantive enough for a lifestyle intervention to demonstrate significant improvements in cardiac or vascular outcomes.
Chapter 9. Cardiovascular disease risk factor profile and lifestyle modification in young women with abdominal obesity: A one-year follow-up.

Introduction

Long-term sustainability of behaviour change addressed with lifestyle intervention programs have been met with limited success (Wycherley et al., 2012). In Chapter 3, a systematic review of the literature found only five RCT studies of premenopausal adult women (mean age ≤ 40 years) in the past decade investigating the effectiveness of a multi-disciplinary lifestyle intervention on CVD risk profile. Of these, three reported that follow-up testing was conducted, at 32 weeks (Chang et al., 2010), 36 weeks (Carroll et al., 2007), and 96 weeks (Silva et al., 2008) after completion of the intervention. However, only one of these studies (Chang et al., 2010) reported data from this follow-up testing. Therefore, there is a clear need for long-term follow-up to evaluate the sustainability of behaviour change and CVD risk factor modification, once the research-based delivery of a lifestyle intervention is completed.

In this supplementary chapter, data from a subsample of intervention participants who completed follow-up testing at 52 weeks post-intervention are addressed. The aim of this testing was to evaluate the sustainability of CVD risk factor improvements and lifestyle behaviour changes observed immediately post-intervention.

Methods

The ‘longitudinal’ follow-up was performed on a subsample of women (n=7) who completed the lifestyle intervention and were available at 52 weeks post-intervention. ‘Longitudinal’ testing was identical to that performed at the pre-intervention, post-intervention, and ‘sustainability’ phases. Briefly, metabolic, vascular and cardiac variables were collected over two laboratory sessions for the assessment of anthropometry, metabolic syndrome markers, blood biochemistry, aerobic capacity, vascular morphology, cardiac morphology and function, and myocardial deformation and mechanical indices. Data relevant to lifestyle
behaviour, including weekly physical activity, dietary habits, and stage of change were also collected. The methodological procedures for the collection of these data are reported in Chapters 4 to 8. All data were checked for normality according to established standards (Peat & Barton, 2005) prior to statistical analyses. A linear mixed model was then computed to assess within-group comparisons across the four testing periods.

Results

Tables 9.1 and 9.2 present metabolic, vascular and cardiac data for a subsample of participants (n=7) in the Young Women’s Heart Health Study across four time-points (pre-intervention, 0 weeks; post-intervention, 12 weeks; sustainability, 24 weeks; longitudinal follow-up, 52 weeks). The metabolic outcome measures (Table 9.1), from pre-intervention to post-intervention, participants showed significant reductions in WC-dependent measures (WC, WHR, WHtR), increased HDL-cholesterol, improved predicted VO2max, increased weekly physical activity, and a reduced daily energy intake. Some of these measures (WHR, WHtR), together with fasting glucose and resting heart rate, were significantly improved from pre-intervention to sustainability. At longitudinal follow-up, indices of WC (WC, WHR, WHtR), resting heart rate, weekly physical activity and daily energy intake were again significantly improved from pre-intervention. Additionally, body mass, BMI, WC, hip circumference and WHtR all improved from sustainability (24 weeks) to longitudinal follow-up (52 weeks).

For vascular measures (Table 9.1), blood pressure was unchanged by the intervention. Conversely, carotid IMT was significantly reduced from pre-intervention to sustainability, but was no longer different from pre-intervention at longitudinal follow-up.
Table 9.1. Metabolic, lifestyle and vascular data collected at pre-intervention (0 wk), post-intervention (12 wk), sustainability (24 wk), and longitudinal follow-up (52 wk), for a subsample (n = 7) of participants in the Young Women’s Heart Health Study.

<table>
<thead>
<tr>
<th>Metabolic</th>
<th>Pre-intervention (0 weeks)</th>
<th>Post-intervention (12 weeks)</th>
<th>Sustainability (24 weeks)</th>
<th>Longitudinal (52 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass (kg)</td>
<td>85.4 ± 18.9</td>
<td>85.4 ± 21.3</td>
<td>84.7 ± 22.2</td>
<td>80.3 ± 17.2</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>31.7 ± 4.0</td>
<td>31.5 ± 5.07</td>
<td>31.3 ± 5.6</td>
<td>29.8 ± 4.5</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>93.5 ± 6.8</td>
<td>88.9 ± 8.5a</td>
<td>90.4 ± 9.8</td>
<td>86.1 ± 8.9ab</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>115.8 ± 12.7</td>
<td>116.2 ± 14.3</td>
<td>116.5 ± 15.3</td>
<td>110.9 ± 12.3</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.81 ± 0.06</td>
<td>0.77 ± 0.05a</td>
<td>0.78 ± 0.05</td>
<td>0.78 ± 0.05a</td>
</tr>
<tr>
<td>Waist-height-ratio</td>
<td>0.57 ± 0.02</td>
<td>0.54 ± 0.03a</td>
<td>0.55 ± 0.05a</td>
<td>0.53 ± 0.05ab</td>
</tr>
<tr>
<td>Fasting glucose (mmol·L⁻¹)</td>
<td>4.9 ± 0.5</td>
<td>4.5 ± 0.2</td>
<td>4.4 ± 0.2a</td>
<td>4.0 ± 1.8</td>
</tr>
<tr>
<td>Fasting insulin (mU·L⁻¹)</td>
<td>8.9 ± 3.1</td>
<td>8.3 ± 1.9</td>
<td>9.4 ± 6.5</td>
<td>7.4 ± 2.5</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.1 ± 0.8</td>
<td>1.8 ± 0.4</td>
<td>2.1 ± 1.3</td>
<td>1.6 ± 0.6</td>
</tr>
<tr>
<td>Total cholesterol (mmol·L⁻¹)</td>
<td>4.7 ± 0.6</td>
<td>4.4 ± 0.8</td>
<td>4.2 ± 0.5</td>
<td>4.3 ± 0.8</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol·L⁻¹)</td>
<td>1.5 ± 0.5</td>
<td>1.9 ± 0.5a</td>
<td>1.4 ± 0.2</td>
<td>1.8 ± 0.4</td>
</tr>
<tr>
<td>Triglycerides (mmol·L⁻¹)</td>
<td>1.3 ± 0.6</td>
<td>1.6 ± 1.0</td>
<td>1.8 ± 1.5</td>
<td>1.7 ± 0.7</td>
</tr>
<tr>
<td>hs-CRP (mg·L⁻¹)</td>
<td>3.5 ± 1.9</td>
<td>3.8 ± 2.6</td>
<td>4.0 ± 2.3</td>
<td>3.3 ± 1.9</td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>81 ± 10</td>
<td>72 ± 8</td>
<td>65 ± 10a</td>
<td>66 ± 18a</td>
</tr>
<tr>
<td>Predicted VO₂max (mL·kg⁻¹·min⁻¹)</td>
<td>29.8 ± 8.2</td>
<td>31.8 ± 6.1b</td>
<td>34.5 ± 11.2</td>
<td>30.6 ± 5.8</td>
</tr>
<tr>
<td>Physical activity (min·wk⁻¹)</td>
<td>98.6 ± 63.3</td>
<td>282.8 ± 81.0a</td>
<td>159.28 ± 38.88</td>
<td>216.4 ± 112.9a</td>
</tr>
<tr>
<td>Daily energy intake (KJ)</td>
<td>61117 ± 666</td>
<td>4957 ± 1315a</td>
<td>5331 ± 1175</td>
<td>4359 ± 745a</td>
</tr>
</tbody>
</table>

Vascular

<table>
<thead>
<tr>
<th>Vascular</th>
<th>Pre-intervention (0 weeks)</th>
<th>Post-intervention (12 weeks)</th>
<th>Sustainability (24 weeks)</th>
<th>Longitudinal (52 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carotid IMT (mm)</td>
<td>0.40 ± 0.02</td>
<td>0.42 ± 0.03</td>
<td>0.37 ± 0.01a</td>
<td>0.42 ± 0.03b</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>121 ± 7</td>
<td>117 ± 8</td>
<td>115 ± 12</td>
<td>117 ± 14</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>71 ± 6</td>
<td>66 ± 11</td>
<td>63 ± 6</td>
<td>67 ± 10</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD. n = 7. HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; IMT, intima-media thickness. #log10 transformation to satisfy Gaussian distribution prior to further statistical tests. a significantly different to pre-intervention (P ≤ 0.05); b significant difference from sustainability to longitudinal (P ≤ 0.05).

Among cardiac outcomes (Table 9.2), systolic mitral annular plane tissue velocity (Sₘₐₜ), myocardial twist, and rate of twist/untwist were significantly reduced from pre-intervention to post-intervention. Differences from pre-intervention to sustainability were observed for increased IVRT and reduced circumferential strain. However, by longitudinal testing, no differences were present when compared with pre-intervention, nor were there changes from the sustainability phase.
Table 9.2. Echocardiographic data collected at pre-intervention (0 wk), post-intervention (12 wk), sustainability (24 wk), and longitudinal follow-up (52 wk), for a subsample (n = 7) of participants in the Young Women’s Heart Health Study.

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Pre-intervention (0 weeks)</th>
<th>Post-intervention (12 weeks)</th>
<th>Sustainability (24 weeks)</th>
<th>Longitudinal follow-up (52 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA diastolic diameter (mm)</td>
<td>26.6 ± 12.7</td>
<td>31.7 ± 2.1</td>
<td>33.2 ± 3.5</td>
<td>31.0 ± 3.1</td>
</tr>
<tr>
<td>LV mass (g)</td>
<td>153.5 ± 39.9</td>
<td>175.3 ± 34.4</td>
<td>175.5 ± 34.6</td>
<td>154.9 ± 33.6</td>
</tr>
<tr>
<td>LV mass indexed (g·m⁻²)</td>
<td>41.4 ± 13.6</td>
<td>47.1 ± 11.5</td>
<td>48.1 ± 7.9</td>
<td>42.0 ± 13.9</td>
</tr>
<tr>
<td>LVED diameter (mm)</td>
<td>42.9 ± 4.5</td>
<td>41.7 ± 4.5</td>
<td>44.8 ± 3.1</td>
<td>43.0 ± 4.5</td>
</tr>
<tr>
<td>LVES diameter (mm)</td>
<td>27.3 ± 5.7</td>
<td>26.8 ± 2.8</td>
<td>28.4 ± 3.9</td>
<td>29.7 ± 4.1</td>
</tr>
<tr>
<td>LV PW thickness (mm)</td>
<td>10.4 ± 1.7</td>
<td>12.1 ± 3.3</td>
<td>11.2 ± 1.6</td>
<td>10.0 ± 2.0</td>
</tr>
<tr>
<td>IVS thickness (mm)</td>
<td>10.4 ± 1.7</td>
<td>11.9 ± 1.7</td>
<td>10.8 ± 1.9</td>
<td>11.0 ± 1.0</td>
</tr>
<tr>
<td>LV EF (%)</td>
<td>55.2 ± 3.1</td>
<td>61.9 ± 7.4</td>
<td>75.3 ± 10.9</td>
<td>76.0 ± 13.4</td>
</tr>
<tr>
<td>E velocity (cm·s⁻¹)</td>
<td>84.9 ± 7.8</td>
<td>75.9 ± 9.4</td>
<td>75.3 ± 10.9</td>
<td>76.0 ± 13.4</td>
</tr>
<tr>
<td>A velocity (cm·s⁻¹)</td>
<td>38.7 ± 11.4</td>
<td>31.0 ± 4.6</td>
<td>37.0 ± 3.5</td>
<td>45.2 ± 14.3</td>
</tr>
<tr>
<td>E/A ratio</td>
<td>2.4 ± 0.7</td>
<td>2.5 ± 0.3</td>
<td>2.1 ± 0.4</td>
<td>1.9 ± 0.5</td>
</tr>
<tr>
<td>IVRT (ms)</td>
<td>71.9 ± 31.8</td>
<td>94.7 ± 14.8</td>
<td>96.3 ± 17.6</td>
<td>92.4 ± 8.5</td>
</tr>
<tr>
<td>Deceleration time (ms)</td>
<td>215.3 ± 22.5</td>
<td>233.9 ± 69.6</td>
<td>276.7 ± 33.9</td>
<td>236.0 ± 37.1</td>
</tr>
<tr>
<td>$S_m$ velocity (cm·s⁻¹)</td>
<td>9.4 ± 1.8</td>
<td>8.7 ± 1.5²</td>
<td>8.9 ± 1.6</td>
<td>9.0 ± 1.1</td>
</tr>
<tr>
<td>$E_m$ velocity (cm·s⁻¹)</td>
<td>14.9 ± 1.7</td>
<td>13.3 ± 2.9</td>
<td>13.4 ± 2.4</td>
<td>14.8 ± 4.1</td>
</tr>
<tr>
<td>$A_m$ velocity (cm·s⁻¹)</td>
<td>7.0 ± 1.6</td>
<td>7.4 ± 1.6</td>
<td>6.9 ± 1.6</td>
<td>7.3 ± 1.1</td>
</tr>
<tr>
<td>$E/E_m$ lateral wall</td>
<td>5.2 ± 1.2</td>
<td>4.6 ± 1.2</td>
<td>4.4 ± 1.2</td>
<td>4.1 ± 0.4</td>
</tr>
<tr>
<td>Longitudinal strain (%)</td>
<td>-17.2 ± 2.4</td>
<td>-17.5 ± 0.5</td>
<td>-16.7 ± 1.5</td>
<td>-17.1 ± 2.1</td>
</tr>
<tr>
<td>Circumferential strain (%)</td>
<td>-19.2 ± 5.2</td>
<td>-19.3 ± 2.6</td>
<td>-18.2 ± 4.6</td>
<td>-17.3 ± 4.5</td>
</tr>
<tr>
<td>Apical rotation (˚)</td>
<td>5.4 ± 2.3</td>
<td>4.7 ± 1.8</td>
<td>4.2 ± 2.4</td>
<td>5.1 ± 2.0</td>
</tr>
<tr>
<td>Basal rotation (˚)</td>
<td>-3.6 ± 3.0</td>
<td>-4.3 ± 1.7</td>
<td>-5.3 ± 3.6</td>
<td>-3.9 ± 0.8</td>
</tr>
<tr>
<td>Twist (˚)</td>
<td>9.0 ± 3.2</td>
<td>5.8 ± 1.5²</td>
<td>5.6 ± 2.0</td>
<td>6.5 ± 2.1</td>
</tr>
<tr>
<td>Twist rate (˚·s⁻¹)</td>
<td>79.5 ± 15.5</td>
<td>42.2 ± 22.7³</td>
<td>53.8 ± 26.8</td>
<td>65.1 ± 21.6</td>
</tr>
<tr>
<td>Untwist rate (˚·s⁻¹)</td>
<td>-7.3 ± 20.7</td>
<td>-31.6 ± 19.3³</td>
<td>-52.3 ± 28.1</td>
<td>-56.5 ± 10.7</td>
</tr>
</tbody>
</table>

Data presented as mean ± SD. n=7. $S_m$, $E_m$ and $A_m$ are means of four sites at the mitral annulus from apical 4-chamber and 2-chamber view. LA, left atrium; LV, left ventricle; LVED, left ventricle end-diastolic; LVES, left ventricle end-systolic; PW, posterior wall; IVS, inter-ventricular septum; EF, ejection fraction; IVRT, isovolumetric relaxation time; S, systolic; E, early-diastolic; A, late-diastolic; SR, strain rate. #log10 transformation to satisfy Gaussian distribution prior to further statistical tests. *significantly different to pre-intervention (P ≤ 0.05).

Figure 9.1 presents data for “stage of change for exercise”. Of note, at pre-intervention, all participants indicated that they were in ‘contemplation’ (n=3) or ‘preparation’ (n=4). However, upon completion of the lifestyle intervention at post-intervention testing, six of the seven women had moved into the ‘action’ phase. At sustainability, three participants were still in the ‘action’ phase, an indication that they had maintained exercise beyond the completion of the intervention, while the other four had returned to ‘preparation’. Responses varied at longitudinal follow-up, with three participants indicating for the first time that they had entered the ‘maintenance’ phase. Meanwhile, one participants was in ‘action’, while others had returned to ‘contemplation’ (n=1) or ‘preparation’ (n=2).
Discussion

In this supplementary study, a subsample of participants who completed the multi-disciplinary lifestyle intervention was followed up one year later. At this longitudinal follow-up, participants exhibited significant reductions in WC-dependent anthropometric measures when compared to pre-intervention values, representing a favourable change in abdominal adiposity. These women also reported increased engagement in weekly physical activity and reductions in daily energy intake, representing positive modifications to lifestyle behaviours to support weight management. However, care must be taken when interpreting these data for possible bias, given that the women returning for longitudinal testing may have been the more compliant of the intervention participants.

Immediately post-intervention (12 weeks), results for this subsample demonstrated that a short-term, multi-disciplinary lifestyle intervention was effective for reducing a number of metabolic and lifestyle risk factors, including WC-dependent anthropometric measures, fitness variables and energy intake. However, at the sustainability phase (24 weeks), an emergent ‘rebound’ trend was evident for several variables, with the post-intervention
improvements in WC, fitness and nutritional measures no longer different from pre-intervention. There was also a reduction in weekly physical activity by 24 weeks from post-intervention. This rebound effect is also observed in the sustainability data presented for the intervention group as a whole (n=19) in Chapter 7, and has previously been reported in adults in intervention studies investigating chronic disease (Wycherley et al., 2012). At longitudinal follow-up, WC-dependent measures, physical activity levels and energy intake displayed changes were again significantly improved compared with pre-intervention values. This is in contrast to another lifestyle intervention study with young adult women with overweight/obesity (Chang et al., 2010), where reported improvements in fruit and vegetable intake behaviour at post-intervention were no longer present at 8-month follow-up.

This rebound trend was reflected in the “stage of change” data, which showed that some participants formerly in ‘action’ at post-intervention had regressed to the ‘preparation’ phase at sustainability. However, at longitudinal follow-up, several participants returned to ‘action’ or ‘maintenance’. It is speculated that this pattern of regression noted at sustainability testing was initiated by the suspension of supervised physical activity and CBT group sessions when the lifestyle intervention concluded (Wycherley et al., 2012). The trigger for renewed improvements in lifestyle behaviours from sustainability to longitudinal follow-up, which resulted in improvements in the WC-dependent measures, requires further investigation.

Further evidence of this ‘rebound’ effect is evident from individual data obtained from the primary outcome variable of WC (data not shown). It was revealed that from post-intervention to sustainability: (i) one participant had a reduced WC (3.0 cm); (ii) three participants had maintained their WC; and (iii) three had increased WC (range: 4.1 to 5.0 cm). In comparison, from sustainability to longitudinal follow-up: (i) five participants had reduced WC (range: 4.0 to 10.6 cm); and (ii) two participants had maintained WC. Moreover, at longitudinal testing, all but one participant displayed a WC that was less than at pre-intervention. In addition, at longitudinal follow-up, two participants were no longer considered ‘abnormally obese’ (i.e., their WC < 80 cm). And although not statistically different from pre-intervention, mean body mass and hip circumference had reduced by 4.5% and 5%, respectively, at longitudinal follow-up, further suggesting sustained lifestyle behaviours beyond the completion of the intervention.

There were changes observed in some cardiac and vascular (ultrasonography) markers, from pre-intervention to post-intervention and sustainability, in this subsample of seven women.
These changes are difficult to explain given that they were not observed in the post-intervention (Chapter 8) and sustainability (Addendum 8.1) data of the entire intervention cohort (n=19), except for a decrease in circumferential strain at the sustainability phase. However, by one-year follow-up, there were no differences from pre-intervention values for any cardiac or vascular measure assessed with ultrasonography.

In summary, the follow-up testing at 24 weeks provides evidence that positive behaviour modifications developed during the lifestyle intervention demonstrate a ‘rebound’ after withdrawal of the intervention and its intensive support. However, further follow-up testing at 52 weeks suggests that participants re-engage in positive lifestyle behaviours and, concomitantly, exhibit improvements in CVD risk factors similar to those observed immediately post-intervention. Importantly, the key improvement in CVD risk status at 52 weeks was a significant reduction in WC, representing a favourable change in abdominal adiposity. Therefore, despite a small sample size at one-year follow-up, a multi-disciplinary lifestyle intervention comprising physical activity, nutrition education and CBT can be considered an effective approach for long-term, sustained improvements in CVD risk profile for young adult women with abdominal obesity. However, it is possible that this outcome reflects a bias of only the most committed participants returning for longitudinal testing.
Chapter 10. Discussion and Conclusion

10.1. Overview

Overweight and obesity continues to escalate in developed and developing countries (Ng et al., 2014). Obesity is an independent risk factor for CVD and is associated with the progression of other risk factors that increase the chance of developing CVD (Kahn et al., 2006) in middle-aged and older adults, particularly in post-menopausal women (Galassi et al., 2006; Hubert et al., 1983; Worrall-Carter et al., 2011). Similar trends are now emerging in premenopausal women (Peterson, Herrero, et al., 2004; Peterson, Waggoner, et al., 2004). Young women in particular are at risk of future CVD events, with weight gain rising steeply between the ages of 19 to 40 years (Ng et al., 2014). Despite this, premenopausal women are under-represented in CVD research (Chomistek, Mukamal, Eliaseen, & Rimm, 2014; Hutchesson et al., 2013). Data on the prevalence, characteristics and consequences of overweight/obesity in young women are important for early detection, timely treatment and adaptation of lifestyle interventions (van Emmerik et al., 2012).

10.2. Linking of the studies

The narrative literature review (Chapter 2) highlighted an under-representation of work examining CVD risk in premenopausal adult women, with a paucity of data regarding more contemporary early detection markers such as ultrasonographic measures of cardiac and vascular risk. There was limited attention to strategies within population to address CVD risk progression, with multi-component lifestyle intervention proposed as an effective non-pharmacological approach for reducing overweight/obesity and other modifiable risk factors. The systematic literature review (Chapter 3) revealed only five RCT studies since 2004 to address the efficacy of a multi-disciplinary lifestyle intervention for reducing CVD risk in premenopausal women (≤ 40 years of age) with overweight/obesity. Of these five studies: (i) only one had a mean participant age below 36 years; (ii) none had investigated cardiac and/or
vascular measures using ultrasonography, and (iii) sustainability measures following interventions were lacking.

The series of studies described in Chapters 5 to 8 were conducted with the primary purpose of advancing the knowledge of reducing CVD risks in young women and, in particular, those with overweight/obesity. This thesis first focussed on the early identification of CVD risk factors that are modifiable, reversible and preventable, using a cross-sectional design for the assessment of metabolic, cardiac and vascular markers of CVD risk and associated lifestyle behaviours. This was followed with a RCT intervention study of lifestyle modification (intended at being realistic, sustainable, and age- and gender-appropriate) to assess its effectiveness in reducing identified risk factors, and included tracking the sustainability of any intervention-induced changes in CVD risk. These investigations of CVD risk in young adult women with overweight/obesity presented in this thesis have produced a number of notable and novel contributions towards the understanding of early detection and intervention of CVD in this population.

Research question 1: What (cardio)metabolic, cardiac and vascular risk factors are associated with overweight/obesity in premenopausal women aged 18-30 years?

It was hypothesised that young women with overweight/obesity exhibit elevated markers of CVD risk for metabolic and lifestyle factors, and display cardiac and vascular dysfunction measured by ultrasonography. These risk factors may evolve as a result of excess adiposity and lead to the development of CVD. Many risk factors are modifiable, reversible and preventable with appropriate strategies. In this thesis, waist circumference ≥ 80 cm as a surrogate measure of abdominal obesity was selected to define ‘overweight/obesity’. Waist circumference is a reliable and inexpensive index of adiposity that correlates well with advanced measuring techniques (Goh et al., 2014; National Health and Medical Research Council, 2003). Compared with non-overweight/obese (WC < 80 cm), age-matched (18-30 years) controls, it was established that young women with abdominal obesity had elevated CVD risk in measures of insulin resistance (HOMA-IR), low-grade systemic inflammation (hs-CRP) and systolic blood pressure, and lower levels of physical activity and fitness. In contrast, traditional markers of CVD risk, such as those associated with the metabolic
syndrome (i.e., blood lipids and fasting glucose), did not differentiate between overweight/obese women and age-matched women in the healthy anthropometric range. Similarly, increased c-IMT as a vascular marker of developing atherosclerosis was not evident in the overweight/obese group. However, the elevations in HOMA-IR and systolic blood pressure for women with abdominal obesity were within ‘acceptable’ limits (Jensterle et al., 2008; Pearson et al., 2003), while the elevated hs-CRP was deemed ‘high’ risk (> 3.0 mg·l⁻¹). But given the between-group differences, these elevated CVD risk markers might be more useful for early detection of future CVD risk in this population than those (e.g., metabolic syndrome markers) currently used in standard health checks. Moreover, the calculation of unadjusted odds ratios produced significant outcomes for insulin resistance and physical activity, indicating that a HOMA-IR score ≥ 2.0 and exercise engagement < 210 min per week were risk factors associated with overweight/obesity in this population. Therefore, mild abdominal obesity could be considered as among the first stages in a sequence of early markers of CVD risk.

Young women with abdominal obesity also displayed cardiac remodelling. Obesity is independently associated with increased LV mass, with eccentric hypertrophy the most common form associated with this metabolic disorder (Wong et al., 2004). In this thesis, the increased LA diameter was consistent with these findings, and has been reported to occur to compensate for a greater haemodynamic load in obesity. Thus, cardiac hypertrophy may be an early marker in the sequence of cardiac events (Wong & Marwick, 2007b). These women also displayed subtle, subclinical cardiac dysfunction, providing support to the only other study to report such measures in young obese women (Peterson, Waggoner, et al., 2004). In the present study, the overweight/obese group exhibited reduced systolic (Sₘ) and diastolic (Eₘ) mitral annular plane velocities, increased LA filling pressure surrogates (E/Eₘ), and prolonged timing measures of diastolic function. While the specific values for these measures in the overweight/obese group are still considered ‘normal’ in the clinical setting (Nagueh et al., 2009), the presence of between-group differences again suggest their usefulness as early detection markers. In addition, the advances in echocardiographic techniques over the past decade may provide avenues for earlier detection of cardiac dysfunction. In this thesis, circumferential deformation and myocardial mechanical indices (twist indices and rotation) were similar between groups. However, longitudinal deformation was impaired in women with overweight/obesity compared with controls. Similarly, reduced global longitudinal LV strain was observed in a cross-sectional study of obese children and adolescents when
compared to age-matched non-obese controls (Shah et al., 2011). These results indicate emerging systolic involvement early in the process of obesity in these young populations (Barbosa, Mota, e Silva, Maria do Carmo, & Barbosa, 2013).

Taken together, these findings suggest that WC was useful as a first-line diagnostic measure of CVD risk. Similarly, BMI ($\geq 25 \, \text{kg/m}^2$) and WHtR ($> 0.50$) as anthropometric measures for overweight/obesity were also useful as first-line diagnostic measures of CVD risk in this age group, given they predicted CVD risk factors (i.e., insulin resistance and physical inactivity) similar to waist circumference. Anthropometric measures of abdominal adiposity have previously shown strong and positive associations with all-cause CVD mortality independent of BMI (Zhang et al., 2008). Specifically, elevated WC has been associated with increased CVD mortality even among normal-weight women (Zhang et al., 2008).

Furthermore, the Emerging Risk Factors Collaboration [ERFC] (2011) showed that WC, BMI, WHtR, and WHR each had similar strengths of association with CVD risk. Therefore, data in this thesis are in agreement with previous literature, given the results of the present study found WC, BMI and WHtR each predicted similar CVD risk factors in young women, while WHR was not a strong predictor.

The detection of differences in selected metabolic and cardiac parameters in young obese women in this thesis, albeit relatively subtle, is concerning and, thus, a better understanding of heart health in these early stages of adulthood is required. When seeking deeper insight into the progression of CVD risk, measures of glycaemic control and lifestyle factors appear more informative than traditional metabolic syndrome markers at this younger age. There is also value in echocardiographic techniques for advancing this insight, given the findings of this thesis that premenopausal women with mild abdominal obesity demonstrate abnormal cardiac function at a younger age, and in earlier stages of obesity, than previously reported (Kosmala et al., 2009; Wong, Byrne, et al., 2006). In summary, the data from the cross-sectional studies of this thesis support the hypotheses that young women with overweight/obesity (compared with their non-obese counterparts) exhibit markers of CVD risk in their metabolic profile and display subclinical cardiac dysfunction measured from echocardiography. These findings demonstrated the emerging importance of early intervention strategies in this population to arrest further progression of CVD. Effective lifestyle intervention strategies that promote weight loss and reduce risk factors for CVD
through early detection and prevention will, ultimately, reduce CVD and the associated personal and financial burden of the disease on individuals and society.

**Research question 2: Does a multi-disciplinary lifestyle intervention comprising physical activity, nutrition education and CBT improve CVD risk factors in young women with abdominal obesity? And if so, are these improvements sustainable beyond the completion of the program?**

A number of multi-component lifestyle intervention studies have produced beneficial outcomes for body composition, fitness, and cardiometabolic parameters (Carroll et al., 2007; Dutheil et al., 2013; Irving et al., 2008). Lifestyle interventions incorporating exercise, dietary and behavioural components are considered the most successful design for health outcomes, including weight loss and reductions in CVD risk factors (Wing, 2002). As highlighted in the systematic literature review (Chapter 3), the effects and sustainability of multi-disciplinary lifestyle interventions for young adult women with overweight/obesity (particularly aged ≤ 30 years) are noticeably under-researched. In the present study, the 12-week multi-disciplinary lifestyle intervention produced some within-group improvements in CVD risk factors for young women with abdominal obesity. Interestingly, these risk factor improvements were primarily limited to the metabolic and lifestyle markers identified in the cross-sectional studies (Chapters 5 and 6) as showing poorer values in women with overweight/obesity. Specifically, anthropometric measures related to waist circumference, systolic (and diastolic) blood pressure, and measures of physical activity engagement, aerobic fitness and total energy intake improved at post-intervention. Improvements in these CVD risk factors are consistent with other RCT studies that have assessed the effectiveness of multi-disciplinary interventions with premenopausal women with overweight/obesity (Kerksick et al., 2010; Silva et al., 2010). While metabolic risk factors related to anthropometry and blood pressure improved to be better aligned with young, non-obese women (see Chapter 5), in contrast, other risk factors like fasting insulin, HOMA-IR and hs-CRP were unaffected by the intervention. Similarly, cardiac and vascular properties assessed with ultrasonography were unaffected at post-intervention. This might reflect an intervention of insufficient duration or intensity or lifestyle manipulation to drive change in many of the outcome measures. But it is also possible that this early stage of CVD progression in women
with abdominal obesity insufficiently advanced for a lifestyle intervention to generate sizeable or detectable improvements in metabolic, cardiac and/or vascular risk factors. This was supported by the between-group findings in Chapter 5, in which elevated hs-CRP in the overweight/obese women was the only risk factor deemed to be of ‘high’ risk. Similarly, while differences between obese and non-obese women were observed in echocardiographic markers in Chapter 6, the specific values for these measures in the women with abdominal obesity were still considered ‘normal’ in the clinical setting.

Once leaving the intervention program, women maintained their post-intervention improvements in anthropometric measures, blood pressure, resting heart rate and physical activity engagement at 24 weeks. Similarly, daily energy intake was still 15% lower than pre-intervention levels, although statistical significance was not reached ($P = 0.269$). However, levels of physical activity at 24 weeks had declined significantly from the greatly increased weekly engagement at immediately post-intervention, and this likely explains the return of aerobic fitness to a level no longer different from pre-intervention. This might reflect the frequent rebound that can occur once the intensive support of an intervention program is withdrawn, even when behavioural change strategies have been implemented (Wycherley et al., 2012). However, collectively, the maintenance of the intervention-induced improvements above suggest that the intervention produced longer lasting lifestyle modifications and, thus, its characteristics were realistic, sustainable, and age- and gender-appropriate for young, university-educated adult women.

The data collected at one-year post-intervention provide supportive evidence of an intervention that was successful in establishing sustainable lifestyle behaviours in young adult women. For the seven women who returned for this follow-up testing, the outcomes for the majority of the metabolic, cardiac and vascular measures did not differ from the pre-intervention data. This could be considered a positive outcome from the perspective of an absence of deleterious progression of CVD risk in these participants. Moreover, there was a significant decrease in all anthropometric markers at this time point, including WC, BMI, WHR, WHtR, body mass and hip circumference. These body composition changes reflect a significant decrease in general adiposity, with the reduction in waist circumference indicating a decrease in abdominal adiposity. It is predicted that these reductions in adiposity will result in positive changes in the intermediate modifiable risk factors (Bastien et al., 2014) and in circulating adipokines and inflammatory mediators (Berggren et al., 2005; Matsuzawa,
It is likely that improvements in other CVD risk markers will emerge more explicitly over a longer time period if the anthropometric corrections are maintained or further enhanced.

From a behavioural modification perspective, the seven participants at one year had substantially increased their weekly engagement in physical activity and reduced their dietary energy intake when compared to pre-intervention values. The combination of these outcomes result in a negative shift in total energy balance, which is consistent with the decreases in body mass and related anthropometry observed at this time point. These one-year post-intervention data for physical activity and dietary patterns also reversed the rebound towards pre-intervention levels observed at 24 weeks in these lifestyle behaviours. These positive lifestyle modifications developed by one year also provide evidence that the intervention delivered in this thesis was successful and sustainable long-term for this population. However, it is important to acknowledge that a possible bias exists with the seven women who returned for longitudinal testing. These women may have been more compliant than other intervention participants given their availability for one-year follow-up testing.

While within-group changes observed in the intervention group showed the lifestyle intervention to be successful in mitigating some CVD risk, between-group comparisons with the overweight/obese control group suggested a research design that was largely unsuccessful in discriminating the effectiveness of the intervention phase. In fact, only physical activity engagement was significantly different between groups, with the overweight/obese women in the wait-list control group displayed similar patterns of effect in anthropometric, biochemical, fitness and dietary measures at post-control testing. Most notable was a decrease in WC that paralleled changes in the intervention group, despite undetected changes in self-reported physical activity and nutrition behaviour of the control group participants. Unanticipated improvements in the behaviour of control participants have been observed in intervention trials targeting physical activity and chronic disease management, but weight loss improvements are not normally observed in wait-list control conditions (Waters et al., 2012). In the current study, participants appear to have experienced an increase in motivation for change simply through assignment to a control group. Therefore, a wait-list (delayed-start) control group design may not be appropriate for ‘Generation Y’ women who share urgency for feedback and success (Griffin et al., 2013) This was highlighted by the (presumed) poor compliance to pre-recruitment lifestyle behaviours, as indicated by a decrease in WC similar
to the intervention group, as well as poor continuation into the intervention phase upon completion of the control phase. These limitations and difficulties have been previously documented, with one study acknowledging that young obese women are difficult to recruit to weight management trials (Griffin et al., 2013). Young women have been identified in the research as a high risk group (Gokee-LaRose et al., 2009; Hutchesson et al., 2013), with standard weight loss programs not meeting the weight control needs of young adults and research urgently required to improve recruitment and retention efforts within this group (Gokee-LaRose et al., 2009).

In summary, results from the intervention study of this thesis support the hypothesis that a 12-week multi-disciplinary lifestyle intervention would produce anthropometric and CVD risk factor improvements, albeit subtly, in young adult women with abdominal obesity. Similarly, the behaviour change associated with the intervention was successful in sustaining several improvements in the cardiovascular health profile of these women longer term. Given the association of abdominal obesity with CVD risk, an important outcome was that the decrease in WC exhibited at the completion of the intervention phase was maintained at 24 weeks and 1 year later. However, this perspective extends from the intervention group data alone, where the intervention itself appeared appropriate to initiate improvements in CVD risk and behaviour change for the sustainability of healthier lifestyle management. In contrast, the RCT research design with its use of a wait-list control group does not appear appropriate for testing the effectiveness of an intervention when control participants are seeking change.
10.3. Practical applications

The series of studies comprising this thesis have contributed knowledge to direct future interventions and strengthen the evidence base for health promotion strategies in young women at risk of chronic disease. Moreover, the findings reported in this thesis have implications for the design and implementation of effective multi-disciplinary lifestyle interventions for young adult women. Based on the evidence from the cross-sectional studies and the intervention study, the following practical applications are recommended for the future of cardiovascular health in young women with abdominal obesity:

- Traditional markers of CVD risk, including markers of the metabolic syndrome, may not be appropriate for the early detection of risk in this age group (18 to 30 years) of women. Indicators of low-grade systemic inflammation (i.e. hs-CRP) appear more sensitive for identifying early stages of CVD progression. Indicators of insulin resistance (HOMA-IR) and physical activity engagement may also be useful adjuncts in the early detection of CVD progression, rather than metabolic syndrome markers.

- WC, BMI and WHtR all show similar risk factors for CVD in young adult women and, given their ease and cost of measurement, are useful first-line detection tools for CVD risk in clinical settings.

- The inclusion of mechanistic data obtained from cardiac and vascular imaging may improve diagnosis.

Additionally, based solely on evidence obtained from the lifestyle intervention program in this thesis, the following points for the implementation of future multi-disciplinary lifestyle interventions are recommended:

1. Provide opportunities for women to develop self-efficacy for behavioural change. In this study, women were introduced to exercise techniques in training that can be implemented in everyday life.

2. Provide opportunities for social interaction and support (groups).
3. Teach women to value exercise and use the health belief model to provide experiences and empowerment in the knowledge around the importance of healthy lifestyle choices.

4. Ensure that women who exercise outdoors have access to low-cost, local locations in which they feel safe.


10.4. Limitations

The following are potential study limitations and associated strengths, when considering the respective study designs, population, and statistical methodologies employed:

- The lifestyle intervention sample was under-powered.

Power calculations showed that 44 participants were required to meet appropriate power, taking into account a 20% attrition rate. From an initial recruitment of 39 women, there were 30 by program completion. This was primarily due to the greater attrition rate in control group, given that the retention rate in intervention group was as expected. This provides further support to the supposition that wait-list control designs may not be an appropriate approach for this population.

- Intra- and inter-rater reliability for some STE parameters (e.g. rotation and twist) with a CV of 9% to 12%

Despite this, both intra- and inter-reliability was comparable to other studies reporting similar variables (K. A. Marcus et al., 2011). Additionally, a minimum of three cycles/images were averaged for all echocardiography analyses, in order to further minimise measurement error. However, other reliability measures of STE were acceptable and well within previous reports.
• Due to the lack of echogenicity in the study population (particularly women with abdominal obesity), clear echocardiographic imaging was difficult in some circumstances. This precluded accurate estimation of radial deformation and, thus, these data were not included in any analyses.

• STE represents an objective and angle-independent modality for non-invasive quantification of LV deformation (strain and strain rate) and mechanics (rotation and twist) that play an important role in ejection and filling of the LV (ref). The importance of STE lies in its potential for early detection of pathology (Obert et al., 2012). However, despite STE showing excellent agreement with gold-standard heart imaging techniques such as tagged magnetic resonance imaging, it is not without its limitations. For example, preload and afterload may influence contractile responses of the myocardium and should be considered in all STE analyses (Burns et al., 2010).

• Advanced techniques, such as DEXA, were not used for the assessment of body composition. Despite the popularity of weight loss among populations of young women, weight loss was not the goal of this thesis. The focus was on metabolic health outcomes and as such remained on waist circumference rather than whole body weight loss. Ideally, weight loss refers to losses of fat mass, but without a DEXA, this type of evidence was not possible. In an intervention with a high probability of increasing lean mass (at the same time as decreasing fat mass) weight changes may not have been observed. Furthermore, WC is recognised as a clinically relevant tool in the assessment of abdominal obesity (National Health and Medical Research Council, 2003). Additionally, while WC is a simple measure, it is unrelated to height, correlates closely with BMI and WHR, and is an approximate index of intra-abdominal fat mass and total body fat (Australian Institute of Health and Welfare, 2010). In this study, the intra-rater reliability for WC was very strong (CV = 1.3%), highlighting that it was reliably implemented as a tool for body composition assessment.
• Recruitment of Caucasian participants and from middle-high socioeconomic status.

Caution must be exercised when generalising the results of this thesis to other race/ethnic populations, given previous work highlighting differences in CVD risk between ethnicities (Ajjan et al., 2007). Additionally, participants in this study were university students, mostly residing in middle-high socioeconomic areas, non-smoking and possibly well informed about health issues. Therefore, the limit to external validity is acknowledged.

• Validity, reliability and sensitivity of outcome measures.

It is possible to be critical of the sensitivity to change of both the waist circumference and ultrasound measures used in this program of research. Selected outcome measures were often dependent on the available budget but could be more carefully considered in future funding initiatives. Additionally, the validity and reliability of dietary recall of the types, amounts, preparations and brands of food recall are well acknowledged in the literature (Magarey et al., 2011) and apply to the interpretation of results in the current program of research. Furthermore, despite the acknowledged rigour of assessors being blinded to group allocation, not all researchers involved in data collection in the present program of research were able to be precluded to the knowledge of the participants’ grouping. As such, larger, future trials should have a greater number of staff to avoid the bias that potentially comes with knowledge of group allocation.

• Effects of the menstrual cycle and the oral contraceptive pill on outcome measures.

Participants were tested during the same phase of their menstrual cycle at baseline and on subsequent testing occasions but the differences in the phase of the menstrual cycle is a limitation of this protocol. Furthermore, future studies should also consider the potential limitations imposed by young women’s use of oral contraception, particularly if vascular function is of interest (Minson, Halliwill, Young, & Joyner, 2000).
10.5. Future directions

Early detection or progression of CVD, may indicate that impaired endothelial function in the vascular system is the beginning of physiological event in atherogenesis, often detected before the existence of vascular plaques and the clinical detection of vascular disease (Celermajer, et al., 1992). Furthermore, endothelial dysfunction may act as a prospective indicator of increased cardiovascular risk (Kuvin, et al., 2001), and can be measured via a technique known as flow-mediated dilation, which describes the vasodilatory response of a vessel to elevations in blood flow (Pyke, & Tschakovsky, 2005). It is recommended that future studies of CVD risk incorporate markers of vascular dysfunction, including future work investigating young adult women with overweight/obesity.

The implementation of intervention studies with young adult women requires paramount consideration of the research design for targeting this population. Specifically, the use of a randomised, wait-list control design might not be appropriate for gauging the effectiveness of an intervention with this population. This is particularly important if participants recruited into a study are ready for change. Thus, knowledge of the current ‘state of change’ of proposed participants, as well as an understanding of their barriers to lifestyle change, will help direct the research design in order to increase the likelihood of short-term retention and long-term sustainability. Future studies with larger sample sizes should also consider stratification for age and baseline waist circumference (e.g. categories such as 80-90 cm and >90 cm). Interventions with a multi-disciplinary approach, incorporating exercise, diet and behavioural therapy components, are recommended. In addition, long-term follow-up (e.g. at one year or later) is likely to provide greater insight into the sustainability success of the intervention, rather than shorter-term follow-up only.
10.6. Conclusion

In this thesis, young adult women, a population under-represented in CVD research, were investigated from a perspective of early identification of CVD risk and progression, and from a perspective of lifestyle and behavioural change for weight loss. This involved the use of traditional and contemporary measures of metabolic, cardiac and vascular risk, including a mechanistic evaluation of cardiac function performed with traditional and advanced echocardiography techniques. It was established that young women with mild abdominal obesity have elevated markers of insulin resistance and low-grade systemic inflammation (i.e. hsCRP) as well as subclinical cardiac dysfunction, when compared with a healthy control group (defined by WC < 80 cm). However, these comparative perturbations in CVD markers were still within clinical norms, with the exception of elevated hsCRP. Despite this, the early identification of changes in CVD risk factors in young women in the current study may help guide future detection strategies. Such strategies may be critical to halting and reversing CVD development while in its earliest stages of progression. This outcome would substantially decrease the social and financial costs from the perspective of the individual, as well as the longer term burden on national health costs.

The intervention component of this thesis demonstrated that a multi-disciplinary approach to lifestyle change, incorporating exercise, nutrition and behavioural strategies, can be effective in short-term maintenance or improvements in modifiable CVD risk factors. There was also evidence, among highly compliant individuals, that this type of intervention can be effective for lifestyle behaviour modifications conducive to sustainable weight loss and, thus, improved CVD risk profile. For future implementation studies targeting young adult women, the current study provides important information when considering the features of study design. Most notably, a RCT design with a wait-list control group may not meet the needs of “Generation Y” women who share a need for urgent feedback and success.

Findings from larger, future trial, informed by this thesis will hopefully contribute to stronger clinical outcomes, translatable to the broader community.


Syndrome and Obesity: Targets and Therapy, 5, 347-355. doi: 10.2147/DMSO.S35115


ventricular anatomic measurements. *Journal of the American College of Cardiology, 4*(6), 1222-1230. doi: 10.1016/s0735-1097(84)80141-2


Elliott, S., & Brown, J. (2002). What are we doing to waiting list controls? *Behaviour Research and Therapy, 40*(9), 1047-1052. doi: 10.1016/s0005-7967(01)00082-1


doi:10.1056/NEJM199901143400207


Kosmala, W., O'Moore-Sullivan, T., Plaksej, R., Przewlocka-Kosmala, M., & Marwick, T. H. (2009). Improvement of left ventricular function by lifestyle intervention in obesity: contributions of weight loss and reduced insulin resistance. Diabetologia, 52(11), 2306-2316. doi: 10.1007/s00125-009-1507-4


Kuller, L. H., Simkin-Silverman, L. R., Wing, R., Meilahn, E. N., & Ives, D. G. (2001). Women’s Healthy Lifestyle Project: A Randomized Clinical Trial Results at 54 Months. Circulation, 103(1), 32-37. doi: 10.1161/01.CIR.103.1.32


urgent need for more research and knowledge on cardiovascular disease in women. 

*European Heart Journal, 32*(11), 1362-1368. doi: 10.1093/eurheartj/ehr048


Miller, W., & Jacob, A. (2001). The health at any size paradigm for obesity treatment: The scientific evidence. *Obesity Reviews, 2*(1), 37-45. doi: 10.1046/j.1467-789x.2001.00023.x


Share, B. L., Naughton, G. A., Obert, P., Peat, J. K., & Kemp, J. G. (2013). Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures. *Journal of Science and Medicine in Sport*. doi:


Appendix 1. Research Portfolio

Publications:

This thesis contains five papers for publication in peer-reviewed journals, three of which have been published, and two that are ready for submission. All five papers are authored by Bianca Louise Share, her three supervisors and other contributing authors.

Presentations:

This thesis was presented at three international conferences, two national conferences, and two institution-facilitated conferences, as an oral presentation or poster presentation. All seven presentations were presented by Bianca Louise Share, and prepared with assistance from her three supervisors and other contributing authors.
Manuscript 1:

Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures (Chapter 5).

Bianca L Share¹ (BExSci (Hons)), Geraldine A Naughton¹,² (PhD), Philippe Obert³ (PhD), Jennifer K Peat⁴ (PhD), Justin G Kemp¹ (PhD)


¹ School of Exercise Science, Australian Catholic University, Melbourne, Australia
² Murdoch Childrens Research Institute, Melbourne, Australia
³ Laboratory of Cardiovascular Pharmacology, University of Avignon, France
⁴ Faculty of Health Sciences, Australian Catholic University, Sydney, Australia

All authors met the criteria for authorship and agreed on the final version of the manuscript. None of the authors had a conflict of interest in relation to this manuscript.

Signatures:

Bianca L Share: ............................................................ Date: ………………………

As principal supervisors, I certify that the contributions below are true and correct

Justin G Kemp: ............................................................ Date: ………………………
In the case of this publication, the following contributions were made:

<table>
<thead>
<tr>
<th>Author</th>
<th>Statement of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bianca L Share</strong></td>
<td>Conception and design of the study (including developing the scientific basis for the research; identification of outcome testing methodology; formulating the ethics proposal; preparation of data record forms, information and results sheets), recruitment and screening of participants, co-ordinated the study, performed all data collection (including intravenous blood draws, fitness testing, blood pressure, and anthropometric assessment), performed all data analyses (including auto-analyser biochemical analysis of blood lipids), managed the study data files, performed statistical tests (including reliability and validity analyses), interpreted the data, and co-ordinated the writing of the manuscript.</td>
</tr>
<tr>
<td><strong>Geraldine A Naughton</strong></td>
<td>Contributed to conception and study design, data interpretation, and writing of the manuscript</td>
</tr>
<tr>
<td><strong>Philippe Obert</strong></td>
<td>Contributed to conception and study design.</td>
</tr>
<tr>
<td><strong>Jennifer K Peat</strong></td>
<td>Advised statistical analyses and assisted with data interpretation.</td>
</tr>
<tr>
<td><strong>Justin G Kemp</strong></td>
<td>Contributed to conception and study design, and writing of the manuscript.</td>
</tr>
</tbody>
</table>
Other contributors (non-authors):

<table>
<thead>
<tr>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dietitian</td>
<td>Analysed the 3-day food recall in FoodWorks® 7 Professional</td>
</tr>
<tr>
<td>Pathology</td>
<td>Performed some biochemistry analyses (glucose, insulin, hs-CRP)</td>
</tr>
<tr>
<td>Nurse</td>
<td>Assisted with some intravenous blood draws</td>
</tr>
</tbody>
</table>
Manuscript 2:
Young women with abdominal obesity have sub-clinical myocardial dysfunction (Chapter 6).

Bianca L Share¹ (BExSci (Hons)), Andre La Gerche² (PhD), Geraldine A Naughton¹,³ (PhD), Philippe Obert⁴ (PhD), Justin G Kemp¹ (PhD)


¹ School of Exercise Science, Australian Catholic University, Melbourne, Australia

² St. Vincent’s Hospital, Melbourne, Australia

³ Murdoch Childrens Research Institute, Melbourne, Australia

⁴ Laboratory of Cardiovascular Pharmacology, University of Avignon, France

All authors met the criteria for authorship and agreed on the final version of the manuscript. None of the authors had a conflict of interest in relation to this manuscript.

Signatures:

Bianca L Share: ............................................................ Date: …………………………

As principal supervisors, I certify that the contributions below are true and correct

Justin G Kemp: ............................................................ Date: …………………………
In the case of this publication, the following contributions were made:

<table>
<thead>
<tr>
<th>Author</th>
<th>Statement of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bianca L Share</td>
<td>Conception and design of the study (including developing the scientific basis for the research; identification of outcome testing methodology; formulating the ethics proposal; preparation of data record forms, information and results sheets), recruitment and screening of participants, co-ordinated the study, performed all data collection (including echocardiography and ultrasonography image acquisition, intravenous blood draws, fitness testing, blood pressure, and anthropometric assessment), performed all data analyses (including offline echocardiography image assessment, and auto-analyser biochemical analysis of blood lipids), managed the study data files, performed statistical tests (including reliability and validity analyses), interpreted the data, and co-ordinated the writing of the manuscript.</td>
</tr>
<tr>
<td>Andre La Gerche</td>
<td>Provided expertise in the field of echocardiography, data interpretation, and contributed to writing of the manuscript.</td>
</tr>
<tr>
<td>Geraldine A Naughton</td>
<td>Contributed to conception and study design, data interpretation, and writing of the manuscript</td>
</tr>
<tr>
<td>Philippe Obert</td>
<td>Contributed to conception and study design. Provided expertise in the field of echocardiography/ultrasonography, and contributed to writing of the manuscript</td>
</tr>
<tr>
<td>Justin G Kemp</td>
<td>Contributed to conception and study design, and writing of the manuscript</td>
</tr>
</tbody>
</table>
Other contributors (non-authors):

<table>
<thead>
<tr>
<th><strong>Dietitian</strong></th>
<th>Analysed the 3-day food recall in FoodWorks® 7 Professional</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
<td>Performed some biochemistry analyses (glucose, insulin, hs-CRP)</td>
</tr>
</tbody>
</table>
Manuscript 3:
Effects of a multi-disciplinary lifestyle intervention on cardiometabolic risk factors in young women with abdominal obesity: A randomised controlled trial (Chapter 7).


**Bianca L Share**¹ (BExSci (Hons)), Geraldine A Naughton¹,² (PhD), Philippe Obert³ (PhD), Jennifer K Peat⁴ (PhD), Elizabeth A Aumand¹ (MA), Justin G Kemp¹ (PhD)

¹ School of Exercise Science, Australian Catholic University, Melbourne, Australia

² Murdoch Childrens Research Institute, Melbourne, Australia

³ Laboratory of Cardiovascular Pharmacology, University of Avignon, France

⁴ Faculty of Health Sciences, Australian Catholic University, Sydney, Australia

All authors met the criteria for authorship and agreed on the final version of the manuscript. None of the authors had a conflict of interest in relation to this manuscript.

**Signatures:**

Bianca L Share: ............................................................ Date: ……………………

As principal supervisors, I certify that the contributions below are true and correct

Justin G Kemp: ............................................................ Date: ……………………
In the case of this publication, the following contributions were made:

<table>
<thead>
<tr>
<th>Author</th>
<th>Statement of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bianca L Share</td>
<td>Conception and design of the study (including developing the scientific basis for the research; identification of outcome testing methodology; development of the exercise training protocols; formulating the ethics proposal; preparation of data record forms, information and results sheets; developing appropriate questions for the focus group), recruitment and screening of participants; co-ordinated the study (troubleshooting participant concerns; personal training for exercise groups; presented nutrition information), performed all data collection (including intravenous blood draws, fitness testing, strength assessment, blood pressure, and anthropometric assessment), performed all data analyses (including auto-analyser biochemical analysis of blood lipids), managed the study data files, performed statistical tests (including linear mixed model; reliability and validity analyses; transcribing the focus group audio recordings; program evaluation), interpreted the data, and co-ordinated the writing of the manuscript.</td>
</tr>
<tr>
<td>Geraldine A Naughton</td>
<td>Contributed to conception and study design, data interpretation, and writing of the manuscript.</td>
</tr>
<tr>
<td>Philippe Obert</td>
<td>Contributed to conception and study design, and revised the manuscript.</td>
</tr>
<tr>
<td>Jennifer K Peat</td>
<td>Advised statistical analyses, and assisted with data interpretation.</td>
</tr>
<tr>
<td>Justin G Kemp</td>
<td>Contributed to conception and study design, and writing of the manuscript.</td>
</tr>
<tr>
<td><strong>Elizabeth A Aumand</strong></td>
<td>Designed and conducted the group CBT sessions, and facilitated the focus group.</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

**Other contributors:**

<table>
<thead>
<tr>
<th><strong>Dietitian</strong></th>
<th>Analysed the 3-day food recall in FoodWorks® 7 Professional, delivered a one-hour tutorial, and developed the nutrition education.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
<td>Performed some biochemistry analyses (glucose, insulin, hs-CRP)</td>
</tr>
</tbody>
</table>
Manuscript 4:
Effects of a lifestyle intervention on cardiac and myocardial measures in young women with abdominal obesity: A randomised controlled trial (Chapter 8).

Manuscript ready for submission to Canadian Journal of Cardiology.

Bianca L Share¹ (BExSci (Hons)), Geraldine A Naughton¹,² (PhD), Philippe Obert³ (PhD), Andre La Gerche⁴ (PhD), Justin G Kemp¹ (PhD)

¹ School of Exercise Science, Australian Catholic University, Melbourne, Australia
² Murdoch Childrens Research Institute, Melbourne, Australia
³ Laboratory of Cardiovascular Pharmacology, University of Avignon, France
⁴ St. Vincent’s Hospital, Melbourne, Australia

All authors met the criteria for authorship and agreed on the final version of the manuscript. None of the authors had a conflict of interest in relation to this manuscript.

Signatures:

Bianca L Share: ............................................................ Date: ……………………………

As principal supervisors, I certify that the contributions below are true and correct

Justin G Kemp: ............................................................ Date: ……………………………
In the case of this publication, the following contributions were made:

<table>
<thead>
<tr>
<th>Author</th>
<th>Statement of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bianca L Share</td>
<td>Conception and design of the study (including developing the scientific basis for the research; identification of outcome testing methodology; development of the exercise training protocols; formulating the ethics proposal; preparation of data record forms, information and results sheets; developing appropriate questions for the focus group), recruitment and screening of participants; coordinated the study (troubleshooting participant concerns; personal training for exercise groups; presented nutrition information), performed all data collection (including echocardiography and ultrasonography image acquisition; intravenous blood draws; fitness testing; strength assessment; blood pressure; anthropometric assessment), performed all data analyses (including offline echocardiography image assessment auto-analyser; biochemical analysis of blood lipids), managed the study data files, performed statistical tests (including linear mixed model; reliability and validity analyses; transcribing the focus group audio recordings; program evaluation), interpreted the data, and co-ordinated the writing of the manuscript.</td>
</tr>
<tr>
<td>Geraldine A Naughton</td>
<td>Contributed to conception and study design, data interpretation, and writing of the manuscript.</td>
</tr>
<tr>
<td>Philippe Obert</td>
<td>Contributed to conception and study design. Provided expertise in the field of echocardiography/ultrasonography, and contributed to writing of the manuscript.</td>
</tr>
<tr>
<td>Andre La Gerche</td>
<td>Provided expertise in the field of echocardiography, data interpretation, and contributed to writing of the manuscript.</td>
</tr>
<tr>
<td><strong>Justin G Kemp</strong></td>
<td>Contributed to conception and study design, and writing of the manuscript.</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>

**Other contributors:**

<table>
<thead>
<tr>
<th><strong>Dietitian</strong></th>
<th>Analysed the 3-day food recall in FoodWorks® 7 Professional, delivered a one-hour tutorial, and developed the nutrition education.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pathology</strong></td>
<td>Performed some biochemistry analyses (glucose, insulin, hs-CRP)</td>
</tr>
</tbody>
</table>
Manuscript 5:
The effectiveness of randomised controlled trial lifestyle interventions on cardiovascular disease risk factors in premenopausal women with overweight and obesity: A systematic review (Chapter 3).

Manuscript prepared for submission to the *International Journal of Behavioral Nutrition and Physical Activity*.

**Bianca L Share**\(^1\) (BExSci (Hons)), Geraldine A Naughton\(^{1,2}\) (PhD), Justin G Kemp\(^1\) (PhD)

\(^1\) School of Exercise Science, Australian Catholic University, Melbourne, Australia

\(^2\) Murdoch Childrens Research Institute, Melbourne, Australia

All authors met the criteria for authorship and agreed on the final version of the manuscript. None of the authors had a conflict of interest in relation to this manuscript.

**Signatures:**

Bianca L Share: ............................................................ Date: ……………………………

As principal supervisors, I certify that the contributions below are true and correct

Justen G Kemp: ............................................................ Date: ……………………………
In the case of this publication, the following contributions were made:

<table>
<thead>
<tr>
<th>Author</th>
<th>Statement of contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bianca L Share</td>
<td>Performed electronic and manual searches, journal elimination, interpreted the data, and co-ordinated the writing of the manuscript.</td>
</tr>
<tr>
<td>Geraldine A Naughton</td>
<td>Assisted with initial search strategy, journal elimination, and writing of the manuscript.</td>
</tr>
<tr>
<td>Justin G Kemp</td>
<td>Contributed to writing of the manuscript.</td>
</tr>
</tbody>
</table>
Appendix 2: Ethical Approval

Human Research Ethics Committee
Committee Approval Form

Principal Investigator/Supervisor: JUKEMP Melbourne Campus
Co-Investigators: Geraldine Naughton, Philippe Obert, Elizabeth Aurnaud Melbourne Campus
Student Researcher: Bianca Share Melbourne Campus

Ethics approval has been granted for the following project:
The metabolic syndrome in young women
for the period: 18.12.09 – 01.10.11
Human Research Ethics Committee (HREC) Register Number: V2009 91

The following standard conditions as stipulated in the National Statement on Ethical Conduct in Research Involving Humans (2007) apply:

(i) that Principal Investigator / Supervisors provide, on the form supplied by the Human Research Ethics Committee, annual reports on matters such as:
- security of records
- compliance with approved consent procedures and documentation
- compliance with special conditions, and

(ii) that researchers report to the HREC immediately any matter that might affect the ethical acceptability of the protocol, such as:
- proposed changes to the protocol
- unforeseen circumstances or events
- adverse effects on participants

The HREC will conduct an audit each year of all projects deemed to be of more than low risk. There will also be random audits of a sample of projects considered to be of negligible risk and low risk on all campuses each year.

Within one month of the conclusion of the project, researchers are required to complete a Final Report Form and submit it to the local Research Services Officer.

If the project continues for more than one year, researchers are required to complete an Annual Progress Report Form and submit it to the local Research Services Officer within one month of the anniversary date of the ethics approval.

Signed: ___________________________ Date: 18.12.09
(Research Services Officer, Melbourne Campus)

F:/BiancaPhD/Files/Ethics/V2009 91 Approval Form.doc
From: Gabrielle Ryan [mailto:Gabrielle.Ryan@acu.edu.au]
Sent: Wednesday, November 23, 2011 11:30 AM
To: Geraldine Haughton; Justin Kemp; Elizabeth Aumand; Bianca Share
Subject: Extension approved

Dear Justin Guy,

V2009 91
The metabolic syndrome in young women

Thank you for returning the Ethics Progress Report for your project V2009 91 The metabolic syndrome in young women

The Deputy Chair of the Human Research Ethics Committee has approved your request to extend the period of data collection. The new expiry date for data collection is the 30/04/2012

We wish you well in this ongoing project.

Kind regards,
Gabrielle Ryan

Ethics Officer | Research Services
Office of the Deputy Vice Chancellor (Research)
Australian Catholic University
Locked Bag 4115, Fitzroy, VIC, 3065
T: 03 9953 3150 F: 03 9953 3315

THIS IS AN AUTOMATICALLY GENERATED RESEARCHMASTER EMAIL
Appendix 3: ANZ Clinical Trials Registration

![ANZCTR Logo]

**Trial from ANZCTR**

<table>
<thead>
<tr>
<th>Trial ID</th>
<th>ACTRN12612001017819</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Status</td>
<td>Registered</td>
</tr>
<tr>
<td>Date Submitted</td>
<td>18/09/2012</td>
</tr>
<tr>
<td>Date Registered</td>
<td>20/09/2012 Retrospectively registered</td>
</tr>
</tbody>
</table>

**Page 1**

| Public title | The Young Women's Heart Health Study: the effects of a lifestyle intervention on cardiovascular disease risk factors in overweight women aged 18-30 years |
| Study title in 'Participant- Intervention- Comparator- Outcome (PICO)' format | The effects of a randomised control trial 12-week multidisciplinary lifestyle intervention on cardiovascular disease risk factors in young Caucasian women aged 18-30 years with abdominal obesity |
| UTRI         | U1111+1134-7515 |

**Page 2**

<table>
<thead>
<tr>
<th>Health condition(s) or problem(s) studied:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overweight/obesity</td>
</tr>
<tr>
<td>Cardiovascular disease risk factors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition category</th>
<th>Condition code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>Other cardiovascular diseases</td>
</tr>
<tr>
<td>Diet and nutrition</td>
<td>Obesity</td>
</tr>
</tbody>
</table>
Appendix 4: Information letter to participants and informed consent - Cross-sectional Studies

INFORMATION LETTER TO PARTICIPANTS

TITLE: The metabolic syndrome in young women
SUPERVISOR: Dr Justin Kemp
CO-SUPERVISORS: Professor Geraldine Naughton; Professor Philippe Obert
STUDENT RESEARCHER: Miss Blanca Louise Share
PROGRAM IN WHICH ENROLLED: PhD

Dear Participant,

You are invited to participate in a research study investigating early risk factors for the metabolic syndrome in young women aged 18 to 30 years. The metabolic syndrome is characterised by a combination of conditions that increase one's risk of developing cardiovascular disease and type 2 diabetes. Limited data exist in the understanding of early risk factors for the metabolic syndrome in young women. Therefore, your involvement will provide us with important data currently not available for this age group.

Data collection will include completion of the following:

1. Cardiovascular Risk Assessment Form
2. The Young Women’s Heart Health Study Survey
3. Three-day Activity and Food Record
4. Basic body measurements of height, body mass and girth measurements. All measurements will be performed by a female researcher in a private room.
5. Measurement of blood pressure.
6. Supplying a 15 ml intravenous blood sample for established health markers of blood glucose, triglycerides, total cholesterol, HDL-cholesterol concentrations, insulin, and inflammatory markers. The sample will be collected by an individual trained in blood collection and sent to a pathology clinic for subsequent analysis. This will require abstaining from all food and beverage products, except water, for a minimum of 12 hours prior to arriving for testing (e.g. after an overnight sleep). Furthermore, you will be required to refrain from all alcoholic products and strenuous physical activity in the 24 hours prior to testing.
7. Obtaining cardiovascular information (heart structure and function) using non-invasive ultrasound techniques with simultaneous ECG trace.
8. Determination of vascular endothelial function – an early marker of cardiovascular disease – by non-invasive ultrasound techniques measuring arterial diameter and blood flow velocity at the brachial artery. The assessment of vascular endothelial function requires a pneumatic cuff to be placed around the forearm and inflated to 250 mmHg for 5 minutes whilst lying in a supine position, as well as the ingestion of 400 µg of nitroglycerin, a vasodilator substance.
9. A measure of cardiovascular endurance by performing a sub-maximal cycle ergometer stress test lasting up to 10 minutes.
10. A measure of upper and lower body strength via a five-repetition max resistance test.

Australian Catholic University Limited
ABN 45 092 192 660
Melbourne Campus (St. Patrick’s)
115 Victoria Parade Fitzroy VIC 3065
Telephone: 613 9953 3000
Facsimile: 613 9953 3005
www.acu.edu.au
The data collection will be divided into three sessions. Each session will take approximately two hours to complete. Each data collecting session will be conducted in the School of Exercise Science at Australian Catholic University, St. Patrick’s Campus, Melbourne.

Overall, this project is expected to contribute to the advancement of young women’s health. It is hoped that the findings of this study will be published in peer-reviewed journals and presented at conferences in an effort to advance the knowledge of the metabolic syndrome in young women. All personal data collected will be kept confidential and only be known to the researcher. All data will be analysed collectively, thus individual data are not reported. Any published data will be anonymous and cannot in any way be associated with you. You are also offered the opportunity to obtain any information regarding any aspect of the research project.

Be advised that as a participant you are free to refuse consent altogether without having to justify that decision, and if you wish to, can withdraw consent and discontinue participation in the study at any time without giving a reason. Should you have any questions regarding this project, please contact the supervisors and/or student researcher:

**Dr Justin Kompp**  
Phone: (03) 9953 3031  
(Supervisor)

**Prof. Geraldine Naughton**  
Phone: (03) 9953 3034  
(Co-supervisor)

**Miss Bianca Share**  
Phone: (03) 9953 3225  
(Student Researcher)

Address:
School of Exercise Science  
Australian Catholic University  
Locked Bag 4115  
Fitzroy VIC 3065

Furthermore, you are warmly encouraged to apply for feedback regarding the results of the study by contacting the aforementioned supervisors and/or student researcher.

Please be advised that this study has been presented and approved by the University Human Research Ethics Committee at Australian Catholic University. In the event that you have a query or complaint about the way you have been treated during this study, you may write care of the Office of Research at the following address:

**Chair, HREC**  
**C/- Research Services**  
**Australian Catholic University**  
**Melbourne Campus**  
**Locked Bag 4115**  
**FITZROY VIC 3065**  
Tel: 03 9953 3155  
Fax: 03 9953 3315

Any complaint or concern will be treated in confidence and fully investigated. The participant will be informed of the outcome.

Upon agreement to participate in this study please sign both copies of the Consent Form, retain one copy for your records and return the other copy to the Supervisor, Co-supervisor or Student Researcher.
INFORMED CONSENT FORM
(Researcher Copy)

TITLE OF PROJECT: The metabolic syndrome in young women
SUPERVISOR: Dr Justin Kemp
CO-SUPERVISORS: Professor Geraldine Naughton; Professor Philippe Obert
STUDENT RESEARCHER: Miss Bianca Louise Share

I …………………………………………………….(the participant) have read and understood the information provided in the Information Letter to Participants. Any questions I have asked have been answered to my satisfaction. I agree to participate in this activity, realising that I can withdraw at any time. I agree that research data collected for the study may be published or may be provided to other researchers in a form that does not identify me in any way. I agree to participate in the following testing procedures

1. Completing the Cardiovascular Risk Assessment Form
2. Completing the Young Women’s Heart Health Study Survey
3. Completing an Activity and Food Record
4. Abstaining from all food and beverage products (except water) for 12 hours prior to arriving for testing
5. Refraining from consumption of alcohol and strenuous physical activity in the 24 hours prior to testing
6. Provide measures of height, body mass and girth measurements
7. Measurement of blood pressure
8. Supplying a 15 ml intravenous blood samples for subsequent analysis of fasting plasma glucose, lipid-profilig, insulin and inflammatory markers
9. Echocardiography for analysis of cardiac structure and function (with ECG tracing)
10. Ultrasound measurements at the carotid artery for the calculation of intima-media thickness
11. Vascular endothelial function (requiring occlusion and nitroglycerin ingestion) for flow-mediated dilatation.
12. A measure of cardiovascular endurance by performing a sub-maximal cycle ergometer test
13. A measure of upper and lower body strength via a five-repetition maximal resistance test

Name of Participant: ……………………………………… Phone: ……………………………
(block letters) Date: ………………………………………

Signature: ………………………………………………… Date: ………………………………………

Supervisor: Dr Justin Kemp

Signature: ………………………………………………… Date: ………………………………………
Co-Supervisor: Professor Geraldine Naughton

Signature: ………………………………………………… Date: ………………………………………
Student Researcher: Miss Bianca Share

Signature: ………………………………………………… Date: ………………………………………
INFORMED CONSENT FORM
(Participant Copy)

TITLE OF PROJECT: The metabolic syndrome in young women

SUPERVISOR: Dr Justin Kemp

CO-SUPERVISORS: Professor Geraldine Naughton; Professor Philippe Obert

STUDENT RESEARCHER: Miss Bianca Louise Share

I ………………………………………(the participant) have read and understood the information provided in the Information Letter to Participants. Any questions I have asked have been answered to my satisfaction. I agree to participate in this activity, realising that I can withdraw at any time. I agree that research data collected for the study may be published or may be provided to other researchers in a form that does not identify me in any way. I agree to participate in the following testing procedures:

1. Completing the Cardiovascular Risk Assessment Form
2. Completing the Young Women’s Heart Health Study Survey
3. Completing an Activity and Food Record
4. Abstaining from all food and beverage products (except water) for 12 hours prior to arriving for testing
5. Refraining from consumption of alcohol and strenuous physical activity in the 24 hours prior to testing
6. Provide measures of height, body mass and girth measurements
7. Measurement of blood pressure
8. Supplying a 15 ml intravenous blood samples for subsequent analysis of fasting plasma glucose, lipid profiling, insulin and inflammatory markers
9. Echocardiography for analysis of cardiac structure and function (with ECG tracing)
10. Ultrasound measurements at the carotid artery for the calculation of intima-media thickness
11. Vascular endothelial function (requiring occlusion and nitroglycerin ingestion) for measures of flow-mediated dilatation.
12. A measure of cardiovascular endurance by performing a sub-maximal cycle ergometer test
13. A measure of upper and lower body strength via a five-repetition maximal resistance test

Name of Participant:……………………………………. Phone: ……………………………
Signature: ……………………………………… (block letters) Date: ………………………………

Supervisor: Dr Justin Kemp
Signature: ……………………………………… Date: ………………………………

Co-Supervisor: Professor Geraldine Naughton
Signature: ……………………………………… Date: ………………………………

Student Researcher: Miss Bianca Share
Signature: ……………………………………… Date: ………………………………
Appendix 5: Information letter to participants and informed consent – Intervention Study

INFORMATION LETTER TO PARTICIPANTS

TITLE: The effects of a lifestyle intervention on the metabolic syndrome in young women

SUPERVISOR: Dr Justin Kemp

CO-SUPERVISOR: Professor Geraldine Naughton

STUDENT RESEARCHER: Miss Bianca Louise Share

PROGRAM IN WHICH ENROLLED: PhD

Dear Participant,

You are invited to participate in a study to determine the effects of a lifestyle intervention program on the progression of the metabolic syndrome in young women aged 18 to 30 years. The metabolic syndrome is characterized by a combination of conditions that increase one’s risk of developing cardiovascular disease and type 2 diabetes. Several studies have investigated the effects of exercise on underlying risk factors leading to the development of the metabolic syndrome in older populations. However, limited data exist in the understanding of early risk factors for the metabolic syndrome in young women. Therefore, through implementation of a lifestyle intervention program of physical activity, nutrition education, and behavioural counselling, we aim to assess the influence of this program on risk factors of the metabolic syndrome and other cardiovascular and blood measures of health.

Your participation in this study will include involvement in a lifestyle intervention program, where you will engage in regular physical activity (lasting up to 60 minutes) three days per week for twelve weeks, supervised by the researchers. One exercise session may be performed unsupervised at home. You will be required to wear a heart rate monitor and a pedometer, and keep a training diary throughout the duration of the intervention. Additionally, you will engage in a weekly focus group session for health coaching about nutrition education and sustainable behavioural change, consulted by a dietitian and delivered by a qualified counsellor. Following the completion of the lifestyle intervention program, you will be asked to return for a final assessment.

If you agree to participate in this study, you will be randomly assigned to either an experimental or control group. The experimental group will begin the lifestyle intervention program immediately while the control group will maintain their normal routine for 3 months, then have the opportunity to complete the lifestyle intervention program following this time period.

Throughout the study, you will be asked to attend three data collecting sessions, each separated by 12 weeks. Prior to starting the study, you will be asked to gain medical clearance from your general practitioner and complete a cardiovascular risk assessment form. On your first visit only (prior to engaging in the exercise intervention), you will be asked to complete the following documents:
1. Young Women’s Heart Health Study Survey
2. Activity and Food Record
Each of the three sessions will also involve the following testing procedures and take approximately two hours to complete:

1. Basic body measurements of height, body mass and girth measurements. All measurements will be performed by a female researcher in a private room.


3. Measurement of the established health markers of blood glucose, triglycerides, total cholesterol and HDL-cholesterol concentrations, obtained by the standard aseptic finger prick technique. This will require abstaining from all food and beverage products, except water, for a minimum of 12 hours prior to arriving for testing (e.g. after an overnight sleep).

4. Supplying a 10 ml intravenous blood sample for assessment of other cardiovascular health markers. The sample will be collected by an individual trained in blood collection and sent to a pathology clinic for subsequent analysis. This will require you to abstain from all food and beverage products, except water, for 12 hours prior to arriving for testing, and to refrain from consuming alcohol and exercising strenuously in the 24 hours prior to testing.

5. Supplying a 15 ml urine sample. You will be provided with a urine sample container and asked to supply a sample from the first void (urination) of the morning on the day of testing. You will be required to bring the urine sample with you to the testing session.

6. Obtaining cardiovascular information (e.g., heart structure and function; blood vessel wall thickness; blood vessel diameter; ECG) using non-invasive ultrasound techniques.

7. Determination of vascular endothelial function — an early marker of cardiovascular disease — by non-invasive ultrasound techniques measuring arterial diameter and blood flow velocity at the brachial artery. The assessment of vascular endothelial function requires a pneumatic cuff to be placed around the forearm and inflated to 250 mmHg for 4.5 minutes whilst lying in a supine position, as well as the ingestion of 400 μg of nitroglycerin, a vasodilator substance.

8. A measure of cardiovascular endurance by performing a sub-maximal cycle stress test lasting up to 10 minutes.

9. A measure of upper and lower body strength via a five-repetition max resistance test.

10. Complete five psychological inventories about personal beliefs and attitudes towards exercise.

All data collecting sessions will be conducted in the School of Exercise Science at Australian Catholic University, St. Patrick’s Campus, Melbourne. You will be advised of your results following each testing session. The two supervised training sessions per week (for the 12-week exercise programme) will take place at a local park and/or gym. At the conclusion of the lifestyle intervention and all testing session, you will be rewarded with a token of appreciation for your time and commitment to the study.

The potential benefits of this research to you and to society in general include: (1) assisting young women at risk of the metabolic syndrome to engage in appropriate physical activity and provide sustainable educational advice about dietary and behavioural changes; and (2) further establish the benefits of a lifestyle intervention in the management and prevention of the metabolic syndrome and related chronic diseases. Overall, this project is expected to contribute to the advancement of young women’s health. It is hoped that the findings of this study will be published in peer-reviewed journals and presented at conferences in an effort to advance the knowledge of the metabolic syndrome in young women.

All personal data collected will be kept confidential and only be known to the researcher. All data will be analysed collectively, thus individual data are not reported. Any published data will be anonymous and cannot in any way be associated with you. You are also offered the opportunity to obtain any information regarding any aspect of the research project.
Be advised that as a participant you are free to refuse consent altogether without having to justify that decision, and if you wish to, can withdraw consent and discontinue participation in the study at any time without giving a reason.

Should you have any questions regarding this project, please contact the supervisors and/or student researcher:

**Prof. Geraldine Naughton**  
Phone: (03) 9953 3034

**Miss Bianca Share**  
Phone: (03) 9953 3031  
(Student Researcher)

**Dr Justin Kemp**  
Phone: (03) 9953 3225

Address:  
School of Exercise Science  
Australian Catholic University  
Locked Bag 4115  
Fitzroy VIC 3065

Furthermore, you are warmly encouraged to apply for feedback regarding the results of the study by contacting the aforementioned supervisors and/or student researcher.

Please be advised that this study has been presented and approved by the University Human Research Ethics Committee at Australian Catholic University (ACU National). In the event that you have a query or complaint about the way you have been treated during this study, you may write care of the Office of Research at the following address:

*Chair, HREC*  
*C/- Research Services*  
*Australian Catholic University*  
*Melbourne Campus*  
*Locked Bag 4115*  
*FITZROY VIC 3065*  
*Tel: 03 9953 3158*  
*Fax: 03 9953 3315*

Any complaint or concern will be treated in confidence and fully investigated. The participant will be informed of the outcome.

Upon agreement to participate in this study please sign both copies of the Consent Form, retain one copy for your records and return the other copy to the Supervisor, Co-supervisor or Student Researcher. Furthermore, please make an appointment to see your local GP and have him/her complete the Cardiovascular Risk Assessment Form during your consultation.

Yours sincerely,

**Dr Justin Kemp**  
**Prof. Geraldine Naughton**  
**Miss Bianca Share**  
**SUPERVISOR**  
**CO-SUPERVISOR**  
**STUDENT RESEARCHER**
INFORMED CONSENT FORM
(Participant Copy)

TITLE OF PROJECT: The effects of a lifestyle intervention on the metabolic syndrome in young women

SUPERVISOR: Dr Justin Kemp

CO-SUPERVISOR: Professor Geraldine Naughton

STUDENT RESEARCHER: Miss Bianca Louise Share

I ................................................ (the participant) have read and understood the information provided in the Information Letter to Participants. Any questions I have asked have been answered to my satisfaction. I agree to participate in this activity, realising that I can withdraw at any time. I agree that research data collected for the study may be published or may be provided to other researchers in a form that does not identify me in any way. I agree to participate in the following testing procedures, which will last up to 2 hours in duration per session, on three separate occasions (over a six-month period):

1. Completing the Cardiovascular Risk Assessment Form (with my local GP)
2. Completing the Young Women’s Heart Health Study Survey, and Activity and Food Record
3. Complete five psychological inventories about my personal beliefs and attitudes towards exercise
4. Abstaining from all food and beverage products (except water) for 12 hours prior to arriving for testing
5. Refraining from consumption of alcohol and strenuous physical activity in the 24 hours prior to testing
6. Provide measures of height, body mass and girth measurements
7. Measurement of blood pressure
8. Supplying blood samples (from a finger-prick) for analysis of fasting plasma glucose and lipid-profiling
9. Supplying 10 ml intravenous blood samples for subsequent assessment of cardiovascular risk factors
10. Supplying a 15 ml urine sample from the first urination of the morning
11. Echocardiogram images of the heart for analysis of cardiac structure and function (with ECG tracing)
12. Ultrasound measurements at the carotid artery for the calculation of intima-media thickness
13. Vascular endothelial function (requiring 4.5 min occlusion & nitroglycerin ingestion) for FMD measures
14. A measure of cardiovascular endurance by performing a sub-maximal cycle test
15. A measure of upper and lower body strength via a five-repetition maximal resistance test
16. Aerobic exercise and resistance training program (3 days per week for 12 weeks)
17. Wearing a heart rate monitor and a pedometer, and keeping a training diary
18. Participate in focus group sessions for educational coaching about nutrition and behavioural change

Name of Participant: .......................................................... Phone: ..........................................................
Signature: .................................................................................. Date: .....................................................

Supervisor: Dr Justin Kemp
Signature: .................................................................................. Date: .....................................................

Co-Supervisor: Professor Geraldine Naughton
Signature: .................................................................................. Date: .....................................................

Student Researcher: Miss Bianca Louise Share
Signature: .................................................................................. Date: .....................................................
INFORMED CONSENT FORM

(Teacher Copy)

TITLE OF PROJECT: The effects of a lifestyle intervention on the metabolic syndrome in young women

SUPERVISOR: Dr Justin Kemp

CO-SUPERVISOR: Professor Geraldine Naughton

STUDENT RESEARCHER: Miss Bianca Louise Share

I ...........................................................................................................(the participant) have read and understood the information provided in the Information Letter to Participants. Any questions I have asked have been answered to my satisfaction. I agree to participate in this activity, realising that I can withdraw at any time. I agree that research data collected for the study may be published or may be provided to other researchers in a form that does not identify me in any way. I agree to participate in the following testing procedures, which will last up to 2 hours in duration per session, on three separate occasions (over a six-month period):

1. Completing the Cardiovascular Risk Assessment Form (with local GP)
2. Completing the Young Women's Heart Health Study Survey, and Activity and Food Record
3. Complete five psychological inventories about my personal beliefs and attitudes towards exercise
4. Abstaining from all food and beverage products (except water) for 12 hours prior to arriving for testing
5. Refraining from consumption of alcohol and strenuous physical activity in the 24 hours prior to testing
6. Provide measures of height, body mass and girth measurements
7. Measurement of blood pressure
8. Supply blood samples (from a finger-prick) for analysis of fasting plasma glucose and lipid-profiling
10. Supply a 15 ml urine sample from the first urination of the morning
11. Echocardiogram images of the heart for analysis of cardiac structure and function (with ECG tracing)
12. Ultrasound measurements at the carotid artery for the calculation of intima-media thickness
13. Vascular endothelial function (requiring 4.5 min occlusion & nitroglycerin ingestion) for FMD measures
14. A measure of cardiovascular endurance by performing a sub-maximal cycle test
15. A measure of upper and lower body strength via a five-repetition max resistance test
16. Aerobic exercise and resistance training program (3 days per week for 12 weeks)
17. Wearing a heart rate monitor and a pedometer, and Keeping a training diary
18. Participate in focus group sessions for educational coaching about nutrition and behavioural change

Name of Participant: .............................................................. Phone: ........................................

Signature: ............................................................................ Date: ........................................

Supervisor: Dr Justin Kemp

Signature: ............................................................................ Date: ........................................

Co-Supervisor: Professor Geraldine Naughton

Signature: ............................................................................ Date: ........................................

Student Researcher: Miss Bianca Louise Share

Signature: ............................................................................ Date: ........................................
Cardiovascular Risk Assessment Form

Name: ........................................ Date of Birth: .........................

Person to contact in case of emergency
Name: ........................................ Relationship: .........................

Address: ..................................................................................

Telephone: .................. (W)  ............(H)  ...................(M)

Medical History
In the past have you ever had, or currently have... (Tick no or yes):

No  Yes
Stroke  ⬜  ☑
Myocardial Infarction  ☑  ⬜
Heart Murmur  ☑  ⬜
Heart Arrhythmia  ☑  ⬜
Congenital Heart Disease  ☑  ⬜
Disease of the Arteries  ☑  ⬜
Asthma  ☑  ⬜
Other Respiratory Disease  ☑  ⬜
Insulin Dependent Diabetes  ☑  ⬜
Gestational Diabetes  ☑  ⬜
Polygynous Ovarian Syndrome  ☑  ⬜
Thyroid abnormalities  ☑  ⬜
Liver or Kidney Disease  ☑  ⬜
IVF treatment  ☑  ⬜

Are you pregnant or breastfeeding?  ☑  ⬜

Other Illness (Give Details):
..................................................................................

List any prescribed medications being taken:
..................................................................................

Symptoms during or after exercise:
As a result of exercise, have you ever experienced any of the following:

No  Yes
Chest pain or discomfort  ☑  ⬜
Severe shortness of breath or problems with breathing  ☑  ⬜
Dizziness or nausea  ☑  ⬜
Pulitation in heart  ☑  ⬜
Pain in the legs during mild exertion  ☑  ⬜
Severe heat exhaustion  ☑  ⬜

Cardiovascular Risk Factors:
Do you have...... No  Yes  Don’t Know
High blood pressure  ☑  ⬜  ☑
High blood cholesterol/triglycerides  ☑  ⬜  ☑
Diabetes  ☑  ⬜  ☑
Regular Alcohol Consumption  ☑  ⬜  Yes, Days......
Smoking Habit  ☑  ⬜  Number/Day.....

Family Medical History:
Have members of your immediate family ever had any of the following conditions.
(If you answer “Yes” or “Don’t Know”, write beside this which member of the family
has been affected):

No  Yes  Don’t Know  Family Member  Age  Still Alive?
Stroke  ☑  ⬜  ☑  ☑  ☑
Myocardial Infarction  ☑  ⬜  ☑  ☑  ☑
Angina Pectoris  ☑  ⬜  ☑  ☑  ☑
High Blood Pressure  ☑  ⬜  ☑  ☑  ☑
Diabetes  ☑  ⬜  ☑  ☑  ☑
High blood cholesterol  ☑  ⬜  ☑  ☑  ☑

Is there anything not mentioned that you believe the research staff should be aware
of? If yes, please explain:  ..................................................................
Appendix 7: Poster

Young Women’s Heart Health Study

‘Exercise training for health improvements in young women aged 18 to 30 years’

- Did you know that moderate exercise training can improve heart health by lowering the chances of developing cardiovascular disease and type 2 diabetes?
- The aim of the Young Women’s Heart Health Study is to test the influence and sustainability of a 12-week lifestyle intervention on risk factors for heart health.

The lifestyle intervention will include the following:
- Exercise training 2-3 days per week of a circuit program with gentle strength training and aerobic activities
- Nutrition advice from a qualified dietician
- Group counselling sessions aimed at helping change and social support

Are You?
- Female
- 18 to 30 years old
- Healthy
- Have a waist circumference above 80 cm
- Not doing regular physical activity or sport - but willing to try some changes

If you would like to volunteer for this study or require further details please contact Bianca Share
Ph: 9953 3225 or email: bianca.share@acu.edu.au
Appendix 8: Face Validation Questions

I am undertaking the process of validating the Young Women’s Heart Health Study (YWHHS) Survey, which is an important document for my PhD research project. Your contribution is greatly appreciated.

Instructions: Please take your time to complete the YWHHS Survey and answer the questions below as honestly as possible.

1. Please record the time taken to complete the survey: ...................................... mins

2. Is the language clear/ easy to understand? YES □ NO □
   If no, please state where the problem occurs in the survey ..............................

3. Please identify any ambiguities and/or difficult questions:
   ........................................................................................................
   ........................................................................................................
   ........................................................................................................

4. Did you answer all questions? If not, please record those you skipped and briefly explain why:
   ........................................................................................................
   ........................................................................................................
   ........................................................................................................

5. Please provide any comments which you feel may improve this survey (i.e. suitability to the population group; ease of use etc.):
   ........................................................................................................
   ........................................................................................................
   ........................................................................................................

Thank you for taking the time to complete my survey.

Bianca Share
Appendix 9: Custom Survey

Young Women's Heart Health Study Survey
Health & Lifestyle

BACKGROUND INFORMATION

Date of Birth: ............................................. Age: ............................................. Years

Height: ............................................. cm Weight: ............................................. kg

How long have you lived in your local area? ............................................. Years

Highest level of education completed? (Tick one box)

☐ Year 10 or below
☐ Year 11 or 12
☐ Tertiary degree
☐ Other .............................................

Country of your birth?

☐ Australia
☐ Other country (please name) .............................................

What is the ancestry of your parents?

Mother: .............................................
Father: .............................................

PLEASE NOTE: This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University.

No individuals will be identified.
PERSONAL INFORMATION

Whom are you currently living with?
☐ Alone
☐ My parents
☐ My parents and sibling/s
☐ My partner
☐ My partner and child or children
☐ My child or children only
☐ Relatives
☐ House mate/s

Do you have a child or children?
YES ☐ NO ☐
If yes, how many: .................................................................

What is your employment status? (tick all that apply)
☐ Unemployed
☐ Part-time employment
☐ Full-time employment
☐ Casual employment
☐ Full-time student
☐ Part-time student
☐ House duties

List your occupation:
............................................................................................................

FAMILY HISTORY

Has any of your close relative (parents, grandparents, aunt / uncles, siblings) suffered from the following? (If yes, state their relationship to you):

<table>
<thead>
<tr>
<th>RELATIONSHIPS</th>
<th>YES ☐</th>
<th>NO ☐</th>
<th>Don’t Know ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Obesity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. High blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. High cholesterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Heart disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Stroke</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Mental disorder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Any other known hereditary diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Specify: ..................................)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DIETARY INFORMATION

Do you think you have a weight problem?
YES ☐ NO ☐ UNSURE ☐

Do you have difficulty in controlling your food intake?
YES ☐ NO ☐ SOMETIMES ☐

How many times a week do you eat out or have take away for dinner? ..................................

Do you eat between meals? (i.e. between breakfast, lunch and dinner)?
YES ☐ NO ☐ SOMETIMES ☐

Do you take care with your fatty food intake?
YES ☐ NO ☐ SOMETIMES ☐
HEALTH STATUS

In general, would you say your health is: (tick one only)
- Excellent
- Very good
- Good
- Fair
- Poor

In regards to your current weight, how much would you like to weigh now? (circle one only)
- 5 kg more
- 1-5 kg more
- Happy as I am
- 1-5 kg less
- 5 kg less

How often have you gone on a diet in order to lose weight during the last year?
- Never
- 1 to 4 times
- 5 to 10 times
- More than 10 times
- I am always on a diet to lose weight

Have you had an illness in the last 12 months that has affected your health, and in particular, your weight?
- YES ☐
- NO ☐
If yes, provide details:

Have you had any significant accidents in the last 12 months that has affected your health, and in particular you weight?
- YES ☐
- NO ☐
If yes, provide details:

MENSTRUAL STATUS

At what age did you first start menstruating? (nearest half year e.g. 12.5 yrs) ....................

How regularly are you currently menstruating? (tick one)
- Every two weeks
- Every 4 weeks
- Every 4-6 weeks
- Every 6-8 weeks
- > 8 weeks

Is the time between your cycles predictable? (i.e. is the time between your periods the same)
- YES ☐
- NO ☐
- SOMETIMES ☐

If you menstruate regularly, how many days between the end of your period and the start of the next period?

On average, how heavy is the flow of your period? (tick one)
- Very light
- Light
- Moderate
- Heavy
- Very heavy

On average, how long is the flow of your period? (tick one)
- 1-2 days
- 2-3 days
- 3-5 days
- 5-7 days
- > 7 days

Do you experience any pain or discomfort during your period?
- YES ☐
- NO ☐
- SOMETIMES ☐

If yes, what do you do for the pain or discomfort.
## MEDICAL HISTORY

Do you have any medical history of the following conditions? (please tick if applicable)

**Breathing or respiratory conditions**
- □ Asthma
- □ Bronchitis
- □ Other (please specify)

**Blood disorders**
- □ High blood pressure (hypertension)
- □ High cholesterol
- □ Anemia

**Cardiovascular system**
- □ Heart disease or vascular conditions
- □ Stroke
- □ Chest pain
- □ Heart rhythm abnormalities
- □ Other (please specify)

**Reproductive system**
- □ Polycystic ovarian syndrome
- □ Other (please specify)

**Metabolic**
- □ Insulin Dependent Diabetes Mellitus/ Type 1 Diabetes
- □ Non Insulin Dependent Diabetes Mellitus/ Type 2 Diabetes
- □ Gestational diabetes (during pregnancy)
- □ Other (please specify)

**Psychological**
- □ Depression
- □ Anxiety disorder
- □ Insomnia
- □ Postnatal depression
- □ Other (please specify)

## MEDICATION USE

Do you take prescribed medication in the past 6 months?
- □ YES
- □ NO

If yes, provide details: .................................................................

Has your doctor ever prescribed you medication for your triglyceride levels?
- □ YES
- □ NO

If yes, are you taking it now? ...........................................................

Has your doctor ever prescribed you medication for your cholesterol levels?
- □ YES
- □ NO

If yes, are you taking it now? ...........................................................

Do you take vitamins, minerals or any other form of health preparations?
- □ YES
- □ NO
- □ SOMETIMES

If yes, provide details: .................................................................

Do you take an oral contraceptive pill, hormone implant or injection?
- □ YES
- □ NO

If yes, please specify the brand: ....................................................

Do you smoke cigarettes/cigars?
- □ YES
- □ NO
- □ PREVIOUSLY

If yes, how many per day: ............................................................

If you no longer smoke indicate when you stopped: ..........................
### SLEEP

On average, how many hours of sleep do you get per night on weekdays:

- [ ] < 4 hrs
- [ ] 4-6 hrs
- [ ] 6-8 hrs
- [ ] 8-10 hrs
- [ ] 10-12 hrs
- [ ] > 12 hrs

On average, how many hours of sleep do you get per night on weekends:

- [ ] < 4 hrs
- [ ] 4-6 hrs
- [ ] 6-8 hrs
- [ ] 8-10 hrs
- [ ] 10-12 hrs
- [ ] > 12 hrs

Do you snore during sleep?

- [ ] YES
- [ ] NO
- [ ] SOMETIMES
- [ ] NOT SURE

Do you stop breathing during sleep?

- [ ] YES
- [ ] NO
- [ ] SOMETIMES
- [ ] NOT SURE

Do you take sleeping pills?

- [ ] YES
- [ ] NO
- [ ] SOMETIMES

### SCREEN TIME

On average, how many hours of TV (including DVD) do you watch per day on weekdays:

- [ ] < 1 hr
- [ ] 1 hr
- [ ] 2 hrs
- [ ] 3 hrs
- [ ] 4 hrs
- [ ] 5 + hrs

On average, how many hours of TV (including DVD) do you watch per day on weekends:

- [ ] < 1 hr
- [ ] 1 hr
- [ ] 2 hrs
- [ ] 3 hrs
- [ ] 4 hrs
- [ ] 5 + hrs

On average, how often do you use a computer for work or study purposes per week?

- [ ] < 1 hr
- [ ] 1-3 hr
- [ ] 4-6 hrs
- [ ] 7-10 hrs
- [ ] 10-15 hrs
- [ ] 15 + hrs

On average, how often do you use a computer (including video games and play station) for recreational purposes or in your free time per week?

- [ ] < 1 hr
- [ ] 1-3 hr
- [ ] 4-6 hrs
- [ ] 7-10 hrs
- [ ] 10-15 hrs
- [ ] 15 + hrs

---

**PLEASE NOTE:** This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University. No individuals will be identified.
1. How many pieces of fresh fruit do you usually eat per day?

☐ I don't eat fruit
☐ Less than 1 piece of fruit per day
☐ 1 piece of fruit per day
☐ 2 pieces of fruit per day
☐ 3 pieces of fruit per day
☐ 4 or more pieces of fruit per day

2. How many different vegetables, including potatoes, do you usually eat per day?

☐ I don't eat vegetables
☐ Less than 1 vegetable per day
☐ 1 vegetable per day
☐ 2 vegetables per day
☐ 3 vegetables per day
☐ 4 vegetables per day
☐ 5 vegetables per day
☐ 6 or more vegetables per day

3. What type of milk do you usually use?

☐ None
☐ Full cream milk
☐ Reduced fat / skim milk
☐ No fat milk
☐ Lactose free milk
☐ Soya milk

4. What type of bread do you usually eat?

☐ I don't eat bread
☐ High fibre white bread
☐ White bread
☐ Wholemeal bread
☐ Rye bread
☐ Multi-grain bread

5. What type of spread or oil do you usually put on your bread?

☐ None
☐ Margarine
☐ Butter
☐ Nutella
☐ Olive oil
☐ Pro Activ
☐ Soy
☐ Sterol

6. On average, how many eggs do you usually eat per week?

☐ I don't eat eggs
☐ Less than 1 egg per week
☐ 1 to 2 eggs per week
☐ 3 to 5 eggs per week
☐ 6 or more eggs per week

7. What type of cheese do you usually eat?

☐ I don't eat cheese.
☐ Hard cheese e.g. parmesan, romano
☐ Firm cheese, e.g. cheddar, edam
☐ Soft cheese, e.g. camembert, brie
☐ Ricotta or cottage cheese
☐ Cream cheese
☐ Low fat cheese

8. On average, how many times per week do you eat breakfast?

☐ Never
☐ 1 to 2 days per week
☐ 3 to 4 days per week
☐ 5 to 6 days per week
☐ Everyday
9. On average, how many glasses of \textit{regular} carbonated soft drink do you drink per day? (Note: include Coca-Cola, Pepsi, Sofi, lemonade and flavoured mineral water, but not unflavoured mineral water or soda water)

\begin{itemize}
\item $375 \text{ ml can} = 2 \text{ glasses}$
\item $750 \text{ bottle} = 4 \text{ glasses}$
\item $1.25 \text{ litre bottle} = 7 \text{ glasses}$
\item $1.5 \text{ litre bottle} = 8 \text{ glasses}$
\item $2 \text{ litre bottle} = 11 \text{ glasses}$
\end{itemize}

\begin{itemize}
\item None
\item Less than 1 glass per day
\item 1 glass per day
\item 2 glasses (or 1 can) per day
\item 3 glasses per day
\item 4 glasses per day
\item 5 glasses per day
\item 6 glasses per day
\item 7 glasses per day
\item 8 glasses per day
\item 9 glasses per day
\item 10 or more glasses per day
\end{itemize}

10. On average, how many glasses of \textit{diet} carbonated soft drink do you drink per day?

\begin{itemize}
\item None
\item Less than 1 glass per day
\item 1 glass per day
\item 2 glasses (or 1 can) per day
\item 3 glasses per day
\item 4 glasses per day
\item 5 glasses per day
\item 6 glasses per day
\item 7 glasses per day
\item 8 glasses per day
\item 9 glasses per day
\item 10 or more glasses per day
\end{itemize}

11. On average, how many times per month, per fortnight, per week or per day do you drink the following beverages?

\begin{tabular}{|l|c|c|c|c|c|c|}
\hline
\textbf{ALCOHOLIC BEVERAGES} & \textbf{Never} & \textbf{1-2 times per month} & \textbf{1-2 times per fortnight} & \textbf{1-3 times per week} & \textbf{4-6 times per week} & \textbf{1 time per day} & \textbf{2-3 times per day} & \textbf{\geq 4 times per day} \\
\hline
Beer (low alcohol) & & & & & & & & \\
Beer (full strength) & & & & & & & & \\
Red wine & & & & & & & & \\
White wine (incl. sparkling wine) & & & & & & & & \\
Fortified wines, port, sherry etc. & & & & & & & & \\
Spirits, liqueurs & & & & & & & & \\
\hline
\textbf{HOT BEVERAGES} & \textbf{Never} & \textbf{1-2 times per month} & \textbf{1-2 times per fortnight} & \textbf{1-3 times per week} & \textbf{4-6 times per week} & \textbf{1 time per day} & \textbf{2-3 times per day} & \textbf{\geq 4 times per day} \\
\hline
Coffee & & & & & & & & \\
Decaffeinated coffee & & & & & & & & \\
Tea & & & & & & & & \\
Herbal tea & & & & & & & & \\
Chi latte & & & & & & & & \\
Hot chocolate & & & & & & & & \\
\hline
\end{tabular}
12. On average, how many times per month, per fortnight, per week or per day do you eat the following:

<table>
<thead>
<tr>
<th>CEREAL-BASED FOODS</th>
<th>Never</th>
<th>1-2 times per month</th>
<th>1-2 times per fortnight</th>
<th>1-3 times per week</th>
<th>1 time per day</th>
<th>2-3 times per day</th>
<th>4+ times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Porridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breakfast cereal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pasta or noodles (including lasagna)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crackers, crispbread, dry biscuits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sweet biscuits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cakes, tarts or sweet pastries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DAIRY FOODS and FATS</th>
<th>Never</th>
<th>1-2 times per month</th>
<th>1-2 times per fortnight</th>
<th>1-3 times per week</th>
<th>1 time per day</th>
<th>2-3 times per day</th>
<th>4+ times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margarine or butter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oil (for cooking)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salad dressing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mayonnaise</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ricotta or cottage cheese</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All other cheeses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cream or sour cream</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ice-cream</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoghurt</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Milkshake or thick-shake</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Custard</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

13. On average, how many times per month, per fortnight, per week or per day do you eat the following:

<table>
<thead>
<tr>
<th>MEATS and FISH</th>
<th>Never</th>
<th>1-2 times per month</th>
<th>1-2 times per fortnight</th>
<th>1-3 times per week</th>
<th>1 time per day</th>
<th>2-3 times per day</th>
<th>4+ times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beef or veal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chicken</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pork</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sausages or frankfurts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Processed meats (e.g. ham, salami)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fried fish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steamed, grilled or baked fish</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tinned fish (e.g. salmon, tuna)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MISCELLANEOUS FOODS</th>
<th>Never</th>
<th>1-2 times per month</th>
<th>1-2 times per fortnight</th>
<th>1-3 times per week</th>
<th>1 time per day</th>
<th>2-3 times per day</th>
<th>4+ times per day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pizza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pastries with cheese (e.g. quiche)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meat pies, pasties, sausage rolls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hamburgers with a bun</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chocolate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confectionary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peanuts or peanut butter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other nuts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corn chips or potato chips</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jam, marmalade, syrups or honey</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vegemite, Promite or Marmite</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tomato sauce or ketchup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Questions adapted and revised from:
The cancer Council Victoria Dietary Questionnaire for Epidemiological studies (Version 3.1)
14. How much do you agree or disagree with the following statements:

<table>
<thead>
<tr>
<th>Statement</th>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neutral</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>I don’t have time to prepare and eat healthy meals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>My lack of cooking skills limits what I can eat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sometimes I don’t have enough money to purchase food</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>My lifestyle habits mean I often skip meals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sometimes I just don’t feel like eating healthy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I get food cravings throughout the day</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sometimes I engage in comfort eating</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I only eat when I feel hungry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I always eat good nutritious meals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I don’t like fruit and vegetables</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy food isn’t always available where I work/study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Someone else cooks for me so I don’t have a choice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>My religion / culture has a strong effect on the way I eat</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


**Physical Activity**

**PLEASE NOTE:** This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University. No individuals will be identified.
1. Please complete the following table to help you understand the activity patterns that you have done during the past week:

<table>
<thead>
<tr>
<th>Day of the week</th>
<th>Type of activity (e.g. running, swimming, gardening)</th>
<th>Where the activity happened, and who you were with</th>
<th>How long the activity went for</th>
<th>Approximate intensity (e.g. very, moderate, hard)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saturday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunday</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


2. Please state how many times you did each type of activity and how much time you spent altogether doing each type of activity last week.

   If you did not do an activity, please write "0" in the boxes.

<table>
<thead>
<tr>
<th>Number of times</th>
<th>Time in minutes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walking briskly (e.g. recreational, exercise, travel)</td>
<td></td>
</tr>
<tr>
<td>Moderate leisure activity (e.g. social tennis, swimming, dancing)</td>
<td></td>
</tr>
<tr>
<td>Vigorous leisure activity (that which makes you breathe hard)</td>
<td></td>
</tr>
<tr>
<td>Vigorous household or gardening chores (that which makes you puff and pant)</td>
<td></td>
</tr>
</tbody>
</table>

3. The following items are about activities that you might do during a typical day. Does your health limit you in these activities? If so, how much?

<table>
<thead>
<tr>
<th>Yes, limited a lot</th>
<th>Yes, limited a little</th>
<th>Not limited at all</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vigorous activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate activities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lifting or carrying groceries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Climbing several flights of stairs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bending or kneeling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walking several blocks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bathing or dressing yourself</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
4. How often do you do each of the following? (mark one on each line)

<table>
<thead>
<tr>
<th>Activity</th>
<th>Never</th>
<th>Once per month</th>
<th>1-3 times per month</th>
<th>Once per week</th>
<th>More than once per week</th>
</tr>
</thead>
<tbody>
<tr>
<td>Take a dog for a walk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Walk, swim, cycle for exercise or fitness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Go to a gym, do aerobics or other classes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do yoga, Tai Chi or similar activities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Play competitive sport (e.g. netball, tennis)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5. How important is it for you to set time aside for regular physical activity? (tick one box please)

<table>
<thead>
<tr>
<th>Importance</th>
<th>Very important</th>
<th>Important</th>
<th>Neither important nor unimportant</th>
<th>Unimportant</th>
<th>Very unimportant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

6. What physical activities would you like to do regularly?

__________________________________________________________

__________________________________________________________

PLEASE NOTE: This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University. No individuals will be identified.
### STAGE OF CHANGE FOR EXERCISE

**Instructions:** Please read each of the following statements and indicate which best describes your current exercising habits.

**Note:** regular exercise = 3 or more times per week for 20 minutes or more each time

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>I currently do NOT exercise, and I do NOT intend to start exercising in the next 6 months</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>I currently do NOT exercise, but I am thinking about starting in the next 6 months</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>I currently exercise some, but not regularly</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>I currently exercise regularly, but I have only begun in the last 6 months</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>I currently exercise regularly, and I have done so for longer than 6 months</td>
<td>☐ ☐</td>
</tr>
<tr>
<td>I have exercised regularly in the past, but I am not doing so regularly</td>
<td>☐ ☐</td>
</tr>
</tbody>
</table>

---

### MOTIVES FOR PHYSICAL ACTIVITY - REVISED (MPAM-R)

**Instructions:** The following is a list of reasons why people engage in physical activities, sport and exercise. Please respond to each question on the basis of how true that response is for you.

<table>
<thead>
<tr>
<th>I engage in physical activity because….</th>
<th>Not at all true for me</th>
<th>Somewhat true</th>
<th>Moderately true</th>
<th>Mostly true</th>
<th>Very true for me</th>
</tr>
</thead>
<tbody>
<tr>
<td>I want to be physically fit</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>It’s fun</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like engaging in activities which physically challenge me</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to obtain new skills</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to lose or maintain weight so I look good</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to be with my friends</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like to do physical activity</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to improve existing skills</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like the challenge</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to define my muscles so I look better</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>It makes me happy</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to keep up my current skill levels</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to have more energy</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like activities which are physically challenging</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like to be with others who are interested in physical activity</td>
<td>☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

I engage in physical activity because... 

<table>
<thead>
<tr>
<th>Reason</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>I want to improve my cardiovascular fitness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to improve my appearance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I think it’s interesting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to maintain my physical strength to live a healthy life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to be attractive to others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to meet new people</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I enjoy this activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to maintain my physical health and well-being</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to improve my body shape</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I want to get better at my activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I find this activity stimulating</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I will feel physically unattractive if I don't</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>My friends want me to</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I like the excitement of participation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I enjoy spending time with others doing this activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


PERCEIVED BARRIERS TO ACTIVITY

Instructions: What prevents you from doing the physical activities that you would like to do? Please respond to each of the items below.

<table>
<thead>
<tr>
<th>Barriers to you being physically active</th>
<th>1: Never</th>
<th>2: Sometimes</th>
<th>3: Neutral</th>
<th>4: Often</th>
<th>5: Very often</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not having a safe place to exercise</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor weather</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No other people to be active with</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High cost of classes or venues</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of transport</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of time</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nowhere to be active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Having other people discourage you</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feeling self-conscious about looks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Being afraid of injury</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feeling too tired</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poor health in the past 4 months</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I find it hard to want to be active</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I find it difficult to be motivated for activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caring for children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Questions adapted and revised from: Booth et al., 1997; King et al., 2000.
Food Recall

TWO week days & ONE weekend day

INSTRUCTIONS

• This food recall is to be completed on two consecutive weekdays and one weekend day (either Saturday or Sunday)
• Please write down everything you eat and drink for the same three days that you keep your activity record
• This is not a test. There are no right or wrong answers. Please do not report the foods you think you should be eating

HOW TO FILL IN YOUR RECORD

• Fill in the date and day of the week at the top of the record sheet
• Use as many pages as you need for each day’s record (number each page)
• Start a new page for a new day

Column 1 – Time

• Every time you have something to eat or drink, write down the time you started
• Write down ‘am’ for morning and ‘pm’ for afternoon or evening

Column 2 – What you are measuring

Name and full description of all food and drink.
• Write down everything you eat and drink (This include snacks, water, vitamins and mineral supplements).
• For each food and drink use a new line
• Measure each food individually, for example, bread and margarine are each separate foods and are recorded on separate lines.
• Always record cooking methods such as boiling, frying, etc.
• Write down a cut of meat, that is lamb loin chop, chicken leg,ump steak etc.
• Write down if the fat on meat or skin on chicken was eaten or not eaten
• Give a detailed description of the food or drink and brand names, for example: Arnott’s Milk arrowroot Biscuit. Tip Top White Bread

PLEASE NOTE: This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University.
No individuals will be identified.
Column 3 – Amount eaten

- In order to get the best estimate of your nutrient intake we need an accurate estimate of quantities of food and drink consumed.
- Estimate everything as accurately as possible in either metric cups or spoonfuls eg teaspoons, tablespoons (level or rounded) such as for breakfast cereal, rice, vegetables or spaghetti, or use a metric measuring tape or ruler to give length and width such as for sausage rolls, bananas, etc.

RECIPEs

This includes mashed potato, mixed vegetables dishes, gravies and sauces.
- On a separate page record the individual ingredient with quantities. Report the total amount made and the amount of total recipe consumed. See example attached on blue paper.

EATING OUT

- Estimate food eaten as described above.
- Record the main ingredients in the food if recipe is unknown.
- Record where the food came from, such as McDonald's.
- Record weights on wrappers, drink cans and other food containers.

DRINKS

- Measure these in metric cups or in litre measurements.
- For cordial, measure the volume of cordial concentrate first then the volume of water added.
- If diluting fruit juice, measure fruit juice and water separately.
## Training Diary – during lifestyle intervention

### Instructions:
Please complete the table below to record your training days. Make a list of those activities you do each week, and write down how often you do them, the duration, and the intensity (e.g., gardening, hiking, walking the dog, bike ride, etc.).

<table>
<thead>
<tr>
<th>Date</th>
<th>Physical Activity</th>
<th>Duration (min)</th>
<th>Intensity (RPE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please note: This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University. No individuals will be identified.

---

299 | Page
**Non-Training Days**

*Instructions:* Please complete the table (below) on your non-training days. Make a list of those activities you undertook during these days (e.g. list your daily duties, work activities, incidental exercise etc.).

<table>
<thead>
<tr>
<th>Date</th>
<th>Physical Activity</th>
<th>Duration (mins)</th>
<th>Intensity (RPE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Use these RPE images as a guide for intensity (Robertson, 2004):
Appendix 12: Training Diary – during sustainability

Activity Record

Instructions: Please make a list of these activities (i.e. structured exercise and incidental activities) you undertook during the week.

<table>
<thead>
<tr>
<th>Day</th>
<th>Mon</th>
<th>Tues</th>
<th>Wed</th>
<th>Thurs</th>
<th>Fri</th>
<th>Sat</th>
<th>Sun</th>
<th>Intensity (RPE)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Use the Rating of Perceived Exertion (RPE) image on the previous page as a guide for intensity (Godin et al., 2004)

PLEASE NOTE: This information will be held in strict confidence and will only be seen by researchers based at the Australian Catholic University. No individuals will be identified.
Appendix 13: Report

Information to assist with the interpretation of your results

The following literature has been provided to assist you in the understanding of your results. Should you require further information regarding your current health status please contact your local GP or healthcare professional for additional information. Refer to the attached document for your individual data.

Introduction
The aim of the Young Women’s Heart Health Study was to assess the influence and sustainability of a 12-week lifestyle intervention on risk factors of cardiovascular disease (CVD) in young Caucasian women aged 18 to 30 years. To date, limited data exist in the understanding of early risk factors for CVD in young women. Therefore, your involvement as a participant will provide data which is not available for this age group. Furthermore, the outcomes of this work aim to advance the understanding of cardiovascular health in young women.

Participants
Healthy Caucasian women aged between 18 and 30 volunteered for this study. Exclusion criteria for the study included current smoking, pregnant or lactating, liver, kidney or respiratory disease, heart arrhythmia, insulin dependent diabetes mellitus, gestational diabetes, polycystic ovarian syndrome, thyroid abnormalities and medication treatment for lipid abnormalities.

The metabolic syndrome
The metabolic syndrome is characterised by a combination of risk factors (Table 1) that include elevated waist circumference (WC), raised serum triglyceride levels, reduced high-density lipoprotein (HDL) cholesterol, elevated fasting plasma glucose concentrations, and elevated blood pressure, which increase the chances of developing CVD (IDF, 2006).
Table 1. Components of the metabolic syndrome (IDF, 2006)

<table>
<thead>
<tr>
<th>Component</th>
<th>Threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal obesity</td>
<td>WC ≥ 80cm</td>
</tr>
<tr>
<td>Raised serum triglyceride levels</td>
<td>≥1.7 mmol-L⁻¹</td>
</tr>
<tr>
<td>Reduced HDL-cholesterol</td>
<td>&lt;1.29 mmol-L⁻¹</td>
</tr>
<tr>
<td>Raised blood pressure</td>
<td>Systolic ≥130 mmHg or diastolic ≥85 mmHg</td>
</tr>
<tr>
<td>Elevated plasma glucose concentrations</td>
<td>Fasting plasma glucose ≥5.6 mmol-L⁻¹</td>
</tr>
</tbody>
</table>

Lipid profile

High cholesterol is a key risk factor for coronary heart disease and stroke (AHA, 2010) (Table 2).

Table 2. Total cholesterol (NCEP, 2002).

<table>
<thead>
<tr>
<th>Level (mmol/L)</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 5.17</td>
<td>Desirable</td>
</tr>
<tr>
<td>5.18 – 6.18</td>
<td>Borderline High</td>
</tr>
<tr>
<td>≥ 6.20</td>
<td>High</td>
</tr>
</tbody>
</table>

hs-CRP: high sensitive C-reactive protein is an inflammatory biomarker that has proven to be a strong independent predictor of diabetes and CVD (Pearson, et al, 2003). According to the American Heart Association elevated levels of hs-CRP in the bloodstream (> 3.0 mg/L) is associated with an increased chance of CVD (Pearson, et al, 2003).

- < 1.0 mg/L      low risk
- 1.0-3.0 mg/L    Average risk
- > 3.0 mg/L      High risk

BMI: Body mass index is a simple index of weight-for-height that is commonly used to classify underweight, overweight and obesity in adults. BMI does not distinguish between weight associated with muscle and weight associated with fat (WHO, 2000). A BMI within the range of 18.5-24.9 kg/m² is classified as desired and healthy (refer to Table 3).

BMI is defined as: weight (kg) / height (m)² (WHO, 2000).
Table 3. Classification of adults according to BMI (WHO, 2000).

<table>
<thead>
<tr>
<th>BMI (kg/m²)</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 18.5</td>
<td>Underweight</td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>Normal range</td>
</tr>
<tr>
<td>≥ 25</td>
<td>Overweight</td>
</tr>
<tr>
<td>25–29.9</td>
<td>Pre-obese</td>
</tr>
<tr>
<td>30–34.9</td>
<td>Obese class I</td>
</tr>
<tr>
<td>35–39.9</td>
<td>Obese class II</td>
</tr>
<tr>
<td>≥ 40</td>
<td>Obese class III</td>
</tr>
</tbody>
</table>

WC: waist circumference is a simple measure used as an approximate index of central adiposity. An increased risk of metabolic complications is associated with a raised WC ≥ 80cm in women. Meanwhile, a WC ≥ 88cm represents substantially increased risk (IDF, 2006).

WHR: waist-to-hip ratio is a useful measure of overweight and obesity (WHO, 2000). WHR is obtained by dividing waist circumference - halfway between the lower border of the ribs, and the iliac crest - and hip circumference - the widest point over the buttock (Norton & Olds, 1996).

- WHR 0.80–0.84 Overweight
- WHR ≥ 0.85 Obese

WHRR: waist-to-height ratio can be used as a predictor of CVD and diabetes. WHRR is calculated by dividing WC by height. A ratio of 0.5 is indicative of increased risk (Browning, Heigh & Anhwell, 2010).

HOMA-IR: homeostasis model assessment of insulin resistance (HOMA-IR) is used as a relative index of insulin resistance. The model yields an estimate of insulin sensitivity and β-cell function from fasting plasma insulin and glucose concentrations (Matthews, et al, 1985). HOMA-IR is calculated from the following formula: fasting glucose (mM) x fasting insulin (μU/mL)/22.5

Insulin resistance can be measured using the euglycemic hyperinsulinemic clamp technique, which is regarded as the reference method for an accurate assessment of insulin sensitivity.
however the use of HOMA-IR (in which only a fasting blood sample is used) has shown to be a reliable technique (Bonora, et al. 2000). A HOMA-IR Score ≥2.0 is considered insulin resistance (Jensterl et al., 2008).

VO₂₅max: submaximal tests attempt to predict functional capacity from the heart rate response during a submaximal bout of exercise. Submaximal tests rely on the nearly linear relationship between oxygen consumption and heart rate. Functional capacity measured on the bicycle ergometer is typically 8-15% lower than on a treadmill. Factors that impact on heart rate (e.g. caffeine, medications, illness etc.) may also affect the result obtained (Brooks, Fahey, & Baldwin, 2005). See table 4 for fitness classifications.

Table 4. Cardiorespiratory fitness classifications of maximal oxygen consumption (ml kg⁻¹ min⁻¹) for women aged 39 years and under (Brooks, Fahey, & Baldwin, 2005).

<table>
<thead>
<tr>
<th>Category</th>
<th>VO₂ (ml kg⁻¹ min⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Low</td>
<td>&lt; 24</td>
</tr>
<tr>
<td>Low</td>
<td>24-30</td>
</tr>
<tr>
<td>Moderate</td>
<td>31-37</td>
</tr>
<tr>
<td>High</td>
<td>38-48</td>
</tr>
<tr>
<td>Very High</td>
<td>&gt; 48</td>
</tr>
</tbody>
</table>

e-IMT: carotid intima-media thickness has become a standard for assessing arteriosclerosis and is recommended by the American Heart Association for the non-invasive assessment of cardiovascular risk. A normal e-IMT range for the right common carotid artery for women < 30 years is: 0.39-0.43 mm (Chodakauskas, 2006).
Appendix 14: Graphs

Chapter 5.

Figure 1. Cross-sectional data of statistically significant cardiometabolic variables. *P≤0.05. Green, control (WC < 80 cm); pink, women with abdominal obesity (WC ≥ 80 cm) for A. body mass; B. waist circumference; C. physical activity; D. predicted VO₂max.

Figure 2. Cross-sectional data of WC (green) and BMI (orange) independent predictor of IR and physical inactivity in young women, with unadjusted odds ratios.

Figure 3. Cross-sectional data of dichotomization cut-off points for WC (pink) and BMI (green) in young women, from ROC curves.
Chapter 6.

Cross-sectional data of statistically significant cardiac variables: *P<0.05.
Green, control (WC < 80 cm); pink, women with abdominal obesity (WC ≥ 80 cm).
A. L.A diameter; B. Indicators of diastolic function; C. Myocardial deformation.
Chapter 7.

Figure 4. Between- and within-group differences for the control group (blue) at pre/post, and the intervention group (red) at pre/post/sustainability for physical activity. *P<0.05

Figure 5. Within-group changes for the intervention group, at pre/post/sustainability for blood pressure. *P<0.05

Figure 6. Within-group changes for the intervention group, at pre/post/sustainability for: A. waist circumference, B. Energy, C. Vo2max, D. physical activity. *P<0.05.
Figure 7. Within-group changes for the control group at pre/post for waist circumference and blood pressure. *P<0.05.

Chapter 8.

Figure 8. Within-group changes for the control (blue) and intervention (red) groups for LV mass indexed from pre to post intervention. *P<0.05.
Appendix 15: Published Manuscripts

Cardiometabolic and behavioural risk factors in young overweight women identified with simple anthropometric measures

Bianca L. Share a,b, Geraldine A. Naughton a, Philippe Obert a,b,c, Jennifer K. Peat b,c, Justin G. Kemp a

a School of Exercise Science, Australian Catholic University, Australia
b Faculty of Health Sciences, Australian Catholic University, Australia
c Laboratory of Cardiovascular Pharmacology, University of Arizona, France

Abstract

Objectives: This study aimed to (1) investigate cardiometabolic risk markers in young women (18–30 years) with overweight/obesity, and (2) establish whether the measures of waist circumference and body mass index possess similar associations of cardiometabolic risk.

Methods: Cardiometabolic risk factors including, anthropometric, metabolic syndrome markers, biochemical, and other health/fatness indicators were assessed in women when classified as overweight/obese by waist circumference [waist circumference >91.9 cm, age 25.3 ± 3.5 years, n = 38] versus control [n = 30, waist circumference 71.4 ± 3.5 cm, age 20.1 ± 0.9 years], and when classified by body mass index [BMI = 35, body mass index 32.2 ± 3.2 kg/m², age 22.5 ± 3.6 years] versus control [body mass index 21.7 ± 2.8 kg/m², age 20.1 ± 0.9 years, n = 35].

Results: Compared with controls, women with overweight/obesity (classified by waist circumference or body mass index) displayed elevated body mass, systolic blood pressure and homoeostasis model assessment of insulin resistance, and reduced estimated VO2max and weekly physical activity, with no differences in self-reported energy intake. The adjusted odds ratio of being classified with overweight/obesity and an elevated homoeostasis model assessment of insulin resistance and/or less than recommended physical activity ranged between 5.1 and 10.0. Receiver operator characteristic curves indicated waist circumference, body mass index and waist-to-height ratio cut-off points of ≥84.2 cm, ≥30.0 kg/m² and ≥0.5, respectively, for homoeostasis model assessment of insulin resistance, and ≥80.0 cm, ≥25.2 kg/m² and ≥0.46, respectively, for less than recommended physical activity.

Conclusions: Waist circumference and body mass index have similar associations with cardiometabolic risk, with greater homoeostasis model assessment of insulin resistance and lower physical activity, rather than differences in traditional metabolic syndrome markers, observed in young women with overweight/obesity.

© 2013 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.

1. Introduction

In Australia, the prevalence of overweight/obesity is 35% for women aged 18–24 years, and 42% for women aged 25–34 years.1 However, cardiometabolic risk data are more frequently described in adolescents2 and even more so in older people,3 with women in young adulthood under-represented. The gains in weight in young adult women are paralleled by substantial declines in physical activity,4 with the greatest declines occurring between 25 years and 34 years of age.5 When assessed against current National Physical Activity Guidelines,5 50% of Australian women aged 18–34 years failed to achieve recommended weekly amounts (210 min) of moderate exercise,6 while the Australian Longitudinal Study on Women’s Health found that 45% of overweight/obese women aged 18–23 years performed none or very low levels of daily physical activity.7 A better understanding of cardiometabolic risk factors in this age group is important for early detection of chronic disease risk, especially given the rise in overweight/obesity and low prevalence of physical activity of young women.

With overweight/obesity being a modifiable risk factor for cardiovascular disease (CVD), Type 2 diabetes mellitus, and the metabolic syndrome,2 simple anthropometric measures of body mass index (BMI) and waist circumference (WC) are in frequent clinical use. BMI is an estimate of total fat mass and has been used as a predictor of health risk.8 For adults, a BMI of 25.0–29.0 kg/m²...
is classified as overweight, and a BMI ≥ 30 kg/m² is classified as obese. Correspondingly, centrally distributed (abdominal) obesity using WC has gender and ethnic-specific criteria available. For Caucasian women, abdominal obesity is defined as a WC ≥ 80 cm. Given the differing criteria for BMI and WC in classifying overweight/obesity in young women, it is important to establish whether these anthropometric measures identify the presence and/or similar relative risk of other markers of cardiometabolic risk.

Therefore, the aims of this study were to: (1) investigate blood-borne and lifestyle markers of cardiometabolic risk in young women (18–30 years) with overweight/obesity classified by clinically useful methods, and (2) establish whether WC and BMI possess similar associations of cardiometabolic disease risk in these women. For comparative purposes, waist-to-height ratio (WHtR) was included in some statistical analyses.

2. Methods

Ninety-three university-enrolled participants responded to recruitment advertisements and emails. Of these, 11 did not meet the inclusion criteria (below) and a further 14 eligible participants did not complete through testing. Therefore, 68 Caucasian women aged 18–30 years completed all testing, between 2010 and 2012. Participants were divided into two groups: (1) an “elevated” waist circumference ≥ 80 cm (n = 38, abdominal obesity, mean ± standard deviation, WC 91.5 ± 10.1 cm, age 22.3 ± 3.5 years), or (2) a waist circumference < 80 cm control group (n = 30, WC 71.4 ± 3.5 cm, age 20.1 ± 0.9 years). There was no difference between groups in socio-economic status (χ² (4, n = 66) = 0.42, p = 0.932), with 51.4% of participants in the elevated WC group and 62.1% of participants in the control group living in metropolitan suburbs of the most advanced quintile of socio-economic status. Exclusion criteria included being pregnant or breastfeeding, liver or kidney disease, heart arrhythmia, insulin dependent diabetes melitius, gestational diabetes, polycystic ovary syndrome, thyroid abnormalities and a history of bariatric surgery or liposuction. All participants were non-smokers. For additional analysis, the same 68 participants were divided into two groups according to the classifications of BMI, resulting in participants being classified as either overweight/obesity [n = 35, defined as a BMI ≥ 25 kg/m², BMI 32.2 ± 5.2 kg/m², age 22.5 ± 3.6 years] or normal BMI [n = 33, BMI 18.5–24.9 kg/m², BMI 21.7 ± 1.9 kg/m², age 20.1 ± 0.9 years].

Following approval by the University Human Research Ethics Committee (V2009-91), written informed consent was obtained and all participants completed a Cardiometabolic Risk Assessment Form prior to testing. Participants arrived at the laboratory following a 12h fast. They were also requested to refrain from strenuous physical activity in the 24h prior to testing.

Waist circumference (WC) was measured to the nearest 0.1 cm using a non-elastic measuring tape, with the average of two measurements reported. The coefficient of variation for WC, assessed from duplicate measures, was 1.0%, with an intra-class correlation (ICC, 2, 1) of 0.986 and measurement error of 1.34%, which equates to an error range of ± 0.6 cm. Body mass was measured to the nearest 0.1 kg using digital scales (Tanita, Tokyo, Japan). Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer (Seca, Germany). Body mass index (BMI) [weight (kg)/height (m²)] was defined as overweight BMI 25.0–29.9 kg/m² and obese BMI ≥ 30.0 kg/m². Participants were dichotomised by waist-to-height ratio (WHtR) using WC divided by height. A ratio of 0.5 was defined as the boundary value. Metabolic syndrome was defined according to the most recent and unified criteria, where three of the following five are met: (1) waist circumference ≥ 80 cm, (2) raised serum triglycerides ≥ 1.7 mmol/l, (3) reduced HDL cholesterol < 1.30 mmol/l, (4) raised systolic blood pressure ≥ 130 mmHg or raised diastolic blood pressure ≥ 85 mmHg, and (5) elevated fasting plasma glucose ≥ 5.6 mmol/l or previously diagnosed type 2 diabetes. No participants in this study were taking medication to treat elevated triglycerides or reduced HDL-cholesterol, which is considered an alternative indicator of abnormal levels. Additional measurements of insulin resistance, including fasting insulin and HOMA-IR, and the pro-inflammatory marker high sensitivity C-reactive protein (hs-CRP) were also measured in participants.

Intravenous blood sampling provided blood lipid profiles: serum concentrations of triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol (Refletron Plus, Roche, Switzerland). A CV of 3.8% was found between Refletron automatic analyser measurements for total cholesterol and a standardised wet-chemistry method. Fasting plasma glucose, insulin and hs-CRP concentrations were analysed by a pathology unit at a leading hospital (reagents Beckman Coulter, assays on Olympus AU2700, Abbott Architect i1000, and Olympus AU640 analysers). Insulin resistance was estimated by the homeostasis model assessment (HOMA-IR); using the equation: HOMA-IR = fasting insulin concentration (µg/ml) × fasting glucose concentration (µg/ml)/22.5. HOMA-IR was used as a surrogate measure of whole body insulin sensitivity and β-cell functioning and has been shown to correlate well with estimates using the euglycemic clamp method (r = 0.88) (14, 15). A HOMA-IR value ≥ 2.0 was considered indicative of insulin resistance. For hs-CRP, a value of > 3.0 mg/l was deemed high risk. Blood pressure was obtained with an automated digital sphygmomanometer (Dinamap, GE technology, USA).

The YMCA submaximal cycle ergometer test (16) was used to estimate maximal oxygen uptake (predicted VO₂max). After completing a short submaximal warm-up, participants cycled (Monark, Ergomedic 818E, Sweden) at an intensity corresponding to 70% of maximum heart rate at a constant cadence of 50 rpm, and an initial power output of 25 W, resulting in a total test time of 9 min. Heart rate during the last 15s of stage one was used to determine subsequent work loads. At the completion of the test, heart rate was extrapolated against work rate (W) using regression analysis to estimate maximal aerobic capacity.

Within the acknowledged limitations of dietary recall, participants completed a three-day food diary of food and beverage intake on two weekdays and one weekend day. Macro and micro-nutrients, and average daily energy intake were estimated (FoodWorks 7 Professional) by a research dietician, blinded to grouping.

Participants completed a self-administered lifestyle survey addressing (i) health status and medical conditions, (ii) self-reported physical activity and exercise, (iii) nutrition habits, and (iv) perceived barriers to physical activity. Additionally, type, frequency and duration of typical leisure and/or sporting activities were confirmed during an interview with the researchers.

Data were analysed using IBM SPSS Statistics, Version 19 for Windows (SPSS Inc., Chicago, IL) and first tested for normal distribution using the Shapiro-Wilk statistic and skewness and kurtosis values. Log transformation was used when data were not normally distributed. All data are presented as mean ± standard deviation, with the exception of medians [interquartile range] for non-normally distributed data, reported prior to log transformed treatment. An alpha level of p < 0.05 was used to determine significance. Group comparisons were performed using independent t-tests. Due to uneven group size, Hedge’s g calculated effect size. An effect size of ≥ 0.2 was considered small, ≥ 0.5 was considered medium, and ≥ 0.8 was considered large. The mean difference between overweight/obesity and control participants for each cardiometabolic risk factor included 95% confidence intervals. Unadjusted odds ratios were used to estimate disease risk given exposure and describe the strength of association between

---

The above text is a natural representation of the document's content. It is important to note that the text is a transcription and may not capture the full context or layout of the original document. For a comprehensive understanding, including formatted tables, figures, and other visual elements, the original document should be consulted.
3. Results

Anthropometric and cardiometabolic data are shown in Tables 1 and 2. Compared with controls, women with abdomi-
nal obesity (WC ≥ 80 cm) had greater body mass, body mass index, waist circumference and waist-to-height ratio (p < 0.001). Similar differences were observed for BMI.

None of the women with overweight/obesity were diagnosed with the metabolic syndrome. Of the metabolic syndrome

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control WC&lt;80cm (n=30)</th>
<th>Abdominal obesity WC ≥ 80cm (n=35)</th>
<th>p value</th>
<th>Effect size</th>
<th>Hedge’s g</th>
<th>Mean difference</th>
<th>% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthropometric assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>60.34 ± 6.08</td>
<td>68.74 ± 10.35</td>
<td>&lt;0.001</td>
<td>1.61</td>
<td>26.40</td>
<td>19.01, 32.66</td>
<td></td>
</tr>
<tr>
<td>Stature (cm)</td>
<td>1.67 ± 0.06</td>
<td>1.66 ± 0.06</td>
<td>0.331</td>
<td>0.15</td>
<td>-0.01</td>
<td>-0.44, 0.001</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.59 ± 1.94</td>
<td>31.47 ± 5.54</td>
<td>&lt;0.001</td>
<td>2.00</td>
<td>88.8</td>
<td>7.01, 118.2</td>
<td></td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>75.38 ± 4.48</td>
<td>91.83 ± 10.19</td>
<td>&lt;0.001</td>
<td>2.28</td>
<td>20.49</td>
<td>16.06, 24.92</td>
<td></td>
</tr>
<tr>
<td>Waist-to-height ratio (WHR)</td>
<td>0.44 ± 0.02</td>
<td>0.55 ± 0.06</td>
<td>&lt;0.001</td>
<td>2.41</td>
<td>0.13</td>
<td>0.11, 0.15</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome markers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>114.63 ± 13.90</td>
<td>138.79 ± 23.37</td>
<td>&lt;0.001</td>
<td>0.60</td>
<td>5.66</td>
<td>1.59, 9.72</td>
<td></td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>67.30 ± 8.16</td>
<td>86.32 ± 6.66</td>
<td>0.634</td>
<td>0.04</td>
<td>-0.38</td>
<td>-4.01, 3.21</td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.58 ± 0.32</td>
<td>1.60 ± 0.51</td>
<td>0.214</td>
<td>0.06</td>
<td>-0.08</td>
<td>-0.31, 0.15</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.18 ± 0.35</td>
<td>1.30 ± 0.37</td>
<td>0.400</td>
<td>0.17</td>
<td>-0.10</td>
<td>-0.16, 0.25</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>4.83 ± 0.36</td>
<td>4.67 ± 0.52</td>
<td>0.152</td>
<td>0.29</td>
<td>0.16</td>
<td>-0.39, 0.06</td>
<td></td>
</tr>
<tr>
<td>Additional biochemical parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.68 ± 0.98</td>
<td>4.39 ± 0.62</td>
<td>0.333</td>
<td>0.26</td>
<td>0.23</td>
<td>-0.04, 0.23</td>
<td></td>
</tr>
<tr>
<td>Fasting insulin (mU/L)</td>
<td>5.00 [2.25]</td>
<td>8.00 [2.00]</td>
<td>&lt;0.001</td>
<td>0.84</td>
<td>3.08</td>
<td>1.85, 5.38</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.34 [0.53]</td>
<td>1.75 [1.23]</td>
<td>&lt;0.001</td>
<td>0.75</td>
<td>0.74</td>
<td>0.35, 1.13</td>
<td></td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>1.38 [1.36]</td>
<td>1.59 [1.49]</td>
<td>0.294</td>
<td>0.46</td>
<td>1.30</td>
<td>0.16, 2.23</td>
<td></td>
</tr>
<tr>
<td>Health and fitness evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted VO2max (ml/kg/min)</td>
<td>40.26 ± 8.84</td>
<td>32.41 ± 6.21</td>
<td>&lt;0.001</td>
<td>1.61</td>
<td>11.03</td>
<td>0.74, 15.02</td>
<td></td>
</tr>
<tr>
<td>Physical activity (min/wk)</td>
<td>280 [193.25]</td>
<td>100 [123.25]</td>
<td>&lt;0.001</td>
<td>1.11</td>
<td>-19.37</td>
<td>-72.36, -111.37</td>
<td></td>
</tr>
<tr>
<td>Daily energy intake (kcal)</td>
<td>5977 ± 1443</td>
<td>6263 ± 2478</td>
<td>0.343</td>
<td>0.187</td>
<td>-46.17</td>
<td>-1443.34, 1510.58</td>
<td></td>
</tr>
</tbody>
</table>

Data presented as mean ± SD or median [IQR range].

* p ≤ 0.05.

Blood pressure (BP); high-density lipoprotein (HDL); high-sensitivity C-reactive protein (hs-CRP); and homeostasis model assessment of insulin resistance (HOMA-IR).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control BMI &lt;24.0 kg/m² (n=33)</th>
<th>Overweight/obesity BMI ≥25.0 kg/m² (n=35)</th>
<th>p value</th>
<th>Effect size</th>
<th>Hedge’s g</th>
<th>Mean difference</th>
<th>% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthropometric assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>60.81 ± 6.60</td>
<td>88.56 ± 17.06</td>
<td>&lt;0.001</td>
<td>2.00</td>
<td>27.74</td>
<td>21.11, 34.37</td>
<td></td>
</tr>
<tr>
<td>Stature (cm)</td>
<td>1.67 ± 0.06</td>
<td>1.61 ± 0.06</td>
<td>0.324</td>
<td>0.18</td>
<td>-0.00</td>
<td>-0.46, 0.00</td>
<td></td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>23.75 ± 1.50</td>
<td>32.71 ± 5.30</td>
<td>&lt;0.001</td>
<td>2.60</td>
<td>10.82</td>
<td>5.50, 16.14</td>
<td></td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>73.51 ± 4.78</td>
<td>92.65 ± 10.29</td>
<td>&lt;0.001</td>
<td>2.48</td>
<td>20.06</td>
<td>16.12, 25.98</td>
<td></td>
</tr>
<tr>
<td>Waist-to-height ratio (WHR)</td>
<td>0.43 ± 0.03</td>
<td>0.56 ± 0.06</td>
<td>&lt;0.001</td>
<td>0.39</td>
<td>0.12</td>
<td>0.10, 0.15</td>
<td></td>
</tr>
<tr>
<td>Metabolic syndrome markers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>115.35 ± 8.42</td>
<td>130.38 ± 6.42</td>
<td>0.014</td>
<td>0.60</td>
<td>5.13</td>
<td>1.06, 9.17</td>
<td></td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>68.81 ± 7.86</td>
<td>87.34 ± 6.87</td>
<td>0.770</td>
<td>0.07</td>
<td>-0.02</td>
<td>-3.04, 3.00</td>
<td></td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.49 ± 0.32</td>
<td>1.66 ± 0.52</td>
<td>0.114</td>
<td>0.38</td>
<td>0.17</td>
<td>-0.04, 0.38</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.16 ± 0.30</td>
<td>1.36 ± 0.31</td>
<td>0.050</td>
<td>0.01</td>
<td>-0.00</td>
<td>-0.18, 0.17</td>
<td></td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>4.75 ± 0.41</td>
<td>4.72 ± 0.48</td>
<td>0.881</td>
<td>0.06</td>
<td>-0.01</td>
<td>-0.25, 0.20</td>
<td></td>
</tr>
<tr>
<td>Additional biochemical parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.66 ± 0.94</td>
<td>4.34 ± 0.40</td>
<td>0.128</td>
<td>0.40</td>
<td>-0.22</td>
<td>-0.73, 0.00</td>
<td></td>
</tr>
<tr>
<td>Fasting insulin (mU/L)</td>
<td>5.00 ± 3.09</td>
<td>8.00 ± 5.09</td>
<td>&lt;0.001</td>
<td>1.00</td>
<td>0.23</td>
<td>0.13, 0.34</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.07 ± 0.71</td>
<td>1.81 [1.04]</td>
<td>&lt;0.001</td>
<td>1.00</td>
<td>0.74</td>
<td>0.34, 1.14</td>
<td></td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>1.41 [0.00]</td>
<td>1.58 [2.36]</td>
<td>0.079</td>
<td>0.43</td>
<td>0.98</td>
<td>-0.11, 2.07</td>
<td></td>
</tr>
<tr>
<td>Health and fitness evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predicted VO2max (ml/kg/min)</td>
<td>40.87 ± 8.96</td>
<td>30.00 ± 7.96</td>
<td>&lt;0.001</td>
<td>1.31</td>
<td>15.87</td>
<td>6.89, 24.85</td>
<td></td>
</tr>
<tr>
<td>Physical activity (min/wk)</td>
<td>260 [125.0]</td>
<td>100 [123.54]</td>
<td>&lt;0.001</td>
<td>1.13</td>
<td>-17.00</td>
<td>103.19, 144.01</td>
<td></td>
</tr>
<tr>
<td>Daily energy intake (kcal)</td>
<td>6164 ± 1055</td>
<td>5946 ± 2434</td>
<td>0.671</td>
<td>0.10</td>
<td>28.14</td>
<td>188.14, 204.52</td>
<td></td>
</tr>
</tbody>
</table>

Data presented as mean ± SD or median [IQR range].

* p ≤ 0.05.

Blood pressure (BP); high-density lipoprotein (HDL); high-sensitivity C-reactive protein (hs-CRP); and homeostasis model assessment of insulin resistance (HOMA-IR).
markers, only systolic blood pressure was higher than controls in participants with overweight/obesity, regardless of classification. The proportion of women in the intervention and control groups, respectively exhibiting each of the metabolic syndrome markers were: WC (100%, 0%); triglycerides (8%, 6%); HDL-cholesterol (32%, 27%); systolic blood pressure (10%, 3%); diastolic blood pressure (0%, 0%); glucose (3%, 6%).

Again, independent of the classification used, the two predictors of glycemic risk, fasting insulin and HOMA-IR, were more elevated in participants with a raised WC and/or BMI > 25 kg m\(^{-2}\) than controls (Tables 1 and 2).

The pro-inflammatory marker hs-CRP was significantly (40%) higher in women with elevated WC than controls but did not differ when using BMI thresholds. Additionally, the prevalence of elevated hs-CRP > 3 mg L\(^{-1}\) was 27% for women with overweight/obesity compared with 20% in the control group, for WC > 82 cm (1, n = 67) > 1,200, p < 0.043). Aerobic fitness estimated from a submaximal cycling protocol was 26% lower in participants with elevated WC than controls. Similarly, subjective approximations of weekly physical activity were 63% less in women with elevated WC than controls. Estimated daily energy intake did not differ between groups. Similar results were observed using BMI (Tables 1 and 2).

HOMA-IR, fasting insulin, hs-CRP and physical activity were used as dependent variables and anthropometric measures of WC, BMI and WHR were the independent variables in calculating unadjusted odds ratios (Table 3). Approximately 41% of participants in the exposed group (overweight/obesity - classified by WC, BMI and WHR) and 67-11.0% in the non-exposed group (controls) were diagnosed with elevated HOMA-IR. Furthermore, the unadjusted odds ratio for the association between overweight/obesity and elevated HOMA-IR ranged between 5.1 and 10.0. The percentage of less than recommended physical activity levels in the exposed group (approximately 80%) was double that of the non-exposed group (approximately 40%) (Table 3).

ROC curves determined the cut-off point for three anthropometric (WC, BMI, WHR) measures. The area under the curve (AUC) for elevated HOMA-IR was 0.78 (p < 0.001) and a cut-off value of 84.25 cm when calculated for WC. Additionally, the positive likelihood ratio was 2.9, less than recommended physical activity produced a value of 0.72 for the AUC (p = 0.002), with a cut-off value of 80.56 cm and a positive likelihood ratio of 3.3 for WC. For BMI, HOMA-IR produced a value of 0.82 for the AUC (p < 0.001), with a BMI cut-off value of 0.63 kg m\(^{-2}\), and a positive likelihood ratio of 4.5. Moreover, the AUC for less than recommended physical activity levels was 0.73 (p = 0.002), with a BMI cut-off of 25.25 kg m\(^{-2}\), and a positive likelihood ratio of 3.7. For WHR, HOMA-IR value for AUC was 0.76 (p < 0.001), with a WHR cut-off value of 0.50, and a positive likelihood ratio of 1.2. Additionally, the AUC for less than recommended physical activity levels was 0.71 (p = 0.003), with a WHR cut-off of 0.46, and a positive likelihood ratio of 1.5.

Participants completed a questionnaire, rating their perceived barriers to physical activity. Chi-square frequencies revealed 84% of participants agreed that exercise was important to them. Despite this, 65% of women with elevated WC or BMI > 25 kg m\(^{-2}\) shared difficulties in motivation for physical activity (17% in controls), however both groups ranked feeling too tired as their number one barrier (Supplementary Table 1). Additionally, 56% of participants with elevated WC or BMI > 25 kg m\(^{-2}\) reported that being self-conscious about their looks was a major barrier to regular physical activity (35% in controls).

Supplementary material related to this article can be found, in the online version, at http://dx.doi.org/10.1016/j.jsams.2013.09.011.

4. Discussion

Data on the prevalence, characteristics and consequences of overweight/obesity in young women are important for providing an indication of the need for early detection, timely treatment, and the adaptation of lifelong interventions.\(^2\) In this study, classification of overweight/obesity using WC and BMI were associated with similar cardiometabolic risk. Risk markers commonly used in standard health checks did not differentiate between women with overweight/obesity and those in healthy anthropometric ranges, while women with overweight/obesity did display higher markers of insulin resistance (fasting insulin and HOMA-IR) and lower estimates of physical activity (weekly exercise duration and aerobic fitness). This finding suggests that anthropometric measures are useful first-line diagnostic measures of cardiometabolic risk, with insulin resistance and lifestyle factors providing deeper insight into this risk for young adult women than traditional metabolic syndrome markers.

No individual was diagnosed with the metabolic syndrome and, as a group mean, none of the markers (i.e., other than WC) was elevated to that of the current metabolic syndrome definition. In contrast, data from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab) reported the prevalence of the metabolic syndrome in women aged between 25 years and 34 years to be 6%,\(^2\) and those with insulin resistance (fasting insulin and HOMA-IR) and lower estimates of physical activity (weekly exercise duration and aerobic fitness) provided deeper insight into this risk for young adult women than traditional metabolic syndrome markers. Therefore, markers of insulin resistance may be more useful indicators of future cardiometabolic risk in younger women with overweight/obesity than markers currently used in the metabolic syndrome definitions and during standard health checks.
As a marker of insulin dysfunction, elevated HOMA-IR ≥ 2.0,15 was present in more than 41% of women with overweight/obesity in the present study, compared with 6.7–11.0% of the control group. Moreover, the odds ratio for the association between overweight/obesity and an elevated HOMA-IR score was large, suggesting a strong relationship between these two variables. Raised concentrations of circulating hs-CRP were also present in women with an elevated WC, in agreement with previous reports.25,26 These raised hs-CRP concentrations could have contributed to higher HOMA-IR scores in the overweight/obesity group, given that hs-CRP disrupts insulin signalling and action.25

Similar predictors of cardiometabolic risk were found when using WC and BMI as proxy measures of overweight/obesity, suggesting that both are useful markers for potential insulin resistance in young women. This agrees with previous results showing WC and BMI have a significant independent association with CVR risk in adults, when assessed using individual records from 58 cohorts.7 Results from ROC curves showed that the WC cut-off point for determining increased risk of insulin resistance, as measured by both fasting insulin and HOMA-IR, was ≥ 84 cm. This value is higher than current guidelines of ≥ 80 cm for Caucasian females.8 Similar trends were observed for the cut-off point for classifications of BMI, in which a measure of ≥ 30.0 kg/m², rather than ≥ 25.0 kg/m², was identified an increased risk of elevated HOMA-IR. In contrast, the dichotomization cut-off points for cardiometabolic risk associated with low physical activity (≤ 210 min of weekly exercise) in our study were determined to be ≥ 80 cm for WC and ≥ 25.25 kg/m² for BMI, strongly supporting the probability of risk within the existing overweight/obesity classification scores.8,10

The WC of WHtR may also be a suitable and easy to administer anthropometric screening tool for the prediction of cardiometabolic outcomes applicable to a variety of populations.11,12 ROC curves showed that the WHtR margin for determining increased risk of insulin resistance, as measured by HOMA-IR, was ≥ 0.5, strongly supporting the current global boundary value.11 Additionally, a cut-off value of ≥ 0.46 was determined for cardiometabolic risk associated with low physical activity (≤ 210 min of weekly exercise), which is lower than the current threshold. Furthermore, the unadjusted odds ratios of WHtR in predicting risk factors are comparable to WC and BMI.

In the present study, 80% of women with overweight/obesity failed to achieve minimum weekly exercise recommendations compared with 15% of the control group, while 3-day dietary recall data showed no differences in daily energy intake between the groups. Although dietary recall has limitations, these data show insufficient energy expenditure from physical activity relative to energy intake appears to be a significant factor in weight gain in the young women in our study. From data reported in a qualitative questionnaire, a prominent barrier to being active for the overweight/obesity women was self-conscious feelings about their own appearance. Therefore, lifestyle interventions for the prevention/reduction of overweight/obesity need to address psychological barriers to physical activity.

The study has several limitations. The cross-sectional design could conceivably be a weakness, but it provided proof of concept prior to larger trials. Future studies using a prospective design could provide predictive data that addresses WC/BMI and the development of cardiometabolic disease. Ideally, central fat distribution would be measured using MRI, but waist circumference still provided a level of sensitivity relevant to most clinical settings. Additionally, the results are specific to Caucasian women at a tertiary institution and largely from suburbs in the most advantaged quintile of socio-economic status. Given this however, our data raise concerns that key health promotion messages are either poorly sourced or understood, and/or are very difficult to apply. When more educated, advantaged young women have difficulties, it may be assumed that individuals from less advantaged backgrounds may at least share these health issues.

5. Conclusion

This study supports the use of WC and BMI as first-line diagnostic measures of cardiometabolic risk. However, risk markers beyond the traditional metabolic syndrome blood-borne criteria, such as fasting insulin and HOMA-IR, may be required when screening further for cardiometabolic risk in young women. A higher order of investigation (e.g., blood sampling) may help convince young women of the need to take action. Furthermore, sedentary behaviour in young women with overweight/obesity is a lifestyle risk factor of concern, with a need for addressing identified age- and gender-specific barriers to engagement. The value of additional research into managing cardiometabolic risk in young women cannot be understated.

Practical implications

- In young adult women, WC and BMI as measures of overweight/obesity have similar associations with other cardiometabolic risk factors.
- Markers of insulin and HOMA-IR may be useful indicators of future cardiometabolic risk in younger women with overweight/obesity.
- The first line of treatment for cardiometabolic risk should be centered on modifiable lifestyle changes, such as those associated with sedentary behaviour through increased physical activity.
- Given the poor engagement in physical activity in our study population, the approach to engagement should be age and gender appropriate, and take into account perceived barriers to physical activity.

Conflict of interest

None.

Financial assistance

None.

Acknowledgements

The authors would like to express their gratitude to all participants involved in the Young Women’s Heart Health Study. Thanks are also extended to Bianca Gazzola, Tanya Wilson and Melissa Nicholls.

References


Basic Research
Young Women With Abdominal Obesity Have Subclinical Myocardial Dysfunction

Bianca L. Share, BSc(Hon),1 André La Gerche, MBBS, PhD, a,b
Geraldine A. Naughton, PhD, a,c Philippe Obert, PhD, a,d and Justin G. Kemp, PhD a

1School of Exercise Science, Australian Catholic University, Melbourne, Australia
2Cardiac Investigation Unit, St Vincent’s Hospital, Melbourne, Australia
3Munich Children Research Institute, Royal Children’s Hospital, Melbourne, Australia
4LPCI, ESFRI, Angers University, Angers, France

ABSTRACT
Background: Abdominal obesity is an independent risk factor for cardiovascular disease. The effect of abdominal obesity on myocardial function in young obese women remains unknown. Therefore, we aimed to investigate cardiac morphology and function, myocardial deformation, and mechanical indices, in young women with and without abdominal obesity.

Methods: Cross-sectional analyses of 39 women with abdominal obesity (waist circumference ≥ 80 cm) and 33 nonobese control subjects (waist circumference ≤ 80 cm) aged 18-50 years underwent conventional echocardiographic measures of cardiac morphology and function together with tissue Doppler, and 2-dimensional speckle tracking measures of myocardial deformation and mechanics. Cardiometabolic risk factors including anthropometric, hypertension, biochemistry, and fitness were also assessed.

Results: Standard echocardiography results for cardiac morphology and function were similar between groups, with the exception of larger left atrial dimensions in women with abdominal obesity (P ≤ 0.05).

RéSUMÉ
Introduction : L’obésité abdominale est un facteur de risque indépendant de la maladie cardiovasculaire. Nous ignorons les conséquences de l’obésité abdominale sur la fonction du myocarde chez les jeunes femmes obèses. Par conséquent, notre but était d’examiner la morphologie et la fonction cardiaque, la déformation myocardique et les indices mécaniques chez les jeunes femmes souffrant ou non d’obésité abdominale.

Méthodes : Les analyses transversales de 39 femmes souffrant d’obésité abdominale (tour de taille ≥ 80 cm) et 33 sujets témoins non obèses (tour de taille < 80 cm) étaient âgés de 18 à 30 ans et subissaient des mesures échocardiographiques traditionnelles de la morphologie et de la fonction cardiaque par Doppler tracé et des mesures par échocardiographie bidimensionnelle en Speckle Tracking (suit de pixel) de la déformation et de la mécanique du cœur. Les facteurs de risque cardiometabolique, y compris l’anthropométrie, l’hypertension, la biochimie et la condition physique ont également été évalués.

Obesity is an established independent risk factor for cardiovascular disease (CVD), with prevalence reaching epidemic proportions.1 In countries such as Australia, the prevalence of obesity in young women appears to be increasing at an exponential rate.1 Increased waist circumference (WC) is a reliable anthropometric index of abdominal obesity1 that allows early identification of CVD risk.2 However, the cardiac consequences of risk factors are poorly understood in young women, a population emerging as highly vulnerable to cardiometabolic disorders.

Young women specifically continue to be underrepresented in cardiac research,2 perhaps because of the misperception that women are ‘protected’ against CVD via the role of estrogen in premenopausal women.1 Additionally, enrollment of women in clinical and epidemiological research remains relatively low in studies of populations with chronic disease.1

Obesity can unfluorably alter left ventricular (LV) morphology and function with greater LV hypertrophy and cardiac remodelling observed in adolescent,1 middle-aged women,3 and older female populations.10 Early detection of myocardial abnormalities in obese individuals might represent a critical and cost-effective strategy to attenuate the time-related consequences of CVD.17 Despite this, the understanding of the effects of obesity on CVD risk in women is largely limited to middle-aged and older individuals with scarce attention to young obese women.12 Therefore, it remains unclear whether obesity in young women is associated with cardiac dysfunction. As such, identification of subclinical disease such as myocardial dysfunction in young women with obesity would highlight a group in which targeted interventions might have the greatest effect.

Received for publication November 6, 2014. Accepted February 4, 2015.

Corresponding author: Bianca L. Share, School of Exercise Science, Australian Catholic University, 115 Victoria Parade, Fitzroy, Victoria 3065, Australia. Tel: +61 3 9953-3477; fax: +61 3 9953-3095.
E-mail: bianca.share@acu.edu.au.

See page 6 for disclosure information.

http://dx.doi.org/10.1016/j.cjca.2015.02.004
#28-382X/© 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
Compared with control subjects, women with abdominal obesity also demonstrated reduced systolic and diastolic mitral annular plane velocities, increased left atrial pressure surrogates (E/diastolic mitral annular plane velocity), and prolonged timing measures of diastolic function including isovolumic relaxation time and transmural deceleration time (P ≤ 0.05). In addition, longitudinal strain and diastolic strain rate were reduced in women with abdominal obesity (P ≤ 0.05) but circumferential deformation and myocardial mechanics (twist and rotation) were preserved. Markers of abdominal obesity retained an independent direct correlation with parameters of cardiac dysfunction, explaining 12%-39% of the overall variability.

Conclusions: A young, otherwise healthy group of women with abdominal obesity displayed subclinical cardiac dysfunction indicated using tissue Doppler imaging and speckle tracking echocardiography measures.

Subclinical cardiac dysfunction can be detected using noninvasive conventional and tissue Doppler imaging (TDI) echocardiography. However, speckle tracking echocardiography (STE), a deformation imaging technique, was developed to address potential limitations in the sensitivity of existing measures for detecting subtle myocardial dysfunction. The aim of this study was to investigate cardiac morphology and function, myocardial deformation, and mechanical indices, in a cross-sectional profile of young women with and without abdominal obesity using traditional and advanced techniques of echocardiography.

Methods
Participants
Ninety-three university-enrolled participants responded to recruitment advertisements that specifically sought Caucasian women aged 18-30 years. Participants were free of hypertension, diabetes, smoking, endocrine disorders, had not undergone bariatric surgery, and were not pregnant or breastfeeding. Eleven women did not meet the inclusion criteria and 10 eligible participants did not complete testing. Therefore, 72 women completed testing between August 2010 and February 2012. Participants were divided into 2 groups: (1) 39 women with abdominal obesity defined by a WC > 80 cm; and (2) 33 women without abdominal obesity (WC < 80 cm). Five women in the abdominal obesity group were previously pregnant to full-term (≥ 1.5 years ago). Participants arrived at the laboratory after a 12-hour fast and were requested to refrain from strenuous physical activity in the 24 hours before testing.

The study was approved by the Australian Catholic University Human Research Ethics Committee (V2009-91), and participants provided written informed consent.

Résultats : Les résultats de l’échocardiographie standard de la morphologie et de la fonction cardiaque étaient similaires entre les groupes, à l’exception des dimensions plus grandes de l’oreillette gauche chez les femmes souffrant d’obésité abdominale (P ≤ 0.05). Comparativement aux sujets témoins, les femmes souffrant d’obésité abdominale démontraient également une réduction des vitesses systoliques et diastoliques du plan de l’anneau mitral, une augmentation des substitutions de la pression auriculaire gauche (E/veitesse diastolique du plan de l’anneau mitral) et des mesures prolongées de la durée de la fonction diastolique, y compris le temps de relaxation isovolymique et le temps de décelération du flux transmural (P ≤ 0.05). De plus, la déséquilibre longitudinal et le taux de déformation diastolique étaient réduits chez les femmes souffrant d’obésité abdominale (P ≤ 0.05), mais la déséquilibre circumferentielle et la mécanique du myocarde (indices de torsion et rotation) étaient préservées. Les marqueurs de l’obésité abdominale conservaient une corrélation directe indépendante avec les paramètres de la dysfonction cardiaque, ce qui explique 12 % à 39 % de la variabilité globale.

Conclusions : Un groupe de femmes jeunes, mais en santé, souffrant d’obésité abdominale montraient une dysfonction sous-clinique cardiaque selon les mesures de l’imagerie Doppler tissulaire et de l’échocardiographie Speckle Tracking (sud de pixel).

Cardiometabolic risk factors
A range of clinical characteristics were assessed to profile the population including anthropometric, blood pressure, blood biochemistry, and fitness variables (see the Cardiometabolic Risk Factors section of the Supplementary Material).

Echocardiography examination
Participants underwent a standard 2-dimensional trans-thoracic echocardiography examination for the assessment of global and regional ventricular function in accordance with the American Society of Echocardiography. Image acquisition was performed by the same experienced operator using commercially available ultrasound equipment (Vivid i, GE Healthcare, Horten, Norway) with a 3.5 MHZ phased-array transducer. Participants were examined in the left lateral decubitus position in a dark room and connected to a 3-lead electrocardiogram. A minimum frame rate of 70 Hz was used during acquisition of grey-scale cine loops. Digital data were stored for subsequent off-line analyses with specific software (EchoPAC v108, GE Medical Systems, Horten, Norway) by an observer blinded to group assignment. All reported measurements were averaged from 3 consecutive cardiac cycles (see the Echocardiography Examination section of the Supplementary Material).

Statistics
Data were analyzed using IBM SPSS Statistics, Version 20 for Windows (Chicago, IL). Log transformation was used when quantitative variables were not normally distributed. Group comparisons were performed using independent t tests. Hedge g was used to calculate magnitudes of differences (≥ 0.2, small; ≥ 0.5, medium; and ≥ 0.8, large). A power analysis determined the power achieved for effect size on variables that were statistically significant. Multiple linear regression analysis based on a stepwise algorithm was used to
detect independent predictors of variability in cardiac parameters. Partial correlation was used to assess the degree of association between dependent variables (cardiac parameters) and independent variables (cardiometabolic risk factors) in the final model. An α level of P < 0.05 was considered statistically significant. Intra- and interobserver reproducibility were estimated for major cardiac variables in randomly selected participants (see the Reliability section of the Supplementary Material).

Results
Cardiometabolic risk factors
No differences were found for height, blood pressure, triglycerides, high-density lipoprotein cholesterol, or resting heart rate in a comparison of women with abdominal obesity (WC range, 80.5-123.0 cm) and control subjects (WC range, 63.6-77.8 cm; Supplemental Table S1). Women with abdominal obesity had greater body mass, body mass index, WC, hip circumference, waist-to-hip ratio, waist-to-height ratio, increased levels of fasting insulin, homeostasis model assessment of insulin resistance, and high sensitivity C-reactive protein than those in the control group. The mean homeostasis model assessment of insulin resistance values remained within the normal range but increased levels of high sensitivity C-reactive protein in the women with abdominal obesity was deemed ‘high’ risk. Women with abdominal obesity performed 63% less weekly physical activity and had reduced aerobic capacity. Contested participants had increased fasting glucose and total cholesterol levels but notably values remained within normal ranges.

Cardiac morphology and function
Women with abdominal obesity displayed greater left atrial (LA) dimensions than control subjects. No differences were found for LV ejection fraction or LV structural parameters (Table 1). Women with abdominal obesity displayed impaired LV diastolic parameters (decreased transmitral E, diastolic mitral annular plane velocity [Em], and increased EEm, isovolumic relaxation time [IVRT], and deceleration time), and reduced systolic tissue velocity than control subjects. Although these values remained within ranges that would be considered “normal” in clinical settings, statistically significant differences were supported by moderate effect sizes. No differences were found between groups for E/Ea ratio, and parameters of late-diastolic function.

Myocardial deformation and mechanics
Women with abdominal obesity had lower longitudinal strain and diastolic strain rate (SR) than control subjects (Table 2). Circumferential strain and SR, apical and basal rotation, and twist/un twist parameters were not different between groups.

Relationship between cardiac parameters and cardiometabolic risk factors
Multivariate analyses showed that anthropometric markers of obesity were the strongest predictors of variability in cardiac parameters (Supplemental Table S2). Physical activity was not an independent predictor of cardiac dysfunction and was consequently eliminated from the model. Overall, cardiometabolic risk factors (predictors) explained approximately 12%-39% of cardiac dysfunction.

Discussion
We investigated measures of cardiac morphology and function, myocardial deformation, and mechanical indices in young women with and without abdominal obesity. We showed that young women with abdominal obesity displayed subtle early myocardial impairment identified using traditional and advanced echocardiography measures compared with control subjects. These data advance the understanding of CVD risk factors in a population that is currently underrepresented in the literature. Specifically, our findings demonstrated that young women with abdominal obesity displayed some markers of (1) subclinical cardiac abnormalities associated with remodeling; and (2) myocardial dysfunction. We can confirm, for the first time in this population, the presence of suble myocardial dysfunction in the longitudinal axis but preserved circumferential deformation and twist mechanics—identified using STE—of young women with abdominal obesity.

Effects of obesity on subclinical cardiac abnormalities in cardiac morphology
Women with abdominal obesity had larger LA dimensions but otherwise cardiac morphology was similar. The left atrium enlarges in response to increases in LV pressure due to impaired LV filling, making it a useful adjunct in the assessment of chronic diastolic dysfunction.25 Abnormalities in LA diameter have been linked to obesity in a group of young women (29 ± 10 years of age; n = 48) with isolated obesity,26 in a population of slightly older (32 ± 4 years of age) obese young adults,27 and in obese middle-aged adults,28,29 with normal ejection fraction. This finding from our study is potentially of even greater concern in a population of women who were notably younger and had milder obesity than in these previously reported studies. Mechanisms behind this link might occur as a consequence of the hemodynamic changes associated with obesity.30

Effects of obesity on subclinical cardiac abnormalities in cardiac function
Obesity impairs cardiac loading.22 In our study, conventional load-dependent parameters of LV diastolic function, indicators of filling and relaxation, and measures of LV stiffness were observed in women with abdominal obesity. Previous literature has shown underlying abnormalities in relaxation and/or myocardial compliance in obese individuals without hypertension or cardiac hypertrophy.31 However, this is the first study to identify diastolic impairment in such a young group of women.

In the present study, women with abdominal obesity also demonstrated attenuated TDI-derived velocities. The TDI echocardiography parameters of systolic mitral annular plane velocity, Em, and EEm, have established independent prognostic value in a wide variety of cardiac disorders and are powerful predictors of cardiac mortality.32 We reported
Table 1. Cardiac morphology and function parameters in participants with and without abdominal obesity

<table>
<thead>
<tr>
<th></th>
<th>WC &lt; 88 cm (n = 33)</th>
<th>Abdominal obesity</th>
<th>P</th>
<th>Hedge g effect size</th>
<th>Power (1-β)</th>
<th>Mean difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, Years</strong></td>
<td>20.0 ± 0.7</td>
<td>22.4 ± 3.5</td>
<td>0.003*</td>
<td>0.87</td>
<td>0.95</td>
<td>2.6 (3.39 to -0.60)</td>
</tr>
<tr>
<td><strong>WC, cm</strong></td>
<td>72.5 ± 6.8</td>
<td>92.3 ± 10.6</td>
<td>&lt; 0.001*</td>
<td>2.54</td>
<td>1.60</td>
<td>20.0 (16.2-23.8)</td>
</tr>
<tr>
<td><strong>Cardiac morphology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA diameter, mm</td>
<td>36.2 ± 3.3</td>
<td>32.7 ± 4.6</td>
<td>0.02*</td>
<td>0.55</td>
<td>0.60</td>
<td>2.5 (0.04 to 4.0)</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>144 ± 31</td>
<td>149 ± 40</td>
<td>0.98</td>
<td>0.03</td>
<td>-1.0</td>
<td>-17 (17.2 to 9.1)</td>
</tr>
<tr>
<td>LV mass indexed, g/m²</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVED diameter, mm</td>
<td>44.5 ± 4.5</td>
<td>44.0 ± 5.8</td>
<td>0.71</td>
<td>0.09</td>
<td>0.6</td>
<td>0.4 (0.2 to 0.3)</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>29.4 ± 4.5</td>
<td>29.4 ± 4.4</td>
<td>0.55</td>
<td>0.05</td>
<td>-1.0</td>
<td>-6 (2.0 to 1.1)</td>
</tr>
<tr>
<td>LV posterior wall thickness, mm</td>
<td>10.5 ± 1.7</td>
<td>10.5 ± 1.7</td>
<td>0.12</td>
<td>0.08</td>
<td>-1.0</td>
<td>-6 (0.02 to 0.1)</td>
</tr>
<tr>
<td>IVS thickness, mm</td>
<td>9.7 ± 1.4</td>
<td>9.7 ± 1.7</td>
<td>0.31</td>
<td>0.01</td>
<td>-1.0</td>
<td>-5 (0.03 to 0.01)</td>
</tr>
<tr>
<td>LV function</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LV shortening fraction, %</td>
<td>34.9 ± 5.7</td>
<td>32.7 ± 6.9</td>
<td>0.17</td>
<td>0.04</td>
<td>-2.2</td>
<td>-3 (3.5 to 1.0)</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>64.0 ± 8.1</td>
<td>61.0 ± 10.2</td>
<td>0.09</td>
<td>0.02</td>
<td>-3.0</td>
<td>-9.6 (6.7)</td>
</tr>
<tr>
<td>Stroke volume, mL</td>
<td>58.6 ± 16.0</td>
<td>53.7 ± 12.7</td>
<td>0.16</td>
<td>0.05</td>
<td>-5.1</td>
<td>-13.3 (3.6)</td>
</tr>
<tr>
<td>LVEF, %</td>
<td>47.7 ± 13.8</td>
<td>87.0 ± 15.7</td>
<td>0.01*</td>
<td>0.70</td>
<td>-9.7</td>
<td>-13.3 (9.3 to -0.03)</td>
</tr>
<tr>
<td>LV ED, cm²</td>
<td>42.4 ± 12.8</td>
<td>42.4 ± 11.0</td>
<td>0.04</td>
<td>0.02</td>
<td>-2.3</td>
<td>-9.0 (0.08)</td>
</tr>
<tr>
<td>E-wave, cm/s</td>
<td>3.3 ± 0.7</td>
<td>3.2 ± 0.6</td>
<td>0.44</td>
<td>0.15</td>
<td>-0.1</td>
<td>-6 (0.03 to 0.02)</td>
</tr>
<tr>
<td>Deceleration time, ms</td>
<td>174.4 ± 34.9</td>
<td>209.0 ± 29.8</td>
<td>&lt; 0.001*</td>
<td>1.06</td>
<td>1.00</td>
<td>34.6 (19.2-50.1)</td>
</tr>
<tr>
<td>IVRT, ms</td>
<td>78.4 ± 9.9</td>
<td>85.8 ± 10.7</td>
<td>0.01*</td>
<td>0.71</td>
<td>0.87</td>
<td>7.4 (2.5-12.4)</td>
</tr>
<tr>
<td>S-wave, cm/s</td>
<td>10.4 ± 2.3</td>
<td>9.0 ± 2.4</td>
<td>&lt; 0.001*</td>
<td>0.04</td>
<td>0.99</td>
<td>-14 (-0.02 to -0.01)</td>
</tr>
<tr>
<td>T-wave, cm/s</td>
<td>17.2 ± 2.3</td>
<td>14.6 ± 2.7</td>
<td>&lt; 0.001*</td>
<td>1.10</td>
<td>1.00</td>
<td>-2.6 (2.04 to -0.01)</td>
</tr>
<tr>
<td>A-wave, cm/s</td>
<td>6.9 ± 1.2</td>
<td>6.9 ± 1.1</td>
<td>0.59</td>
<td>0.00</td>
<td>0.5</td>
<td>0.0 (0.01 to 0.011)</td>
</tr>
<tr>
<td>FLA, lateral wall</td>
<td>4.9 ± 0.7</td>
<td>5.4 ± 1.4</td>
<td>0.04*</td>
<td>0.47</td>
<td>0.60</td>
<td>0.5 (0.03 to 1.1)</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD, except where otherwise noted. S-wave, T-wave, and A-wave are means of 4 sites at the mitral annulus from the apical 4-chamber and 2-chamber views.

Effects of obesity on myocardial dysfunction via deformation

Noninvasive ultrasound techniques such as conventional and TDI echocardiography have a major role in the diagnosis and management of CVD. An inability to accurately differentiate actively contracting myocardium from passive myocardial motion is one of the principal limitations of conventional and TDI echocardiography. The innovation of STE allows unique acoustic speckles within the myocardium to track thereby permitting analysis of the relative regions of the myocardium, thus separating deformation from passive motion. In some settings, STE has enabled early diagnosis of systolic and diastolic dysfunction, even when conventional and TDI echocardiography parameters of LV function remain within the normal range. In our study, we confirmed and extended previous data by demonstrating that young women with abdominal obesity displayed impaired longitudinal myocardial dysfunction, but preserved circumferential function, compared with control subjects. Although the exact mechanisms behind this remain unclear, the finding is consistent with previous studies in older, disease-free populations. The reduced longitudinal strain and SR in our women with abdominal obesity highlight early diastolic and systolic dysfunction that could be explained by depressed relaxation and contractile properties of myocardial fibres. It is possible that increases in ventricular and atrial filling pressure are a cause and a consequence of reduced myocardial deformation.

Reduced LV strain observed in our women with abdominal obesity has been previously reported. A study of obese middle-aged women (n = 663; 47.8 ± 13.6 years of age;
WC, 88.5 ± 11.7 cm) showed a strong relationship between increased WC and reduction in LV strain. Similarly, research has shown reduced strain indices and reduced $E$ velocity in 26 middle-aged women (49 ± 8 years of age) with isolated obesity (WC, 105 ± 7 cm), compared with 18 age-matched nonobese control subjects. Comparable to the present study, depressed longitudinal LV strain but preserved circumferential strain was observed in a group of 37 obese adolescent participants (aged 14.6 ± 1.5) compared with 24 lean control subjects (aged 14.0 ± 1.5 years). Identification of these preclinical myocardial abnormalities in young obese women provides a marker that could be followed through treatment interventions; we postulate that weight reduction and increased physical activity might attenuate further decline in myocardial function. Weight reduction has been associated with improvements in measures of LV function in some studies, but has proven disappointing in others. However, the efficacy of a lifestyle intervention in preventing overt cardiac dysfunction in young overweight women has not been tested.

**Effects of obesity on myocardial dysfunction via mechanics**

Myocardial mechanics such as twist and twist rate describe the torsional rotation of the heart produced by the helical structure in which the myocardial fibres are arranged. Twist and the rate of untwist have been promoted as sensitive determinants of cardiac performance, particularly during diastolic relaxation and filling. However, their acceptance in clinical practice has been limited by reproducibility issues. Nevertheless, the role of LV twist as a major contributor to LV filling has generated much interest. Reductions in diastolic and systolic LV twist and basal rotation showed a stronger correlation with WC ($R = -0.24; P < 0.05$) in obese middle-aged (aged 44 ± 10 years) participants compared with nonobese control subjects. Similarly, obese adolescents had more pronounced LV twist and greater apical rotation than lean control subjects, confirming the feasibility of detection in younger populations. It was postulated that the greater LV twist in the obese individuals could be viewed as a compensatory phenomenon for their depressed longitudinal function, critical for LV filling and ejection. Rotational indices of twist/untwist rates were not supported by the results from the present study. Variability might have limited accurate conclusions from these results. Discrepancies in twist mechanics between obese and control subjects could also be related to difficulties in imaging capacities, particularly for apical rotation.

In our study, changes in cardiac and myocardial parameters were accompanied by some biological markers in women with abdominal obesity compared with control subjects. However, the correlations between significant markers of TDI and STE with biomarkers of CVD risk were only moderate. We propose that obesity is directly related to a sequence of yet to be clarified early markers of cardiac risk.

**Study limitations**

The study design means that we cannot address changes in myocardial function over time. However, this novel demonstration of myocardial dysfunction in a young population provides necessary motivation for longitudinal interventional studies. Although physical activity was not found to be an independent predictor of variability in cardiac dysfunction, the between-group differences in habitual physical activity cannot be discounted as a confounder in myocardial function. Objective measures of physical activity could clarify this relationship in future studies. We did not assess right ventricular function or myocardial reserve and hemodynamic responses during exercise. Central fat distribution could have been more ideally assessed using more precise estimations. Despite this, WC as a measure of abdominal obesity is widely recognised as a reliable tool.

**Conclusion**

Young women with abdominal obesity displayed larger LA dimensions and reduced measures of diastolic and systolic myocardial function, compared with nonobese control subjects. Low-grade systemic inflammation was also present in young women with abdominal obesity. These findings might...
provide important insights into the links between obesity and the increased incidence of cardiometabolic disease.

Acknowledgements
The authors thank Professor Jennifer Peat for her statistical assistance and Associate Professor Guillaume Walther for his contribution to the report.

Disclosures
The authors have no conflicts of interest to disclose.

References
17. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63.
RESEARCH ARTICLE

Effects of a Multi-Disciplinary Lifestyle Intervention on Cardiometabolic Risk Factors in Young Women with Abdominal Obesity: A Randomised Controlled Trial

Bianca L. Sharre1,*, Geraldine A. Naughton1,2, Philippe Oberti1,4, Jennifer K. Peat2,6, Elizabeth A. Aumand1, Justin G. Kemp1

1 School of Exercise Science, Australian Catholic University, Melbourne, Victoria, Australia; 2 Faculty of Health Sciences, Australian Catholic University, Sydney, NSW, Australia; 3 Murdoch Children’s Research Institute, Melbourne, Victoria, Australia; 4 LAPEC, EA4278, University of Avignon, Avignon, France

* BLS, GAN, and JGK contributed equally to this work. PO, JKP, and EAA also contributed equally.

Abstract

Background

Young women are under-represented in cardiovascular disease research, with obesity and cardiometabolic risk factor interventions generally targeting older adults. Furthermore, appropriate study designs for young women remain uncertain. This study aimed to assess the impact of a 12 week multi-disciplinary lifestyle intervention on cardiometabolic risk factors in premenopausal women with abdominal obesity.

Methods

Women aged 18–30 y with abdominal obesity (waist circumference (WC) > 80 cm) were randomised to a 12 week lifestyle intervention (n = 26) of physical activity, nutrition education and cognitive behavioural therapy, or a wait-list control group (n = 17). Both groups completed anthropometric, biochemical, nutrition and fitness testing, at pre (0 weeks) and post (12 weeks), with intervention participants completed follow-up testing at 24 weeks.

Results

Results from a linear mixed model showed no between-group differences, other than increased physical activity in the intervention group, at post. In the intervention group alone, positive within-group changes were observed in WC, waist-hip ratio (WHR), waist-height ratio (WHHR), resting heart rate, blood pressure, predicted VO2max and total energy intake. Most changes were maintained at 24 weeks post-intervention. Similar within-group improvements were observed in control participants in WC, WHR, WHHR, and systolic blood pressure but no changes were detected in physical activity and nutrition.
Conclusions
Cardiometabolic risk factors were decreased as a result of a lifestyle intervention in young women with abdominal obesity. It is difficult to describe observations in the control group without greater understanding of the behaviour of wait-list participants.

Trial Registration
Australian New Zealand Clinical Trials Registry ACTRN12612001017819

Introduction
Cardiovascular disease (CVD) represents a major health threat to women worldwide [1], consequently placing substantial burden on public health systems. Most risk factors for CVD, including overweight/obesity and physical inactivity, can be modified through lifestyle interventions [2,3]. The rising prevalence of overweight and obesity is a worldwide concern among young women from developed and developing nations [4]. Currently, 51% of non-Hispanic white American women aged 20–39 years are either overweight or obese [5], while prevalence among women in the United Kingdom [6], and Australia [7] aged 25–34 years are 47% and 42%, respectively. An average weight gain of 6 to 12 kg between the ages of 20 to 30 years was noted in a large longitudinal study of women’s health [8], and this weight gain was more than for any other age group [8,9]. Concurrently, sedentary behaviour is increasing in young women [10], with 85% of women aged 18–35 years reporting inactive lifestyles and decreased physical activity [9]. Among women, weight gain is not only a risk factor for CVD but increases the risk of the metabolic syndrome [11], type 2 diabetes mellitus, depression, polycystic ovarian syndrome, infertility and adverse pregnancy outcomes [12].

Despite global strategies for preventive health, there is poor understanding of early risk factors (cardiometabolic risk factors) in young women, and lifestyle interventions can improve health outcomes. Moreover, research assessing the effectiveness of weight management interventions specifically targeting young women is relatively recent [13]. Effective age-appropriate interventions for improving cardiometabolic risk are required for young adults born between 1977 to 1994 (“Generation Y”) who share an urgency for feedback and success [14,15]. The limited research that has been conducted in young overweight/obese women suggests they are difficult to recruit for weight management trials, with high attrition and limited success in losing weight compared with older populations [16]. Furthermore, limited evidence exists to inform the implementation of lifestyle intervention programs targeting young women [17].

Poorer retention but greater success has been reported when results of an online team-based weight loss lifestyle intervention were compared in younger and older adults [17]. However, not all studies of weight loss in young adults following lifestyle interventions report statistical significance [18]. To date, the effectiveness and long-term success of multi-disciplinary lifestyle interventions delivered face-to-face that directly target weight loss in young women remain uncertain [19]. Nonetheless, exercise interventions appear to require strong familiarisation of the required physical activity along with some formal contact with the participant. Also, exercise alone is less likely to be effective in weight loss than when combined with some nutrition and psychological support [20].

Therefore, the primary aim of this study was to assess the effectiveness of a lifestyle intervention for reducing CVD risk in young women with abdominal obesity, using a randomised
controlled trial (RCT) design. Specifically, the RCT involved a 12-week multi-disciplinary program (physical activity, nutrition education, cognitive behavioural therapy) with Caucasian women aged 18 to 30 years, who shared the cardiometabolic risk factor of abdominal obesity [elevated waist circumference (WC) ≥ 80 cm]. A secondary aim was to examine the effectiveness of the intervention through an improved understanding of the sustainability of any changes. It was hypothesised that the lifestyle intervention would be effective (and sustainable) in reducing cardiometabolic risk in young women with abdominal obesity.

**Materials and Methods**

The study protocol was approved by the Australian Catholic University Human Research Ethics Committee (V2009-91) on December 18th 2009 (S1 and S2 Texts). The authors confirm that all ongoing and related trials for this intervention are registered with the Australian New Zealand Clinical Trials Registry (Identifier: ACTRN12612001017819) and the CONSORT reporting guidelines for clinical trials were followed (S1 Table). Data were collected between August 2010 and February 2012. Written informed consent was obtained from all participants.

**Participants**

Sixty-two female Caucasian tertiary students at risk of CVD volunteered for this study. Advertisements for recruitment specifically sought young women with abdominal obesity (WC ≥ 80 cm), who were also leading a sedentary lifestyle. Included were women aged 18 to 30 years; with a waist circumference ≥ 80 cm, and who were physically inactive (< 210 minutes per week of organised physical activity in the past six months). Exclusion criteria were being pregnant or breastfeeding; a history of bariatric surgery; and/or having a diagnosis of liver or kidney disease; heart arrhythmia; insulin dependent diabetes mellitus; polycystic ovarian syndrome; thyroid abnormalities. All participants were non-smokers.

A power analyses estimated that 18 participants per group would provide the appropriate sample size to detect a large between-subject difference of 1.0 standard deviation (β = 80%, alpha P < 0.05) in waist circumference from pre-intervention to post-intervention. To allow for 20% attrition, there was an attempt to recruit an initial sample size of 44 participants (22 per group). Fig 1 shows the participation of individuals in this study. From 62 women who responded to the recruitment strategy, 11 prospective participants were excluded, and a further 12 did not respond to preliminary contact. Therefore, 39 willing participants underwent pre-intervention/pre-control testing, after which group (block) randomisation occurred via a central administrator who allocated participants to either the intervention group or wait-list (delayed-start) control group. A wait-list control design was chosen because the investigators desired an ethically-sound model which provided all participants with access to the lifestyle intervention. Also, a wait-list control group was considered more appropriate than a passive control group given that health risks were comparable in both groups. After allocation to the wait-list control group for 12 weeks, only four participants continued into the lifestyle intervention phase. Participants were not blinded to their group, but where possible assessors were blinded to group allocation.

**Experimental design**

For each testing period (0, 12, 24 weeks), participants attended the laboratory on two occasions. They were requested to refrain from strenuous physical activity in the 24 hours prior to all laboratory sessions. The first visit required the participant to arrive in a fasted state and clinical testing lasted 75 minutes. The second visit of 60 minutes required participants to abstain from caffeine and alcohol for 12 hours.
Fig 1. CONSORT participant flow-chart of intervention and control participants.

cb:10.1371/journal.pone.0130270.g001
For the intervention group, testing of cardiometabolic risk factors was performed at pre-intervention (0 weeks), post-intervention (12 weeks) and following a short-term sustainability phase (24 weeks). The control group underwent testing at pre-control and post-control (12 weeks) time periods only. For all testing, measurements were taken at the same time of day (±2 hours) and by the same researcher. For participants in the control group, monthly contact was made to remind them of the control criteria. For the sustainability phase between post-intervention (12 weeks) testing and the following 12 weeks, a sustainability strategy was delivered electronically to the intervention group. This involved a fortnightly newsletter on healthy living tips from evidence-based resources.

Neither the investigators nor the participants were blinded to group allocation as this was considered impractical for the long-term investigation and limited members of the research team. However, to minimize contamination, participants in the intervention group were asked to refrain from disclosing their intervention experience to researchers assigned to data collection and/or analysis and to wait-list control participants. To further minimize bias, assessor blinding occurred within dietary measures and biochemical analyses. For the primary outcome variable of WC, measures were completed in duplicate with reported measures of reliability: coefficient of variation (CV), intraclass correlation coefficient (ICC) and measurement error (ME).

Testing measures

Survey data. A self-administered lifestyle survey was completed to provide data on (i) health status and medical conditions, (ii) nutrition (including alcohol consumption), and (iii) current physical activity habits. The lifestyle survey (S2 Text) was developed specifically for the study and validated using the process of face validation [21].

Anthropometric assessment. Body composition was assessed via waist circumference (WC), hip circumference, body mass index (BMI), and body mass. WC was measured to the nearest 0.1 cm in the horizontal plane at the level of the midpoint between the iliac crest and lower costal margin [11]. For WC, CV = 1.26%, ICC (3, 3) = 0.986 and MB = 1.34%, which equates to an error range of ± 2.6 cm. Body mass was measured to the nearest 0.1 kg using digital scales (Tanita, Tokyo, Japan), and height was estimated to the nearest 0.1 cm using a wall-mounted stadiometer (Seca, Germany). BMI was calculated, with overweight/obesity defined as BMI ≥ 25 kg m⁻² [11]. Waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR) were calculated by dividing participants' WC (cm) by their hip circumference (cm) and height (cm), respectively (Browning 2010, WHO, 2006).

Metabolic syndrome markers and additional biochemical parameters: Metabolic syndrome was defined according to the most recent and unified criteria [11]. Markers of insulin resistance, including fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR), and the pro-inflammatory marker high sensitivity C-reactive protein (hs-CRP), were also measured in this study.

Following an overnight fast, intravenous blood was collected Blood lipid profiling of serum concentrations of triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol were measured using the Reflotron Plus desktop analyser (Roche, Switzerland). Fasting plasma glucose, insulin and hs-CRP concentrations were analysed by clinical pathology at a leading hospital. Insulin resistance was estimated by HOMA-IR using the equation [12]. For hs-CRP, a value > 3.0 mg L⁻¹ was deemed high risk [22].

After 10 minutes of rest in a quiet, temperature controlled room SBP and DBP were obtained in duplicate from the left arm with an automated digital sphygmomanometer (Carestream V100, Dinamap, GE technology, USA) with the participant in the supine position.
Health and fitness evaluations. The YMCA graded submaximal cycle ergometer test [24] was used to estimate aerobic power (predicted VO\text{max}), where heart rate was extrapolated against work rate (W) using regression analysis. Physical activity behaviour (S3 Text) was obtained via a 7-day recall [25].

Within the acknowledged limitations of dietary recall [26], 100% of participants completed a three-day food and beverage recall on two consecutive weekdays and on either a Saturday or Sunday of their usual diet. Instructions were provided on how to complete the diary and diagrams of portion sizes were also shown and discussed (S3 Text). Participants were encouraged not to alter their habitual diet during the three day recall period. Macro- and micro-nutrient intakes were analysed by a research dietician, blinded to grouping, using the FoodWorks7 Professional program (Xyris software, Highgate Hill, Queensland, Australia). An estimation of average daily energy intake was also calculated.

Intervention

The 12-wk lifestyle intervention was comprised of three main components: (1) physical activity (2) nutrition education, and (3) cognitive behavioural therapy (S2 Table). In contrast, participants in the wait-list control group (n = 17) were instructed to continue existing lifestyle choices, and after 12 weeks were invited to complete the lifestyle intervention.

Physical activity. Participants undertaking the intervention completed two supervised exercise sessions (progressive circuit training) and one unsupervised, but were prescribed one home-based session (brisk walk or jog) per week. All sessions were devised and administered by a qualified Exercise Scientist who has experience in exercise prescription for elite and healthy populations. The supervised sessions consisted of a general warm-up, a combination of aerobic activities, dynamic strength and/or resistance training, abdominal conditioning, and stretching. Session duration lasted approximately 60 min, with the intensity of the exercise increasing from 6.0 to 8.5 on the OMNI Picture System (ranging from 0 = extremely easy to 10 = extremely hard)[27], by the end of the 12-week period. Intensity was verified during most exercise sessions with a Polar heart rate monitor (Polar Electro, Finland). The home-based, unsupervised training session involved a brisk walk or jog at an RPE of 5–7 on the OMNI Picture System [27]. Participants were encouraged to incorporate intermittent high-intensity intervals into their session. Duration of the session progressed from 30 minutes at intervention commencement to 45 minutes at program completion. As a measure of compliance, participants maintained a detailed training diary including any extra activities they completed during the intervention. The Bruce protocol [28] was completed every three weeks to ensure accuracy of progressive overload of aerobic fitness during the program. Upper (chest-press) and lower (leg-press) body strength was tested via a 5-repetition maximum test to guide the strength and resistance component of the exercise intervention [29]. Sessions occurred in both the gym on campus and at a local park.

Nutrition education. Participants in the intervention group received weekly nutrition education sessions guided by a qualified dietician about healthy eating choices from the existing Australian Dietary Guidelines [30]. This information provided education regarding non-dieting weight management and healthy eating principles. Following baseline analysis of a three-day food and beverage recall, nutrition education topics (S2 Table) targeted the perceived needs of the female participants. As such, nutrition was a workshop (educational focus) and did not prescribe a specific caloric intake nor ask participants to monitor their nutritional intake during the intervention.

Cognitive behavioural therapy. Within the framework of self-determination theory [31], weekly 60-minute group sessions with a qualified counsellor provided participants with
psychosocial support and developed skills to overcome personal barriers to lifestyle change [32]. The program aimed, ultimately, to empower individuals to develop healthier eating and physical activity patterns [32].

Statistical analyses
Data were analysed using IBM SPSS Statistics, Version 20 for Windows (SPSS Inc, Chicago IL). Data were tested for normal distribution [33], with log transformation performed on data not normally distributed. All data are presented as means ± standard deviation. Statistical significance was set at P ≤ 0.05. A linear mixed-model analysis was used to calculate the differences between groups and across time for the intervention and control groups. Hedge’s g effect size was used to assess the magnitude of effect. An effect size ≥ 0.2 was considered small, ≥ 0.5 medium, and ≥ 0.8 large [34]. Mean differences and 95% confidence intervals (CI) are reported. An additional linear mixed-model calculation was determined for only the participants in each group who started and completed the study. No differences were found using both models. An independent t-test was used to compare differences between the two groups in changes from baseline to 12 weeks.

Results
A total of 39 participants were included in the linear mixed-model analysis. For reasons described (Fig 1), 27% of intervention participants and 35% of control participants failed to maintain study involvement beyond pre-intervention/pre-control measures. However, for those completing the intervention, compliance rates were high with 80% attendance at physical activity sessions and 74% at CBT sessions.

Between group differences
Table 1 shows the results of comparisons between the intervention and control groups before and following the intervention, using a linear mixed model analysis. With only one difference observed between groups at pre-intervention, this supports the homogeneity of the groups. At baseline none of the participants were classified as having the metabolic syndrome [11] however, a baseline difference was found in a higher resting heart rate, in the intervention group, with a moderate effect size (g = 0.79). With the exception of WC and weekly physical activity most cardiometabolic risk factors were within normal limits for the population at baseline testing (see footnotes Table 1). At post-intervention, only physical activity was higher in the intervention group than the control group, with a large effect size (g = 2.14). Similarly, both the absolute and percentage change in physical activity from pre to post testing were greater for the intervention group, as were the absolute and percentage changes in predicted VO\textsubscript{2}\text{max} when compared to controls.

Intervention group
For the intervention group, there were positive significant (P ≤ 0.05) changes pre-to post-intervention for WC (-5.8 cm, -6.4%), WHR (-0.02, -2.5%), WHtR (-0.03, -5.5%), SBP (-4 mmHg, -3.4%), DBP (-4.0 mmHg, -5.8%), resting heart rate (-6.0 bpm, -11%), predicted VO\textsubscript{2}\text{max} (+1.7 m\text{L} kg\textsuperscript{-1} min\textsuperscript{-1}, +15%), physical activity (+183 m\text{L} kg\textsuperscript{-1} week\textsuperscript{-1}, +97%) and total energy intake (-1332 kJ, -22%) (Table 2). Absolute protein intake (g) decreased but this difference disappeared when the decreased total energy intake was accounted for.

Many of the improvements observed at post-intervention were maintained at sustainability (24 weeks) testing including, WC, WHR, WHtR, DBP and resting heart rate (Table 2). The
Table 1. Between-group comparisons of cardiometabolic risk factors for the intervention and control group at pre (0 weeks) and post (12 weeks).

<table>
<thead>
<tr>
<th></th>
<th>Pre-control/pre-intervention (0 weeks)</th>
<th>Post-control/post-intervention (12 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n = 17)</td>
<td>Intervention (n = 26)</td>
</tr>
<tr>
<td></td>
<td>P value</td>
<td>Effect size (Hedge’s g)</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>86.1 ± 17.8</td>
<td>89.8 ± 21.1</td>
</tr>
<tr>
<td>Body mass index (kg m⁻²)</td>
<td>31.4 ± 6.6</td>
<td>32.2 ± 5.9</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>92.0 ± 10.8</td>
<td>93.1 ± 11.7</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>113.8 ± 11.5</td>
<td>116.3 ± 13.3</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.81 ± 0.03</td>
<td>0.79 ± 0.05</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>119 ± 8</td>
<td>120 ± 11</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>64 ± 8</td>
<td>68 ± 6</td>
</tr>
<tr>
<td>HDL cholesterol (mM; mg/dL⁻¹)</td>
<td>1.7 ± 0.6</td>
<td>1.7 ± 0.5</td>
</tr>
<tr>
<td>Triglycerides (mM; mg/dL⁻¹)</td>
<td>1.2 ± 0.4</td>
<td>1.3 ± 0.5</td>
</tr>
<tr>
<td>Fasting glucose (mM; mg/dL⁻¹)</td>
<td>106.2 ± 35.4</td>
<td>115.0 ± 44.2</td>
</tr>
<tr>
<td>insulin (μU/mL⁻¹)</td>
<td>4.5 ± 0.6</td>
<td>4.6 ± 0.4</td>
</tr>
<tr>
<td>Total cholesterol (mM; mg/dL⁻¹)</td>
<td>4.3 ± 0.5</td>
<td>4.4 ± 0.6</td>
</tr>
<tr>
<td>Fasting insulin (μU/mL⁻¹)</td>
<td>166.0 ± 19.3</td>
<td>166.9 ± 23.1</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>8.1 ± 4.4</td>
<td>9.4 ± 4.7</td>
</tr>
<tr>
<td>hsCRP (mg/dL⁻¹)</td>
<td>1.6 ± 1.0</td>
<td>1.9 ± 1.0</td>
</tr>
<tr>
<td>Refeeding heart rate (bpm)</td>
<td>2.9 ± 2.6</td>
<td>3.5 ± 3.0</td>
</tr>
<tr>
<td>Predicted VO₂max (l/min⁻¹)</td>
<td>67 ± 10</td>
<td>76 ± 12</td>
</tr>
<tr>
<td>Predicted VO₂max (mlkg⁻¹min⁻¹)</td>
<td>2.7 ± 0.2</td>
<td>2.4 ± 0.5</td>
</tr>
</tbody>
</table>

(Continued)
### Table 1. (Continued)

<table>
<thead>
<tr>
<th></th>
<th>Pre-control/pre-intervention (0 weeks)</th>
<th>Post-control/post-intervention (12 weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control (n = 37)</td>
<td>Intervention (n = 63)</td>
</tr>
<tr>
<td>Physical activity (min/week)</td>
<td>118 ± 89</td>
<td>97 ± 62</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy (kJ; kcal)</td>
<td>6857 ± 3310</td>
<td>6535 ± 2193</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHO (g)</td>
<td>194 ± 87</td>
<td>166 ± 74</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein (g/d)</td>
<td>135 ± 93</td>
<td>173 ± 86</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total fat (g/d)</td>
<td>66 ± 38</td>
<td>66 ± 34</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation

* log10 transformation;

* two-tailed t-test for control group (pre to post), P ≤ 0.05.

Greater change from baseline to 12 weeks in the intervention versus control group at P ≤ 0.01 and ΔP ≤ 0.05.

BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein, CHO carbohydrates.

Number of participants who were outside the normal range (see Table 2 for values) for adult women at baseline: BMI n = 35, WC n = 39, WHR n = 16, WHFR n = 25, SBP n = 1, HDL cholesterol n = 7, triglycerides n = 3, total cholesterol n = 1, HOMA-IR n = 13, hsCRP n = 11, predicted VO2max (mL/kg/min) n = 28, physical activity n = 39.

doi:10.1371/journal.pone.0130270.k001

Furthermore, cardiomediabocetic markers were significant from pre-intervention to sustainability testing (i.e. maintenance had occurred) but no further improvements were seen between post-testing to sustainability testing. In fact, predicted VO2max and physical activity reduced during the 12-week sustainability phase however, physical activity remained greater than at pre-intervention.

Control group

Despite being requested to maintain normal lifestyle habits, the control group displayed several improvements from pre- to post-testing, including WC (-5.6 cm, -6.2%), WHR (-0.03, -3.8%), WHFR (-0.03, -5.5%) and SBP (-8.0 mmHg, -7.0%), while circulating triglycerides rose (Table 2). In contrast to the intervention group, there were no changes in reported DBP, reported physical activity, predicted VO2max, resting heart rate and energy intake following the 12-week control period.

Discussion

The effectiveness of the multi-disciplinary lifestyle intervention for reducing CVD risk in young women was highlighted by within-group improvements in a range of risk factors for the...
Table 2. Within-group comparisons of cardiometabolic risk factors for the intervention group at pre-intervention, post-intervention, and sustainability.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-int. (0 weeks) (n = 20)</th>
<th>Post-int. (12 weeks) (n = 19)</th>
<th>Sustainability (24 weeks) (n = 19)</th>
<th>Pre-int. vs Post-int.</th>
<th>Pre-int. vs Sustainability</th>
<th>Post-int. vs Sustainability</th>
<th>Population norms/range for adult women</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body mass (kg)</td>
<td>89.8 ± 21.1</td>
<td>86.9 ± 20.5</td>
<td>86.1 ± 20.3</td>
<td>0.791</td>
<td>0.408</td>
<td>0.369</td>
<td>-</td>
</tr>
<tr>
<td>Body mass index (kg·m⁻²)</td>
<td>32.2 ± 5.9</td>
<td>31.3 ± 5.9</td>
<td>31.0 ± 6.1</td>
<td>0.447</td>
<td>0.197</td>
<td>0.291</td>
<td>18.5-24.9 [1]</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>90.1 ± 11.7</td>
<td>87.3 ± 9.8</td>
<td>87.8 ± 9.4</td>
<td>&lt; 0.001*</td>
<td>0.002*</td>
<td>0.696</td>
<td>≤ 80 [11]</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>116.3 ± 13.3</td>
<td>114.2 ± 13.5</td>
<td>114.5 ± 13.9</td>
<td>0.309</td>
<td>0.627</td>
<td>0.734</td>
<td>-</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.79 ± 0.05</td>
<td>0.77 ± 0.04</td>
<td>0.77 ± 0.04</td>
<td>0.002*</td>
<td>0.018*</td>
<td>0.998</td>
<td>&lt; 0.80 [1]</td>
</tr>
<tr>
<td>Waist-height ratio</td>
<td>0.56 ± 0.06</td>
<td>0.53 ± 0.05</td>
<td>0.53 ± 0.05</td>
<td>&lt; 0.001*</td>
<td>0.001*</td>
<td>0.841</td>
<td>&lt; 0.50 [10]</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>120.0 ± 11</td>
<td>116.9 ± 11</td>
<td>116.9 ± 11</td>
<td>0.047*</td>
<td>0.131</td>
<td>0.967</td>
<td>≤ 130 [11]</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>68.6 ± 6</td>
<td>64.9 ± 6</td>
<td>64.5 ± 6</td>
<td>0.040*</td>
<td>0.050*</td>
<td>0.841</td>
<td>≤ 85 [11]</td>
</tr>
<tr>
<td>HDL-cholesterol (mM·mg·dl⁻¹)</td>
<td>1.7 ± 0.5</td>
<td>1.9 ± 0.5</td>
<td>1.9 ± 0.4</td>
<td>0.193</td>
<td>0.386</td>
<td>0.726</td>
<td>≥ 1.29 [11]</td>
</tr>
<tr>
<td>Triglycerides (mM·mg·dl⁻¹)</td>
<td>65.6 ± 19.3</td>
<td>73.5 ± 19.3</td>
<td>73.5 ± 16.4</td>
<td>0.115</td>
<td>0.241</td>
<td>0.498</td>
<td>≥ 49.8</td>
</tr>
<tr>
<td>Fasting glucose (mM·mg·dl⁻¹)</td>
<td>115.0 ± 44.2</td>
<td>122.9 ± 61.9</td>
<td>122.7 ± 68.5</td>
<td>0.728</td>
<td>0.559</td>
<td>0.756</td>
<td>≥ 5.6 [11]</td>
</tr>
<tr>
<td>Total cholesterol (mM·mg·dl⁻¹)</td>
<td>169.9 ± 23.1</td>
<td>166.0 ± 30.9</td>
<td>166.0 ± 23.1</td>
<td>0.542</td>
<td>0.671</td>
<td>0.937</td>
<td>≤ 212.3</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>9.4 ± 4.7</td>
<td>8.1 ± 2.6</td>
<td>8.8 ± 4.7</td>
<td>0.957</td>
<td>0.466</td>
<td>0.344</td>
<td>-</td>
</tr>
<tr>
<td>hsCRP (mg·l⁻¹)</td>
<td>3.5 ± 3.0</td>
<td>4.6 ± 4.9</td>
<td>4.7 ± 3.8</td>
<td>0.743</td>
<td>0.148</td>
<td>0.140</td>
<td>&lt; 3.0 [23]</td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>76.0 ± 12</td>
<td>68.8 ± 8</td>
<td>66.0 ± 9</td>
<td>0.020*</td>
<td>0.004*</td>
<td>0.489</td>
<td>-</td>
</tr>
<tr>
<td>Predicted V̇O₂max (mM·kg⁻¹·min⁻¹)</td>
<td>2.4 ± 0.5</td>
<td>2.8 ± 0.6</td>
<td>2.5 ± 0.6</td>
<td>0.029*</td>
<td>0.471</td>
<td>0.179</td>
<td>-</td>
</tr>
<tr>
<td>Predicted V̇O₂max (mM·kg⁻¹·min⁻¹)</td>
<td>27.9 ± 7.0</td>
<td>32.6 ± 6.8</td>
<td>30.9 ± 9.7</td>
<td>0.000*</td>
<td>0.248</td>
<td>&lt; 0.001*</td>
<td>≥ 31.0 [38]</td>
</tr>
<tr>
<td>Physical activity (min week⁻¹)</td>
<td>97 ± 62</td>
<td>280 ± 67</td>
<td>143.7 ± 48.4</td>
<td>&lt; 0.001*</td>
<td>0.002*</td>
<td>&lt; 0.001*</td>
<td>≥ 210 [39]</td>
</tr>
<tr>
<td>Energy (kJ·kcal)</td>
<td>6035 ± 2183</td>
<td>5223 ± 1725</td>
<td>5538 ± 2586</td>
<td>0.007**</td>
<td>0.209</td>
<td>0.161</td>
<td>-</td>
</tr>
<tr>
<td>CHO (g)</td>
<td>1982 ± 522</td>
<td>1248 ± 412</td>
<td>1225 ± 618</td>
<td>0.638</td>
<td>0.928</td>
<td>0.638</td>
<td>-</td>
</tr>
<tr>
<td>Protein (g·d⁻¹)</td>
<td>173 ± 66</td>
<td>138 ± 63</td>
<td>150 ± 96</td>
<td>0.012*</td>
<td>0.520</td>
<td>0.079</td>
<td>-</td>
</tr>
<tr>
<td>Total fat (g·d⁻¹)</td>
<td>66 ± 34</td>
<td>56 ± 14</td>
<td>56 ± 28</td>
<td>0.227</td>
<td>0.575</td>
<td>0.513</td>
<td>-</td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation
* log₁₀ transformation
** P < 0.05.
Int = intervention, BP = blood pressure, HDL = high-density lipoprotein, HOMA-IR = homeostasis model assessment of insulin resistance, hs-CRP = high sensitivity C-reactive protein, CHO = carbohydrates.

doi:10.1371/journal.pone.0130270.K002
intervention group, with several of these improved markers retained 12 weeks after completion of the lifestyle intervention. Thus, these data suggest a relatively successful intervention for reducing CVD risk with promising sustainability. However, when between-group comparisons were made with the control group, the findings suggested a research design that was largely unsuccessful in identifying the effectiveness of the intervention phase. This raises several concerns associated with a wait-list control design when used with overweight/obese young women. Concerns from the current study support previous findings that describe more difficulties in retaining younger than older females to research trials [13].

Positive changes within the intervention group were demonstrated with improvements in WC-related measures, systolic and diastolic blood pressure, aerobic fitness and physical activity, and dietary energy intake. Collectively, these measures imply that the intervention produced cardiovascular, more so than metabolic, benefits for the intervention group. The use of investigative procedures such as non-invasive echocardiography or MRI may provide insight into the significance of these changes [40].

Improvements in fitness and physical activity and reduced energy intake also suggest that the exercise and nutrition education components of the intervention, respectively, were effective. Moreover, there was strong evidence for sustainability of intervention-induced improvements at 24 weeks, suggesting that the CBT component produced positive behavioural change in participants. It has been shown that poor adherence to behavioural programs is a barrier to successful long-term weight maintenance beyond the completion of the intervention [41]. In the present study, adherence to the physical activity component and attendance at the CBT sessions was high amongst intervention participants. This might explain the success in maintenance of some cardiometabolic risk factors observed during the short-term sustainability phase. Additionally, it has been suggested that improvements in maintenance might be achieved through incorporating technology to monitor weight, physical activity and behaviour [42]. This type of innovation could be easily integrated into a population of young adults.

However, similar post-intervention changes in our wait-list control group made it difficult to detect any anthropometric, biochemical, fitness or dietary differences between groups following the 12-week intervention phase. The control group in this RCT also displayed a decrease in WC that paralleled the intervention group, despite undetectable changes in self-reported physical activity and nutrition. The decreased WC of the control group is particularly difficult to explain without further investigative procedures such as accelerometry for physical activity and more rigorous dietary monitoring, but does suggest that basic awareness of CVD risk might be enough to evoke change in targeted populations [43,44].

Randomised controlled trials provide the highest level of evidence for the effects of an intervention and are deemed to be scientifically rigorous [45], with control groups employed to provide a contrast for the experimental group [46] for establishing the efficacy of an intervention [47]. But changed outcomes that arise from a wait-list control condition can be detrimental rather than beneficial to a randomised controlled trial [48], and this occurred in the current study. Therefore, wait-list control designs might not be appropriate for this population.

Retention and compliance of wait-list participants is also an issue for consideration when planning control conditions essential for maintaining the rigour of a randomised control design. In this study, more than one-third of the control group failed to return for post-testing at 12 weeks despite researcher attempts to maintain contact. In contrast, once engaged in the intervention group, retention to lifestyle change was high for at least 24 weeks. It is postulated that assigning participants to the control group decreased their motivation to participate. Thus, the duration (12 weeks) and/or conditions (no changes to existing lifestyle) of the control group do not appear suitable for women of this age group and demographic. Alternative
strategies for immediate engagement; perhaps via topics of interest using multimedia such as health-related apps or support groups might improve commitment and maintain control group compliance. There were also some difficulties encountered with recruitment, with almost a quarter of interested and eligible participants failing to engage after initial commitment (prior to group allocation). Complexities associated with recruiting young women for weight management trials, especially from ‘Generation Y’, may result in smaller sample sizes and require shorter periods of engagement [16].

Although not always the case [48], successful outcomes have been observed following lifestyle interventions with middle-aged [2] and older women [3]. Furthermore, a large scale success of weight loss has been observed in a recent eight year study of adults aged 45–65 years showing an 8.5% mean body weight loss after year one of a lifestyle program [49]. Subsequent monitoring indicated maintenance of approximately 4–5% over the 7 years. However difficulties in the external validity amongst younger adults (21–44 years) was acknowledged [19].

Moreover, there is a lack of effective lifestyle interventions for young adults, with no weight loss programs to date developed specifically to address the needs of this age group. Outcomes, enrolment and retention rates have been compared between younger (18–35 years, n = 21) and more mature (> 35 years, n = 277) adults (66% female) engaged in similar behavioural weight loss and physical activity programs [15]. Results showed attendance was 30% lower in young adults and they were 30% less likely to be retained for the 6-month assessment. Weight loss and increases in total physical activity from baseline to 6 months were significantly less in the younger population. Although the number of younger adults was relatively small, these results indicated that traditional interventions were less successful in young adults [15]. These findings are supported by results from other studies attempting to engage young adults [50-52].

This study is not without limitations. Despite recruitment and retention strategies, the sample size, particularly in the control condition, was lower than anticipated at completion of the study, suggesting it was slightly under-powered. Additionally, the results are specific to Caucasian women at a tertiary institution. To capture any potential changes to control groups in a wait-list design, objective measures (e.g. accelerometers, fortnightly anthropometric measures) might be useful. In addition, the use of more objective measures of physical activity and dietary compliance would strengthen evidence of change in this age group of women. In agreement with previous reports, not all food and activity diaries were completed with precision. Future researchers may benefit from the use of diet quality changes rather than diet intake.

Nonetheless, the study contributes to a very limited number of healthy lifestyle interventions in young adult women (<30 years of age) with cardiometabolic risk factors [50]. The multi-disciplinary lifestyle intervention confirms the potential value in health changes observed post-intervention, with favourable sustainability at a 12 weeks.

Conclusions

Within-group analysis showed that the multi-disciplinary lifestyle intervention comprising physical activity, nutrition education and CBT was positive for the reduction of CVD risk factors both immediately after and beyond the completion of the program. However, we also observed positive, but unexpected and difficult to explain, changes in the wait-list control group. Therefore, comparative lifestyle benefits for the intervention group may have been masked by undetectable weight management behaviour in the control group. When considered alongside the difficulties faced with recruitment and retention, especially in the nature of the control group, these results provide a challenge for prospective study designs with young women with cardiometabolic risk factors. Traditional RCT designs may be problematic for healthy lifestyle interventions in young women.
Supporting Information
S1 Table. CONSORT checklist. (DOC)
S2 Table. Lifestyle intervention: Outline of the 12-week multi-disciplinary lifestyle intervention of physical activity, nutrition education and cognitive-behavioural therapy. (DOC)
S1 Text. Application for ethical approval of research projects with human participants. (DOC)
S2 Text. Summary of research for ethics application. (DOC)
S3 Text. Lifestyle survey. (DOC)

Acknowledgments
The authors are grateful to Bianca Gazzola for her contribution to the nutrition education component of the lifestyle intervention. Thanks are also extended to all of those women who participated in the Young Women’s Heart Health Study.

Author Contributions
Conceived and designed the experiments: BLS GAN PO JGK. Performed the experiments: BLS EAA. Analyzed the data: BLS JKP. Wrote the paper: BLS GAN JGK.

References


Appendix 16: Focus Group Transcript
your way to go to a gym or something like that which is fairly boring environment which you personally don’t like.

- **Facilitator.** Yep, yep.
- **KP.** I think you know, it gave me locus because at the start the only reason I went was because I knew people would notice me like not going (laughing).
- **Facilitator.** Right, ok!
- **KC.** There was definitely a level of obligation (laughing).
- **BP.** To see people also, you know.
- **Facilitator.** Social accountability?
- **BP.** Yeah, the social aspect definitely.
- **Facilitator.** Ok. Umm, just to get a sense of where we are at currently, who is exercising now? And what are you doing? Just go ahead and say it.
- **KC.** Well, umm, I started doing more during the holidays especially when the gym at uni was still open because I mean I live in Brunswick and the gym is still open but there is like nobody there. Me and one of the other girls from uni we went there about two times per week.
- **Facilitator.** Yep.
- **KC.** Mainly just doing strength stuff, like not much cardio cos I hate it (laughing) but I’m walking to school now like two or three times per week which is like an hours walk.
- **Facilitator.** Brilliant.
- **KC.** Which I actually quite enjoy now. When I first started I was like I’m having a heart attack just from walking (laughing) because I walk pretty fast but now it’s actually like therapeutic in a way which is really good.
- **BP.** Yeah, I’ve been going to the gym a bit sort of and flows a little bit and obviously it was really good because after I was in the first group I went to a lot of sessions with the third group so that was really good to get back on that and yeah, I go to the gym probably only once or twice per week but I walk a lot as well and my job is quite physical so it’s a lot of running around.
- **Facilitator.** So are you making some conscious decisions to be active when you can like for example at work?
- **BP.** So yeah, my work is about a 25-30 minute walk from home so I always walk there and back.
- **Facilitator.** Great. What else? What else are people doing?

- **ES.** Just like walking in parks where you would have normally taken the tram. Instead of, like, I used to take the tram into the city and now I just walk into the city instead. And like every morning I walk to class instead of like getting on the tram. So it’s like small.
- **Facilitator.** Ok, great.
- **KC.** The tram from school to Parliament? Yeah. (Laughing).
- **Facilitator.** But that conscious choice to take that effort. Well, does anybody else have anything?
- **RR.** Umm, I still like do my bicycle commuting but I also make those conscious choices to go and like go for a swim or go out for a “walk/jog” I like to call it (laughing). umm but also now I don’t really care about if I’m out there and people see me… yeah, so I just go out and not worry about that kind of stuff.
- **Facilitator.** Good. And you used to worry?
- **RR.** Yes, yep.
- **Facilitator.** Forbidden someone sees me running in the park because what would they think? (laughing). ugh, there’s an active girl! (laughing).
- **Facilitator.** Umm, ok, so we’ve got a few people who are still using the gym. Anybody intending on doing more physical activity?
- **MT.** Yeah, well after I finished the study I joined belly dancing classes but I had trouble because after last year my teacher moved interstate… so she’s not doing class anymore, so I have to find another class and with uni back I haven’t really made that a priority but yeah I want to do that because that sort of gave me, like if I wasn’t pushing myself at least I had that hour, hour and a half class.
- **Facilitator.** Yep, ok, yep.
- **MT.** But yeah, like other people I’m sort of like instead of taking the tram I’m walking.
- **Facilitator.** Yep, great.
- **MT.** I try and fit it in when I can but id like to make it more a stable thing now that I know my timetable and everything.
- **Facilitator.** Great. Belly dancing, chat with MT (laughing). Is anybody else doing a class or have a class that they are thinking about doing?
- **KP.** I’m going to start doing more Zumba… I really like it. It’s really hard (laughing). Are you (RR) going to come back with me?
- **RR.** Umm, (laughs) (laughing)
K. It's at a gym, that's quite cheap so I'm going to try and incorporate it into my life and with my boyfriends... like if he's going to go and workout or whatever, I'll go along to a class and try to go like three times per week. We've just come back from Europe so it's our plan.

Facilitator. Umm, ok. What or who are the biggest challenges to your healthy lifestyle?

RB. Me. [laughing]

Facilitator. Why are you the biggest challenge?

RB. For me, umm, it's like my brain... yeah, basically.

Facilitator. What does the 'me' say?

RB. I'm cold, I'm tired, I want to stay in bed [laughing]. Yeah, I think that is always a struggle but at least you know about it now and are a little bit more like...

Facilitator. You feel more powerful against that me?

RB. Yeah! Definitely.

ER. My biggest struggle is work because like, well when I got back from Europe I was really motivated to keep up walking a lot because I lost like 25 kg when I was over there because I was walking all the time... umm, and so when I got back I was walking everyday and being really active and stuff and then I started working these 10 hour shifts for my job which is like 12 o'clock until 10.30 pm and then you don't get home until like 12 and you know, the next morning you wake up and have to sleep in a bit because you got home so late and then you know, you have to be back at work at 12 again so that's the biggest thing for me. And then my job is just sitting down all day... on the phone.

Facilitator. Ok, yep.

MT. I find that too. Work and study... trying to juggle both I'm finding that I'm needing to sort of try and find time with that and at the moment I'm having family issues so that goes on top of it so yeah, but I think it can be done... even like what we learnt you know through CRT and that sort of thing about how to deal with these issues. I need to go back to that and have a look at that. But yeah, look, it can be done, I know it can but at the time, you know, 10 hour work day and that sort of thing it seems like you can't fit it in. at the time, but you can.

ER. Like I could get up early and go for a walk like easily because I don't start until 12 so I'd have plenty of time to go for a walk but it's just a matter of then by the time I get home at the end of the night all be dead [laughing].

Facilitator. What about some of you guys? What's your biggest challenge?

BP. Being lazy. Like if I don't do something straight away when I get home and I sit down, there is no way it's going to happen. It's the same with exercise and like meal planning and cleaning. it's all the same, if I don't do either first thing in the morning or first thing when I get home I will lay down or sit down and then I'll be there for three hours [laughing].

Facilitator. So the planning component is still that organisation component is something to work on.

ES. I do the thing where I'm like as I'm walking home I'm like 'ok, when I get home I'll do this, this and this... and then it's like you get home and it's like aww but I'm tired from that walk, it was like four minutes so I'll sit down now [laughing].


TC. Yeah, I think yeah it's pretty much just laziness and business as well... and I know in my head that obviously that is really important and probably should be a high priority but at the time like when you're trying to fit all you stuff in and then you're like 'aw, I should be doing my uni work' but yeah, I'm going to start to be more regular. Now that uni is back I'm going to start to use the gym a bit.

Facilitator. Ok, so when I asked the 'who' is the greatest challenge we had a couple of people say 'me'. Anyone else have somebody else that would be somebody in your life? Is there a 'who' that is a greater challenge to your lifestyle change?

MT. Yes, my mother! She sabotages [laughing]

Facilitator. Ok.

MT. She'll cook like cakes and things... but then she'll do the double standards thing where she'll say 'have it because I've cooked it'... and then you have it... "well you should not have that because you're meant to be watching your weight" [laughing].

Yeah, she does it all the time, I know she does but I fall into the trap.

BP. My housemate started baking which is very dangerous so there is always like a bowl of something on the bench which you have to walk past like to go to the fridge [laughing] which is very tempting and she is very talented [laughing].

Facilitator. Mmm, mmm, interesting. Ok, so moving into nutrition, what have some of the nutritional changes been that you've made?

ER. I think my main thing was portion sizes. My portion sizes are a lot smaller now... umm, yeah, and that's made a huge difference.
P: Yeah. I put away my milk with vegetables instead of carrots, and um... eat dinner.
M: I put away my milk with vegetables instead of carrots, and um... eat dinner.

**Facilitator:** Oh, hi! I’m not sure if I’ve met Dr. Robinson yet. Can you say your name, please?

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one. 

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.

**Doctor:** I think the thing I’ll say is that I’ve been feeling really good lately. I’ve been eating really well and I’ve been feeling really good. I’ve been eating really well and I’ve been feeling really good.

**Doctor:** Yeah, that’s just one.
• MT. Because that’s the best for me. I won’t do anything unless I’m doing it with someone else. So that’s why classes work for me. I think if I sort of had people that I could regularly go for a walk with at the park or whenever someone had a break at the same time because you can do a lot from uni like if you have a one hour break and fitting that in... I think that may be an option or me.

• Facilitator. I’m hearing a healthy lifestyles club... at ACU (laugh)... sounds great!

• KC. You’re so right though, like having someone to do it with even though, you know you do have to be self-motivated... does help you along, because if I do go to the gym without Steph who is the girl I have been going with I will go and do stuff but I probably won’t do half as much if she wasn’t there putting me in check. You know what I mean?

• Facilitator. Hmm, yep.

• HB. I think short term, to keep exercising is not perceived as a chore and almost try and not see it as something you have to do or you have to plan and almost something that you can do like because you want to do it with your friends or something... because you want to go swimming, you want to walk, you want to ride to uni or something like that.

• Facilitator. It’s a bit of me time.

• HB. Yeah, and just using it more as a relaxation technique. I think because I’m going to start work this year, soon, and it’s going to be shift work so I want to use it as a relaxation technique, something I REALLY want to do.

• Facilitator. Great. Because it feels good and you feel great about yourself after.

• HB. Long term, no heart attack or diabetes (laughing).

• Facilitator. Are those in your family?

• HB. Umm, oh, diabetes is but not really heart attack because of living a healthy life. Living, you know like when you’re really not having arthritis would be good, that type of thing.

• Facilitator. Ok, what else? What about you?

• ES. Umm, yeah, just like what everyone said, just to be healthy and after like when you first start doing exercise like afterwards you feel really, really bad... like I want to get to that period where I just feel like really good and healthy and just like fit, not crap.

• KC. Yep, dieting in the locker room (laugh).

• ES. Like be able to train for like an hour or two hours and then at the end of it not go well now I want to go to sleep and die.

• Facilitator. Ok. Any other short-term or long-term aspirations?

• KC. I think just maintain; keeping it going because I know we were doing all our exercise before Christmas then I had a month off from doing gym stuff over Christmas, the first gym session back I like died... I probably should have eased into it but I had the worst muscle pain I have ever had in my life the following week afterwards and I was like oh my goodness that’s only like a month off. It’s so much easier just to keep it up and keep it going then stop and start all over again. Like I really noticed it and it really surprised me, like I couldn’t pick anything up of the ground... there was all this stuff on the ground and my husband came home and I was like help me! (laughing). I can’t do anything by myself. Yeah, it was pretty bad.

• BP. Yeah, I think for me, definitely maintaining the healthy lifestyle when I go into shiftwork next year because it could be so easy just to let things slide when you are doing shifts and knits and you know, afternoons and stuff so I can develop it now...

• KC. The endurance for nursing and midwifery, totally.

• BP. Ugh, and just strength as well.

• KC. It’s physically demanding (laughing).

• ES. And I want to kinda do exercise that feels like exercise. I just walk around and stroll around and I do it for like an hour or two hours or three hours but it doesn’t actually feel like exercise because you like walk and then you sit down and then you walk and then you sit down for a while and you stand around looking at things (laughing). I want like exercise, exercise.

• Facilitator. Ok. Very good. So if we think about the next six months then what’s one thing your planning on integrating into your repetatur of activity?

• ER. Walking every day.

• Facilitator. Walking every day. Ok, how long?

• ER. An hour.

• Facilitator. An hour, wow.

• ER. Because that’s what I was doing (laughs).

• KP. I should be walking to uni because I only live in Brunswick as well. It’s not that far; it’s actually quite a nice walk, it’s flat.

• Facilitator. Ok, great.

• KP. Like I was on the tram this morning and I thought I should have walked it.

• Facilitator. Even just a couple of times per week, you know, just start small and build. Cool. What about you BP?
Facilitator: Absolutely. Okay, and you said something about exercising besides walking. What is something you particularly like to do, and what I meant is, you mentioned you do yoga, and you really love swimming, I want to know if you just feel really healthy and physically active in general, and what's that like for you?

ES: Yeah, I probably will do yoga at some point. It's, like, every single day, and after you work out, you want to make sure that you're eating healthy and exercising. And for one thing, I really like swimming, which is great for my back. So I really like doing it, and I also like doing yoga, but yoga is more of a mindful practice, and swimming is more of a physical activity.

Facilitator: Okay. So, how do you feel about that?

KC: Yeah, probably just one direction. I did the 20 and 30 last week and did it on a good day, and I'll try to do that again this week. I probably won't do the 20 tomorrow, but I'll try to do something, something that's going to be a good day. And I think my day to day is going to be a good day, and I think it's going to be a good day, and I think it's going to be a good day, and I think it's going to be a good day.

ES: Yeah, I think it's a good day. I think it's a good day.

Facilitator: How do you feel about that?

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, so let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Alright, so, what do you think about the Bramston baths?

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.

Facilitator: Okay, let's talk about the Bramston baths.

KC: Yeah, I think it's a good day.

ES: Yeah, I think it's a good day.
• RB. Well I’m starting nursing in two weeks so basically I’ve planned to ride from Northcote to Peter Mac each day which will be nearly twenty minutes one way. I’ve never really cycled commuting as exercise because it doesn’t really increase your heart rate a lot whereas I own if I want to train I’ll be doing it and hopefully I’m going to try and go to the Fitzroy pool and go for a swim once or twice a week or something like that. Then I get into a routine of bit, so if I’ve got a PM, I’ll do some swimming before then going to work if I’ve got a PM, swimming after work. But I’m also going to Melbourne Uni bush walking club on Tuesday night to have a look because at different stages of my life I’ve really enjoyed gym and it’s been really good but I suppose this time I realise I’m not really a fan of being inside and with the gym I find it quite boring so I actually been doing some hiking with friends and I’m really want to get out there so I’ll check that club out hopefully. They organise trips throughout the year, so am, join up with them. Also because I’m starting work I’m going to organise getting a veggie box delivered.

• Facilitator. Oh wow.

• RB. Plus my dairy and stuff delivered through Farm Australia because the first thing people tell you is that first year you’re just too tired because of the work and it’s an easier way to cope. You have to plan your meals a lot and make it as easy as possible.

• Facilitator. Wow, that’s great.

• Facilitator. What or who is going to help you lead this healthier lifestyle that you have planned... that you are currently engaging in. So what or who?

• ER. Me.

• Facilitator. OK, so obviously you.

• ES. My dog.

• Facilitator. OK, so having the dog.

• ES. Whenever I don’t take him for a walk he gets really annoyed and comes and jumps on me.

• Facilitator. OK, so a great reminder

• ES. Yeah. And whenever we are walking he always runs away. He sees something and he runs so I have to like run after him (laughing). So that’s like a good little pusher.

• Facilitator. OK, very good. What else?

• KP. I know my boyfriend will be. I know like together we are both either, like we help each other be either healthy or unhealthy (laughing). So I guess we are both like on the thing together but he is really focused at the moment and because we have just been away both of us are seeing the trip as like when you get back that is when you really have to change I guess and he is really linear so I think I’ll just go along with him (laughing). So hopefully we can keep each other on track and try to make a difference.

• Facilitator. OK. Anybody else have a...

• BP. The kids I work with because I have to exercise a lot to keep up with them (laughing).

• Facilitator. OK, ok. Yep.

• TC. My little sister wants to start exercising more regularly so she is pulling me along.

• Facilitator. Yep. A bit of social support. OK. Anybody else have a what or who that helps you? Does everybody need a what or who?

• KC. My husband is pretty supportive, but he is generally supportive of anything I decide we are doing (laughing). We have a pretty good diet and everything but I have been dragging him to the park and playing Frisbee and stuff like that... more exercise through play rather than making it a drag like we go and grab some friends and so we go for a bike ride or play in the park.

• Facilitator. Active activities.

• KC. Active activities, yeah, that’s right! So now we have a couple of friends who came back from Berlin in winter and now they are all happy its summer so we’re going out together all the time... instead of going to the bar or whatever we just go and, if it’s a nice day, it’s not too hot or raining we just go to the park and hang out.

• Facilitator. Lovely.

• RB. The what for me would be like goals, so over the holidays I went and rode the east coast of Tasmania and I know the west side and south west side of Tasmania has lovely walks and stuff like that and because I love hiking and I love cycling I want to be able to do those and I know I have to be at a certain fitness level to be able to do them. And just to live a lifestyle that I want to live which includes those types of activities you have to be, you know, responsible for something like that and I also think a few of my friends that I have become good friends with over the past year like who are very much into hiking and stuff like that and I have similar sort of ideas about what is fun like camping and stuff like that and its easier to go out when you have people to do that with.
PP: Yeah, like I thought about having high cholesterol and like, what’s it doing to your heart and mind and all that sort of stuff but never really thought about the actual numbers and the actual thing. Like I don’t know. If you were really healthy then that stuff is better but I never really thought about that.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think being a bit more aware of what’s going on in our bodies is helpful.

MR: Yeah, I think that’s the first time I’ve said that this thing, I don’t think it’s a bit more influenced. I think it’s a bit more influential about the actual thing.

PP: Yeah, I think it’s a bit more influenced. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

PP: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

SR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.

MR: Yeah, I think it’s a bit more influenced about the actual thing. I think it’s a bit more influenced about the actual thing.
know, it was way down and that is fantastic because you forget that it’s not only what you can see that is really important, it’s the other stuff. Um, and that was really cool.

- **Facilitator**: So the weight, the number isn’t your value as a person? I think that is a great thing to take away.
- **ES**: I found that, um, I ride the light after like doing exercise, because after I’d do exercise I felt so good that I wanted to do exercise the next day to keep feeling good and the day that I’d miss exercise I’d start feeling bad so I’d have to do more exercise to feel good again.
- **KC**: Yeah, you start craving it a little bit don’t you?
- **ES**: Exactly. I remember I was talking to KP and she said her boyfriend always thought she was cranky when she wasn’t doing exercise and I realised that I found that. Until that point I hadn’t really realised that or days when I wasn’t doing exercise I was like meander or I’d snap at people.
- **KC**: I’m a much nicer person as well after I exercise.
- **Facilitator**: Anything else that you think you have to say about your experiences or learning?
- **TC**: It’s just really great to know that we can do it... like I’ve done health kicks before and I’ve never actually seen any difference at all and then you go after a few weeks... so yeah, it was awesome! You know, like I can exercise three times per week for a long period of time and loose weight and notice a difference and feel better.
- **MT**: Yeah, and there is other ways that you can loose weight. For me, I’ve always struggled with my weight and I’d go through stages where I’d say ‘I’m not going to eat anything’ and that’s how I’m going to loose weight and then you do things the unhealthy way. I think it’s the fact that I did loose weight and I do feel better about myself and you know physical changes as well as mental changes, doing it where I was eating healthy and exercising proved to me that I can do it that way... I don’t have to do it the unhealthy way.
- **RR**: I think learning about these fad diets and stuff like that was really important because you know how they were saying you go on this health kick and it never lasts and you put on weight and then you put more weight on top of what you were originally.
- **KC**: Yeah, it was really good to address that unhealthy but easy way to loose weight; like the fad diets and you know, drink nothing but maple syrup or lemon juice or whatever (laughter)... it’s just ridiculous... and people think that is the easy way but actually you can, you know, just eat normal food and just move around a little bit and that’s all you have to do to loose weight and that is the easiest thing to do, you’re not going to starve yourself, you don’t have to run yourself ragged and sweat. You know, it’s about being kind to yourself... and dieting is not (laughter).
- **Facilitator**: Yeah, yeah.
- **RR**: I know one of my friends little sister is on weight watchers and stuff and maybe that is good for her to a degree but I was like that is so limiting on your social. When I’m at home with friends I don’t want to count it because I would find it really socially limiting.
- **KC**: Your little book... your little points book.
- **RR**: Like I’ve done it before and I know it doesn’t suit me because once I stop.
- **KC**: It’s like a bandaid solution a lot of these things, like weight watchers, it’s just giving people instruction but once they get out of it they may not have the skills to actually keep it up on their own (laughter). I had a friend who did Tony Ferguson and lost heaps of weight and looked so good.
- **KP**: Isn’t that like a shake diet though?
- **KC**: Yeah, and like heaps of vegetables.
- **RR**: But like you obsess over the wrong things again... you start obsessing over the food where I think it’s moving out of there and socialising.
- **KC**: But he never develops the skills to cook proper meals anyway. I was having weird frozen Tony Ferguson meals which I think is just yuck.
- **Facilitator**: So that is a really great point because do you guys think that you have the skills? So even if life is busy and you perhaps have to make changes to the amount of physical activity you are doing do you still feel like you have learned some skill and learned you know, just a healthy way to move forward?
- **Group**: Yep.
- **Facilitator**: And does that feel powerful? Does that feel like the power you have perhaps not had previously?
- **BP**: Yeah, I think it really is a power. For me I found it really good because I obviously lost a certain amount of weight throughout the study but I was really fit for about six months after and continued to just keep going and have then sort of maintained it since then. Because I got to do the second half myself, you know, it gives you a lot of strength to know you can do it if you fall backwards.
Facilitator: Great. Well I think you guys should really tap into this momentum and exchange emails and numbers and BS (researcher) I think we should seriously look at starting some kind of club or maybe there are walks that people are doing at lunchtime, or bushwalks because this momentum is awesome.

END
## Lifestyle Intervention Evaluation

Please rate each of the following sections by using a number from 0 to 10

<table>
<thead>
<tr>
<th>No, Not at all</th>
<th>Yes, Definitely</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

### 1. Trainer Characteristics

<table>
<thead>
<tr>
<th>Had useful knowledge about exercise programming</th>
<th>Ratings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>______</td>
</tr>
<tr>
<td>Had a positive, constructive attitude</td>
<td>______</td>
</tr>
<tr>
<td>Made my exercise experience fun</td>
<td>______</td>
</tr>
<tr>
<td>Provided me with the appropriate support</td>
<td>______</td>
</tr>
</tbody>
</table>

Did Not Like | Liked Very Much
--- | ---
0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10

### 2. Rate your experience

<table>
<thead>
<tr>
<th>Frequency of training</th>
<th>Ratings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>______</td>
</tr>
<tr>
<td>Length of training</td>
<td>______</td>
</tr>
<tr>
<td>Variety of activities during training</td>
<td>______</td>
</tr>
<tr>
<td>Location of training (i.e. ACU gym, fitness gardens)</td>
<td>______</td>
</tr>
<tr>
<td>The social aspect of training</td>
<td>______</td>
</tr>
</tbody>
</table>

### 3. How has your attitude towards exercise changed as a direct result of this lifestyle intervention?

### 4. How has your attitude towards food/nutrition changed as a direct result of this lifestyle intervention?

### 5. How has your emotional state and general well-being changed as a direct result of this lifestyle intervention?

### 6. What were your main physical activity goals at the start of the program?

### 7. What were your main nutrition goals at the start of the program?

### 8. Did you have any other goals?

### 9. Did you achieve these goals?  YES □  NO □

### 10. If yes, please elaborate:

### 11. If no, what do you think prevented you from achieving your goals?

### 12. What did you enjoy and find most helpful about the physical activity component? Please comment below.

### 13. What did you find least enjoyable or least helpful about the physical activity component? Please comment below.

### 14. What did you enjoy and find most helpful about the nutrition education component? Please comment below.

### 15. What did you find least enjoyable or least helpful about the nutrition education component? Please comment below.

### 16. Please provide any recommendations for how to improve the quality or effectiveness of the lifestyle intervention.

### 17. Please provide any additional feedback or comments you may have?
Appendix 18: OMNI Scale of Perceived Exertion

Appendix A: OMNI Scale of Perceived Exertion: Adult, Cycle Format

OMNI Scale of Perceived Exertion: Adult, Cycle Format

Appendix B: OMNI Scale of Perceived Exertion: Adult, Walking to Running Format

OMNI Scale of Perceived Exertion: Adult, Walking to Running Format
Appendix 19: YMCA Submaximal Cycle Ergometer Protocol

<table>
<thead>
<tr>
<th></th>
<th>1st stage</th>
<th>150 kg m min⁻¹ (0.5 kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR &lt; 80</td>
<td>750 kg m min⁻¹ (2.5 kg)</td>
<td>600 kg m min⁻¹ (2.0 kg)</td>
</tr>
<tr>
<td></td>
<td>900 kg m min⁻¹ (3.0 kg)</td>
<td>750 kg m min⁻¹ (2.5 kg)</td>
</tr>
<tr>
<td>3rd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR &lt; 80</td>
<td>1050 kg m min⁻¹ (3.5 kg)</td>
<td>900 kg m min⁻¹ (3.0 kg)</td>
</tr>
<tr>
<td>4th</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR &lt; 80</td>
<td>300 kg m min⁻¹ (1.0 kg)</td>
<td>450 kg m min⁻¹ (1.5 kg)</td>
</tr>
<tr>
<td></td>
<td>450 kg m min⁻¹ (1.5 kg)</td>
<td>600 kg m min⁻¹ (2.0 kg)</td>
</tr>
</tbody>
</table>
Appendix 20: Example of Participant Results

BP

Table I. Metabolic syndrome data

<table>
<thead>
<tr>
<th>Metabolic Syndrome (IDF)</th>
<th>Recommendations</th>
<th>Pre-Intervention</th>
<th>Post-Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Waist circumference</td>
<td>≤ 80 cm</td>
<td>90.3 *</td>
<td>81.4 *</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>≤ 130/85</td>
<td>116/69</td>
<td>108/59</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>≤ 5.5 mmol-L⁻¹</td>
<td>4.9</td>
<td>4.2</td>
</tr>
<tr>
<td>HDL-Cholesterol</td>
<td>≥ 1.29 mmol-L⁻¹</td>
<td>1.4</td>
<td>2.1</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>≤ 1.7 mmol-L⁻¹</td>
<td>1.2</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Table II. Anthropometric and additional biochemical data

<table>
<thead>
<tr>
<th>Anthropometry</th>
<th>Recommendations</th>
<th>Pre-Intervention</th>
<th>Post-Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>18.5-24.9 kg·m⁻²</td>
<td>26.0 *</td>
<td>24.0</td>
</tr>
<tr>
<td>WHR</td>
<td>&lt; 0.80</td>
<td>0.88 *</td>
<td>0.82 *</td>
</tr>
<tr>
<td>Body mass</td>
<td>N/A</td>
<td>67.9 kg</td>
<td>63.7 kg</td>
</tr>
<tr>
<td>Biochemical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hs-CRP</td>
<td>&lt; 3.0 mg·L⁻¹</td>
<td>4.4 *</td>
<td>2.0</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>&lt; 2.0</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Insulin</td>
<td>&lt; 10</td>
<td>6.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>&lt; 5.5</td>
<td>5.4</td>
<td>4.7</td>
</tr>
</tbody>
</table>

Table III. Fitness data

<table>
<thead>
<tr>
<th>Fitness</th>
<th>Pre-Intervention</th>
<th>Post Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resting HR</td>
<td>71 bpm</td>
<td>65 bpm</td>
</tr>
<tr>
<td>Predicted VO₂peak</td>
<td>29.5 ml·kg⁻¹·min⁻¹</td>
<td>39.5 ml·kg⁻¹·min⁻¹</td>
</tr>
</tbody>
</table>

* Your results for this variable are outside the recommendations. There may be nothing to worry about but should you be concerned please consult your local GP or healthcare professional.
Table 1. Normality. Pre and Post-intervention. Cardiometabolic and fitness data.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre (n = 30)</th>
<th>Post (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Shapiro-Wilk</td>
<td>df</td>
</tr>
<tr>
<td>Body mass (kg)</td>
<td>0.055</td>
<td>30</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>0.090</td>
<td>30</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>0.019</td>
<td>30</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>0.075</td>
<td>30</td>
</tr>
<tr>
<td>Waist-hip ratio</td>
<td>0.709</td>
<td>30</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>0.678</td>
<td>30</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>0.250</td>
<td>30</td>
</tr>
<tr>
<td>Resting heart rate (bpm)</td>
<td>0.912</td>
<td>30</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>0.788</td>
<td>30</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>0.014</td>
<td>30</td>
</tr>
<tr>
<td>Triglycerides (mmol/L) #</td>
<td>0.000</td>
<td>30</td>
</tr>
<tr>
<td>Fasting glucose (mmol/L) #</td>
<td>0.000</td>
<td>30</td>
</tr>
<tr>
<td>Fasting insulin (mU/L) #</td>
<td>0.024</td>
<td>30</td>
</tr>
<tr>
<td>HOMA-IR #</td>
<td>0.050</td>
<td>30</td>
</tr>
<tr>
<td>hs-CRP (mg/l) #</td>
<td>0.005</td>
<td>30</td>
</tr>
<tr>
<td>Predicted VO2max (l/min) #</td>
<td>0.036</td>
<td>30</td>
</tr>
<tr>
<td>Physical activity (m/wk) #</td>
<td>0.032</td>
<td>30</td>
</tr>
</tbody>
</table>
Appendix 22: Example Output from EchoPac Analyses

A. Intima-media thickness

B. Pulsed Doppler
C. Tissue Doppler Imaging

D. Longitudinal strain
E. M-Mode chamber quantification

F. Simpson's bi-plane ejection fraction
END OF DOCUMENT